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Abstract 
 
Solid epithelial tumours are complex structures in which the associated stroma 
supports cancer cells (Quail and Joyce, 2013). During metastatic progression, 
cancer cells disseminate from their tissue of origin and recapitulate the tumour 
structure at distant organs, including the stromal compartment. Metastasis initiating 
cells (MICs) are functionally discriminated among the bulk of cancer cells for their 
high ability to establish metastasis (Malanchi et al., 2012, Baccelli et al., 2013). 
Additionally, efficient metastasis requires the expression of specific molecules 
within the local microenvironment (Oskarsson et al., 2014). Thus, a favourable 
microenvironment or niche is a crucial early step in metastatic progression. 
However what features of MICs mediate metastatic niche activation is poorly 
characterised.  
One strategy adopted by metastatic cells to disseminate from primary tumours is 
the activation of the developmental programme epithelial-to-mesenchymal 
transition (EMT). However, EMT is a reversible programme that needs to be 
inhibited at the target site for tumour cells to re-acquire epithelial characteristics 
compatible with metastatic outgrowth (Nieto, 2013). To successfully metastasise 
cancer cells need to retain self-renewal and growth properties through epithelial 
plasticity. This implies that during metastasis ‘stemness’ should not be strictly 
coupled to EMT as previously suggested (Mani et al., 2008). To date, both the 
potential advantage of disseminated cancer cells mesenchymal status and the 
source of their epithelial plasticity at the metastatic site remain unknown.  
In this thesis we use metastatic breast cancer models to elucidate the enhanced 
niche-induction ability of mesenchymal MICs, its relationship to EMT and the 
source of its epithelial modulation during metastatic colonisation. Importantly, we 
identify THBS2 as a novel effector linked to the EMT status of cancer cells that 
enhances stromal niche activation. Subsequently, the newly activated stroma 
triggers cancer cell BMP-dependent re-epithelialisation promoting metastatic 
outgrowth. Thereby, we describe a temporally controlled metastatic colonisation 
where the EMT status of cancer cells promotes its own inhibition via a cancer cell-
stromal crosstalk that initially enhances metastatic niche formation, and ultimately 
favours a cancer cell proliferative state compatible with metastatic outgrowth. 
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Chapter 1. Introduction 
1.1 Tumours as complex ecosystems  
Originally, tumours were considered homogeneous masses of aberrant cell growth 
but in the last decades knowledge has built up on the current view of tumours as 
highly dynamic heterogeneous structures. Tumour cell heterogeneity is driven by 
both, genetic determinants that generate clonal evolution among the cancer cell 
mass through new mutations, and epigenetic modulations that generate further 
diversity and functionally distinct populations among those clones. Adding 
complexity to the intricate tumour cell mass, it is now acknowledged that cancer 
cell heterogeneity is highly modulated by the tumour associated microenvironment, 
a compendium of different tissue recruited non-cancer cells and extracellular 
components (Quail and Joyce, 2013). The dynamic relationship between tumour 
cells and the microenvironment throughout tumour progression creates an 
extraordinarily complex structure, where the crosstalk between the different 
components modulates the function of the tumour as a whole. Therefore, by 
functioning as a complex ecosystem, the intrinsic tumour cell properties are 
reinforced, ultimately leading to therapy failure as shown by recent reports (Hirata 
et al., 2015, Junttila and de Sauvage, 2013). In light of these findings, it has now 
become clear that in order to develop more effective therapies and avoid disease 
relapse, tumour cell heterogeneity must be studied in the context of its 
microenvironment. 
 
 
1.1.1 Tumour cell heterogeneity 
1.1.1.1    Genetic origin of cancer 
Carcinogenesis is complex process that depends on multiple determinants, but it 
ultimately has a genetic origin. A founding principle in cancer research is that 
tumour initiation is driven from the sequential acquisition of genetic mutations, 
which leads to malignant transformation of normal human cells that acquire 
sustained chronic proliferation (Bruce Alberts, 2002). One of the first studies 
Chapter 1. Introduction 
 
 
17 
published supporting this view analysed the newly generated mutations across 
different stages of colorectal carcinoma showing that genetic alterations can 
determine phenotypic changes (Vogelstein et al., 1988). Mutations in the cell 
genome occur spontaneously during DNA replication or can be triggered by 
carcinogens. Most mutations are repaired by the DNA repair machinery of the cell 
(Hanahan and Weinberg, 2000), but a very low frequency are missed by these 
repair mechanisms. The majority of mutations occurring in cells are innocuous and 
persist in the genome without major consequences, or are seriously deleterious 
directly inducing programmed cell death (apoptosis). Importantly, only multiple 
mutations in potentially oncogenic genes will generate a malignant cell of origin 
leading to cancer. Oncogenic genes are those that encode proteins with the 
potential of sustaining aberrant cell division directly by activating mitogenic 
signalling pathways, or indirectly inhibiting apoptosis (Hanahan and Weinberg, 
2000).  
Cell proliferation within a normal tissue is tightly regulated by the presence of 
growth factors and anti-growth signals maintaining tissue homeostasis. In this 
context, malignant tumour cells possess oncogenic mutations that make them 
unresponsive to anti-growth and pro-apoptotic signals obtaining a limitless 
replicative potential (Hanahan and Weinberg, 2011). Moreover, to circumvent the 
need of growth factor stimulation to proliferate, cancer cells acquire mutations that 
constitutively activate signalling pathways downstream growth factor receptors. For 
instance, 40% of human melanomas contain activating mutations affecting the B-
Raf protein, which results in constitutive activation of the mitogen-activated protein 
(MAP)-kinase pathway and cell proliferation (Figure 1.4.B) (Davies and Samuels, 
2010). Similarly, mutations in the catalytic subunit of phosphoinositide 3-kinase 
(PI3K), which hyperactivates the Akt signal transducer enhancing proliferation are 
usually detected in different tumour types (Figure 1.4.B) (Jiang and Liu, 2009, Yuan 
and Cantley, 2008). Tumour cells employ other indirect mechanisms that do not 
activate mitogenic pathways but disrupt negative feedback loops that normally 
attenuate proliferation. The prototypic example are the Ras oncoproteins, where 
mutations affecting the Ras GTPases transform their transitory activity in 
permanent leading to the sustained activation of multiple genes involved in 
proliferation and survival (Figure 1.4.B) (Buday and Downward, 2008). Another 
important example of proteins mediating negative-feedback loops that normally 
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regulate proliferation is the phosphatase PTEN. PTEN deactivates PI3K by 
degrading its ligand; therefore loss of function mutations in PTEN leads to PI3K 
ligand accumulation and hyperactivation of the pathway ultimately boosting 
proliferation (Jiang and Liu, 2009, Yuan and Cantley, 2008).  
 
An additional strategy driving carcinogenesis is the inactivation of tumour 
suppressor proteins to bypass programmes that negatively regulate proliferation or 
activate cell death. The most common examples of tumour suppressor genes are 
the RB (retinoblastoma-associated) and TP53. The RB protein integrates several 
extracellular and intracellular signals deciding if the cell cycle should progress or 
stop (Burkhart and Sage, 2008). Therefore, inactivating mutations in the RB protein 
lead to the loss of function of this gatekeeper of the cell cycle, and permit unlimited 
proliferation. Likewise RB, under physiological conditions p53 integrates stress and 
abnormality signals from intracellular sensors and has the ability to halt the cell 
cycle until harmful conditions are normalised. When irreparable cell damage is 
detected, p53 triggers apoptosis to eliminate the aberrant cell. Therefore, 
inactivating mutations or deletions in TP53 allow tumour cells to proliferate under 
severe stress conditions and carrying ample DNA damage (Pflaum et al., 2014). 
Any newly arisen hypermutant tumour cell is at risk of being lost until it acquires the 
first selectively advantageous mutation, also called driver mutation. These driver 
mutations, such as inactivating TP53 mutations, allow cell division without DNA 
repair and cell cycle checkpoints ultimately leading to genomic instability. 
Subsequently, genomic instability is carried along as a hitchhiking phenotype 
further propagating diversity through the accumulation of additional mutations and 
chromosomal rearrangements (Bakhoum and Swanton, 2014). One common 
genomic instability example in many tumour types is the loss of the protective 
chromosomal telomeric DNA, which leads to karyotypic diversification via 
amplification and deletion of chromosomal fragments in tumour cells (Artandi and 
DePinho, 2010). In fully developed tumours, parallel mutagenic processes generate 
countless mutations and chromosomal rearrangements in the genome. Whole 
genome sequencing (WGS) of tumours has enabled complex analysis of the 
selected mutations occurring during tumour progression in patients, but the high 
inter-tumour and intra-tumour heterogeneity makes it difficult to understand 
whether a particular polymorphism is a driver or a passenger mutation. 
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1.1.1.2 The Clonal Evolution model – genetic drivers of cancer 
As briefly explained above, tumour initiation is driven by the sequential acquisition 
of genetic mutations that generate tumour cell heterogeneity through the origination 
of new clones. This leads to the idea of a Darwinian evolutionary process in 
tumours where the acquisition of new mutations will provide the new clones and its 
progeny with a beneficial advantage that the rest of the tumour cells did not share. 
Although most mutagenic processes are deleterious, over time advantageous 
mutations arise promoting selection and survival of a dominant clone and its 
progeny (Figure 1.1.A). These concepts set the basis of the Clonal Evolution model 
(Bakhoum and Swanton, 2014). Over the last years, genome sequencing of 
tumours disclosed many of the founding driver mutations in patients and revealed 
the coexistence of different subclones carrying distinct mutations within tumours. 
This suggests that a branching clonal diversification process rather than a linear 
clonal evolution operates throughout tumour progression (Stratton, 2011). The 
integration of these new findings refined the Clonal Evolution model that currently 
proposes that genetic heterogeneity within the same tumour provides the substrate 
for a Darwinian evolution that often occurs in a branched manner leading to genetic 
diversity. The multiple subclones that emerge trough branching evolution 
processes may differ not only genetically but also functionally, being only some of 
those subclones required to sustain tumour growth. Moreover, branched 
diversification might result from the adaptation of the clones to different 
microenvironments within the tumour suggesting that beyond genetic mutations 
there are other non-genetic determinants of tumorigenesis that can generate 
functional diversity. Indeed, epigenetic mechanisms controlling gene expression 
are more frequent than mutations in cancer genomes; on average only one 
extracellular matrix gene is mutated while four are hypermethylated in individual 
colon or breast tumours (Yi et al., 2011). Notably, although epigenetic modifications 
are not irreversible as mutations, some types of modifications are long lasting and 
heritable, being sufficient to generate distinct cellular states. Furthermore, the 
identification of subclones within single tumours provides strong evidence that 
intra-tumoural heterogeneity could be generated by the unique mutation spectrum 
present in an original clone, emphasising the key role of non-mutagenic processes 
in generating tumour cell heterogeneity (Kreso and Dick, 2014). 
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1.1.1.3 The Cancer Stem Cell model – epigenetic plasticity  
The Cancer Stem Cell model proposes that beyond genetic diversity, cellular 
plasticity and functional diversity contribute to carcinogenesis, and hence cancer 
can be generated from the mutation spectrum present in an original clone 
displaying ‘stem cell’ characteristics. Stem cells in normal tissues are defined by 
their exclusive self-renewal abilities. Self-renewal is the biological process by which 
normal stem cells perpetuate themselves through symmetric division expanding the 
stem cell pool, or asymmetric cell division generating a stem cell and a more 
differentiated cell (Figure 1.1.B) (Reya et al., 2001). Molecularly, there is still 
considerable uncertainty about how self-renewal capacity and cell fate are 
determined, but studies in normal embryonic stem cells (ESCs) suggest a strong 
dependency on epigenetic modifiers such as the Polycomb complex (Sparmann 
and van Lohuizen, 2006, Scaffidi and Misteli, 2011). Likewise ESCs, cell fate 
decisions and self-renewal in cancer stem cells are likely to be controlled by 
numerous dynamic epigenetic changes rather than the permanent mutations that 
generate the cancerous phenotype (Wood et al., 2007). Indeed, next-generation 
sequencing techniques applied to mapping chromatin and DNA methylation have 
revealed that it is the balance between co-existing permissive and repressive 
chromatin modifications, a state termed poised chromatin, what maintains 
functionally distinct gene expression states in normal and cancer stem cells 
(Chaffer et al., 2013, Bernstein et al., 2006).  
One of the most characterised mechanisms modelling the epigenome is the 
hypermethylation of CpG islands by the Polycomb repressive complex. CpG 
islands are DNA sequences localised in the promoter region of genes that become 
silenced upon Polycom recruitment and methylation (Deaton and Bird, 2011). 
Additionally, CpG islands contain multiple microRNAs that are efficiently repressed 
upon methylation. The silencing of these microRNAs can subsequently alter 
multiple target genes leading to upregulation of oncogenes (Saito et al., 2006), or 
constitutive activation of signalling pathways that promote EMT, invasion and 
metastatic activity (Figure 1.4.B – grey box) (Burk et al., 2008, Chi and Bernstein, 
2009). These examples illustrate how epigenetic changes can generate cellular 
plasticity and functional diversity in cancer independently of mutagenic processes. 
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Accordingly, the Cancer Stem Cell (CSC) theory postulates that similar to the 
growth in normal proliferating tissues the growth of tumours is driven by a limited 
number of stem cells that are capable of self-renewal (Clarke et al., 2006). The 
hypothesis that developmental programmes usually underlying normal tissue stem 
cell function might operate in tumours, started back in the late 1970s. Several 
studies in different tumour types suggested that the bulk tumour cells were the 
differentiated progeny of tumour ‘stem’ cells (Bennett et al., 1978, Hager et al., 
1981). Although the molecular mechanisms underlying self-renewal processes are 
still emerging, stem cells can be functionally identified when assayed in tissue 
regeneration assays in vivo, where they require self-renewal and differentiation 
capabilities to recapitulate the original tissue (Reya et al., 2001). Similarly, in 
cancer functional assays are used to identify cancer stem cells (CSCs), where a 
limited number of cells are tested for their ability to initiate and maintain long-term 
growth (Kreso and Dick, 2014).  
Considering this functional definition, early evidence supporting the Cancer Stem 
Cell model came from leukemia studies. It was found that the majority of leukemic 
cells isolated from patients were post-mitotic, suggesting that there could be a 
small population of highly proliferative leukemic cells that would restock the bulk of 
leukemic cells in the blood (Clarkson, 1969). These results sparked the idea of 
tumours as hierarchically organised structures where a small subpool of cells with 
self-renewal capacity is responsible for the maintenance of the tumour structure. 
The development of flow cytometry and xenograft techniques to engraft patient 
cells in immune-compromised mice allowed the identification of CD34+CD38- 
tumour-initiating cells (TICs) in leukemia (Lapidot et al., 1994). These were the only 
cells within the bulk of the tumour that could efficiently engraft in mice and 
recapitulate the disease heterogeneity observed in patients, being termed ‘cancer 
stem cells’ (Bonnet and Dick, 1997). These initial studies in leukemia were followed 
by many others identifying CSC populations in solid tumours. The first one was in 
human breast carcinoma, where a population expressing CD44+CD24- was shown 
to sustain tumour growth in mouse xenografts. Remarkably the xenografts 
generated by this subset of cells could recapitulate to a certain extent the tumour 
heterogeneity observed in the patients (Al-Hajj et al., 2003).  
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To date, potential CSC populations have been described in most solid cancer types, 
skin (Malanchi et al., 2008), brain (Singh et al., 2004, Chen et al., 2012), colon 
(Dalerba et al., 2007, O'Brien et al., 2007) and prostate (Wang et al., 2009). 
Moreover, using mouse models and lineage tracing genetic tools to label tissue 
specific stem cells, it has been possible to determine that skin and intestinal 
carcinomas arise from within the stem cell compartment of these tissues (Malanchi 
et al., 2008, Barker et al., 2007). Supporting the functional evidence that cancer 
arises within the tissue stem cell compartment, epigenetic mechanisms that can 
induce genetic changes favouring cancer development are active in intestinal stem 
cells. For instance, de novo CpG methylations in the promoter of DNA-repair genes 
can create mutational hotspots. The methylation of the promoter and silencing of 
MLH1 leads to microsatellite instability (Shoemaker et al., 2000), and likewise 
silencing of o-6-methylguanin-DNA methyltransferase (MGMT) leads to increased 
G—A mutations (Esteller et al., 2000). Therefore, a working hypothesis in line with 
the Cancer Stem Cell model is that tumorigenesis starts with the abnormal 
expansion of the stem cell compartment of a given tissue (Figure 1.1.B), although 
the mechanisms underlying this process remain to be characterised (Ohm and 
Baylin, 2007, Cedar and Bergman, 2008). 
 
In summary, the cancer stem cell model proposes that tumours like tissues are 
hierarchically organised structures, where only a small subpool of cells with limited 
proliferation and self-renewal capacity sustains tumour growth. 
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Figure 1.1 The Clonal Evolution and the Cancer Stem Cell Models of 
carcinogenesis 
(A) The Clonal Evolution Model: healthy epithelial cells acquire an oncogenic 
mutation (mutation I) that forms a hyperplasia. Some of the cells will acquire 
additional oncogenic mutations becoming cells of origin, and after multiple clonal 
evolutions in parallel the tumour results from different clones (shown in different 
colours). Alternatively, those cells that acquire a few oncogenic mutations but not 
enough to initiate malignant growth will form hyperplasias. (B) The Cancer Stem 
Cell model: normal tissue stem cells have a limited proliferative capacity and give 
rise to progenitor cells that further differentiate in different cell types. When a 
normal stem cell gains oncogenic mutations generates a cancer cell with self-
renewal capacity that can generate a) progenitors with higher proliferative rate, that 
will give rise to highly proliferative differentiated tumours; b) alternatively, when 
oncogenic mutations de-regulate self-renewal, the cancer stem cell pool will 
acquire a high proliferative rate giving rise to undifferentiated tumours.  
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1.1.1.4 Unified model for Cancer Evolution  
The Clonal Evolution and the Cancer Stem Models have been traditionally viewed 
as antagonistic models to explain carcinogenesis. To date, the major caveat when 
trying to establish a general model for carcinogenesis has been the lack of 
integration between the genomic and functional properties of tumour-initiating cells. 
It remains to be determined which genetic clones can graft in mice and display 
stem-like properties. In an integrative effort, sequencing studies in breast cancer 
have shown how the common ancestor containing conserved driver mutations 
appears early during clonal evolution indicating that much of the time is spent 
driving subclonal diversification (branching evolution) (Nik-Zainal et al., 2012). 
Moreover, this study showed that driver mutations leading to clonal expansion 
occur rarely in long-lived populations, which rather passively accumulate mutations 
without expanding (Nik-Zainal et al., 2012). These findings suggest that rare clones 
with limited proliferative capacity within tumours maintain long-term growth. 
Additionally, studies in leukemia have defined the functional role in tumorigenesis 
of different subclones. Shlush et al. tracked somatic mutations in large numbers of 
single leukemia cells isolated from patients, and found a driver recurrent mutation 
(DNMT3A) in a fraction of the hematopoietic stem cell (HSC) pool. DNMT3A 
mutant HSCs showed a repopulation advantage over the non-mutated HSCs in 
xenografts, establishing their identity as pre-leukemic HSCs. Moreover, these 
DNMT3A mutated pre-leukemic HSCs were enriched in relapses compared to 
samples at diagnosis, indicating that they are chemoresistant. These findings 
demonstrate that an early appearing clone can drive the clonal expansion of HSCs 
from which Acute Myeloid Leukemia (AML) originates and potentially trigger 
relapse after persisting chemotherapy (Shlush et al., 2014).  
 
In line with these preliminary studies integrating genomic and functional data, 
Kreso and Dick propose that the Clonal Evolution and CSC models can be 
harmonised: the acquisition of favourable mutations impacting on self-renewal 
properties (i.e. acquiring the DNMT3A mutation that drives AML) can result in 
clonal expansion of the original CSC population, and in parallel another cell can 
gain a different mutation that allows it to form a new stem-like subclone. Over time, 
genetic mutations accumulate and subclones evolve in parallel presenting CSCs as 
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dynamic entities that evolve over time (Figure 1.2 – X axis, genetic determinants). 
The CSC subclones generated will further divide giving rise to three types of 
scenarios: 1) hierarchically organised clonal populations where only a few cells 
retain self-renewal capacity; 2) an intermediate hierarchy where the number of 
CSCs is relatively high (symmetric divisions equal asymmetric divisions); 3) a 
homogeneous mass of CSCs, that due to the acquisition of mutations directly 
impacting on self-renewal, divides symmetrically giving rise to predominantly 
undifferentiated tumours (Figure 1.2 – pink CSC subclones) (Kreso and Dick, 2014).  
In parallel to this mutagenic evolution in cancer stem cells, context-dependent 
phenotypic plasticity can be gained through epigenetic modulations enabling 
cancer cells to gain/lose stem cell properties (Figure 1.2. – Y axis, epigenetic 
determinants) (Lim et al., 2009, Quail et al., 2012). This epigenetically driven 
plasticity is key to reconcile the Clonal Evolution and the Cancer Stem Cell models 
(Plaks et al., 2015): microenvironment-induced epigenetic regulations would 
determine whether CSCs will transiently amplify (self-renewal) (Figure 1.2 – grey 
curved arrows) or differentiate to nonCSCs (Figure 1.2 – black arrows). Moreover, 
recent reports claim that the gain of stem-like features is possible, and tumour cells 
have been proposed to interconvert between stem-like and differentiated states 
depending on the microenvironmental cues received (Chaffer et al., 2013, Gupta et 
al., 2009). Although still under debate, these studies propose nonCSCs could de-
differentiate regaining stem-like properties (Figure 1.2 – blue arrows).  
 
In conclusion, the unified model of carcinogenesis proposes CSCs as dynamic 
entities that evolve trough the acquisition of mutations generating new CSC 
subclones and in parallel undergo epigenetic modulations that ultimately control 
their fate. Given the complexity of the regulatory mechanisms driving cancer stem 
cell phenotypes during tumour progression, it is of central importance to develop 
assays to study their function in situ, which would allow examination of their fate 
decisions and clonal identity within their biological context. In the future, the 
integration of genomic and functional data acquired in the native microenvironment 
of cancer stem cells would allow the identification of definitive markers to identify 
and isolate these populations in different human cancer types.  
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Figure 1.2 Unified Model of carcinogenesis: clonal evolution in cancer stem 
cells and cellular plasticity 
Genetic determinants - The founder low cycling CSC population can gain new 
mutations over time that impact on their stem-cell-like features (pink triangle – 
clonal diversity), creating new CSCs subclones in the tumour with higher self-
renewal capacity that evolve in parallel. Epigenetic determinants - CSCs are not 
static entities, and their proliferative status can be modulated extrinsically 
(differentiation/plasticity arrows) changing their relative frequency in the tumour 
mass. As a result of the combined genetic and epigenetic factors, some subclones 
will organise as differentiated tumours, with a hierarchical structure where CSCs 
are rare (blue CSC subclone); others will show a high frequency of CSCs but still 
display a hierarchy (green CSC subclone), while subclones with high self-renewal 
potential will form homogeneous undifferentiated tumours (pink CSC subclone). 
Reverse transitions can occur as well, differentiated nonCSCs can re-acquire a 
stem-like status (blue arrows – plasticity) through new mutations impacting on self-
renewal or microenvironmental modulations regulating their epigenetic status.  
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1.1.1.5 Cancer stem cell: concept implications 
To date, many studies have highlighted the unique properties of CSCs in different 
human xenografts and mouse models leading to the compilation of the ‘CSC 
hallmarks’ (Malanchi, 2013). The first hallmark of CSCs is their exclusive ability to 
self-renew and differentiate, being able to initiate tumour growth in clonal or limited 
dilution assays (Malanchi, 2013). The second hallmark is their ability to sustain 
tumour growth as demonstrated in skin carcinoma mouse models, where the 
ablation of the CSC population led to tumour regression in two independent studies 
(Malanchi et al., 2008, Beck et al., 2015); Lastly, CSCs display unique molecular 
mechanisms that make them chemoresistant compared to the bulk of the tumour 
cells in glioblastoma, colon cancer, breast cancer and other tumours (Bao et al., 
2006, Ishikawa et al., 2007, Saito et al., 2010, Diehn et al., 2009), suggesting that 
they are the main drivers of relapse in patients. These hallmarks emphasise the 
functional relevance of CSCs in tumours.  
 
Although the central role of CSCs in tumorigenesis is increasingly recognised, 
there is still a great controversy in the field due to the way they have been defined 
and the different tests that are used to assess their potential (Badve and Nakshatri, 
2012, Barrett et al., 2012, Kreso and Dick, 2014, Nguyen et al., 2012).  
First, regarding their definition, the term cancer ‘stem’ cell implies that as normal 
stem cells, CSCs possess self-renewal capacity. However, self-renewal is typically 
deregulated in CSCs. For instance, leukemic stem cells display abnormally 
elevated levels of the RNA-binding protein Musashi that ultimately triggers 
symmetric cell division expanding the leukemic stem cell pool (Ito et al., 2010). Also, 
we previously mentioned how mutations in the epigenetic modifier DNMT3A lead to 
leukemic stem cells clonal expansion in AML (Shlush et al., 2014). Second, a major 
problem with stem cells studies is that usually the assays used to assess self-
renewal potential are performed in exogenous microenvironments after cell 
isolation, and therefore they do not consider the key microenvironmental factors 
that normally regulate stem cell function. 
 
 All of the above facts indicate that the term cancer ‘stem cell’ poses a problem and 
its use therefore should be limited to those cases where clonal self-renewing CSCs 
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can be prospectively purified from primary tumours for functional testing. 
Consequently, we define putative CSCs functionally according to the tests used to 
assess their intrinsic potential in vivo as tumour-initiating cells (TICs) or metastasis-
initiating cells (MICs) (Oskarsson et al., 2014, Ombrato and Malanchi, 2014). 
 
 
 
1.1.2 Microenvironmental heterogeneity 
Traditionally the biology of tumours was studied as being ruled by the genetic and 
epigenetic modifications driving tumour cell heterogeneity, however over the last 
few decades the tumour microenvironment has emerged as an equally important 
component for disease onset and progression. It is now acknowledged that tumour 
heterogeneity is not only determined by the diversity in the cancer cell 
compartment but also by the miscellaneous composition of its microenvironment, 
and the proportion and activation status of the stromal cells within it (Hanahan and 
Weinberg, 2011). To date, it is acknowledged that the dynamic bidirectional 
communications between tumour cells and the microenvironment determine the 
overall tumour fitness, invasive potential and therapy outcome (Junttila and de 
Sauvage, 2013). Moreover, disease initiation and patient prognosis can be 
determined by the intricate mechanisms taking place in this complex tumour-
stroma ecosystem (Farmer et al., 2009). 
 
1.1.2.1 Stromal cells 
The systemic interactions between tumour and stromal cells resemble other normal 
physiological processes, such as inflammation or wound healing, where the 
microenvironment transiently exerts a direct regulation on epithelial tissue 
homeostasis. However, in contrast to the transient activation of stromal cells during 
these physiological processes, tumour’s recruitment and activation of stromal cells 
persists and constantly evolves throughout disease progression and never resolve 
(McAllister and Weinberg, 2014).  
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Immune cells are one of the best-characterised components of the 
microenvironment. Indeed, chronic inflammatory stress in tissues is known to have 
a direct effect in cancer incidence (Grivennikov and Karin, 2010). Generally, 
immune cells can contribute to tumorigenesis by directly regulating tumour cells 
function through paracrine signals or mediating more complex immune-suppressive 
responses. Some immune cells, such as macrophages and neutrophils exert direct 
pro-tumorigenic functions. Macrophages and neutrophils are critical effectors 
during immune defence, but in the tumour context there is evidence of their pro-
tumorigenic role (Figure 1.3). It is not currently understood how these innate 
immune cells change from a tumour suppressor to a tumour promoting phenotype 
during tumour initiation. However, it is widely proven that during tumour 
progression tumour-associated macrophages (TAMs) and neutrophils can directly 
enable tumour cell invasion through paracrine signalling (Wyckoff et al., 2007, 
Glogauer et al., 2015) or secrete crucial extracellular components that will affect 
disease progression (Akkari et al., 2014). Consequently, depletion of macrophages 
and neutrophils during tumour progression can partially impair metastatic 
dissemination (Lohela et al., 2014, Gregory and Houghton, 2011). In addition to the 
pro-tumorigenic roles of some immune components, complex immunosuppressive 
mechanisms have been observed during tumour development. These mechanisms 
allow tumour cells to escape from the surveillance mechanisms implemented in 
normal physiological conditions and are usually mediated by myeloid-derived 
suppressor cells (MDSCs) recruited to the tumour site and regulatory T-cells 
(Figure 1.3). It is well characterised that infiltrating MDSCs in developing tumours 
impair different defence mechanisms, such as T-cell activation (Mazzoni et al., 
2002), inhibition of NK cells cytotoxicity (Liu et al., 2007a) and antigen presentation 
by dendritic cells (Gabrilovich et al., 2012). Notably, depletion of MDSCs with 
neutralizing antibodies can reduce metastatic outcome in several animal models 
(Talmadge and Gabrilovich, 2013). In the same way, regulatory T-cells (T-reg) can 
also impair cytotoxic T-cells and natural killer (NK) cells function by disrupting 
immune-surveillance mechanisms (Gasteiger et al., 2013, Fu et al., 2007). 
Altogether, these findings exemplify the pro-tumorigenic role of the altered immune 
system in the context of the tumour microenvironment compare to normal 
physiological conditions. 
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Figure 1.3 Main cellular and extracellular components of the tumour 
microenvironment 
The cancer cell mass in tumours is heterogeneous, and hierarchically organised in 
CSC and nonCSC that recruit stromal components through the secretion of 
cytokines and ECM components. Recruited macrophages (i.e. by tumour cell 
derived SPARC) and neutrophils, exert pro-tumorigenic activities through the 
secretion of cytokines, growth factors such as EGF, and support tumour cell 
invasion by secreting MMPs. CAFs are activated by tumour-cell derived factors (i.e. 
TGFβ, FGF, PDGF) and have a crucial role in producing ECM matrix (Fibronectin, 
TCN and collagen-I) components. CAF-derived factors enhance cancer cell 
dissemination at the tumour-stromal interface (TGFβ) and stimulate tumour cell 
self-renewal and proliferation (WNT, FGF). Angiogenesis increases as 
macrophages and CAFs are recruited to the tumour site contributing to the 
secretion of angiogenic factors (i.e. VEGF). As tumours grow and vasculature 
develops, immune-suppressive cells such as T-reg cells and MDSCs are mobilised 
and disrupt the immune-surveillance mechanisms typically performed by NK, T, B 
and dendritic cells.  
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Another key cellular component of the tumour microenvironment are fibroblasts. 
Traditionally, fibroblasts have been described as non-vascular, non-epithelial and 
non-inflammatory cells of the connective tissue (Tarin and Croft, 1969). These 
multifunctional cells have roles in ECM deposition, wound healing, epithelial 
differentiation and regulation of inflammation in physiological conditions (Kalluri and 
Zeisberg, 2006). Fibroblasts are key in maintaining tissue homeostasis through the 
deposition of specific ECM components that define the biomechanical properties of 
the tissue and form the basement membrane that confines tissue limits. Indeed, in 
tissues rich in ECM such as the skin, fibroblasts consist of a number of distinct 
mesenchymal cells types with different origins, locations and functions, giving an 
insight into the complexity of the fibroblastic stroma (Driskell and Watt, 2015). In 
physiological conditions, fibroblasts also secrete factors that directly regulate 
epithelial cell function in a paracrine manner (Luhr et al., 2012, Visco et al., 2009).  
In the tumour microenvironment cancer-associated fibroblasts (CAFs) display 
distinct characteristics compared to those of normal tissue fibroblasts and are 
present in aberrantly high numbers. CAFs result from normal fibroblasts that 
become activated by pro-fibrotic tumour-derived factors such as TGFβ, platelet-
derived growth factor (PDGF) and fibroblast growth factor 2 (FGF2) (Figure 1.3) 
(Kalluri and Zeisberg, 2006). In breast cancer, normal fibroblasts get activated as 
matrix stiffness in the tumour microenvironment increases as a result of TGFβ 
signalling and matrix deposition by tumour cells themselves and recruited normal 
fibroblasts (Calvo et al., 2013). The aberrantly stiff matrix promotes nuclear 
translocation of the transcriptional co-activator YAP (Yes associated protein-1) that 
governs further fibroblast activation. YAP signalling activation leads to CAFs 
morphological changes through the expression of cytoskeletal components such as 
smooth muscle action (SMA) and fibroblast activation protein (FAP). Once 
activated, CAFs secrete aberrantly high levels of ECM components, such as type I, 
III and IV collagen and fibronectin that increase further matrix stiffness sustaining 
this YAP-dependent mechanical signalling loop that maintains fibroblasts activated 
throughout disease progression (Calvo et al., 2013). During cancer progression, in 
mammary carcinomas CAFs have been shown to influence tumour initiation 
through the secretion of TGFβ and HGF. Moreover, when immortalised mammary 
epithelial cells were grafted into mice with either normal fibroblasts or CAFs 
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isolated from mammary gland or mammary carcinoma respectively, only in the 
presence of CAFs tumours were developed (Olumi et al., 1999). 
Additionally, CAFs are known to confer mesenchymal-like features to malignant 
epithelial cells promoting their metastatic ability. This is mediated by the secretion 
of TGFβ, MMPs and ECM components that stimulate integrin signalling, and 
production of growth factors, such as EGF and FGF2 that can activate tyrosine-
kinase receptor signalling on cancer cells (Dumont et al., 2013). Furthermore, in 
line with this mesenchymal induction ability, CAFs have been shown to promote 
both single cell invasion through TGFβ stimulation, and collective cell invasion by 
leading the way and in turn opening micro-tracks in the dense ECM (Gaggioli et al., 
2007). Altogether, these findings illustrate the multiple pro-tumorigenic functions of 
CAFs throughout tumour progression. 
 
Additional fundamental cellular components of the tumour microenvironment are 
the blood vessels that supply tumours with oxygen and nutrients from the 
bloodstream. The vasculature also determines the possibility of stromal cell 
recruitment to the tumour site, and the exit of tumour cells to reach circulation and 
metastasise (Figure 1.3). Tumour vasculature development requires the co-
operation of different cell types: pericytes to provide vessel coverage, endothelial 
cells that conform the building blocks of vessels and bone-marrow progenitors. In 
addition to the cells forming the blood vessels, other stromal cells such as TAMs, 
CAFs and mesenchymal stem cells (MSCs) contribute to promote vascularisation 
by releasing pro-angiogenic molecules such as VEGF and FGF, or downregulating 
the expression of anti-angiogenic factors such as thrombospondin-1 or β-interferon 
(Hanahan and Weinberg, 2000). Angiogenesis is a hallmark of cancer, and 
therapeutic disruption of pro-angiogenic mechanisms can impair tumour 
progression in most cancer types (Hanahan and Weinberg, 2000). 
 
There are other emerging stromal cell types that can influence tumorigenesis and 
are currently being studied. Mesenchymal stem cell (MSC) recruitment to the 
tumour site has been reported in several cancer types (Johann and Muller, 2015). 
MSCs are stromal progenitors that can differentiate into osteoclast, chondrocytes, 
myocytes and adipocytes (Pittenger et al., 1999). This differentiated progeny 
further influences the tumour microenvironment; for instance, adipocytes have 
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been shown to play a role in obesity-associated cancers (Morris et al., 2011, 
Nieman et al., 2011). Also, it is interesting the pro-tumorigenic impact of the 
resident microbiota in organs such as the skin (Hoste et al., 2015) or the gut 
(Zackular et al., 2013), where they directly regulate tumour cells though the 
secretion of factors in a paracrine manner, or exacerbate the pro-tumorigenic 
inflammatory responses in the tumour. Last, it is intriguing the emerging systemic 
role of tumour and stromal cell-derived exosomes as microenvironmental 
components regulating disease progression (Peinado et al., 2011). The increasing 
complexity of the tumour microenvironment requires further investigation to 
uncover potentially targetable mechanisms to efficiently complement cancer cell-
directed therapies.  
 
 
1.1.2.2 The extracellular matrix 
Together with the different stromal cells discussed above, the extracellular matrix 
(ECM) is a crucial element of the tumour microenvironment. Although long 
considered as a steady structure supporting tissue morphology the ECM can 
actually exert both mechanical and biochemical instructions to all cellular 
components in tumours (Lu et al., 2012). Particularly in cancer, it is well 
characterised how an abnormal composition of the ECM can change the behaviour 
of both epithelial and stromal cells, impacting in the success of tumour initiation as 
well as triggering invasion during later disease development (Lu et al., 2012). Thus, 
abnormal ECM composition and dynamics are considered today a hallmark of 
cancer (Hanahan and Weinberg, 2011). ECM matrix components can be secreted 
by most cell types; as previously mentioned, in physiological conditions fibroblasts 
are the main producers and modellers of the tissue matrix (section 1.1.2.1), but in 
the tumour microenvironment other cell types such as tumour cells themselves and 
some immune components are known to secrete key ECM components supporting 
tumour progression (Quail and Joyce, 2013).  
 
The ECM is composed of secreted proteins, glycoproteins, proteoglycans and 
polysaccharides with different physical and biochemical properties (Lu et al., 2012). 
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Its composition will determine the physical properties (rigidity, porosity, insolubility, 
spatial organisation) and biochemical properties that per se can enhance cell 
growth and the invasive behaviour of primary breast cancer cells in vivo (Lo et al., 
2000). Physically, a stiffer microenvironment can be achieved by a single 
component variation in the ECM, having enormous effects in cell morphology and 
migration. Nguyen-Ngoc et al. have shown how a collagen-I rich stiff 
microenvironment is enough to induce a conserve dissemination response in 
normal and malignant mammary epithelium (Nguyen-Ngoc et al., 2012). On the 
other hand, the biochemical properties of the ECM define its signalling capabilities: 
ECM components will trigger signal transduction cascades initiated at the cell 
surface that ultimately will reach the nucleus resulting in dramatic changes in cell 
behaviour. Additionally, the ECM can bind different signalling ligands such as TGFβ, 
BMPs, WNTs, FGFs, limiting their diffusive range, accessibility and signal direction 
implementing an extra level of modulation to autocrine and paracrine signalling 
mechanisms (Hynes, 2009). 
 
Integrins are the main mean by which ECM molecules initiate transduction 
cascades to change cell behaviour. Integrins are heterodimeric receptors formed 
by a α and β subunit that link the extracellular microenvironment to the intracellular 
actin cytoskeleton. The binding of integrin receptors to ECM ligands provides 
physical information of its location, adhesive state and surrounding matrix (Guo and 
Giancotti, 2004). Indeed, a stiff microenvironment can increase integrin β1 subunit 
expression and activity through mechanotransduction, enhancing cell migration 
through the formation of focal adhesions (Shibue et al., 2013). Integrin biochemical 
stimulation and downstream signalling can be achieved by different ECM 
glycoproteins present in the tumour microenvironment, such as fibronectin (FN), 
Vitronectin (VN), Tenascin-C (TNC) and latent forms of TGFβ. Additionally, 
integrins cooperate with other cell surface receptors to regulate biological 
processes such as cell proliferation and differentiation, cell shape and migration, 
and survival (Yoshida et al., 2015). Thus, preventing integrin biochemical 
stimulation by ECM components inhibits the activation of many downstream 
pathways required for breast cancer progression in both, tumour and stromal cells 
(Guo and Giancotti, 2004, Uberti et al., 2010, Seguin et al., 2014).  
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The biomechanical properties of the ECM also have profound effects in other 
crucial cellular components of the microenvironment. Particularly, angiogenesis is 
complex process where the ECM is involved in endothelial cell survival and 
proliferation (Sweet et al., 2012), lumen formation (Newman et al., 2011) and other 
aspects of tubulogenesis during blood vessel formation. Indeed, there is a fine 
regulation between pro and anti-angiogenic factors in tumours, and ECM 
glycoproteins are key in regulating the accessibility of these factors, or acting 
directly as endothelial cell regulators. For example, in breast cancer the ECM 
glycoprotein biglycan indirectly displays pro-angiogenic functions by sequestrating 
the angiogenic inducer VEGFA in the ECM, generating a reservoir of VEGF that 
will be released with ECM matrix degradation processes promoting angiogenesis 
(Berendsen and Olsen, 2014). While other glycoproteins, such as Trombospondin-
1 (THBS1) and Trombospondin-2 (THBS2) exert anti-angiogenic effects directly on 
endothelial cell survival, inducing apoptosis through activation of CD36 receptor 
(Jimenez et al., 2000). Indeed, THBS2 overexpression results in decreased 
mammary tumour growth in human xenograft mouse models of breast cancer 
(Koch et al., 2011). Certainly, the abnormal ECM composition of the tumour 
microenvironment leads to the formation of functional but morphologically distinct 
tumour vasculature (Myers et al., 2011).  
 
Additionally, the ECM matrix composition can regulate the recruitment of immune 
cells through the diffusivity of chemoattractants, or physically limiting the intersticial 
space. For instance, the ECM matrix glycoprotein SPARC (secreted protein acidic 
and rich in cysteine) is crucial for the production and organisation of the ECM and 
the recruitment of macrophages to the tumour site in Lewis Lung Carcinomas (LLC) 
(Figure 1.3) (Brekken et al., 2003). 
 
Lastly, as emphasised by Lu et al. one of the most relevant functions of ECM-cells 
interactions is that they are reciprocal. Cells continuously produce and rearrange 
the ECM changing its properties, and in turn the new properties of the ECM will 
impact on cell behaviour. As discussed above, in cancer these permanent 
feedback loops will determine disease onset and progression (Lu et al. 2015). 
Indeed, in breast cancers tumours can be stratified according to their ECM 
composition, which is predictive of patient outcome (Bergamaschi et al., 2008). 
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Moreover, high expression of proteases and integrins, which denotes a high ability 
to remodel and interact with the ECM, are associated with poor prognosis and 
relapse (Bergamaschi et al., 2008). These findings complement the in vivo 
evidence that tumours with different metastatic potential differ in their ECM 
composition (Naba et al., 2012). Altogether, these results highlight the crucial role 
of the ECM during cancer progression and denote the prognostic value of 
analysing the ECM composition of tumours. 
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1.2 Overview of the metastatic process 
Metastasis is the multistep process by which tumour cells confined in their tissue of 
origin spread via the circulatory systems of the body to other organs, successfully 
re-initiating tumour growth. In carcinomas, the metastatic process starts when 
epithelial cells acquire invasive characteristics that allow them to infiltrate the 
surrounding tissues and reach the vasculature (intravasation). Subsequently, 
tumour cells in the circulation will spread throughout the body to the 
microvasculature of distant tissues where they will arrest and exit circulation 
(extravasation). Once in the new tissue parenchyma, most cancer cells will die in 
the new environment. Survivors will either stay dormant or if the appropriate 
conditions are encountered they will colonise the naive tissue re-initiating tumour 
growth (Chaffer and Weinberg, 2011).  
A general characteristic of the metastatic process is that it is extremely inefficient. 
Experimental metastasis studies in melanoma performing intravenous injection of 
tumour cells directly into the circulation have shown that around 20% of the cells 
that enter circulation undergo apoptosis. Upon extravasation into the secondary 
sites only around 2% of the cells originally injected will form micrometastasis. 
Moreover, not all these micrometastasis will progress towards metastatic growth, 
being estimated that only around 0.02% of the cells initially injected will 
successfully metastasise (Luzzi et al., 1998). Therefore, the step of metastatic 
colonisation at the secondary site is usually viewed as a series of difficulties that 
tumour cells need to overcome in order to grow, and represents the most promising 
step to be therapeutically targeted.  
Metastases result from disseminated tumour cells and clinical evidence indicates 
that even when primary tumours are surgically removed with perfect marginal 
precision metastases can occur. Indeed, metastasis accounts for 90% for the 
mortality associated to cancer disease. Despite the unquestionable therapeutic 
relevance of targeting metastatic progression, many aspects of this complex 
multistep process remain insufficiently understood (Chaffer and Weinberg, 2011). 
In the next sections, I will summarise the main knowledge built over the past 
decades for each step of this intricate process and discuss the relevance of 
therapies targeting the different steps of the metastatic cascade to ultimately 
prevent metastatic outgrowth in patients. 
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1.2.1 Leaving the primary tumour: single cell versus collective invasion 
As mentioned above, the metastatic cascade starts with local invasion of tumour 
cells that transform a locally growing tumour into a systemic live-threatening 
disease. Typically, solid epithelial tumours have been observed to invade in two 
major ways, as single cells when cell-cell junctions are absent, or collectively as 
cell clusters joined by the maintenance of cell-cell adhesions (Friedl et al., 2011). 
The commonality underlying both ways of invasion is the joint action of the 
cytoskeleton that serves as the cells’ motor, with cell surface receptors that engage 
the surrounding ECM directing cell movement (Ridley et al., 2003). The activation 
of signalling pathways controlling cancer cell cytoskeletal dynamics and hence cell 
migration is sparked by microenvironmental changes occurring during late-stage 
tumour progression (Friedl and Alexander, 2011). 
 
 
1.2.1.1 Single cell migration – a focus on mesenchymal motility  
Although there are different mechanisms underlying single cell dissemination in 
carcinomas, the acquisition of a mesenchymal phenotype via Epithelial-to-
mesenchymal-transition (EMT) is thought to be the main mechanism facilitating 
single cell invasion. This mesenchymal type of motility is based on integrin-
mediated ECM adhesion and the use of proteases to generate traction force. 
Generally, mesenchymal migrating cells contain focalised proteases in the cell 
surface such as metalloproteases (MMPs) that generate microtracks in the ECM 
serving as roads for cells to migrate (Friedl and Alexander, 2011).  
An alternative single cell invasion mechanism is the amoeboid migration 
characterised for the lack of protease activity and integrin-ECM contacts, 
constituting a mesenchymal independent mechanism by which cells ‘squeeze’ 
through tissues by propulsive cytoplasm forward flow cytoskeletal dynamics (Friedl 
et al., 2012). Indeed, integrin blockage in carcinoma cells induces mesenchymal-to-
amoeboid transition (MAT) as an alternative single cell mediated invasion 
mechanism to EMT (Zaman et al., 2007). Also, in squamous cell carcinoma a 
podoplanin-mediated EMT independent single cell invasion mechanism has been 
described (Wicki et al., 2006).  
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Nonetheless, in most carcinomas single cell invasion results from the loss of 
epithelial characteristics usually driven by the induction of EMT, a developmental 
programme by which static polarised epithelial cells change into an invasive 
migratory phenotype. Upon EMT activation cells adopt an elongated morphology 
with focalised cell-matrix interactions and display enhanced ECM remodelling 
abilities (Figure 1.4.A) (Nieto, 2011, Nieto, 2013). Molecularly, the EMT programme 
is driven by the activation of the transcription factors Snail, Twist and Zeb that 
induce a cellular programme to disable cell-cell junctions through repression of 
proteins such as E-cadherin, ZO-1 and claudins. Alongside, EMT provides cells 
with invasive behaviour through changes in the cytoskeleton structure (expression 
of Vimentin) and ECM remodelling ability (expression of proteases) (Peinado et al., 
2007, Tiwari et al., 2013). Nuclear localisation of the EMT transcription factors 
(EMT-TFs) together with E-cadherin loss, and gain of spindle-shaped morphology 
and Vimentin expression are common EMT hallmarks in embryogenesis and 
cancer (Cano et al., 2000, Vesuna et al., 2008, Nieto, 2013).  
 
 
Inducers of EMT in the tumour microenvironment: focus on TGFβ signalling 
Different stimuli present in the tumour microenvironment can trigger the activation 
of the EMT-TFs in cancer cells (Figure 1.4.B): 1) physical constrains imposed by 
the aberrant ECM are transduced via integrins inducing PI3K-AKT activation 
(Figure 1.4.B - grey arrows), which leads to NFkB and JUN mediated SNAIL 
upregulation (Desprat et al., 2008); 2) inflammatory signals such as CCL2 induces 
NFkB activation and Snail expression (Lopez-Novoa and Nieto, 2009); 3) metabolic 
stress, such as hypoxia induces HIF1 mediated Snail activation (Dong et al., 2013) 
and 4) abnormal activation of several signalling pathways such as WNT or NOTCH 
that can indirectly activate the EMT-TFs (Thiery et al., 2009). Moreover, different 
growth factors such as EGF and FGF represent a major way to activate EMT 
through RAS–RAF–ERK-MAPK signalling cascade in cancer cells (Castellano and 
Downward, 2011, Sakuma et al., 2012). 
The main EMT inducer in the tumour microenvironment is TGFβ (Heldin et al., 
2012). The TGFβ superfamily comprises in humans 30 different ligands being the 
best characterised the TGFβs, activins and NODAL that signal through the ALK4/7 
type-I receptors (TGFβ branch of the pathway) and Bone-Morphogenic-Proteins 
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(BMPs) that signal through the ALK1/2/3/6 type-I receptors (BMP branch) 
(Wakefield and Hill, 2013). The canonical bases of TGFβ signalling are that BMPs 
activate SMAD1, SMAD5 and SMAD8 downstream whereas TGFβ, NODAL and 
activins signal through SMAD2 and SMAD3. Upon reception of TGFβ or BMPs 
signals, the corresponding downstream SMADs proteins are phosphorylated and 
form a complex binding to the common node SMAD4 shared by both branches of 
the pathway. These SMADs complexes translocate to the cell nuclei where they 
regulate gene expression (Wakefield and Hill, 2013). TGFβ stimulation directly 
induces EMT through pSMAD2-3 nuclear translocation, which activates the three 
families of EMT core transcription factors Snail, Twist and Zeb (Figure 1.4.B) (Xu et 
al., 2009). Moreover, TGFβ can also indirectly induce the expression of EMT-TFs in 
cancer cells through the activation of PI3K (Schlegel et al., 2015) and ROCK 
signalling pathways (Morin et al., 2011) (Figure 1.4.B - red arrows).  
Functionally, TGFβ displays a dual role during tumour progression; in the initial 
stages of tumour development TGFβ arrests proliferation and can trigger tumour 
cell apoptosis (Levy and Hill, 2006) whereas in fully developed tumours stromal cell 
derived TGFβ enhances invasion and metastatic activity via activation of EMT 
(Thiery, 2009). Indeed, TGFβ in late-stage breast cancer promotes single cell 
dissemination through the bloodstream (Giampieri et al., 2009) suggesting that 
EMT is required for blood vessel intravasation regardless of the local cell invasion 
modality. Moreover, cells undergoing EMT display attenuated proliferation and 
enhanced resistance to cell death (Figure 1.4.B) (Roussos et al., 2010) properties 
that ensure efficient migration and adaptation to reach secondary sites.  
In contrast to all these pro-invasive abilities triggered by TGFβ, BMP usually 
controls cell proliferation (Massague, 2012) and finely tunes the balance between 
self-renewal and differentiation in normal and cancer stem cells (He et al., 2004, 
Lonardo et al., 2011). Importantly, the two different branches of the pathway TGFβ 
and BMP are known to antagonise each other at the level of the SMADs complexes. 
This fits with the idea of a balance between these two pathways regulating EMT 
modulations and the functionally antagonistic migratory and proliferative states 
observed in tumour cells (Figure 1.4.A). For instance, antagonism BMP signalling 
by TGFβ have been reported to involve the formation of inhibitory complexes 
formed by pSMAD3 and pSMAD1 in response to combined TGFβ and BMP 
signalling (Gronroos et al., 2012). Also, the interplay between BMP and their 
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antagonists can determine the ability of disseminated tumour cells to exit dormancy 
and establish metastases at distant sites (Gao et al., 2012). All these emerging 
inter-regulatory mechanisms between BMP and TGFβ seem to be key during 
metastatic progression, where partial EMT states can be observed and are 
modulated in a context dependent manner. We will further discuss the role of TGFβ 
signalling during metastatic colonisation in section 1.4. 
 
 
EMT in breast cancer: AXL-mesenchymal status  
In breast cancer, phenotypic EMT involves E-cadherin loss (Vesuna et al., 2008) 
accompanied by de novo Vimentin and AXL expression. AXL, one of the main 
proteins analysed in this work, have been widely characterised as an EMT defining 
marker in breast cancer (Figure 1.4.A) (Vuoriluoto et al., 2011, Gjerdrum et al., 
2010, Asiedu et al., 2013). AXL is a tyrosine kinase receptor that was first 
described to be overexpressed in leukemia, where it correlates with worse 
prognosis and overall survival in patients (Rochlitz et al., 1999). In breast cancer, 
AXL is typically overexpressed in luminal ER+ and triple negative breast cancers 
(Meric et al., 2002) where as in leukemia represents a poor prognosis indicator 
(Berclaz et al., 2001). As other tyrosine kinase receptors, AXL can be activated by 
binding to its ligand Gas6, mediating signal transduction processes involved in 
epithelial differentiation, proliferation and survival (Korshunov, 2012). Nevertheless, 
in breast cancer AXL usually acts as a downstream effector of the EMT programme 
(Gjerdrum et al., 2010, Vuoriluoto et al., 2011) and its induction in this context can 
be independent from its tyrosine kinase receptor functions (Paccez et al., 2014). 
For instance, in a xenograft model using the basal breast cancer cell line MDA-MB-
231, AXL mediated a mesenchymal-like phenotype providing increased single cell 
migration and metastatic capacity without affecting cell proliferation or survival in 
vivo (Gjerdrum et al., 2010), two typical downstream functions mediated by AXL as 
a tyrosine kinase upon Gas6 stimulation (Korshunov, 2012). Molecularly, the 
master EMT inducer TGFβ positively regulates AXL expression and in turn this 
TGFβ-AXL axis further maintains EMT through the activation of PI3K signalling 
(Figure 1.4.B - purple arrows) (Li et al., 2014b). Accordingly, AXL positively 
correlates with Snail, Slug and Twist1 expression in breast cancer cells (Gjerdrum 
et al., 2010). Moreover, in line with the inter-dependency of AXL and the EMT 
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phenotype, it has been shown that Vimentin expression functionally links both, 
EMT activation and AXL upregulation in breast cancer cells (Vuoriluoto et al., 2011). 
Furthermore, AXL expression is directly regulated by miR34a (Mudduluru et al., 
2011), a microRNA that also targets Snail expression inhibiting EMT processes 
(Figure 1.4.B – grey box) (Siemens et al., 2011). Of therapeutic interest is the 
development of the small molecule inhibitor R428, also known as BGB324, which 
specifically blocks AXL and the downstream EMT-TFs in a dose-dependent 
manner in triple negative breast cancer. This AXL-EMT-TFs negative feedback 
loop ultimately downregulates the expression of the receptor at the cell surface 
(Holland et al., 2010). R428 is currently in phase-I clinical trials to prevent 
metastatic dissemination and circumvent AXL-mediated chemoresistant 
mechanisms in early stage carcinomas (Sheridan, 2013). 
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Figure 1.4 The EMT programme: phenotypic changes and molecular drivers 
(A) Phenotypic characteristics and molecular changes of epithelial breast cancer 
cells undergoing epithelial-to-mesenchymal transitions. Epithelial cells in tissues 
maintain polarity thanks to the expression of cell-cell adhesion molecules such as 
E-cadherin, ZO-1 and claudins. As tumours develop the microenvironment changes 
and different signals (TGFβ, WNT, EGF) can trigger EMT through the activation of 
the core EMT-TFs (Snail, Twist1 and Zeb1). The expression of EMT-TFs drives the 
loss of epithelial characteristics, and the gain of mesenchymal markers (Vimentin, 
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AXL) and spindle-like morphology. Functionally, EMT induction implies the 
acquisition of ECM remodelling abilities (MMPs and ECM secretion), and changes 
in cytoskeletal regulation that enhances motility ultimately driving single cell 
dissemination. The multicolour scale represents an EMT gradient (green-epithelial 
to red-mesenchymal) where partial EMT states rather than an all-or-none 
regulation of the programme can occur in tumour cells. The mesenchymal/EMT 
features of tumour cells can be reverted also in a context dependent manner (BMP, 
lack of EMT inducers) driving cells re-epithelialisation, which functionally confers 
high proliferation. (B) Signalling pathways directly involved in the regulation of EMT 
(bold), and other related processes such as self-renewal, proliferation and survival 
that are molecularly closely related to EMT. TGFβ is the main upstream regulator of 
the EMT programme, directly regulating it through pSMAD2-3 that activates the 
expression of all core EMT-TFs, but also indirectly TGFβ activates PI3K–AKT, ERK 
MAPK and JUN pathways leading to EMT activation (red arrows). TGFβ in breast 
cancer also regulates the expression of the tyrosine kinase AXL, which is a 
downstream effector of the EMT programme that further maintains it through the 
activation of PI3K-ERK signalling (purple arrows). Different growth factors, such as 
EGF and FGF represent another major pathway to activate EMT through the RAS–
RAF–MEK–ERK MAPK signalling cascade. Other signalling pathways such as 
WNT also participate in EMT; WNT signalling indirectly promotes EMT by inhibiting 
glycogen synthase kinase-3β (GSK3β) to stabilise β-catenin, which translocates to 
the nucleus to engage the transcription factors LEF and TCF promoting a gene 
expression programme that favours EMT. Last, biomechanical stimuli from the 
ECM are transduced via integrin-induced AKT activation regulating SNAIL through 
NFkB and JUN, or alternatively integrin-induced ERK activation (grey arrows). The 
grey box displays the connections between the inhibition of the tumour suppressor 
p53 and the EMT-TFs in cancer cells: Twist1 during tumour initiation represses 
p53, this leads to the repression of miR200 and miR34a, which trigger the 
expression of Zeb1 and Snail respectively exacerbating EMT in tumour cells. 
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EMT beyond single cell invasion: the link between EMT and stemness  
The expression of EMT-TFs in carcinomas is evident and has been widely 
characterised at the invasive front of tumours, in both human samples and mouse 
models (De Craene and Berx, 2013). The link between EMT and the intrinsic 
stemness/tumour initiation abilities in cancer cells is not surprising since several 
common phenomena such as inflammation, physical constrains determined by the 
ECM, hypoxia and abnormal activation of TGFβ, WNT or NOTCH signalling are 
known to activate both (Figure 1.4.B). But the first study linking directly EMT and 
stem-like features related to malignant transformation was published in 2008; Morel 
et al. used human normal breast epithelial cells (HMLE) and exogenously 
expressed the oncogene Ras observing a gain in both, EMT mesenchymal features 
and tumorigenic activity (Morel et al., 2008). Conversely, Mani et al. induced the 
exogenous expression of the EMT transcription factor Twist1 in the same epithelial 
cell line (HMLE), resulting in the generation of cancer-stem like cells exhibiting self-
renewal and tumour-initiating abilities (Mani et al., 2008). These findings imply that 
the EMT programme has additional roles beyond invasion, contributing to cancer 
cells tumorigenic abilities. Indeed, more recently Beck et al. used mouse genetics 
in a skin squamous cell carcinoma model where tumours arise from mutations in 
the Ras oncogene, previously shown to synergise with Twist1 (Morel et al., 2012), 
and revealed that Twist1 is required for skin tumour initiation and posterior tumour 
maintenance in a dosage-dependent manner (Beck et al., 2015). These findings 
corroborate the role of the EMT programme in tumorigenesis beyond tumour cell 
dissemination; and highlight the plasticity of cancer cells to transit between more 
epithelial or mesenchymal states during tumour initiation and progression. 
 
 
Partial EMT states 
Traditionally, the EMT process has been viewed as an all-or-none transition where 
once EMT transcription factors are induced epithelial cells will adopt a full 
mesenchymal state. Nevertheless, in many physiological processes such as wound 
healing where EMT is transiently induced in the damaged epithelium, partial EMT 
states can be observed. In these situations, cells can express EMT transcription 
factors but cell-cell contacts are maintained defining a partial EMT state (Arnoux et 
al., 2008). Additionally, in normal breast epithelial cells the induction of the EMT-TF 
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Twist1 leads to single cell dissemination but E-cadherin expression is maintained at 
the cell membrane (Shamir et al., 2014). This observation supports the existence of 
partial EMT states; in this case, Twist1 induces a more mesenchymal invasive 
phenotype in epithelial cells without the concomitant E-cadherin downregulation 
usually observed upon full EMT induction (Nieto, 2011). Indeed, during tumour 
initiation Twist1 is required in a dosage-dependent manner (Beck et al., 2015) 
suggesting that this EMT-TF can be finely regulated generating a gradient of 
Twist1-driven EMT states. Altogether, these observations indicate that a whole 
range of partial EMT states, rather than full epithelial/mesenchymal conversions 
occur in a context dependent manner.  
 
 
In conclusion, in this section I describe how EMT processes are a favoured 
explanation to how single epithelial tumour cells initiate invade locally to ultimately 
disseminate throughout the body. Additionally, EMT is a complex programme that 
can induce global genomic changes affecting other cellular functions, such as cell 
survival or self-renewal that are key during tumour progression. I will further 
discuss the role of EMT in other steps of the metastatic process rather than 
dissemination in sections 1.2.2 and 1.4. 
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1.2.1.2 Collective cell migration 
Collective invasion is the process by which cohesive groups of tumour cells that 
retain cell-cell junctions migrate into the surrounding stroma. The leading edge of 
the clusters generates the migratory force through ECM-cell contacts and 
cytoskeleton contractility pushing the attached neighbouring cells with them (Friedl 
et al., 2012). Cell-cell connections are mediated by cadherins, tight junction 
proteins and adhesion receptors; altogether they maintain front-rear directionality 
and synchronised cytoskeletal rearrangements (Hegerfeldt et al., 2002, Hidalgo-
Carcedo et al., 2011). In breast cancer, collective cell invasion has been described 
to be led by fibroblasts, intrinsically mesenchymal cells, that generate microtracks 
in the ECM that then collective tumour cell strands follow to invade (Gaggioli et al., 
2007). Alternatively, stromal independent collective invasion mechanisms occur 
and can be explained through cancer cell heterogeneity; a recent study by Cheung 
et al. describes K14+ cells leading collective invasion across the different subtypes 
of breast cancers in human patient samples employing 3D invasion assays, and in 
mouse models in vivo. Interestingly, this K14+ invasive leader cells do not undergo 
a molecular EMT programme. Changes in the ECM composition are suggested to 
contribute to the phenotypic invasive switch of these cells, inducing this K14 basal-
epithelial programme that drives collective breast cancer invasion (Cheung et al., 
2013). Over the last years, collective invasion is attracting increasing attention as a 
dissemination mechanism facilitating metastasis, supported by the clinical evidence 
of high numbers of cell clusters at the tumour-stromal interface in patient samples. 
However, although circulating tumour cell clusters can be isolated from patients 
blood, to date it remains unknown how clusters intravasate into the circulation. 
These findings will be further discussed in the next section (section 1.2.2)  
 
In summary, changes in the cytoskeletal dynamics triggered by specific 
microenvironmental signals control cell behaviour in both migrating single cells or 
invasive leader cells driving collective invasion. In contrast, the two ways of 
invasion are distinctively characterised by the loss (single cell invasion) or 
maintenance (collective invasion) of adherens junctions between cells. 
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1.2.1.3 Single versus collective cell migration: one or multiple routes towards 
metastasis? 
Xenograft models using breast cancer cell lines in mice were initially used to 
establish a causal relationship between EMT and metastatic dissemination. In this 
context, interfering with potent EMT inducers or the EMT-TFs has profound effects 
in dissemination (Heldin et al., 2012). Indeed, the first evidence of single cell 
invasion in tumours came from intravital multiphoton imaging in xenograft breast 
cancer models where single-cell dissemination at the stromal border was visualised 
(Wang et al., 2002). In the spontaneous transgenic MMTV-PyMT model, tumours 
display areas of high TGFβ-dependent pSMAD2-3 activity where local single cell 
migration and intravasation into lymphatic and blood vessels can be observed by 
sophisticated intravital imaging techniques (Forrester et al., 2005, Giampieri et al., 
2009). The presence of this potent EMT inducer and single migrating cells predicts 
an active EMT programme, although a detailed examination of these pSMAD2-3 
positive migrating cells regarding EMT markers has not been made. Importantly, 
overexpression of potent EMT inducers, such as TGFβ in late-stage MMTV-PyMT 
tumours dramatically increases metastatic burden, reinforcing the idea of a causal 
relationship between EMT at the primary tumour and metastatic dissemination 
(Muraoka-Cook et al., 2006). Overall, there is convincing evidence that 
mesenchymal tumour cells can be found in metastatic breast carcinomas, however 
its presence does not allow the conclusion that EMT is a pre-requisite for 
metastasis.  
 
Despite this substantial body of evidence reporting EMT in mouse models as the 
main mean of single cell invasion at the primary site, its relevance is still debated 
due to the lack of available tools to observe this process in human samples (Garber, 
2008, Ledford, 2011). Conventional histological analysis of human carcinoma 
samples does not allow the discrimination between mesenchymal stromal cells and 
epithelial cells that underwent EMT, as epithelial adhesion molecules typically used 
to recognise carcinoma cells (EPCAM, E-cadherin, claudins) are downregulated or 
lost during epithelial-to-mesenchymal transitions (Figure 1.4.A). The absence of 
incontestable EMT evidence in patients, together with the fact that histological 
analyses of tumours reveal the presence of all, single invading cells, compact 
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clusters of disseminated cells and elongated invasive strands of tumour cells still 
connected to the main tumour body (Figure 1.5) (Friedl et al., 2012), question 
whether EMT is the preferred mode of dissemination in human primary tumours.  
 
Relevant to collective invasion is that in human carcinoma histological samples the 
most frequent units found at the invasive front of tumours are cancer epithelial cells 
organised as multicellular units (Friedl et al., 2012). Therefore, it has been 
proposed that collective invasion could be an important alternative mechanism to 
single cell EMT intravasation to metastasise, although to date little is known about 
this process. In a cooperative model, Giampieri et al. using intravital imaging in 
breast cancer mouse models found that cell clusters invade through the lymphatic 
system while single cells can infiltrate both lymphatic and vascular vessels 
(Giampieri et al., 2009). If EMT would be required for vascular intravasation, 
collectively invading cells could intravasate following TGFβ transient pulses 
mediated by the surrounding stromal cells, mainly TAMs (Tumour Associated 
Macrophages) and CAFs (Cancer Associated Fibroblasts) that secrete TGFβ and 
could mediate the switch from cohesive to single cell invasion at the blood vessel 
periphery. Indeed, as we will cover in the next section, there is now ample evidence 
of an active EMT programme in circulating tumour cells isolated from patients’ 
blood (Armstrong et al., 2011). This provides convincing proof of EMT in patients 
after intravasation (section 1.2.2).  
 
To date, the current evidence suggests that EMT certainly constitutes one of the 
preferred invasion modes leading to metastasis, but it is still under discussion 
whether other routes towards metastasis, such as collective invasion are required 
as well. The development of new experimental systems such as primary tumour 
organoids derived from patients’ samples will allow elucidating this question.  
 
Regarding therapeutic approaches targeting cancer cell dissemination, they can be 
useful in patients where surgical removal of primary tumours is not possible in 
order to prevent further tumour cell spreading and delay disease progression. 
However, the real problem is the presence of disseminated tumour cells at 
secondary sites, and therefore current therapeutic efforts are directed to develop 
therapies to prevent metastatic outgrowth from disseminated cells.  
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Figure 1.5 The multistep metastatic cascade 
Metastasis is a complex multistep process by which tumour cells leave the primary 
site and reach distant organs of the body through the circulation. The process is 
usually divided in the following steps: (1) Local invasion: at the tumour-stromal 
border the presence of CAFs and macrophages and their secreted factors assist 
local collective and single cell invasion. (2) Intravasation. (3) Travelling in the blood 
stream CTCs are protected by platelets that secrete high levels of TGFβ enhancing 
survival. Both, single mesenchymal CTCs or clusters of CTCs containing epithelial 
and mesenchymal cells can be observed. (4) Extravasation at distant sites: in the 
foreign tissue only those disseminated cells with an intrinsic potential to 
metastasise will successfully overcome quiescence and induce a niche that will 
support their survival. (5) Early colonisation: a switch from a migratory to a 
proliferative phenotype needs to occur, although the triggers and molecular basis of 
this process are not understood. (6) Late colonisation and metastatic outgrowth: 
tumour cells in a proliferative state actively grow at the newly colonised tissue. 
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1.2.2 Travelling in the bloodstream: EMT in circulating tumour cells 
Once the local invasion steps described above are completed, the first indication of 
dissemination is the presence of tumour cells in the draining lymph nodes that are 
in close proximity to the primary tumour. But the spread through the lymphatic 
system usually remains local, and dissemination to distant sites of the body occurs 
almost entirely through the blood (Hanahan and Weinberg, 2000). Intravasation is 
the process by which cancer cells migrate through the endothelial cells that 
constitute blood vessels reaching the blood stream (Wyckoff et al., 2007). Migrating 
cancer cells transitioning between the primary tumour and the metastatic sites 
isolated from the blood stream are termed Circulating Tumour Cells (CTCs). CTCs 
are widely studied as they have the potential to inform about intra-tumour 
heterogeneity and clonal evolution dynamics throughout the different stages of the 
disease and course of treatments in patients (Krebs et al., 2014).  
 
In line with the different types of invasion observed in primary tumours, both single 
cells (CTCs) and cohesive cell clusters of at least 3 cells (CTC-clusters) have been 
isolated from the circulation (Figure 1.5) (Hou et al., 2012). However, one limitation 
when examining CTC-clusters is that the possibility of cell clumping during blood 
sample processing cannot be entirely excluded (Hou et al., 2012). Importantly 
Aceto et al. transplanting different fluorescently label tumours in a spontaneous 
metastatic mouse model excluded that clusters are formed by cell clumping in the 
circulation in vivo, but rather leave the primary tumour as cohesive multicellular 
units that can metastasise (Aceto et al., 2014). Nevertheless, although CTC-
clusters are rare compare to single cells in circulation, they have been shown to 
possess enhanced survival and thereby metastatic potential contributing to poor 
prognosis in lung and breast cancer patients (Hou et al., 2012, Aceto et al., 2014). 
But as previously indicated, it remains unknown how epithelial cell clusters 
intravasate and extravasate during metastasis. 
 
Regarding the EMT status of cells in the blood stream, traditionally CTCs were 
isolated using biased antigen specific techniques, i.e. EPCAM-based isolations that 
would only isolate tumour cells in an epithelial state. However, in recent years 
technological improvements have allowed the development of non-antigen 
Chapter 1. Introduction 
 
 
52 
dependent techniques (Krebs et al., 2014) that have demonstrated the EMT 
heterogeneity displayed by CTCs in lung, breast, prostate and other cancer types 
(Kalluri and Weinberg, 2009, Kallergi et al., 2011, Armstrong et al., 2011). Indeed, 
heterogeneity in the expression of EMT markers has been observed in single CTCs, 
that can be found in epithelial, mesenchymal or partial EMT states (Armstrong et al., 
2011). CTC-clusters reveal an even more interesting scenario: despite the fact that 
cells adhere together suggesting a complete epithelial phenotype, clusters contain 
cells that display partial EMT phenotypes. Remarkably, Vimentin-expressing cells 
form part of these cohesive cell groups (Hou et al., 2011) arguing against the 
mandatory cell-cell contact loss described when undergoing mesenchymal 
transitions (Nieto, 2011). Additionally, in breast cancer patients Yu et al. reported 
CTCs to be in a mixed epithelial-mesenchymal phenotype. Using in situ 
hybridisation probes for a panel of EMT markers they uncover a gradient of EMT 
states along with TGFβ activation in CTCs (Yu et al., 2013). Moreover, they 
described an association between the expression of mesenchymal markers and 
clusters of circulating tumour cells, which further supports the idea of partial EMT 
states being compatible with cell-cell adhesion maintenance (Yu et al., 2013). Also, 
most CTCs analysed in the bone marrow are in a non-proliferative quiescence 
state as they are travelling (Muller et al., 2005, Pantel et al., 1993), which 
correlates with their TGFβ-driven increased expression in EMT markers (Yu et al., 
2013) and the activation of migratory pathways (Patsialou et al., 2015), illustrating 
the previously mentioned ‘grow or go’ alternative states adopted by cancer cells in 
different moments of the metastatic cascade. Notably, in this study they also 
observed that after chemotherapy more mesenchymal cells were enriched in 
patients (Yu et al., 2013). This highlights the reported correlation between EMT and 
stem-like characteristics such as chemotherapy resistance (Hennessy et al., 2009, 
Asiedu et al., 2013). 
 
In summary, CTCs studies have been crucial to provide evidence of epithelial-to-
mesenchymal transitions, collective cell migration and cells with stem-like 
properties within the circulation (Figure 1.5). As CTCs can be easily acquired 
through non-invasive techniques from patients compared to tumour biopsies, they 
can be used to design personalised therapies throughout the course of disease. 
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Analysing the dynamic biological properties of CTCs and the evolution of their 
mutational landscape post-treatment can help the prevention of relapses. 
 
 
 
1.2.3 Reaching the target site: the bottleneck of metastasis 
As we analyse every step of the metastatic process it becomes clear that 
metastatic success is a function of many variables. As previously discussed 
(section 1.2.1), metastasis is an extremely inefficient process where there is a very 
small probability for cancer cells to succeed. To proceed towards colonisation, 
disseminated cancer cells within the foreign microenvironment of the metastatic 
site will need to evade the immune-surveillance mechanisms in place and avoid 
dormancy in the absence of a supportive microenvironment to grow (Valiente et al., 
2014, Luzzi et al., 1998, Nguyen et al., 2009). Moreover, if these initial difficulties 
are overcome, metastatic cells will still need to switch the migratory phenotype they 
display upon arrival to the secondary site towards a more epithelial phenotype 
compatible with proliferation. All these steps make metastatic colonisation the 
bottleneck of the metastatic process; nevertheless it is the most life-threatening as 
well. Therefore, it is of great interest to understand the mechanisms underlying 
colonisation for each cancer type, trying to find the commonalities among these 
programs to develop effective broad-spectrum anti-metastatic therapies.  
 
CTCs will exit circulation at distant organs, as they are physically restrained in the 
microvasculature. Therefore, in each cancer type the favoured metastatic sites are 
influenced by proximity and circulation patterns (Nguyen et al., 2009). However, 
beyond the passive role of circulation, it is known that different tumour types have 
preferred metastatic sites. As proposed by the ‘seed and soil’ theory (Paget, 1989), 
metastasis depends on the combination of the intrinsic tumour cell features (the 
seed), such as the ability to form invadopodia (Leong et al., 2014), secrete specific 
proteases (Sevenich et al., 2014) or recruit stromal components that will facilitate 
extravasation (Labelle et al., 2011, Reymond et al., 2013), as well as on extrinsic 
aspects such as the vasculature composition and the microenvironmental factors 
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present in a given site (the soil) (Nguyen et al., 2009). In agreement with this theory, 
breast cancer typically metastasises to bones, lungs and brain, and several studies 
have identified in xenograft models the organ-specific traits expressed by breast 
tumour cells to successfully colonise those tissues. Massague’s laboratory created 
a model of tissue-specific experimental metastasis by intracardially injecting MDA-
MB-231 cells into immunocompromised mice, and isolating them afterwards from 
the different metastatic sites. After several rounds of experimental metastasis 
injection and isolation, they generated functionally distinct MDA-MB-231 clones that 
preferably metastasise to the lung, brain or bones. Using the, breast to bone MDA-
MB-231 pre-selected cells, Zhang et al. showed that the expression of a Src-
associated gene set is required for breast to bone metastasis (Zhang et al., 2013). 
In the specific breast to brain metastatic variant, the proteolytic enzyme Cathepsin-
S has been described to be crucial mediating the blood-brain barrier transmigration 
of MDA-MB-231 cells allowing extravasation to the brain (Sevenich et al., 2014). 
These findings highlight the relevance of tumour cell heterogeneity to generate 
cells with different organ-specific metastatic traits (seeds) within the same primary 
tumour, which allows adaptation to the requirements needed to metastasise to 
different organs. 
 
Typically, extravasated tumour cells at metastatic sites exist in two modalities, 
solitary dormant cells or actively growing colonies (Figure 1.5). Cellular dormancy 
describes a state of mitotic arrest in which cells exit cell cycle and enter Go phase 
(Naumov et al., 2002). It is known that disseminated cells can remain latent or 
dormant for years after primary tumour excision in patients, and despite the clinical 
relevance of this fact little is known about how cells enter in this dormant state and 
what triggers the eventual exit (Sosa et al., 2014). What determines the entrance of 
disseminated tumour cells into dormancy upon extravasation is not fully understood, 
but growing evidence shows that the particular microenvironment composition can 
determine the initial tumour cell survival and later outgrowth (Oskarsson et al., 
2014). In a recent study in head and neck squamous cell carcinoma (HNSCC), 
Bragado et al. showed how the local microenvironment (soil) to which tumour cells 
arrive is also a key determinant for metastatic success. They found TGFβ2 as a 
key microenvironmental determinant of cell dormancy in the restrictive environment 
of the bone marrow compared to the permissive metastatic lung soil. Systemic 
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inhibition of TGFβ-RI awakens dormant disseminated cells and fuels multi-organ 
metastasis (Bragado et al., 2013). In a similar study in breast cancer, Gao et al. 
reported that BMP signals in the lung parenchyma maintain breast tumour cell in a 
dormant state upon extravasation. Only certain tumour cells that express the BMP 
antagonist Coco overcome dormancy and successfully grow metastases (Gao et 
al., 2012). Altogether, the above studies support the long suggested seed and soil 
hypothesis (Paget, 1989) as a prerequisite to metastasise.  
 
In conclusion, successful metastatic initiation depends on both, the intrinsic cancer 
cell abilities to extravasate and adapt to the foreign microenvironment at distant 
sites, and the organ-specific microenvironmental factors that will help or hinder 
each of these steps (Figure 1.5). In line with the critical role of the 
microenvironment, it is known that in order to successfully metastasise, 
disseminated tumour cells need to ‘educate’ the microenvironment they arrive to 
creating a favourable surrounding to grow (Malanchi et al., 2012, Irmisch and 
Huelsken, 2013). These concept of an active ‘education’ of the microenvironment 
by metastatic cells leads to the idea of Metastasis-initiating Cells (MICs), a distinct 
population of tumour cells that possess unique characteristics to initiate metastasis 
actively inducing a supportive microenvironment or ‘metastatic niche’ upon 
extravasation. Due to the relevance of these ideas for the work presented in this 
thesis, I will further develop them in the next section (section 1.3). 
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1.3 Metastatic colonisation: MICs and metastatic niches 
As described in the previous section, the metastatic process consists of a series of 
sequential complex challenges that tumour cells need to overcome to successfully 
grow at distant sites. In this section, we will summarise the recent discoveries 
indicating that only certain populations within tumours possess the intrinsic abilities 
required to achieve metastatic outgrowth at distant sites, the so-called metastasis-
initiating cells (MICs). As illustrated throughout this introductory chapter, tumour 
progression certainly depends on a favourable microenvironment (section 1.1.2). 
This dependency becomes even more critical during metastasis when 
disseminated cells arrive into a naive tissue and need to re-initiate a supportive 
stroma, the metastatic niche, which will trigger and sustain tumour cell growth. 
Following on the founding ideas of the ‘seed and soil’ theory that illustrate the 
dependency of the metastatic cells (seeds) on the microenvironment (soil) (section 
1.2.3), the MIC concept implies an active role of this distinct population of cells to 
promote a favourable microenvironment (or niche) to grow (Malanchi, 2013). 
Although several metastatic populations might coexist during dissemination 
exhibiting site-specific extravasation and seeding capabilities, ultimately their 
metastatic outgrowth will depend on their capacity to directly or indirectly generate 
a metastatic niche. In light of these notions, the next sections aim to revise the 
essential role of the tumour-driven stromal crosstalks required upon arrival to 
distant tissues to trigger a metastatic niche that will further support tumour growth. 
 
 
1.3.1 Metastasis-initiating cells (MICs) 
As previously described (section 1.1.1.3), tumours are organised hierarchically as 
their tissue of origin, where a small subpool of cells with self-renewal capacity, 
termed cancer stem cells (CSCs), is responsible for the initiation and maintenance 
of the tumour mass (Malanchi et al., 2008, Singh et al., 2004, O'Brien et al., 2007, 
Wang et al., 2009). However, it remains to be determined if metastases display a 
similar hierarchy to the one observed in primary tumours.  
Several studies have shown that there are specific populations within tumours that 
display high metastasis-initiating ability compare to the bulk of tumour cells, and 
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they are accordingly termed metastasis-initiating cells (MICs) (Hermann et al., 2007, 
Pang et al., 2010, Malanchi et al., 2012). This functional definition refers to those 
disseminated tumour cells that are capable of re-initiating macroscopic tumour 
growth at secondary sites (Oskarsson et al., 2014). Importantly, evidence from the 
clinic indicates that high expression of adult stem cell markers in primary tumours 
correlate with poor survival and relapse in patients (Dalerba et al., 2011, Pece et al., 
2010).  
Studies in animal models have allowed the identification of cell populations that 
drive metastatic colonisation. In the breast cancer metastatic mouse model MMTV-
PyMT, Malanchi et al. described a population of MICs within the primary tumours 
defined by the co-expression of CD24 and CD90. CD24 was previously 
characterised as an epithelial marker in the mammary gland tissue, where lineage 
negative, CD24- cells where functionally characterised as non-epithelial (pan-
cytokeratin negative cells), CD24low contains the myoepithelial mammary gland 
cells (co-expressing cytokeratin-5) and CD24high contains the luminal epithelial cells 
(co-expressing cytokeatin-8) (Sleeman et al., 2006). The marker CD90, also known 
as Thy-1, is typically expressed in the immune cell compartment of the tumour 
(CD45+), mainly in T cells (Haeryfar and Hoskin, 2004). Also some adipocytic and 
fibroblastic-like populations of mesenchymal origin can express CD90 in the 
mammary gland, but they do not display the epithelial CD24 marker (Paunescu et 
al., 2011). In the mammary epithelium, CD90 is expressed in bipotent normal 
mammary epithelial progenitor cells in human (Raouf et al., 2008), and by a small 
subpool, 1-4% of the CD24+ mammary epithelial cells in the MMTV-Wnt1 mouse 
model of breast cancer (Cho et al., 2008). Interestingly, this rare CD24+CD90+ 
population displayed high tumour-initiating abilities when isolated from MMTV-Wnt1 
tumours and tested in serial dilution transplantation assays (Cho et al., 2008). 
Moreover, in primary human breast carcinomas CD90 has been recently shown to 
be expressed in a small subpool of epithelial cells with increased tumour-initiating 
abilities, where CD90 functionally mediates an interaction with TAMs (tumour-
associated macrophages) that facilitate the dissemination of this CD90+ tumour 
cells (Lu et al., 2014). Malanchi et al. functionally defined this lineage negative 
(CD45-, Ter119- and CD31-), CD24+CD90+ subpool in the MMTV-PyMT tumours by 
their exclusive ability to initiate metastatic growth in experimental metastasis 
assays: CD24+CD90+ and CD24+CD90- tumour cells were freshly isolated from 
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primary late-stage PyMT carcinomas by cell sorting, and injected intravenously 
directly into the circulation of immune-deficient mice. In this setting, only the 
CD24+CD90+ population was capable of efficiently metastasising, defining a MIC 
population responsible for metastatic colonisation in this model (Malanchi et al., 
2012). Further characterisation of this rare CD24+CD90+ population with exclusive 
metastatic ability in the MMTV-PyMT model, in order to find novel mechanisms that 
allow breast to lung metastatic colonisation, is the starting point of thesis.  
Additionally, Baccelli et al. detected MICs expressing stem cell markers in breast 
cancer patient blood that when isolated and inoculated into immune-deficient 
recipient mice generated bone, liver and lung metastasis. The same study showed 
that high numbers of this MIC population (EPCAM+CD44+CD47+MET+) in the blood 
of patients correlates with lower survival and increased number of metastatic sites 
(Baccelli et al., 2013), underlining the importance of characterising the mechanisms 
by which these cells mediate metastatic colonisation. 
 
One central issue that remains elusive is whether MICs originate from tumour-
initiating cells (TICs) that acquire new priming mutations to metastasise, 
maintaining the intrinsic stemness capacity. In TICs it has been shown that 
mutations impacting on proliferation, self-renewal and survival pathways drive 
tumour initiation (Vogelstein et al., 2013), so the expectation would be that further 
clonal evolution would generate new subclones that acquire pro-metastatic 
mutations. However, genome sequencing analysis of metastases and matched 
tumours in pancreatic cancer patients have revealed little evidence for metastasis-
specific driver mutations other than the mutations found in classic oncogenes that 
are already present at the primary site (Yachida et al., 2010). Therefore metastases 
are unlikely to be the direct consequence of the acquisition of pro-metastatic 
mutations, but rather the consequence of epigenetic programmes that modulate the 
activation of invasive and survival programs, such as EMT (section 1.1.1.3) (Scheel 
and Weinberg, 2011, Quail et al., 2012). In line with this idea, MICs are likely to 
arise from TICs clones that acquire metastatic capacities through epigenetic 
modulations that transitorily activate invasion and survival programmes that allow 
them to disseminate, survive in the circulation and extravasate at distant metastatic 
sites.  
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1.3.2 Emerging metastatic niches 
1.3.2.1 The concept of niche  
In developmental biology, niches are functionally distinct microenvironments 
formed by specialised cells and ECM components that regulate normal stem cell 
function, controlling the required equilibrium between quiescence, and symmetric 
and asymmetric division to maintain tissue homeostasis (Sneddon and Werb, 
2007). In some organs, such as brain or skin, the availability of bona-fide stem cell 
markers combined with lineage tracing techniques have allowed the visualisation of 
the normal stem cell niche, and its evolution during tumour initiation processes 
(Beck et al., 2011, Calabrese et al., 2007). However, the concept of niche in cancer 
to define a specific location where CSCs reside as in normal stem cell biology 
cannot be applied due to the disorganised nature of tumours. Therefore, in cancer 
the term niche is generally used to describe the compendium of 
microenvironmental cues that are essentially required by CSCs to initiate and 
maintain tumour growth. 
 
In line with this definition of niche in the tumour context, increasing similitudes 
between normal and tumour stem cells microenvironments continue to be 
described. For instance, many factors produced by fibroblasts that comprise the 
normal stem cell niche, as such BMP antagonists that limit differentiation are also 
found in the tumour cell niche (Sneddon et al., 2006). In normal skin, hair follicle 
stem cell (HFSC) niche soluble factors need to be critically regulated to maintain 
the balance between quiescence and proliferative states such as BMPs and TGFβ2 
respectively; the same factors are found to be deregulated in squamous skin 
carcinoma (SSC) mediating the aberrant proliferation of CSCs (Oshimori et al., 
2015). Likewise, there are many ECM factors that are known components of the 
adult stem cell niche and can be found in the tumour microenvironment as well 
(Wong and Rustgi, 2013). The glycoprotein Tenascin-C (TNC) modulates EGF 
signalling in adult brain stem cells through limiting the availability of soluble FGF2 
and BMP4 signals in the stem cell niche. This EGF regulation is crucial to ensure 
adult stem cell function and tissue homeostasis in the brain (Garcion et al., 2004). 
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Equally, TNC have been found to be a critical autocrine regulator of CSCs in 
glioma (Nie et al., 2015). Therefore, as their normal counterparts, cancer stem cells 
are thought to reside in niches within the tumour microenvironment that stimulate 
their self-renewal ability, induce angiogenesis and contribute to the recruitment of 
other stromal cells to the initiation site (Plaks et al., 2015). 
 
 
1.3.2.2 The metastatic niche  
We have analysed how after extravasation disseminated tumour cells first need to 
overcome dormancy and survive in the foreign tissue (section 1.2.3). Sub-
sequentially those tumour cells with the intrinsic abilities required to colonise the 
new site (MICs), will trigger a crosstalk of signals with the naïve tissue 
microenvironment inducing a metastatic niche that will ultimately enable successful 
metastatic growth. In contrast to the situation in primary tumours during metastatic 
colonisation single disseminated MICs can be visualised at the metastatic tissue, 
and therefore in this setting the niche induction and its evolution can be monitored.  
 
The first support from the microenvironment after extravasation at the target tissue 
comes from different stromal cells that promote tumour cell survival. In breast 
cancer metastasis to the lungs, survival at the target site has been shown to 
depend on a paracrine interaction with resident lung macrophages that are 
stimulated by tumour-derived colony-stimulating factor-1 (CSF1). In turn, 
macrophages produce epidermal growth factor (EGF) that promotes tumour cell 
survival through AKT signalling activation (Patsialou et al., 2009). Similarly, 
endothelial cells offer a perivascular niche to breast cancer cells upon 
extravasation to the brain promoting survival. Valiente et al. have visualised how 
single tumour cells expressing serpins tightly adhere to the blood vessel wall upon 
extravasation to the brain. In this perivascular niche, endothelial cells provide the 
oxygen and nutrient support that determines tumour cell survival in this new 
environment (Valiente et al., 2014).  
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Next, the surrounding microenvironment will determine whether tumour cells 
undergo dormancy or start proliferating. In breast cancer metastasis to the lungs, 
the perivascular niche has been shown to regulate tumour cell dormancy after 
extravasation in a dynamic fashion. Ghajar et al. have shown how immediately 
after extravasation, the endothelial cells from the naïve lung vasculature secrete 
Thrombospondin-1 (THBS1) promoting breast cancer cells quiescence. However, 
in those vessels where tumour cells trigger angiogenic pathways, vessel sprouting 
is accompanied by TGFβ and periostin secretion, leading to micrometastatic growth 
(Ghajar et al., 2013).  
 
Those cells that survive and are equipped with the intrinsic machinery required to 
overcome pro-dormancy signals and induce a favourable microenvironment, will 
succeed and metastasise. Several studies have described how disseminated 
metastatic cells or their recruited stroma induce ECM changes that are crucial to 
sustain cancer cells self-renewal capacity and re-initiate tumour growth. In mouse 
models of breast cancer metastasis to the lungs, Malanchi et al. described the 
crucial role of Periostin (POSTN) in regulating the self-renewal and differentiation of 
MICs driving metastasis. POSTN is an ECM proteoglycan secreted by fibroblastic 
stroma that serves as a trap for Wnt ligands, amplifying the limited stromal derived 
Wnt and creating a Wnt rich niche around disseminated MICs that supports self-
renewal maintenance. Importantly, a POSTN free microenvironment (POSTN 
knockout mice) impaired wild-type MICs ability to colonise the lungs, highlighting 
the crucial role of this niche ECM protein for metastatic outgrowth (Malanchi et al., 
2012). A similar ECM mediated mechanism was described by Oskarsson et al. 
where Tenascin-C (TNC) secreted by both, cancer cells and fibroblast, creates a 
niche were Notch signalling is amplified activating tumour cell self-renewal in breast 
to lung metastatic colonisation (Oskarsson et al., 2011). These studies highlight the 
decisive role of the ECM in regulating the availability of key soluble signals that 
maintain self-renewal capacity at the metastatic site, allowing colonisation. 
 
In conclusion, the microenvironmental factors present in the naïve tissue 
microenvironment upon extravasation and the intrinsic abilities of cancer cells to 
create a supportive niche determine successful metastatic colonisation. The role of 
the metastatic niche and its relationship with the fact that only some cancer cells 
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(MICs) can successfully metastasise, is currently under systematic investigation to 
elucidate key unanswered questions:  
 
• Do MICs have an enhanced ability to recruit and induce a favourable 
metastatic niche that will support their growth compared to the non-
metastatic cancer cells of the tumour? 
 
• In that case, what are the molecular programmes underlying the crosstalk 
initiated by MICs to educate the stroma? 
 
• Does the ability to induce a niche upon arrival to the target site determine 
the entrance in dormancy or the switch to proliferation? 
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1.4 MICs plasticity: focus on EMT modulation during the 
metastatic cascade 
Since colonisation abilities are required as soon as cancer cells reach the 
metastatic site (section 1.2.3) it is likely that pro-metastatic programmes are 
already induced at the primary site. Indeed, we have discussed earlier how the 
unique stromal composition at the invasive tumour front, rich in ECM and signals 
such as TGFβ, Wnt, Notch and pro-inflammatory cytokines, triggers cell 
dissemination though the activation of different downstream pathways (section 
1.2.1.1) (Figure 1.5). Interestingly, EMT is one of the induced programmes at the 
primary tumour border that mediates invasion but also confers disseminating 
tumour cells with additional roles. For instance, TGFβ-mediated EMT induction is 
active in CTCs as they navigate in the vascular system and enhances their survival 
(Figure 1.6.B) (section 1.2.2). Moreover, induction of the EMT transcription factors 
induces epigenetic plasticity in tumour cells boosting stem-like features and 
tumour-initiating properties (section 1.2.1.1) (Chaffer et al., 2013). In general, 
activation of the EMT programme can induce phenotypic, metabolic and functional 
cell plasticity in MICs through epigenetic changes (Tam and Weinberg, 2013). 
Therefore, it is reasonable to hypothesise this EMT-driven plasticity increases cell 
adaptability to the microenvironmental changes encountered throughout the 
complex multistep metastatic process.  
 
As stated above, many cells leave the primary tumours displaying EMT features 
(section 1.2.1.1) that are maintained within the circulation (section 1.2.2). Therefore, 
the establishment of a direct link between EMT and tumour-initiating abilities would 
imply that disseminated EMT cells with higher stemness abilities had an increased 
metastatic potential. However, carcinoma metastases typically display epithelial 
differentiated features questioning the role of the EMT status of cancer cells in 
metastatic progression (Brabletz, 2012b). This dichotomy can be explained by the 
re-acquisition of epithelial traits during the metastatic colonisation step: EMT is 
induced at the primary site for tumour cells to disseminate, and once at the target 
site the reverse process MET (mesenchymal-to-epithelial transition) will induce a 
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cell status more compatible with proliferation (Figure 1.6.B). MET is a process that 
typically occurs during embryogenesis to reverse EMT allowing re-epithelialization 
after cell migration, and differentiation into multiple cell types in the embryo (Nieto, 
2013). Although many of the molecular bases of EMT have been elucidated (Thiery 
et al., 2009), the signals involved in the induction of MET have not been well 
characterised. The most studied MET process in embryogenesis is the 
epithelialisation of the paraxial and intermediate mesoderm to form somites and 
precursors of the renal system, respectively. During this process, an increasing 
gradient of BMPs, the most prominent epithelialising agents, counteracts TGFβ 
signalling (Nieto, 2013). Several processes have been described where BMP7 
antagonises TGFβ inducing re-epithelialisation, such as kidney development 
(Dudley et al., 1995), reprogramming of fibroblasts (Samavarchi-Tehrani et al., 
2010) and in prostate cancer cells (Buijs et al., 2007). Although the molecular 
drivers of MET remain to be determined, what it is generally required for re-
epithelialisation is the downregulation of the corresponding EMT-TFs (Nieto, 2011). 
Therefore, to date MET might be more precisely referred as an EMT inhibition or 
reversion.  
 
In metastasis two key studies support the idea that EMT is reverted at the target 
site. Tsai et al. using an inducible Twist1 system in a spontaneous model of 
squamous cell carcinoma showed that exogenous Twist1 expression boosted cell 
dissemination as expected, but did not allow efficient metastatic colonisation; when 
after tumour cell dissemination Twist1 expression was turned off metastatic 
colonisation occurred, demonstrating in vivo the requirement of an EMT reversion 
at the target site (Tsai et al., 2012). In the second study, Ocaña et al. used the 
highly mesenchymal breast cancer cell line BT549 that expresses the potent EMT 
inducer Prrx1. When injected in a mouse model of experimental metastasis via tail 
vein injection, BT549 cells reached the metastatic site but did not grow. Inhibiting 
Prrx1 in BT549 cells was sufficient for metastatic colonisation to happen (Ocana et 
al., 2012). Both studies showed the requirement of an EMT reversion process to 
achieve metastatic colonisation.  
 
Interestingly, the later study by Ocana et al. revealed that the potent EMT induction 
mediated by Prrx1 inversely correlated with stemness, questioning the previous 
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described direct link between EMT and stemness (Mani et al., 2008). These 
conflicting results can be harmonised by the idea of a gradient EMT model where 
existing partial EMT states are compatible with stemness (Ombrato and Malanchi, 
2014). The EMT gradient model proposes that EMT modulations in tumour-
initiating cells would be controlled in a dosage dependent manner to be compatible 
with stem-like features throughout tumorigenic evolution (Figure 1.6.A). As 
previously described (section 1.2.1.1), at the molecular level the EMT programme 
is induced by the expression of some of the core EMT-TFs (Twist1/2, Snail1, Slug 
and Zeb1/2). Functionally, the EMT-TFs trigger increased motility and invasion 
along with stemness abilities in epithelial cells that undergo EMT for the first time 
(Figure 1.6.A). According to this EMT gradient model, a further activation of the 
EMT programme in partially mesenchymal cells that already express Snail, Zeb or 
Twist would exacerbate their mesenchymal features and push these tumour cells 
outside the ‘stemness window’ (Figure 1.6.A - late EMT programme). This 
hypothesis can explain the controversial results described by Ocana et al. in 
relationship to an inverse correlation between EMT and stemness in breast cancer 
cells: the expression of the potent EMT inducer Prrx1 exacerbates the 
mesenchymal features of cancer cells driving them outside the ‘stemness window’ 
limits, therefore Prrx1 does not provide a gain, but a loss in stemness and cell 
plasticity (Figure 1.6.A) (Ocana et al., 2012).  
Therefore, according to this EMT gradient model (Ombrato and Malanchi, 2014) 
the same tumour-initiating cells (TICs) defined depending on their stemness 
potential would transit from intermediate epithelial to mesenchymal states 
preserving stemness within some limits in response to the different 
microenvironmental cues (Figure 1.6.A). Consequently, TICs preserving stem-like 
features could be found in a motile mesenchymal state or in a stationary 
proliferative phenotype at the primary site depending on their location.  
 
About the cellular effectors driving EMT reversion, as discussed above it has been 
shown that Twist1 needs to be down-regulated (Tsai et al., 2012) to allow 
metastatic colonisation. Moreover, supporting the role of inhibitor of differentiation 
(ID) proteins as master regulators of stemness in normal tissue stem cells and 
brain CSCs (Niola et al., 2012, Niola et al., 2013), it has been described that ID1 
expression is required for efficient lung metastatic colonisation of breast cancer 
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cells (Gupta et al., 2007). Indeed, a recent study suggested that ID1 expression 
opposes to Twist1 in mesenchymal breast cancer cell lines in vitro, but the 
molecular mechanism underlying this potential ID1-mediated Twist1 
downregulation remains unclear (Stankic et al., 2013). Other potential EMT 
inhibitors that could antagonise the EMT-TFs are the microRNAs miR200 
(Dykxhoorn et al., 2009) and miR34a (Siemens et al., 2011) that antagonise Zeb2 
and Snail respectively (Figure 1.6.A and 1.4.B – grey box). In line with the EMT 
gradient model, the activation of negative EMT regulators, such as ID1, miR200 
and miR34a could potentially drive a mesenchymal reversion or MET that would 
switch MICs back to a more epithelial state compatible with proliferation, but 
different to the original epithelial state before the cells underwent EMT, now inside 
the ‘stemness window’ (Figure 1.6.A).  
 
During the metastatic cascade, EMT is triggered at the invasive front of tumours 
where the stroma provides high levels of the EMT inducer TGFβ (Figure 1.6.B, 
Primary site) (section 1.2.1.1). In line with the hypothetical EMT gradient model, 
MICs undergo EMT acquiring partially mesenchymal features and an enhanced 
stemness state (i.e. poised chromatin status as defined in section 1.1.1.3). This is 
in agreement with the observation that mesenchymal CSCs are subsequently 
found in the blood stream (Yu et al., 2013), where EMT is further sustained by 
platelet-derived TGFβ (Figure 1.6.B, Circulation) (Labelle et al., 2011). In line with 
the reported EMT downregulation required for metastatic colonisation, extravasated 
CTCs need to leave the transient migratory/quiescence state they exhibit in the 
circulation and re-acquire a proliferative status compatible with metastatic 
outgrowth (Gupta et al., 2007). This illustrates the previously proposed ‘go or grow’ 
dichotomy (section 1.2.2) observed at the primary site, where an autocrine CSF1R 
signalling downstream of TGFβ is essential for inhibiting cell proliferation, while it 
activates single cell invasion in a human xenograft breast cancer model (Patsialou 
et al., 2015). This TGFβ-dependent mechanism exemplifies the migratory and 
proliferative cellular states as antagonistic, and linked to a more mesenchymal and 
a more epithelial phenotype respectively (Figure 1.4.A) (Patsialou et al., 2015).  
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Figure 1.6 The EMT gradient model and its implications in the metastatic 
cascade 
(A) EMT gradient model (adapted from Ombrato and Malanchi, 2014). Metastasis-
initiating cells (MICs) transit between partial more epithelial or more mesenchymal 
states within a ‘stemness window’ where cells maintain epithelial plasticity 
preserving stem-like features. The different phenotypes adopted by the stem cells 
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within this ‘stemness window’ are regulated by the microenvironment. EMT 
gradient model explanation: (1) epithelial cells undergo EMT in a biphasic fashion. 
A first induction of the EMT programme (driven by Snail, Twist and Zeb) confers 
partial mesenchymal features compatible with stem-like characteristics. If a further 
exacerbation of this EMT phenotype (driven by potent EMT activators, such as 
Prrx1) occurs, cells would acquire a fully mesenchymal state incompatible with 
epithelial plasticity and would imply the loss of stem-like characteristics. (2) The 
reverse process, an EMT inhibition or MET, allows cancer stem cells in a 
mesenchymal motile state to re-gain a more epithelial phenotype compatible with 
proliferation (driven by miR200, miR34a and ID1), and the stem cell properties of 
self-renewal and differentiation. (B) EMT modulations during metastasis. (1) Local 
invasion: MICs and nonMICs disseminate from primary tumours as single partially 
mesenchymal cells (nonMICs-red, MICs-orange), or collectively as epithelial 
clusters (nonMICs-green, MICS-yellow). (2) Intravasation. (3) Travelling in the 
blood stream CTCs are protected by platelets that secrete high levels of TGFβ 
enhancing their survival and EMT features. Both, single epithelial and 
mesenchymal CTCs or CTC-clusters containing epithelial and mesenchymal cells 
can be observed in blood patient samples. (4) Extravasation at distant sites: in the 
foreign tissue only those cells with an intrinsic potential to metastasise will 
successfully overcome quiescence and induce a niche that will support their 
survival. (5) Early colonisation: the switch from a migratory (EMT) to a more 
epithelial proliferative phenotype (through MET or a mesenchymal inhibition) needs 
to occur for the cells to actively divide, although the triggers and molecular basis of 
this process are not understood. (6) Late colonisation: tumour cells in a more 
epithelial proliferative state actively grow at the newly colonised tissue, forming 
epithelial macro-metastases. 
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In light of these results, the current working model during metastasis is that once at 
the secondary site metastatic cells displaying mesenchymal features need to 
switch back to a more epithelial phenotype compatible with proliferation (Figure 
1.6.B – 6 Secondary site). In agreement with the EMT gradient model (Figure 
1.6.A), the same MICs defined depending on their stemness potential would transit 
from intermediate mesenchymal to a more epithelial state inside the ‘stemness 
window’ in response to the different microenvironmental cues received throughout 
the metastatic process (Figure 1.6.B). Accordingly, MICs could be found in a motile 
mesenchymal state or in a stationary proliferative phenotype (Figure 1.6.A) 
(Ombrato and Malanchi, 2014). 
 
Molecularly, little is known about the microenvironmental factors triggering EMT 
reversion, as well as the downstream effectors that mediate the change towards a 
more epithelial phenotype. As analysed throughout this introduction, the dynamic 
bidirectional communications between tumour cells and the microenvironment 
determine overall disease progression (section 1.1.2). Particularly, metastatic 
colonisation depends on the microenvironmental cues as much as on the cell 
intrinsic properties (section 1.3). Accordingly, it is sensible to hypothesise that the 
lack of microenvironmental pro-EMT signals, such as TGFβ, or the presence of 
epithelializing factors, such as BMPs, at the metastatic niche could modulate the 
EMT phenotype of disseminated metastatic cells, but to date the triggers of this 
process remain unknown. 
 
 
Despite the therapeutic relevance of targeting MICs and preventing their outgrowth 
at secondary sites, there are still many open questions regarding the molecular 
determinants of epithelial plasticity during the metastatic process:  
 
• How is mesenchymal inhibition molecularly modulated in MICs? Is it an 
attenuation of the mesenchymal features via the downregulation of the 
EMT-TFs, or a complete re-epithelialisation (MET) as observed during 
physiological processes?  
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• Are EMT modulations intrinsically controlled by MICs or do they depend on 
microenvironmental cues? And in the assumption of the later, what 
microenvironmental signals trigger epithelial re-acquisition at the metastatic 
site allowing colonisation? 
 
• Can the metastatic niche extrinsically modulate the epithelial plasticity 
(EMT-MET transitions) of MICs, guaranteeing the maintenance of 
stemness? 
 
• Does the mesenchymal reversion need to occur in a temporally controlled 
manner during metastatic colonisation as suggested by the need of Twist1 
loss at the target site (Tsai et al., 2012)?  
 
Shedding some light into these complex questions has been one of the main 
focuses of this thesis. 
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1.5 Mouse models to study the metastatic process  
As a complex multistep systemic process, understanding the means by which 
tumour cells metastasise requires the development of mouse models that closely 
resemble the evolution of the human disease.  
Xenograft models, where human cell lines are grafted into immune-compromised 
mice have been widely used but in the absence of a fully competent immune 
system they tend to grow rapidly not mimicking the slow doubling time of most 
human cancers. Additionally, tumours develop lacking essential microenvironment 
components (immune cells) and in the absence of histocompatible human epitopes 
in the mouse stroma, which might limit tumour-stromal interactions. Altogether, 
these facts emphasise the limited value of xenograft models when trying to 
understand disease evolution in the context of the essential microenvironmental 
crosstalks that define it (Francia et al., 2011). 
The alternative in order to overcome these limitations is the development of 
genetically engineered mouse models (GEMMs) that allow the generation of 
orthotopic tumours in immune competent hosts, containing the stroma and 
vasculature of the same specie. These models are specifically created by 
overexpression of oncogenes or deletion of tumour-suppressor genes relevant in a 
particular cancer type (Ottewell et al., 2006).  
In this thesis, we focus on the study of the previously described metastasis-
initiating cell (MIC) population in the metastatic breast cancer mouse model MMTV-
PyMT (section 1.3.1) (Malanchi et al., 2012). Therefore, in this section we will 
describe the advantages and limitations of this model regarding its resemblance to 
the human disease, and its use to study the mechanisms underlying breast cancer 
metastatic colonisation. 
 
1.5.1 Mouse models of breast cancer metastasis 
Genetic mouse model are specifically created by activation of oncogenes or 
deletion of tumour-suppressor genes relevant to the human tumorigenic processes 
in a particular cancer type (Ottewell et al., 2006). In breast cancers, it is now 
appreciated that a small number of genes (i.e. PTEN, TP53 and PI3K) are 
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recurrently mutated across the different subtypes of breast cancer being the main 
genetic drivers of the disease (Cancer Genome Atlas, 2012).  
Importantly, breast cancers are typically classified in three different molecular 
subtypes according to the cellular expression of the hormone receptors binding 
estrogen (ER) and progesterone (PR), and the oncogene HER2 in: luminal A (ER+, 
PR+, low HER2 expression), luminal B (ER+/-, PR+/-, high HER2 expression) and 
basal (ER-, PR-, low HER2 expression) (Schnitt, 2010). A recent comprehensive 
molecular portrait of human primary breast cancers elaborated employing Whole 
Genome Sequencing (WGS) revealed numerous subtype-associated driver 
mutations that are summarised below (Table 1.1) (Cancer Genome Atlas, 2012). 
Notably, the tumour suppressor TP53 is mutated at double frequencies in the 
luminal B subtype compared to A, and basal-like tumours show a high frequency 
(80%) of TP53 mutations. This TP53 mutational pattern in breast cancer correlates 
with tumour grade and patient prognosis (Cancer Genome Atlas, 2012). 
 
 
Table 1.1 Main genomic features of breast cancer 
 
  
Subtype Luminal A Luminal B Basal-like 
ER+/HER2- (%) 87 82 10 
HER2+ (%) 7 15 2 
TNBCs (%) 2 1 80 
TP53 pathway TP53 mut (12%) TP53 mut (32%) TP53 mut (84%) 
PI3K/PTEN 
pathway 
PI3K mut (49%); 
PTEN mut (13%) 
PI3K mut (32%); 
PTEN mut (24%) 
PI3K mut (7%); 
PTEN mut (35%) 
Additional DNA 
mutations  
GATA3 (14%); 
MAP3K1 (14%) MAP3K1 (5%)   
DNA 
methylation   Hypermethylated  Hypomethylated 
 
 
Many mouse breast cancer models have been created based on genetic alterations 
that typically occur in human breast carcinomas to mimic the morphological and 
mechanistic evolution of the disease. However, most failed to metastasise, as 
exemplified by the mouse model carrying inactivated BRCA1 and BRCA2 genes in 
the mammary epithelium, the most common mutations found in women with 
inherited breast cancers (Lin et al., 2003). Therefore murine models that efficiently 
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develop metastases have been created by the overexpression of the oncogenes 
Her2, Neu and the polyoma middle T antigen (PyMT) under the control of the 
mouse mammary tumour virus LTR (MMTV LTR) – MMTV-Her2, MMTV-Neu and 
MMTV-PyMT – achieving a potent expression of these oncogenes specifically in 
the mammary epithelium that leads to high metastatic burden to the lungs and 
other organs (Herzig and Christofori, 2002).  
 
The PyMT is a membrane-attached protein that, although is not expressed by 
human cells, acts as a potent oncogene because its product binds several 
transduction pathways, including Src kinases and the RAS and PI3K pathways 
(section 1.1.1.1) (Figure 1.4.A), which are all altered in the most common subtype 
of human breast cancers, the luminal B (Dankort, 2000) (Cancer Genome Atlas, 
2012). Lin et al. published a meticulous study analysing disease progression in this 
model, and comparing it histologically and molecularly to the evolution of human 
breast cancers. They found that in the MMTV-PyMT model disease progression 
occurs over a multistage process where early mammary gland hyperplasias appear 
first, and then evolve to adenoma, and early and late carcinoma possibly through 
the microenvironmental changes and new mutations acquired during the different 
stages. As in human breast cancers, each of these four stages is accompanied by 
distinct cell morphological and molecular changes as summarised in Figure 1.7. 
The loss of estrogen receptor (ER) and progesterone receptor (PR) in late stage 
carcinomas resembles the human disease progression. Moreover, the infiltration of 
leukocytes during the adenoma stage correlates with the shift in proliferation and 
the loss of basement membrane integrity, which stresses the role of the 
microenvironment in the disease progression towards the metastatic phase in this 
model, as observed in humans (Lin et al., 2003). 
Sequencing analysis has allowed further in-depth comparisons between this model 
and the different subtypes of human breast cancers. Consistent with the data 
published by Lin et al., a comparative sequencing analysis between human 
tumours and mouse models clustered the MMTV-PyMT model with a group of 
33/44 human Her2+/ER- tumours, classifying it as a luminal B subtype 
(Herschkowitz, 2007). 
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Figure 1.7 Disease progression in the MMTV-PyMT model  
Adapted from Lin et al. 2003. In the top panel, the scheme shows the gross 
development of lesions in the mammary gland (lesions indicated by red dots), and 
the epithelial cell morphology, basement membrane integrity and leukocyte 
infiltration on each stage of tumour development. The histological H&E stains 
below illustrate the corresponding morphological changes in the developing 
tumours described in the schematics above. Last, the changes in biomarkers 
presence on each stage of tumour development are summarised in the lower 
panel, where (T/D) is the ratio of Neu/Her2 expression between tumorigenic lesions 
(T) and normal ducts (D) in age-matched mammary glands. 
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1.5.2 Experimental versus spontaneous models to study metastasis: 
advantages and limitations 
As a systemic process, metastasis should be ideally studied in spontaneous 
models that allow the asynchronic development of the disease and a similar 
therapeutic setting to test preclinical therapies. Nevertheless, there are many 
challenges associated with their uses as tumours have to grow to a considerably 
big size (2-4 cm3) before being surgically resected, and at that stage several 
complications might arise; for example the fact that very big blood vessels are 
connected to the tumours which makes the surgery laborious and reduces the 
number of mice available for the experiment after such a complicated procedure. 
Also the fact that spontaneous tumours develop asynchronically requires a careful 
randomisation of the mice to ensure equal metastatic burden before proceeding 
with the experiments (Francia et al., 2011).  
 
Therefore, alternatively experimental models of metastasis have been widely used 
to study the colonisation step of the metastasis and undercover the molecular 
mechanisms underlying this complex step that constitutes the bottleneck of the 
metastatic cascade, as previously analysed (section 1.2.3). Experimental 
metastatic models consist of the direct injection of tumour cells in the circulatory 
system, via intracardiac or tail vein injections. Therefore, one of the main 
disadvantages of experimental metastasis models is that tumour cells do not 
undergo many challenges occurring during spontaneous tumour dissemination (i.e. 
local invasion, intravasation) as they are seeded directly into the circulation. 
Additionally, experimental metastasis assays are usually carried in the absence of 
an instigating primary tumour, missing the systemic effects of the disease that can 
positively impact on the ability of the cells to metastasise. Systemic tumour 
responses include immune cell recruitment to distant sites or release of certain 
factors to the circulation that will promote metastatic seeding in specific organs 
through the creation of ‘pre-metastatic niches’ before tumour cells reach the target 
tissues (McAllister and Weinberg, 2014). Using spontaneous mouse models of 
breast cancer, it has been shown that tumour-derived IL1β-IL17 results in systemic 
GCSF release that mobilises neutrophils from the bone marrow promoting breast to 
lung metastasis (Coffelt et al., 2015). In prostate cancer, CAFs implanted into mice 
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have been shown to secrete GDF15 systemically into the circulation, promoting the 
metastatic ability of distally implanted benign prostate cancer cells (Bruzzese et al., 
2014). ECM components secreted by tumour cells, such as the lysyl oxidase (LOX) 
enzyme have been shown to act systemically and create a pre-metastatic niche 
favourable for breast cancer lung metastasis. Also, hypoxia-induced LOX secretion 
at the primary site will induce collagen fibers crosslinking increasing tissue stiffness 
and BMDCs recruitment to the lungs, creating a supportive niche before 
disseminated cells arrive (Erler and Giaccia, 2006). These findings are contributing 
to the view of cancer as a systemic disease, questioning the study of the metastatic 
processes in the absence of an instigating primary tumour. 
 
In contrast, experimental metastasis models offer the advantages of synchronising 
the metastatic process circumventing differences in primary tumour development 
and allowing the analysis of the temporal evolution of the colonisation step. Indeed, 
in breast cancer, experimental metastasis assays have proven to be highly 
successful for investigating the molecular basis of organ-specific metastasis and 
their potential therapeutic targeting (Valiente et al., 2014, Sevenich et al., 2014, 
Zhang et al., 2013), as well as for defining specific populations within tumours with 
high metastasis initiating ability (Malanchi et al., 2012, Oskarsson et al., 2011). 
Certainly, as previously described (section 1.3.1), Malanchi et al. have identified a 
population of MICs (CD24+CD90+) in the MMTV-PyMT model that when tested in 
experimental metastasis assays compared to the bulk of tumour cells, retain 
exclusive metastatic colonisation ability (Malanchi et al., 2012).  
Furthermore, experimental metastasis assays are key in the study of metastatic 
colonisation, allowing the synchronisation of the process to study the molecular 
dynamic changes between early and late colonisation. For instance, as we 
analysed in the previous section, EMT is known to be active in circulating tumour 
cells but it is inhibited after extravasation leading to metastatic outgrowth. 
Understanding the molecular basis underlying the dynamic EMT modulations 
during colonisation requires the synchronisation and temporal control of the 
metastatic process, therefore in this case experimental metastasis assays become 
the preferred model. The other advantage of experimental metastasis is that in the 
absence of the systemic pro-tumourigenic responses induced by a primary tumour, 
the pre-metastatic niche is not formed, and the minimum cancer cell intrinsic 
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features required for colonisation can be exposed in light of the naïve tissue 
microenvironment.  
 
In conclusion, the MMTV-PyMT model of breast cancer is a suitable model to study 
the metastatic process: first, disease progression occurs in a slow progressive 
stage-by-stage manner, mimicking the cellular morphology and biomarkers 
changes observed in humans at every stage (section 1.3.1); second, the close 
similarity of this model to human breast cancer is also exemplified by the gradual 
loss of steroid hormone receptors (estrogen and progesterone) and β1-integrin, 
which is associated with overexpression of Neu and cyclin D1 in late-stage 
metastatic cancers (Figure 1.7) (Lin et al., 2003). Importantly, at the molecular level 
the PyMT oncogene activates multiple signalling cascades required for the 
development of human mammary tumours, therefore oncogenic evolution occurs 
through the same processes (section 1.3.1). The high metastatic incidence 
displayed by these mice makes them the most widely used mouse model to study 
metastatic progression in breast cancer (Cheung and Ewald, 2014). Finally, a 
distinct specialised population of metastasis-initiating cells (MICs) have been 
already identified in these tumours (Malanchi et al., 2012), providing the possibility 
of further exploiting this model to study the biology and potential therapeutics 
features of stem-like populations during metastasis. 
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1.6 Aim of the thesis 
The major goal of this work was to assess what differential features of MICs make 
them the main population driving breast cancer metastatic colonisation to the lungs. 
As previously discussed (section 1.3.2), the metastatic niche plays a key role 
supporting tumour cell growth at the newly colonised tissue (Oskarsson et al., 2011, 
Malanchi et al., 2012), but to date knowledge about how and when tumour cells 
induce their metastatic niche is limited. In this project, we wanted to shed light into 
the strategies employed by disseminating tumour cells to induce their metastatic 
niche, and analyse the consequences of the presence of this newly activated 
stroma on metastatic progression. Specifically, we generated the gene expression 
profile of MICs and focused on those features that could contribute to their 
metastatic ability upon dissemination to a distant naïve tissue. We set out to 
answer the question: what intrinsic characteristics allow MICs to generate a 
favourable microenvironment determining metastatic success?  
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Chapter 2. Materials & Methods 
2.1 Statistical Analysis 
Unless otherwise stated, statistical analyses were performed using Prism software 
(GraphPad Software). Mean values and standard errors (sem) are shown in most 
graphs generated from several biological repetitions of experiments. P values were 
obtained by Student t-tests with paired or unpaired samples when analysing the 
differences in one variable between two experimental groups. Two-way ANOVA 
was used where indicated to perform multiple comparisons or multiple variable 
analyses between experimental groups. Significance was set at P < 0.05. Graphs 
show either the actual P value or symbols describing it (*, p<0.05; **, p<0.01; ***, 
p<0.001; ****, p< 0.0001). 
 
 
2.2 Microarray samples and data analysis 
2.2.1 Accession Numbers 
Microarray expression data were deposited in the Gene Expression Omnibus 
(GEO) database, and are publicly available at http://www.ncbi.nlm.nih.gov/geo/ with 
accession number GEO:GSE63558. In this thesis the top hits expressed in MICs 
compared to nonMICs are included in the section 7.1. Appendix. 
 
2.2.2 Microarray samples preparation 
MICs and nonMICs were freshly isolated by FACS from late-stage PyMT tumours 
according to CD24 and CD90 expression. RNA isolation was performed using 
MagMax-96 Total RNA Isolation Kit (AM1830, Ambion) that allows high quality 
RNA extraction from samples with low cell numbers, < 10,000 cells. RNA quality for 
each sample was assessed using Agilent RNA 6000 Pico Kit (5067-1511, Aligent 
Technologies), and only those samples with a RNA Integrity Number (RIN) > 9 
were considered for processing. RNA was amplified and analysed on Illumina gene 
expression arrays (mouse) at the Barts and London Genome Centre. 
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2.2.3 Gene expression data analysis 
Gene expression data were analysed by the Bioinformatics Unit at the LRI using 
Bioconductor version 2.2, available at http://bioconductor.org, running on R version 
2.7.1 (R Core Team, 2013), available at http://www.R-project.org/. Normalised 
probe set expression values were calculated using log2 transformation and quantile 
normalization using the 'lumi' package (Du et al., 2008). To determine significant 
differences of expression levels between the different groups, a moderated 
Student's t test was computed on a probe-by-probe basis using the empirical Bayes 
statistics in the 'Limma' package (Smyth, 2005). The resultant p-values were 
adjusted for multiple testing using the False Discovery Rate (FDR) Benjamini and 
Hochberg method (Benjamini et al., 1995), where any probe sets that exhibited an 
adjusted p-value FDR q<0.05 were called differentially expressed. 
 
Differentially expressed genes identified in MICs versus nonMICs (MIC signature) 
were used to generate a hierarchical Heatmap (Figure 3.1.A). Genes were 
clustered using a Euclidean distance matrix and average linkage clustering. Red 
indicates higher expression and blue indicates lower expression relative to the 
mean expression of probes across the four samples. 
  
Differentially expressed genes were used to determine enrichment of pathways and 
processes using MetaCoreTM integrated software, version 6.19 developed by 
Thomson Reuters (2014), available at http://thomsonreuters.com/metacore/. This 
analysis employs a hypergeometric distribution to determine whether a list of 
differentially expressed genes is enriched in a pathway or process gene set relative 
to all genes on the array. Pathways or processes that showed a FDR of less than 
0.05 were called enriched. Gene ontology analysis of cellular compartments and 
biological processes are shown in Figure 3.1.B-C. The circos plot was generated 
plotting the top overexpressed pathways in MICs and a selection of genes known 
to contribute to breast cancer cells metastatic potential (Figure 3.2.B).  
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2.2.4 GSEA  
The MIC signature was analysed using the GSEA software developed by the Broad 
Institute of MIT and Harvard (USA) and available at www.broadinstitute.org 
following the programme guidelines to determine the correlation of previous 
published signatures with the MIC signature. Microarray data was adjusted to 
contain only the gene symbols, a description column and numerical expression 
values and saved in .txt format. A phenotype file was created to describe the 
columns in the expression data file and the layout of the experiment i.e number of 
repeats. Genesets were obtained from the MSigDB (The Molecular Signatures 
Database), curated by The Broad Institute and also generated from publicly 
available microarray data (as indicated in Figure 3.2). The specific settings applied 
in all analyses are: number of permutations - 1,000, permutation type - gene set, 
enrichment statistic -weighted, metric for ranking genes - t-test. The rest of the 
fields were left as defaulted. 
The free software ranks the genes in the microarray data file according to 
expression changes between conditions. It subsequently tests how a list of genes 
(geneset) is distributed within the ranked data and calculates an enrichment score 
that represents the degree to which the geneset is represented at the top or bottom 
of the ranked list. The score is calculated by walking down the ranked list and 
measuring a running-sum statistic. The score is increased on encountering a gene 
within the geneset and decreased on encountering genes not in the geneset. The 
enrichment score is then the maximum deviation score achieved. An estimate of 
statistical significance is obtained. 
 
 
2.3 In silico data analysis 
2.3.1  cBioPortal for Cancer Genomics 
The correlation analysis between the expression of THBS2 and different EMT 
markers was performed using cBioPortal for Cancer Genomics, develop by 
Memorial Sloan Kettering Cancer Center (Gao et al., 2013, Cerami et al., 2012), 
and available at http://www.cbioportal.org/public-portal/. The tumour data set used 
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was The Cancer Genome Atlas (TCGA provisional), Breast Invasive Carcinoma 
project (Cancer Genome Atlas, 2012). 
 
2.3.2 GOBO 
THBS2 Distant Metastasis Free Survival (DMFS) prognosis prediction according to 
tumour grade from breast cancer patients was done using GOBO (Gene 
expression-based Outcome for Breast cancer Online) 1.0.1 database, develop by 
the Department of Oncology of Lund University and Skåne University Hospital 
(Lund, Sweden), and available at http://co.bmc.lu.se/gobo/. The tumour data set 
consists of 1881 samples (Ringner et al., 2011). All tumour types were selected for 
the analysis, splitting data in 3 quantiles and selecting 5 year for censoring data 
(Figure 3.22). 
GOBO database allowed the Gene Co-expression analysis of AXL in breast cancer 
patient data (Table 4.1), and was also used to assess AXL expression levels in a 
panel of 30 breast cancer cell lines, classified as Luminal, Basal A or Basal B 
subtype according to the sequencing data published in Neve et al., 2006 (Figure 
4.3.A). 
 
2.3.3 String database 
The search for possible interacting partners for THBS2 was done using STRING 
9.1 (Search Tool for the Retrieval of Interacting Genes/Proteins) database, 
developed by CPR, EMBL, SIB, KU, TUD and UZH and available at http://string-
db.org/ following the database guidelines. Confidence interval was set at the 
highest score (0.90) and no more than the highest 10 ‘interactors’ were shown. All 
prediction methods were left selected as defaulted considering co-expression, 
gene-fusion, databases, co-ocurrence, neighboorhood, textmining and 
experimental data. Confidence view of the resulting ‘THBS2 interactome’ where 
stronger associations are represented by thicker lines, is displayed in the diagram 
shown in Figure 3.15.A. 
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2.4 Buffers, solutions and chemicals 
Some common buffers and solutions are listed below. 
 
Phosphate buffered saline (PBS) 
1.5 mM KH2PO4, 8 mM Na2HPO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4 
 
TE buffer 
10 mM Tris HCl pH 7.5, 1 mM EDTA 
 
50 x TAE 
2 M Tris-acetate (242 g Tris base + 57.1 ml glacial acetic acid per litre), 0.05 M 
EDTA pH 8.0 
 
6 x DNA loading buffer 
0.25 % bromophenol blue, 0.25 % xylene cyanol FF, 30 % glycerol 
 
Chemicals: Potassium chloride (KCl), Tris base, Tris HCl, potassium phosphate 
(KH2PO4), sodium phosphate (Na2HPO4), ethylene diamine tetraacetic acid 
(EDTA), glycine, β-mercaptoethanol, sodium hydroxide (NaOH), hydrochloric acid 
(HCl), tetramethylethylenediamine (TEMED), ethanol (EtOH), methanol (MeOH), 
dimethylsulfoxide (DMSO), Tween-20, Triton-X 100, bromophenol blue, bovine 
serum albumin (BSA), deoxynucleotides (dNTPs) and paraformaldehyde (PFA) 
were all purchased from SIGMA. Acetic acid, glycerol, 40 % acrylamide solution, 
sodiumdodecyl sulphate (SDS), sodium acetate, sodium chloride (NaCl), and 
magnesium chloride (MgCl2) were purchased from Fisher Scientific. UltraPure 
agarose was purchased from Invitrogen. 
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2.5 DNA purification and agarose gels 
Agarose gels 
Agarose was melted in 1 x TAE buffer in the microwave at concentrations between 
0.5 and 1 % depending on the DNA fragments to be separated. Gel red nucleic 
acid (Biotium) was added at a concentration of 10,000X form the stock provided 
before casting the gel. DNA samples were mixed with 6 x DNA loading buffer and 
loaded. A 1 kb ladder was also loaded to help identify DNA fragment sizes. Gel 
electrophoresis was performed in TAE buffer at 100V. DNA was visualised using a 
UV transilluminator and if required the band of interest was cut out from the gel. 
 
DNA purification 
DNA was purified from agarose gels using QIAquick Gel extraction kit (Qiagen). 
The agarose band containing the DNA was dissolved at 65 °C in 3 volumes of 
Buffer QG. Then, one volume of isoproponol was added and the solution applied to 
a Qiaquick column. The column was subsequently washed, dried and the DNA 
eluted in dH2O. 
 
 
2.6 Quantitative real time PCR 
For quantitative RT-PCR, RNA preparation was performed using either MagMax-96 
Total RNA Isolation Kit (AM1830, Ambion) when RNA was isolated from less than 
105 cells per sample, or RNeasy Mini Kit (QIAGEN) for higher cell numbers per 
sample. cDNA synthesis was performed using and SuperScript III First-Strand 
Synthesis System (Invitrogen), according to the manufacturer’s protocol.  
Quantitative real-time PCR samples were prepared with 25 ng total cDNA for each 
PCR reaction. Reactions were set-up on ice in a 96 well optical reaction plate 
(Applied Biosystems) as outlined below:  
 
10 µl Platinum SYBR Green qPCR SuperMix-UDG with Rox 
0.5 µl Forward primer (0.5 pmol) 
0.5 µl Reverse primer (0.5 pmol) 
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5 µl cDNA (5 ng/µl) 
4 µl dH2O 
 
The data generation and analysis were performed on a 7500 FAST Real-Time PCR 
System (Life Technologies) using the following PCR cycling conditions: 
 
50 °C 20 s 
95 °C 10 mins 
95 °C 15 s - Denaturing 
60 °C 60 s - Annealing/Extension return to denaturing x 40 cycles 
4 °C hold 
 
All human primers pairs used for each of the mRNA targets are shown in Table 2.1 
and mouse primer in Table 2.2.  
 
 
Table 2.1 Human RT-PCR primers 
 
GENE SYMBOL Forward (5’ – 3’) Reverse (3’ – 5’) 
GAPDH AGGGGTCTACATGGC AACTG CGACCACTTTGTCAAGCTCA 
AXL AACCT TCAACTCCTG CCTTC TCG CAGCTTCTCCTTCAGCTCTTCAC 
THBS2 GCTACATCAGAGTCTTAGTGC AGAGAAGACAAATAGACCCAG 
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Table 2.2 Mouse RT-PCR primers 
 
GENE SYMBOL Forward (5’ – 3’) Reverse (3’ – 5’) 
GAPDH CGTGTTCCTACCCCCAATGT TGTCATCATACTTGGCAGGTTTCT 
SNAIL CTCTGAAGATGCACATCCGAA GGCTTCTCACCAGTGTGGGT 
SLUG TGTGTCTGCAAGATCTGTGGC TCCCCAGTGTGAGTTCTAATGTG 
TWIST1 GCCGGAGACCTAGATGTCATTG CACGCCCTGATTCTTGTGAA 
ZEB1 GCCAGCAGTCATGATGAAAA TATCACAATACGGGCAGGTG 
E-CAD CGACCCTGCCTCTGAATCC TACACGCTGGGAAACATGAGC 
VIM CCAACCTTTTCTTCCCTGAA TTGAGTGGGTGTCAACCAGA 
MYL9 AGGCCTCAGGCTTCATCCACGA ATGGGGTCTAGGCACTGGGGC 
AMOTL2 AACCGCCACCTGGCAAGCAA GGTCCTCGATGGCACCACGC 
ANKRD1 AAACGGACGGCACTCCACCG CGCTGTGCTGAGAAGCTTGTCTCT 
CCL2 CAGGTCCCTGTCATGCTTCT GTCAGCACAGACCTCTCTCT 
CTGF GCTTCGCAGGGCCTGACCAT GCCGTGGGCTGCATTCCTCT 
ICAM1 GAAGCTTCTTTTGCTCTGCC AGCAGTACTGGCACCAGAAT 
PLAC8 TCAGTGACTGCGGAGTCTGCC CAGAGCTCTTGCCATCCAGCTCC 
SPDR GCCCAGCAGGTGCGCTATGA CGGGGTGGCTTCCACGAGGT 
TAGNL AGGCGGCCTTTAAACCCCTCACC CGGCCTACATCAGGGCCACAC 
THBS1 GCGTTGCCAGGCTCCGAGTT GGTGCGCAGGCCCTTCAGTT 
ANGTL4 AAGATGCACAGCATCACAGG ATGGATGGGAAATTGGAGC 
CCL7 AGCTACAGAAGGATCACCAG CACATTCCTACAGACAGCTC 
CCL11 CAGATGCACCCTGAAAGCCATA TGCTTTGTGGCATCCTGGAC 
CXCL10 GACGGTCCGCTGCAACTG GCTTCCCTATGGCCCTCATT 
CYR61 GCCGTGGGCTGCATTCCTCT GCGGTTCGGTGCCAAAGACAGG 
WNT5A GGTGCCATGTCTTCCAAGTT ATCACCATGCCAAAGACAGA 
COL1A1* TCGTGGCTTCTCTGGTCTC CCGTTGAGTCCGTCTTTGC 
COL4A1* ATAGCCAAAGCCAAACCCATT CGCAGAGCAGAAGCAAGAA 
LAMA2* GTATCACCAAATTATCCAAGACCAT TCGCTGGGCATATTTCTCATC 
FN1* AAGAGGACGTTGCAGAGCTA AGACACTGGAGACACTGACTAA 
MMP2* GGACAAGAACCAGATCACATACA GCCCGAGCAAAAGCATCAT 
MMP9* TGATGCTATTGCTGAGATCCAG CCTGTAATGGGCTTCCTCTATG 
MMP13* CCAACCCTAAGCATCCCAAA TCCTCGGAGACTGGTAATGG 
MMP14* CCATCAATACTGCCTACGAGAG CTCCTTAATGTGCTTGGGGTAC 
FSCN1* AAAGACTCCACGGGCAAGTA GTCACAGAACTCAAGGAAGAAATC 
LIMKI* TCTACAAGGACAAGCGGCTAA CTCTGACTCCACGGGTACTG 
MYHL10* TCAGATGACGACACAGAAAGTAA AGACTGGTGCTGGGATGAG 
PFN1* ACCGTTCCCTTTGGCTTTTG ATGTGGTTTTGGCAGCAATAAG 
MYLK* CCACCAGCACCATCACTCT CCCAGGAGAGAAGGACCCTA 
THBS2* GCCACCAGAACAACCAAGAC CACCATCATTGTCATCATCAGAGT 
ACTA2* CTCTTCCAGCCATCTTTCATTG GTTGTTAGCATAGAGATCCTTCCT 
* Design and validated by PrimerDesign Ltd, UK. 
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2.7 Animal procedures 
2.7.1 Mouse strains 
Transgenic FVB/n mice expressing the polyoma middle T antigen oncogene under 
the mouse mammary tumour virus promoter (MMTV-PyMT) (Guy et al., 1992) were 
the sources of primary cancer cells. Cells were always isolated from late stage 
carcinomas, when tumours are at least 2cm. Age matched 6 to 10 weeks Rag1-/- 
FVB/n female mice (Mombaerts et al., 1992) were used as recipients for all 
orthotopic tumour transplantations and tail vein injections experiments, unless 
otherwise specified. Nude CD1-Foxn1 mice (Flanagan, 1966) were bought from 
Harlan UK and used in the experimental metastasis assays to obtain the samples 
for the microarray analysis. All mice were kept in accordance with UK regulations 
under project license PPL 80/2531. 
 
2.7.2 Tumour initiation and metastatic colonisation assays 
In tumour initiation assays (collective challenge), unless otherwise specified, either 
3x105 PyMT primary cells or 106 MDA-MB-231 cells were mixed in 100 µl of Growth 
Factor Reduced Matrigel (356230, Corning), and injected into the mammary fat pad 
of anesthetised mice. Tumour growth was evaluated 2 weeks after injection for 
early tumour initiation, and 6 weeks post-transplantation to evaluate differences in 
primary tumour growth and microenvironment. 
 
For experimental metastasis assays (single cell challenge), unless otherwise stated, 
between 5x105 – 106 PyMT primary cells or MDA-MB-231 cells, were resuspended 
in 100 µl PBS and injected into the tail vein of mice. All metastatic assays were 
performed using endogenously expressing, or lentivirus induced, GFP+ or VENUS+ 
cells. Macrometastasis were evaluated quantifying the number of superficial 
metastatic nodules in a fluorescent stereomicroscope (Lumar V.12, Zeiss), and 
micrometastasis by FACS analysis of lung cell preparations, or histological analysis 
after H&E staining and sectioning of the lungs. 
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2.7.3 Drug treatments 
R428, also known as BGB324 (1946, Axon MedChem), was dissolved in DMSO at 
a final concentration of 21.15 mM or 12.5 mg/ml. In vivo treatments were performed 
as previously described (Holland et al., 2010). Briefly, for the 24 hours treatment 
time point, cells were treated in vitro with either vehicle (DMSO) or 1.5 uM R428 for 
3 hours, 24 hours before injection. For treatment during the first week of metastasis, 
cells were pre-treated in culture as described above, and after tail vein injection 
mice received a daily dose of 12.5 mg/kg R428 by oral administration. Treatments 
between 10-15, and 25-35 days post-injection were performed as described above, 
but cells were not pre-treated in culture before injecting them. 
 
LDN193189 was dissolved in citric acid – sodium citrate buffer solution pH=3.1 at a 
final concentration of 6.25 mg/ml. Mice were injected with 106 PyMT cells 
intravenously, and treated daily with an intraperitoneal dose of 35 mg/kg 
LDN193189 from day 5 to 12 post metastatic seeding.  
 
 
2.8 Histology 
2.8.1 Lung immunofluorescence   
Immunofluorescence to assess in vivo niche activation was performed in 4% PFA 
fixed, paraffin embedded lungs. 4 µm thick lung sections were cut, de-paraffinased 
and re-hydratated using standard methods. After antigen retrival, sections were 
stained with DAPI, an anti-GFP antibody to label tumour cells and either SMA to 
detect activated fibroblasts, or endomucin to detect endothelial cells (antibodies 
description and working concentrations in Table 2.5). Sections were treated with 
Sudan Black B (SBS) to quench background auto-fluorescence. 
Images were acquired in an upright Zeiss LSM780 confocal microscope. 
Quantitative analysis of images was performed manually counting the number of 
SMA+ or Endomucin+ cells in direct contact with the GFP-labelled tumour cells in 
the tissue.   
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2.8.2 Immunohistochemistry (IHC-P) 
Tumours were fixed in 4% PFA for 24h, and then embedded in paraffin blocks. 4 
µm thick tumour sections were cutted, deparraffinased and rehydratated using 
standard methods. After antigen retrival, sections were stained with haematoxylin 
and eosin (H&E) solution, or alternatively with DAPI and antibodies against 
endomucin (endothelial cells) and/or Ki67 (proliferating cells). 
Images were acquired in an upright Nikon Eclipse Ni-U light microscope.  
 
2.9 Lentivirus  
2.9.1 Lentiviral constructs generation 
All lentiviral vectors used in this study were generated using Gateway® technology 
(Life Technologies).  
The lentivirus constructs expressing short hairpin RNAs (shRNAs) were obtained in 
a two-step approach: first, the shRNA paired primers were designed with XhoI, 
BglII restriction sites on the edges to be cloned into a Gateway pENTR plasmid 
under H1 promoter (attL1_H1promoter_cloning-site_attL2). Second, we performed 
a Gateway LR recombination between the pENTR plasmid containing the shRNA 
and the lentiviral vector p4300 (cPPT_CMVenh_attR_hPGK_EGFP_WPRE). 
Construct scheme in Figure 3.17 and Figure 4.5.  
 
Table 2.3 shRNA sequences 
 
shRNA TARGET SEQUENCE (5’ – 3’) 
shAXL F GACATCTTCTTTCTCATGTGAAGCCCATCTGGTCATGGGCTTCACATGAGAAAGAAGATGTC
TTTTT 
shAXL R AAAAAGACATCTTCTTTCTCATGTGAAGCCCATGACCAGATGGGCTTCACATGAGAAAGAAG
ATGTC 
shTHBS2 F GCTGTAGGTTTCGACGAGTTTCTCGAGAAACTCGTCGAAACCTACAGCTTTTT 
shTHBS2 R AAAAAGCTGTAGGTTTCGACGAGTTTCTCGAGAAACTCGTCGAAACCTACAGC 
shTHBS2 II F CCACGTCAAGGACACTTCATTCTCGAGAATGAAGTGTCCTTGACGTGGTTTTT 
shTHBS2 II R AAAAACCACGTCAAGGACACTTCATTCTCGAGAATGAAGTGTCCTTGACGTGG 
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The lentiviral vectors expressing protein-coding DNA sequences were obtained by 
Gateway LR recombination between a pDONR plasmid containing the DNA coding 
sequence and a pDEST lentiviral backbone. For THBS2 overexpression, we 
engineered a lentiviral reporter construct recombining the pDONR plasmid 
containing the mouse DNA coding sequence of THBS2 (Addgene plasmid 12411; 
pcDNA3_mTSP2) with a pDEST lentiviral backbone that drives its expression 
under a mouse PGK promoter. The lentiviral backbone contains as well a truncated 
isoform of the human CD2 receptor (hCD2) and a VENUS reporter gene (Figure 
3.19.A). For a mild AXL expression, we recombined the pDONR plasmid containing 
the DNA coding sequence (Addgene plasmid 23945; pDONR223_AXLORF) with a 
pDEST lentiviral backbone that only has the lentivirus LTR driving regions and a 
CMV enhancer. The lentiviral backbone contains as well an EGFP reporter gene 
(Figure 5.6.A). Below, in Table 2.4 are the detailed descriptions of the expression 
constructs used in this study. 
 
To generate the lentiviral vectors expressing shRNAs, we used hairpin oligomers 
with the target sequences shown in Table 2.3 (shRNA sequences). The shTHBS2 
validated target sequences were obtained from Sigma Mission’s website in 
collaboration with the RNAi consortium (TRC) scientist 
(http://www.sigmaaldrich.com/life-science/functional-genomics-and-rnai/shrna.html). 
The target sequence for shAXL was described previously (Gjerdrum et al., 2010). 
All these sequences do not match any cDNA sequence of the corresponding 
specie (mouse) registered in BLAST other than that of their own target gene. 
 
 
Note: all restriction enzymes used to clone were purchased from New England 
BioLabs (NEB) and were supplied and used with the appropriate buffers. DNA 
polymerase 1 (Klenow fragment) was purchased from NEB and was used to blunt 
DNA ends. Ligation reactions were carried out using T4 DNA Ligase, also from 
NEB. 
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Table 2.4 Lentiviral plasmids description 
 
Name Promoter /driving sequence Marker  Notes 
GFP LTR hPGK-EGFP Mild expression 
LTRAXL LTR-hAXLORF hPGK-EGFP Mild expression 
shCONTROL H1 hPGK-EGFP High expression 
shAXL H1-mshAXL hPGK-EGFP High expression 
shTHBS2 I H1-mshTHBS2 I hPGK-EGFP High expression 
shTHBS2 II H1-mshTHBS2 II hPGK-EGFP High expression 
VENUS mPGK hPGK-VENUS High expression 
THBS2ORF mPGK-mTHBS2ORF hPGK-VENUS High expression 
 
 
2.9.2 Lentiviral constructs sequencing 
DNA constructs were checked by sequencing using the Big Dye terminator (BDT) 
kit (Applied Biosystems). For each sequencing reaction the following components 
were used: 
 
8 µl BDT reaction mix 
1 µl DNA (100ng) 
1 µl Primer (4pmol) 
10 µl dH2O 
 
The PCR settings used to amplify the single stranded DNA for sequencing were the 
following: 
 
96 °C 1 min 
96 °C 10 sec - Denaturing 
50 °C 5 sec - Annealing 
60 °C 4 min - Extension and return to denaturing x 25 cycles 
4 °C hold 
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DNA for sequencing was purified using Performa DTR Gel filtration cartridges 
(EdgeBio). The purified DNA was then dried using vacuum centrifugation and 
analysed by the in house Equipment Park facility. 
 
2.9.3 Lentivirus production 
Third-generation VSV-G pseudo-typed high titers lentiviruses were generated by 
transient co-transfection of 293T cells with a four-plasmid combination as follows: 
One 10 cm dish containing 1x106 293ft cells was transfected using 2M CaCl2, and 
2x HBS (51558, Sigma) with 15 µg lentiviral vector, 6 µg pMD2-VSVG, 6 µg pRSV-
rev and 6 µg pMDL-g/p-RRE. Supernatants were collected 48h and 72h hours after 
transfection. 
 
2.9.4 Primary cell lentiviral infections 
For lentiviral transduction, 105 primary PyMT cells/well were seeded in 6-well tissue 
culture dish and infected with EGFP or VENUS reporter lentiviruses added in 
suspension using 10 µg/ml Polybrene (107689, Sigma). After 48 hours, 
successfully transduced cells were trypsinised and FACS sorted according to their 
EGFP/VENUS expression. 
 
 
2.10   Cell culture 
2.10.1 Culture conditions and reagents 
The human mammary carcinoma cell line MDA-MB-231 and the mouse carcinoma 
4T1 cell line were obtained from London Research Institute - Cell services, and 
maintained in 2D cultures in DMEM with 5% FCS at 37C and 5% CO2.  
 
Mouse mammary carcinoma PyMT cells were seeded 2D in plates coated with 
collagen-solution (100 mg/ml BSA, 1M HEPES, 1:100 PureCol (5005-B, Advanced 
BioMatrix) in HBSS), and maintained in MEM media (DMEM/F12 supplemented 
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with 2% FCS, 10µg/ml Insulin (I9278, Sigma), 20ng/ml EGF (PHG0313, Invitrogen) 
and 1:50 L-Glutamax (35050-061, Life Technologies), and grown at 37C and 5% 
CO2. 
 
Mouse primary lung fibroblasts were isolated from a single-cell suspension of lung 
tissue that was depleted from Ter119+ red blood cells, immune CD45+ cells and 
endothelial CD31+ cells by MACS sorting. The remaining fraction was cultured 
overnight on plastic in DMEM with 10% FCS. Unless otherwise specified, all 
fibroblast experiments were performed on cells seeded on the top of a thin layer of 
a 2:1 mixture of collagen I (354249; BD Biosciences) and Matrigel (354234; BD 
Biosciences) as described previously (Calvo et al., 2013).  
 
Fibroblast cell lines: for generating the NLF3 cell line, normal lung fibroblasts were 
isolated from healthy lungs of aGFP/FVB/n mice. Lung CAFs were isolated from 
metastatic lungs of MMTV-PyMT FVB/n mice, and the mcherry CAFs (mcCAFs) 
were isolated from primary MMTV-PyMT FVB/n tumours in carcinoma stage. All 
fibroblast cell lines were generated according to the published Bio-protocol e1097 
(Calvo, F., Hooper, S. and Sahai, E. (2014). Isolation and Immortalization of 
Fibroblasts from Different Tumoral Stages. Bio-protocol 4(7): e1097), available at 
http://www.bio-protocol.org/e1097. Briefly, tissue pieces are placed into dishes 
where they are compressed under a 20 mm coverslip in DMEM media under sterile 
conditions. After 7 days, fibroblasts have come out of the tissue into the coverslip 
and the dish and can be trypsinased with Trypsin/EDTA and transferred into a new 
dish. Once they reach 80% confluency, primary fibroblasts are immortalised by 
infection with pBABE-HPV-E6-puromycin retroviruses. Positively infected 
fibroblasts are selected by addition of puromycin (2 µg/ml final concentration) in the 
complete culture media for 7-10 days, when resistant clones expressing HPV-E6 
(i.e. immortalised cell lines) are visible.  
 
2.10.2 In vitro drug treatments 
R428 (1946, Axon MedChem) in vitro treatment was performed as previously 
described (Holland et al., 2010). Briefly, PyMT primary cells plated 2D were treated 
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with either vehicle (DMSO) or 1.5 µM R428 for 3 hours before washing and adding 
fresh media. 24 hours after in vitro assays were performed. MDA231 cells were 
treated with 3 µM R428 for 24 hours. Next day, fresh media was added and in vitro 
assays were performed. 
 
LDN193189 and SB431542 were dissolved in DMSO to 10 mM and use at a final 
concentration of 10 µM and 1 µM respectively in the cell culture media. A single 
treatment was used as experiments were done over 24 - 48h. 
 
 
2.11   Tumour sphere assay 
Cells prepared as a single-cell suspension were plated in Ultra Low Attachment 96-
well plates (Constar) with Sphere Media (DMEM/F12 supplemented with 1:50 B27 
(Invitrogen), 20ng/ml EGF (PHG0313, Invitrogen), 20ng/ml FGF (PHG0026, 
Invitrogen), 4mg/ml heparin (H3393, Sigma)), and kept at 37C and 5% CO2.  
PyMT primary cells spheres were established from total tumour cell preparations. 
After tumour dissociation, cells were plated on collagen overnight; trypsinased and 
104 cells/ 200ul per well were seeded. Only the characteristic hollow spheres 
formed by these cells were quantified as tumour-spheres. 
For passaging, tumour-spheres were collected by centrifugation and dissociated 
both enzymatically by trypsin treatment (for 10 min at 37 °C) and mechanically by 
using a 16G needle, and the resulting single-cell suspension was counted and re-
plated at the original density. 
Quantitative analysis of images was performed using ImageJ software, and the 
Sphere Formation Index (SFI) was calculated considering both, number and size of 
the spheres, and was obtained by summing the area of all spheres formed divided 
by the number of single cells initially plated. 
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2.12   Western blotting 
CD24+AXL+ cells were FACS sorted and cultured in collagen-I coated dishes 
overnight, and incubated for 24h with the pertinent media and treatments. Protein 
lysates were obtained after cell lysis with RIPA buffer (50mM Tris-HCl, 1% NP-40, 
0.5% Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA, 50 mM NaF) 
supplemented with Roche cOmplete protease inhibitors cocktail tablets following 
standard procedures. Protein lysates were run in 12% polyacrylamide gels, and 
blotted into AmershamTM Polyvinyllidine difluoride membranes (10-6000-29). 
Membranes blocking and antibody incubations were performed in 5% BSA/PBS.  
Antibody description and working concentration used can be found in Table 2.5. 
 
 
2.13   BrdU proliferation assay 
Cancer cells proliferation rate was assessed measuring their nuclear BrdU 
incorporation after culturing them for 3 hours in 30 µM BrdU supplemented media. 
Then, cells were washed with PBS, trypsinased, fixed with 70% ethanol for 20 mins, 
permebealised with 2N HCl, 0.5% TritonX-100 for 30 mins, and treated with 0.1M 
tetraboric acid for 2 mins. After washing twice with FACS buffer and cells were 
stained with anti-BrdU antibody (Table 2.5). 
 
 
2.14   ELISA 
To measured THBS2 secretion, tumour cells were plated either in sphere or 
adherent conditions at a cell density of 50,000 cells per 100 µl. The resulting 
conditioned-culture media was collected 24h after plating and frozen at -80C. 
To quantify the levels of secreted protein in the conditioned-media, we used two 
different sandwich-ELISA kits, THBS2 ELISA Kit (SED822Mu, Cloud-Clone Corp) 
and Mouse THBS2 ELISA Kit (MBS942662, MyBioSource), and proceed according 
to the manufacturer’s protocols. The resulting colorimetric reaction was measured 
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at 450nm using an automated ELISA plate reader (SpectreMax 190 Microplate 
Reader, Molecular Devices). 
 
 
2.15   Flow cytometry 
2.15.1   FACS 
Flow cytometry analyses were carried out on a BD LSR-Fortessa system (BD 
Biosciences), and PI (Propidium Iodide) was used as a viability dye unless 
otherwise indicated.  
To examine the relationship between MICs, AXL and Sca1 in primary PyMT cells, 
PyMT tumours were dissociated and plated overnight on collagen-I coated dishes. 
Next day, cells were trypsinased and stained for CD24 as an epithelial marker in 
combination with Sca1, AXL and CD90 in MACS buffer (0.5% BSA and 1mM EDTA 
in PBS). Antibody description and working dilutions can be found in Table 2.5. 
. 
To assess AXL expression in metastatic lungs containing GFP labeled cancer cells, 
the tissue was dissociated and prepared as a single cell suspension as previously 
described (Malanchi et al., 2012). Subsequently, it was stained for lineage negative 
markers (CD31, CD45 and Ter119), CD24, CD90 (when expression was targeted 
to MICs) and mAXL-biotin or hAXL in MACS buffer. Antibody description and 
working dilutions can be found in Table 2.5. 
 
The expression of different protein assessed by FACS in NLF3, MDA231 and 4T1 
cell lines was done after trypsinisation of cultured cells and staining with the 
pertinent antibodies in MACS buffer.  
 
Differences in extravasation to the lungs by R428-treated or untreated PyMT cells 
was assessed by perfusing the lungs with PBS to flush out the blood, and then the 
clean tissue was dissociated in single-cell suspension and the number of GFP+ 
MICs present in the lungs were quantified. 
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2.15.2   Cell sorting 
All cell-sorting experiments were carried out on either a BD Influx or FACSAria cell 
sorter systems (BD bioscience). 
To sort the MICs from PyMT primary tumours or lungs containing GFP labeled 
cancer cells, we used the staining indicated above (2.11.1). CD24+AXL+ and 
CD24+AXL- cells were sorted from primary PyMT tumour single-cell preparations. 
The staining protocol previously described (Malanchi et al., 2012), was adapted 
and a mAXL-biotinylated antibody was incorporated (antibody description and 
working dilutions can be found in Table 2.5). 
EGFP+ or VENUS+ cells expressing the lentiviral constructs were trypsinased, 
washed with FACS buffer and sort according to the expression of the reporter gene. 
 
2.15.3   ImageStream 
ImageStream analyses were carried out in an ImageStream®X Mark II Imaging 
Flow Cytometer (Amnis-Millipore). 
 
For the whole lung analysis, cells were dissociated into a single cells suspension 
and depleted by MACS sorting from lineage negative cells (Ter119, CD45 and 
CD31). Next, the remaining fraction was stained with a live/dead fixable Near-
Infrared dye (Invitrogen, L10119), and after, fixed with 2% PFA for 30 min and 
permeabilised with 0.1% Trinton-X for 10 min. Next, cells were resuspended in 
FACS buffer (2% FCS in PBS) and stain with primary antibodies against Twist1, 
pSMAD1-5, ID1 or pSMAD2-3 at 4C overnight (antibody description and working 
dilutions can be found in Table 2.5). Subsequently, cells were washed twice in 
MACs buffer (0.5% BSA and 1mM EDTA in PBS) and incubated for 45 min with 
secondary antibodies at room temperature. DAPI was added at 1 µg/ml to cells 
before analysis for nuclear staining. Tumour cells were identified by GFP 
expression (Figures 5.1.B-D and Figure 5.4.A-F).  
 
In vitro, ImageStream analysis of non-labeled MICs co-cultured with NLF3 for 4-5 
days (as specified in the scheme in Figure 5.1.F) was performed from a single cell 
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suspension after gel digestion. NLF3 were excluded by GFP expression, and MICS 
were analysed for Twist1 expression changes (Figure5.1.F-I). 
 
The acquired data was analysed using Amnis IDEA management software to 
compensate for multi-colour spectral overlap; plot and graphical gating of the cells 
as well as obtaining representative images of cells.  
 
 
2.16   Cell immunofluorescence 
All cancer cell immunofluorescence microscopy was performed on cells seeded on 
glass-bottom 35 mm MatTek dish (P35-1.5-14-C, MatTek) or glass coverslips 
coated (Thermo Scientific) with collagen solution (Cell culture procedure). Samples 
were fixed with 4% PFA for 10 min, permeabilised with 0.5% TritonX-100 for 30 min 
and 0.1% TritonX-100 for 20 min. Samples were blocked for 45 min at room 
temperature in blocking solution: 4% BSA in PBS with 0.05% Tween20 (Sigma). 
Then, cells were incubated with primary antibody in blocking solution overnight at 4 
C. After 3 washes of 5 min in PBS, secondary antibody in blocking solution was 
added. After 3 washes of 5 min in PBS, samples were mounted using Dako 
Fluorescent Mounting Media (S3023, Dako), and analysed using either upright or 
inverted Zeiss LSM710. 
Quantitative analysis of images was performed using Imaris 7.6.4. Tumour cells 
were identified using an automated threshold based on GFP expression or a 
homogeneous cell body staining. The mean intensity of E-cadherin, AXL and 
Vimentin was then measured. 
 
All fibroblast immunofluorescence, unless stated otherwise, were performed on 
cells seeded on the top of a thin layer of a mixture of 2:1 collagen-I:Matrigel as 
described previously (Calvo et al., 2013). Briefly, after 2 days on the gel and the 
pertinent treatments, cells were fixed in 4% paraformaldehyde for 1 h. Cells were 
permeabilised by incubation in PBS 0.5% NP-40 (Sigma) at 4C for 20 min, in PBS 
with 0.3% Triton X-100 (Sigma) at room temperature for 20 min and in PBS with 
0.1% Triton X-100 at room temperature for 15 min. Samples were blocked for 60 
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min at room temperature in blocking solution: 4% BSA in PBS with 0.05% Tween20 
(Sigma). Then, cells were incubated with primary antibody in blocking solution in a 
wet chamber overnight at 4C. After 3 washes of 15 min in PBS, secondary antibody 
in blocking solution was added. After 3 washes of 15 min in PBS, samples were 
mounted and analysed using an inverted Zeiss LSM710. 
Quantitative analysis of images of CAF markers was performed using Imaris 7.6.4. 
To quantify YAP nuclear localization, we calculated for each cell the nuclear YAP 
intensity mean (determined by the intensity within the region delimited by DAPI 
staining) and the cytosolic YAP intensity (determined by the intensity mean of the 
staining within the region delimited by GFP) for at least 50 cells in triplicate. Plots 
represent the ratio of nuclear versus cytosolic YAP staining. To quantify FAP, 
fibroblasts were identified using an automated threshold based on their GFP 
expression. The mean intensity of FAP was then measured. 
 
Antibody description and working dilutions can be found in Table 2.5. 
 
 
2.17   DQ collagen assay 
To assess the collagenase activity of tumour cells degradation of DQ-collagen-I by 
living cells was measured. A single cells suspension of tumour cells was embedded 
in 100 µl of 2:1 collagen-I:Matrigel mixture, being 1/3 of the total collagen DQ 
(D12060, Invitrogen), and seeded on a 24-well glass-bottom MatTek dish (P24G-
1.5-10F, MatTek). Once the gel was set, cells were kept at 37C and 5% CO2 in 
MEM media for 48 hours. Next, the gels were fixed and permeabilised as 
previously described (Calvo et al., 2013), and cells were stain with DAPI and 
Phalloidin-AF555 (A34055, Life Technologies). 
Quantitative analysis of images was preformed using ImageJ software. The 
intensity mean signal of the fluorescent products of DQ collagen I degradation was 
measured drawing a proportional square area to the cell cluster size. 
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2.18 Live cell imaging 
2.18.1   Cell tracking (2D motility) 
For two dimensional image acquisition, cells were plated sub-confluent into 24-well 
glass bottom MatTek plates (P24G-1.5-10F, MatTek) coated with collagen solution. 
Once attached, cells were kept in the microscope chamber at 37C and 5% CO2 and 
images were acquired every 5 mins for 12 hours. The acquired digital images were 
merged using MetaMorph Automation and Imaging Analysis Software (Molecular 
Devices Inc.). Cell tracking speed analysis was performed using Mathematica 8.0 
(Wolfram). 
 
2.18.2   Cell growth curves  
Primary PyMT CD24+AXL+ cells were FACS sorted and plated sub-confluent into 
96-well high content imaging black plates (CLS4580, Corning) coated with collagen 
solution. Cell growth was monitored over 3-4 days using IncuCyteZOOM® Live Cell 
Imaging. All conditions were performed in triplicate and 3 images per well were 
acquired every 3 hours. The total area covered by cells was automatically 
measured, and the percentage of confluency over time was calculated as the 
average area covered by cells relative to the total well area of the triplicates.  
 
 
2.19   CAF induction assays 
To assess fibroblast activation via their ability to remodel an extracellular matrix, 
normal primary lung fibroblasts or the NLF3 cell line were embedded in 100 µl of 
2:1 collagen-I:Matrigel and seeded on a 35-mm glass-bottom MatTek dish (P35-
1.5-14-C, MatTek). Once the gel was set, we introduced a low height co-culture 
insert (PICM-ORG-50, Millipore) were tumour cells were seeded in a 1:3 
fibroblast:tumour cells ratio. The co-culture was maintained in MEM media 
(DMEM/F12 supplemented with 2% FCS, 10µg/ml Insulin (I9278, Sigma), 20ng/ml 
EGF (PHG0313, Invitrogen) and 1:50 L-Glutamax (35050-061, Life Technologies). 
Gel contraction was monitored daily by taking photographs of the gels. Unless 
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stated otherwise, the gel contraction value refers to the contraction observed after 
3 days. To obtain the gel contraction value the relative diameters of the well and 
the gel were measured using ImageJ software, and the contraction was calculated 
as the gel area relative to the well area in arbitrary units (A.U.). 
 
 
2.20   3D spheroid assays 
2.20.1   Mixed spheroid invasion assay 
GFP+ MICs were freshly isolated from an actin-GFP MMTV-PyMT mouse and GFP- 
nonMICs were isolated from unlabelled MMTV-PyMT mouse by cell sorting 
according to their CD24/CD90 expression (see 2.16). 
Next, GFP+ MICs and GFP- nonMICs were re-aggregated in ultra-low attachment 
conditions overnight in 1:9 ratio, in line with their relative distribution in primary 
tumours in vivo. The micro-spheroids formed were embedded in: pure collagen-I 
BD Biosciences cat. no. 354249), a 2:1 mixture of collagen-I and Matrigel (BD 
Biosciences cat. no. 354234), yielding a final collagen concentration of ~4.6 mg/ml 
and a final Matrigel concentration of ~2.2 mg/ml, or pure Matrigel gels. 
Microspheroids were allowed to invade for 48 hours before fixation with 4% PFA 
and staining with Phalloidin-TRITC (Sigma P-1951) and DAPI. Spheroids were 
imaged using a Zeiss LSM780 confocal microscope and invasive cells quantified 
using Volocity 3D Image Analysis Software by PerkinElmer. 
 
2.20.2   Spheroids-CAFs invasion assay 
FACS sorted GFP+ MICs or nonMICs were re-suspended in DMEM with 10% FBS 
and 0.2% methyl cellulose at 2.5 x 105 cells/ml with or without 2.5 x 104 mcherry 
labelled PyMT-CAF. Spheroids were formed by hanging drop overnight and then 
embedded in 2:1 collagen-I:Matrigel mix. Spheroids were allowed to invade for 48 
hours before fixation with 4% PFA, followed by DAPI staining. Spheroids were 
imaged using a Zeiss LSM780 confocal microscope and invasive cells quantified 
using Volocity 3D Image Analysis Software by PerkinElmer. 
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2.20.3   Organoid assay in Matrigel 
A single cell suspension of FACS sorted MICs was directly seeded in pure Matrigel 
and maintain in Sphere Media (DMEM/F12 supplemented with 1:50 B27 
(Invitrogen), 20ng/ml EGF (PHG0313, Invitrogen), 20ng/ml FGF (PHG0026, 
Invitrogen), 4mg/ml heparin (H3393, Sigma)) at 37C and 5% CO2 for 10 days. After 
3 days cells are grouped into clusters. Quantitative analysis of images was 
performed 10 days after seeding using ImageJ software. The Organoid Formation 
Index (OFI) was determined considering both, number and size of the organoids, 
and was obtained by summing the area of all organoids formed divided by the 
number of single cells initially plated. 
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Table 2.5 Antibodies 
 
 
ANTIBODY 
 
COMPANY 
REF 
CODE 
 
CLONAL (CLONE) 
DILUTION 
(TECHNIQUE) 
Endomucin Santa Cruz sc-65495 Rat monoclonal (V.7C7) 1:200 (IHC-P) 
Ki67 (human) Dako A047 Rabbit polyclonal 1:500 (IHC-P) 
Ki67 Novocastra  NCL-Ki67p Rabbit polyclonal 1:200 (IHC-P) 
FAP-α Santa Cruz sc-54539 Goat polyclonal 1:100 (IF) 
YAP Santa Cruz sc-101199 Mouse monoclonal (63.7) 1:50 (IF) 
Vimentin (human) Abcam ab8978 Mouse monoclonal  1:100 (IF) 
Vimentin Sigma V2258 Mouse monoclonal (LN-6) 1:200 (IF) 
E-cadherin Abcam ab11512 Rat monoclonal (DECMA-1) 1:200 (IF) 
Twist Santa Cruz sc-81417 Mouse monoclonal 1:50 (FC) 
Twist1 Abcam ab49254 Rabbit polyclonal 1:200 (IF) 
Zeb1 Santa Cruz Sc-25388 Rabbit polyclonal 1:100 (IF) 
Snail Abcam ab82846 Rabbit polyclonal 1:100 (IF) 
AXL-biotinylated R&D systems BAF854 Goat polyclonal 1:100 (FC) 
AXL R&D systems MAB8541 Rat polyclonal 1:100 (IF) 
AXL (human) R&D systems MAB154 Mouse polyclonal 1:100 (IF/FC) 
Integrin-α4 - PE eBioscience 12-0492-
81 
Rat monoclonal (R1-2) 1:300 (FC) 
Integrin-α6 - PE eBioscience 12-0495-
82 
Rat monoclonal (eBioGoH3) 1:300 (FC) 
Integrin-α7 - PE LS Bio LS-
C106132 
Hamster monoclonal (HMb1-
1) 
1:100 (FC) 
Integrin-β1 active BD bioscience 550531 Rat monoclonal (9EG7) 1:50 (IF) 
Integrin-β1 Abcam ab24693 Mouse monoclonal (P5D2) 1:100 (B/IF) 
Integrin-β1 - APC eBioscience 17-0291-
82 
Hamster monoclonal (HMb1-
1) 
1:300 (FC) 
Integrin-β2  BD bioscience 557440 Rat monoclonal (GAME-46) 1:300 (FC) 
Integrin-β4  eBioscience 50-1049-
82 
Rat monoclonal (439-9B) 1:300 (FC) 
CD24-AF450 eBioscience 48-0242-
82 
Rat monoclonal (M1/69) 1:100 (FC) 
CD90-APC eBioscience 17-0900-
82 
Mouse monoclonal (HIS51) 1:100 (FC) 
CD31-PE eBioscience 12-0311-
82 
Rat monoclonal (390) 1:300 (FC) 
CD45-PE eBioscience 12-0451- Rat monoclonal (30-F11) 1:300 (FC) 
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82 
Ter119-PE eBioscience 12-5921-
82 
Rat monoclonal (Ter-120) 1:300 (FC) 
FAK Santa Cruz sc-558 Rabbit polyclonal 1:300 (IF) 
P-FAK Santa Cruz sc-16563-
R 
Rabbit polyclonal 1:50 (IF) 
THBS2 Santa Cruz sc-12313 Goat polyclonal 1:100 (IF) 
ID1 Biocheck BCH-
1/195-14 
Rabbit monoclonal (195-14) 1:100 (IF) / 
1:5000 (WB) 
ID1 GeneTex GTX53624 Rabbit polyclonal 1:20 (FC) 
pSMAD1-5 Cell signal 13820 Rabbit monoclonal (D5B10) 1:100 (IF) 
pSMAD1-5 Cell signal 9511 Rabbit monoclonal (D5B10) 1:100 (IF) / 
1:20 (FC) 
pSMAD2-3 Cell signal 8828 Rabbit monoclonal (D27F4) 1:100 (IF) / 
1:20 (FC) 
BrdU Abcam ab6326 Rat monoclonal (BU1/75 
ICR1) 
1:100 (FC) 
 
 
• All antibodies are mouse specific, unless otherwise specified. 
• IF: Immunofluorescence 
• FC: Flow cytometry 
• WB: Western Blot 
• IHC-P: Immunohistochemistry – paraffin embedded tissue 
• B: Blocking antibody 
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Chapter 3. MICs display a highly secretory 
mesenchymal status that enhances fibroblasts 
activation and metastasis initiation  
 
3.1 MICs isolated from primary breast tumours display a highly 
secretory mesenchymal phenotype 
As discussed in section 1.3.1, MICs were previously described in the MMTV-PyMT 
mouse model of breast cancer that spontaneously metastasises to the lungs. MICs 
are characterised by the co-expression of the epithelial marker CD24, previously 
shown to stain all epithelial cells in the mammary gland tissue (Sleeman et al., 
2006) and the CD90 marker, which was previously shown to be highly expressed 
by mammary bipotent epithelial progenitor cells in human (Raouf et al., 2008), and 
a small subpool of CD24+ epithelial cells with tumour-initiating abilities in both, 
mouse and human (Cho et al., 2008, Lu et al., 2014); see introduction – section 
1.3.1 for more details about these markers. This lineage negative (CD45-, Ter119- 
and CD31-), CD24+CD90+ subpool in the MMTV-PyMT tumours was functionally 
defined as metastasis-initiating cells (MICs) by their exclusive ability to initiate 
metastatic growth in experimental metastasis assays (Malanchi et al., 2012). In this 
thesis, we used this functionally validated markers, CD24 and CD90, to further 
characterise this population of MICs. 
 
3.1.1 MIC gene expression profile  
In order to investigate which mechanisms allow MICs to successfully seed 
metastases we analysed their gene expression profile using microarrays. MICs 
account for about 2-3% of the total tumour cell mass at the primary site and when 
directly isolated and tested in vivo show a higher metastatic behaviour. To gain 
some insight on the intrinsic characteristics discriminating MICs from the bulk of the 
tumour, we freshly isolated MICs (CD24+CD90+) and nonMICs (CD24+CD90-) from 
late-stage MMTV-PyMT tumours by cell sorting (Figure 3.1.A). In order to identify 
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MICs in total PyMT tumour cell preparations, we excluded small particles and cell 
doublets (scatter), death cells (viability dye) and lineage negative cells (immune 
cells (CD45) endothelial cells (CD31) and erythrocytes (Ter119)) by the gating 
strategy shown in Figure 3.1.A. Next, CD24 allows the discrimination of the total 
mammary epithelial cells, CD24+, compared to other non-epithelial lineages, CD24-
(Figure 3.1.A), such as fibroblasts that cannot be excluded otherwise. The epithelial 
populations of MICs (CD24+CD90+) and nonMICs (CD24+CD90-) were freshly 
isolated from different PyMT tumours and their gene expression profiles were 
generated and compared to create a MIC signature (Figure 3.1.B and Appendix 
7.1). 
 
In collaboration with Probir Chakravarty from the Bioinformatics Unit at the London 
Research Institute, we performed a global gene ontology (GO) analysis to 
determine the cellular compartments and biological processes most represented in 
the MIC signature. Regarding the cellular compartment analysis we found that most 
gene products upregulated in MICs are localised within the cell membrane or in the 
extracellular region (Figure 3.2.A). This highly secretory status suggests that these 
cells are more prone to interact with their surrounding microenvironment. The GO 
analysis on biological processes, consistent with previous reports confirmed high 
Wnt signalling (Malanchi et al., 2012, Malanchi et al., 2008, Reya and Clevers, 
2005) and TGFβ signalling (Oshimori et al., 2015) to be hallmarks of tumour-
initiating cells. Moreover, we observed highly upregulated cell adhesion and 
extracellular matrix (ECM) remodelling gene sets and a protease signature (Figure 
3.2.B), reaffirming the previous cellular compartment analysis that indicated an 
extracellular localisation for most MIC upregulated proteins. Interestingly, we also 
found the MIC signature to highly correlate with an epithelial-to-mesenchymal 
transition (EMT) programme (Figure 3.2.B) that could partially explain the high 
levels of secreted components expressed by these cells (Chong et al., 2012).  
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Figure 3.1 MIC isolation strategy and generation of the MIC signature 
(A) FACS gating strategy to isolate MICs and nonMICs from PyMT tumours. First, 
forward/side scatter; second, single cells; third, exclude death cells (PI-positive); 
forth, gate on lineage negative (Lin-: CD45-, CD31- and Ter119-; excludes immune 
cells, endothelial cells and erythrocytes respectively); fifth, plot CD24 against 
CD90, where double positive cells are MICs and CD24 single positives are 
nonMICs. (B) Heatmap compares the gene expression profiles of MICs and 
nonMICs isolated from late-stage MMTV-PyMT primary tumours. 
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Figure 3.2 MIC signature: a global analysis  
(A) GO analysis of cellular compartments indicates the cellular localisation of genes 
upregulated in MICs. (C) GO analysis of the top biological processes significantly 
upregulated in MICs. 
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Next, we performed a more detailed pathway analysis of the MIC gene expression 
profile validating by Gene Set Enrichment Analysis (GSEA) the observed general 
features described in the initial GO analysis (Figure 3.2). We found the 
transcriptome of MICs highly correlating with previously published signatures for 
Wnt signalling (available at Wnt homepage Stanford University), TGFβ signalling 
and EMT (Figure 3.3.A) (Farmer et al., 2009) as suggested by the GO analysis. 
Moreover, the MIC signature highly correlated also with YAP/TAZ signalling (Figure 
3.3.A) (Dupont et al., 2011), a growth control regulatory pathway with emerging 
potent roles in cancer stem cells and mechanotransduction (Piccolo et al., 2013).  
Subsequently, we generated a circos plot in collaboration with Probir Chakravarty 
summarising the main pathways found in the MIC signature (Figure 3.3.B). We 
established 3 colour-coded categories for these pathways, the first including Wnt 
signalling that is related to self-renewal and tumour-initiating potential (grey), the 
second including YAP/TAZ, TGFβ signalling and EMT is related to cancer cells’ 
invasion (red), and the third category groups different pathways related to 
microenvironmental regulation, secretion and cell-ECM interactions (blue). 
Additionally, we highlighted in the plot several genes related to these pathways that 
are highly expressed in MICs (Appendix 7.1) and were previously characterised to 
contribute to lung metastatic colonisation in breast cancer, such as SPARC, TNC, 
LOX, MMPs and CCL2 (section 1.1.2.2, 1.3.2 and 1.5.2). 
To find the commonalities between these three pathway categories, we decided to 
further characterise the EMT signature found in MICs since EMT have been 
previously described to contribute to all these general features in cancer cells: 
microenvironmental regulation (Taube et al., 2010, Lopez-Novoa and Nieto, 2009), 
invasion (Rhim et al., 2012, Tsai et al., 2012) and stemness (Mani et al., 2008, 
Beck et al., 2015). 
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Figure 3.3 MIC signature: detailed analysis of relevant processes and genes 
involved in metastasis  
(A) GSEA plots show the correlation of the MIC signature with Wnt target genes, 
TGFβ target genes, an EMT and a YAP/TAZ signature. (B) Circos plot displays the 
top up-regulated pathways in MICs: Wnt, related to self-renewal and tumour-
initiation (grey), TGFβ, EMT and YAP/TAZ related to invasion mechanisms in 
cancer cells (red), and pathways related to microenvironmental regulation and cell-
ECM interactions (blue). Relevant genes related to these pathways and previously 
described to contribute to the metastatic abilities of cancer cells such as SPARC, 
TNC or LOX are indicated in white, whereas other genes related to these pathways 
and analysed in this thesis are highlighted in red. 
 
 
 
In summary, MICs express many previously characterised factors that could 
contribute to their metastatic potential, supporting the described high metastatic 
ability of these cells (Malanchi et al., 2012). Importantly, we found different pathway 
categories, all related to a highly secretory EMT status defining the gene 
expression profile of MICs. 
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3.1.2 MICs isolated from primary breast tumours display a partial 
mesenchymal state 
In order to functionally validate the highly secretory EMT status of MICs, we freshly 
isolated MICs and nonMICs from late-stage MMTV-PyMT tumours and analysed 
the presence of different well-characterised EMT markers. Despite the high level of 
heterogeneity, we found the MIC subpool to be in a more mesenchymal state 
compared to nonMICs, defined by the expression of low E-cadherin and high 
Vimentin (Figure 3.4.A-C). However, we could observe that around 25% of the cells 
within the MIC subpool showed mild E-cadherin expression at the membrane 
(Figure 3.4.B). The fact that MICs maintain the epithelial marker E-cadherin 
suggests that these cells are in an intermediate EMT state rather than undergoing 
a full mesenchymal conversion. 
 
The more mesenchymal status of MICs compared to the bulk of the tumour was 
further confirmed by the higher expression of the EMT core transcription factors at 
the mRNA level, as well as the clear nuclear localisation of Zeb1 in MICs compared 
to nonMICs (Figure 3.5).  
 
Consistently with the higher expression of EMT-TFs MICs express many genes 
related to a single cell invasion programme, the mesenchymal type of motility 
based on integrin-mediated ECM adhesion and the use of proteases to generate 
traction force (section 1.2.1.1). The first set of genes is related to the ECM via the 
secretion of ECM components or metalloproteases conferring ECM remodelling 
abilities (Figure 3.6.A). The second gene set is directly linked to motility through the 
regulation of actin cytoskeleton components (Figure 3.6.B). The expression of 
these genes strongly suggests differential ECM remodelling and invasive abilities in 
MICs. 
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Figure 3.4. Mesenchymal phenotypic marker expression in MICs 
(A) Representative images show the expression of E-cadherin and Vimentin in 
freshly isolated nonMICs (CD24+CD90-) and MICs (CD24+CD90+). Cells were 
stained for analysis 12 hours post-plating in collagen-coated dishes. Scale bar, 40 
µm. (B) Graph indicates the percentage of E-cadherin and Vimentin positive cells in 
the MIC and nonMIC populations (n= 4 tumours). (C) Charts indicate the 
expression levels of E-cadherin and Vimentin in freshly isolated nonMICs and 
MICs. Data from one representative experiment from a total of 5 are shown. Line 
and error bars indicate mean ± SD of the population.  
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Figure 3.5 EMT core transcription factor expression in MICs 
(A) Quantitative real time PCR analysis compares the gene expression levels of the 
core EMT transcription factors. Data from 3 different experiments performed in 
triplicate (normalised to Gapdh). Bar represents mean ± sem. p<0.0001 by ANOVA 
comparing the gene sets of MIC versus nonMIC. (B) Charts indicate the level of 
nuclear versus cytoplasmic intensity mean of ZEB1. Data from one representative 
experiment from a total of 2 are shown. Line and error bar indicate mean ± SD of 
the population. (C) Images show ZEB1 cellular localisation (green) and DAPI 
(blue). Scale bars, 30 and 20 µm respectively. 
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Figure 3.6 Expression of invasion-related genes in MICs 
Quantitative real time PCR analysis compares the gene expression levels of 
extracellular matrix (A) and actin cytoskeleton (B) components in MICs and 
nonMICs. Data from 3 different experiments performed in triplicate (normalised to 
Gapdh). Bars represent mean ± sem. p<0.0002 for each plot by ANOVA comparing 
the gene sets in MIC versus nonMIC. 
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Consequently, we next validated these observations by performing functional 
assays ex vivo after MICs isolation from primary tumours. First, in order to 
corroborate the high secretion of ECM remodelling enzymes expected from MIC 
gene expression analysis we performed a DQ-collagen assay. MICs and nonMICs 
were embedded after FACS isolation into DQ-collagen-Matrigel matrices where the 
collagenase-driven hydrolysis of the DQ substrate results in separation of the 
quenched dye molecules from one another increasing the fluorescence signal 
(Figure 3.7.A). Although all tumour cells can degrade collagen fibers, MICs showed 
higher collagenase activity as reported by the DQ signal (Figure 3.7.B). 
Second, to validate the invasive phenotype suggested by the gene expression 
analysis and the partial mesenchymal phenotype, we performed three-dimensional 
invasion assays. GFP-MICs and non-labelled nonMICs isolated from actin-GFP or 
unlabelled MMTV-PyMT tumours were mixed in a 1:9 ratio forming spheroids 
where the in vivo MICs:nonMICs frequency is maintained (Figure 3.7.C). We 
collaborated with Danielle Park, from the Sahai Lab at the London Research 
Institute to perform the 3D invasion assays. Danielle embedded the mixed 
spheroids in matrices with different permissiveness towards invasion: pure Matrigel 
rich in laminins, collagen IV and other basement membrane components that do 
not facilitate invasion; pure collagen-I matrices, a stiffer environment similar to the 
stromal border of tumours that promotes cancer cell invasion; and 2:1 collagen-
I:Matrigel mixes, an intermediate condition that allows mammary cells in vitro to 
closely reproduce their in vivo behaviour (Nguyen-Ngoc et al., 2012). In these 
three-dimensional organotypic assays, PyMT cells in the spheroids can invade into 
the matrices as collective protrusions or as single cells (mesenchymal-like 
invasion). Therefore, to evaluate the mesenchymal features of labelled (MICs) or 
unlabelled (nonMICs) cells in each spheroid, we analysed the invasion of single cell 
elongated protrusions. As expected from the matrices properties all cancer cells 
could invade as elongated protrusions in collagen-I pure matrices whereas only 
some MICs formed elongated protrusions in pure Matrigel (Figure 3.7.D). 
Interestingly, in the 2:1 collagen-I:Matrigel mixture that more closely reproduces the 
in vivo microenvironment we could observe a differential phenotype: nonMICs 
invaded collectively forming bulbous protrusions while MICs clearly invaded as 
single cell elongated protrusions (Figure 3.7.D-E). This result reaffirms that MICs 
display a more mesenchymal invasive phenotype. 
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Figure 3.7 Secretory activity and invasive properties of MICs 
(A) Schematic shows the working principle of the DQ collagen assay. The collagen 
fibers contain a fluorescent substrate that is quenched by the close proximity of the 
molecules within the three-dimensional structure of the collagen (black dots). When 
the collagen fibers are cleaved, substrate fluorescent increases (green dots). (B) 
DQ collagen assay. MICs and nonMICs were freshly isolated from MMTV-PyMT 
tumours and seeded into 2:1 DQ-collagen:Matrigel gels. After 48h, the formed cell 
clusters were fixed and stained, and their enzymatic activity analysed. (Left) 
Images show the DQ collagen signal (green) surrounding nonMIC or MIC clusters 
delimited by F-actin (red) and DAPI (blue) staining. Scale bar, 15 µm. (Right) 
Histogram indicates mean ± sem of the DQ collagen signal relative to the cell 
cluster size. (C) Mixed spheroids invasion assay. Experimental set up: MICs from 
PyMT/actin-GFP tumours, and nonMICs from non-labelled PyMT tumours were 
freshly isolated by FACS, and re-aggregated overnight in suspension in a 1:9 
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MIC:nonMIC ratio. The spheroids formed were embedded in different matrices: 
only collagen-I, 2:1 collagen-I:Matrigel and only Matrigel. (D) Histogram shows 
mean ± sem of cells invading as elongated protrusions within the clusters in the 
different matrices. (E) Representative fluorescent images of one micro-spheroid 
seeded in 2:1 collagen-I:Matrigel mixture stained with DAPI (blue) and F-actin 
(red). Note the invasive MIC cells identified by GFP (green).  
 
 
 
 
Taken together, these functional data indicate that MICs are in a highly secretory, 
more mesenchymal state in comparison to the bulk cancer cells in the tumour mass. 
 
  
Chapter 3. Results I  
 
 
 
118 
3.1.3 MIC mesenchymal features actively contribute to their metastatic 
colonisation potential at the target site 
Next, we aimed to investigate the contribution of the observed mesenchymal 
phenotype to the metastatic colonisation potential of MICs. Therefore we analysed 
the generated microarray data searching for differentially expressed genes in MICs, 
focusing on those directly related to EMT – in Appendix 7.1 of this thesis we display 
the list of genes that showed a fold increment expression (MICs/nonMICs) ≥ 3, and 
below a summary list containing the top 100 upregulated genes in the MIC 
signature can be found (Table 3.1). We found several previously reported EMT-
related genes highly expressed in MICs: Fibronectin1 (FN1) and different 
metalloproteases (MMP13, MMP2, MMP3, MMP14), validated at the mRNA level in 
Figure 3.6; and the mesenchymal intermediate filament protein Vimentin, validated 
at the protein level in Figure 3.4. Among these highly expressed genes in MICs 
related to EMT (Table 3.1 – blue), we found the tyrosine kinase receptor AXL that 
have been previously characterised as a downstream effector of the EMT 
programme (Asiedu et al., 2013). Moreover, AXL expression is also dependent on 
TGFβ and YAP/TAZ pathways in solid cancers, enhancing tumour cell 
dissemination from the primary site (Li et al., 2014b, Li et al., 2014a). Accordingly, 
AXL have been shown to correlate with a higher metastatic risk and poor prognosis 
in breast cancer patients (Gjerdrum et al., 2010) – a more detailed description of 
AXL functions in breast cancer is included in section 1.2.1.1.  
We decided to further validate AXL as an EMT marker in MICs because of 1) its 
correlation with poor prognosis in breast cancer patients, 2) the fact that 3 different 
pathways (EMT, TGFβ and YAP/TAZ signalling) found to be overexpressed in 
MICs can control AXL expression, and 3) the fact that it is a transmembrane 
receptor that facilitates monitoring the EMT status of cancer cells in vivo. First, 
using cBioPortal for Cancer Genomics database, we confirmed in human breast 
cancer patient data the previously published observations in breast cancer animal 
models showing that AXL presence correlates with the expression of different EMT 
markers (Figure 3.8.A). Second, we validated the array data performing 
quantitative real time PCR and immunofluorescence in freshly isolated MICs and 
nonMICs, confirming the higher expression of AXL in the MIC compartment of the 
PyMT tumours (Figure 3.8.B-C). 
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No 
GENE 
SYMBOL 
FOLD 
INCREMENT DEFINITION 
1 Fn1 73.60964635 Mus musculus fibronectin 1 (Fn1), mRNA. 
2 Serping1 60.46920116 
Mus musculus serine (or cysteine) peptidase inhibitor, clade G, 
member 1 (Serping1), mRNA. 
3 Lum 60.06918146 Mus musculus lumican (Lum), mRNA. 
4 Thy1 59.32025165 
Mus musculus thymus cell antigen 1, theta (Thy1) or CD90, 
mRNA.  
5 Mmp3 56.8142886 Mus musculus matrix metallopeptidase 3 (Mmp3), mRNA. 
6 Serping1 54.48133702   
7 Mmp13 50.80097994 Mus musculus matrix metallopeptidase 13 (Mmp13), mRNA. 
8 Loxl1 49.87156687 Mus musculus lysyl oxidase-like 1 (Loxl1), mRNA. 
9 Col1a1 47.68421086   
10 Ctsk 44.40448725 Mus musculus cathepsin K (Ctsk), mRNA. 
11 Dcn 43.61584256 Mus musculus decorin (Dcn), mRNA. 
12 Col6a1 43.02501894 Mus musculus procollagen, type VI, alpha 1 (Col6a1), mRNA. 
13 Mmp2 42.58322206 Mus musculus matrix metallopeptidase 2 (Mmp2), mRNA. 
14 Adamts2 41.75490813 
Mus musculus a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 2 (Adamts2), mRNA. 
15 Lrrc15 41.68029907   
16 Mfap5 41.64301515 Mus musculus microfibrillar associated protein 5 (Mfap5), mRNA. 
17 Col5a1 41.04235801 Mus musculus procollagen, type V, alpha 1 (Col5a1), mRNA. 
18 Rnase4 40.18861336 
Mus musculus ribonuclease, RNase A family 4 (Rnase4), transcript 
variant 1, mRNA. 
19 Pi16 39.30356586 Mus musculus peptidase inhibitor 16 (Pi16), mRNA. 
20 Rarres2 38.82640932 
Mus musculus retinoic acid receptor responder (tazarotene 
induced) 2 (Rarres2), mRNA. 
21 Adamts2 37.03161082 
Mus musculus a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 2 (Adamts2), mRNA. 
22 Pla1a 35.33017006 Mus musculus phospholipase A1 member A (Pla1a), mRNA. 
23 Cpxm1 34.56071134 
Mus musculus carboxypeptidase X 1 (M14 family) (Cpxm1), 
mRNA. 
24 Cygb 34.15923397 Mus musculus cytoglobin (Cygb), mRNA. 
25 Ccdc80 34.05706562 Mus musculus coiled-coil domain containing 80 (Ccdc80), mRNA. 
26 Ccl11 33.36436321 
Mus musculus small chemokine (C-C motif) ligand 11 (Ccl11), 
mRNA. 
27 Fstl1 32.97793885 Mus musculus follistatin-like 1 (Fstl1), mRNA. 
28 Lox 32.66522761 Mus musculus lysyl oxidase (Lox), mRNA. 
29 Col6a1 32.32838235 Mus musculus procollagen, type VI, alpha 1 (Col6a1), mRNA. 
30 Col6a2 32.24366031 Mus musculus procollagen, type VI, alpha 2 (Col6a2), mRNA. 
31 Serpinf1 32.22446558 
Mus musculus serine (or cysteine) peptidase inhibitor, clade F, 
member 1 (Serpinf1), mRNA. 
32 Pcolce 32.16013333 
Mus musculus procollagen C-endopeptidase enhancer protein 
(Pcolce), mRNA. 
33 Scara3 31.79005897 
Mus musculus scavenger receptor class A, member 3 (Scara3), 
mRNA. 
34 Aebp1 31.55275609 Mus musculus AE binding protein 1 (Aebp1), mRNA. 
35 Fbln1 31.30597931 Mus musculus fibulin 1 (Fbln1), mRNA. 
36 Mmp3 31.29927231 Mus musculus matrix metallopeptidase 3 (Mmp3), mRNA. 
37 Fbn1 30.84942594   
38 Ogn 30.62286362 Mus musculus osteoglycin (Ogn), mRNA. 
39 Mmp3 30.22038636 Mus musculus matrix metallopeptidase 3 (Mmp3), mRNA. 
40 Tnxb 29.18681299 Mus musculus tenascin XB (Tnxb), mRNA. 
41 Dpt 28.81349432 Mus musculus dermatopontin (Dpt), mRNA. 
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42 Thbs2 27.92699494 Mus musculus thrombospondin 2 (Thbs2), mRNA. 
43 
LOC10004
7583 27.8890865 
PREDICTED: Mus musculus similar to apolipoprotein D 
(LOC100047583), mRNA. 
44 Serpina3n 27.67160631 
Mus musculus serine (or cysteine) peptidase inhibitor, clade A, 
member 3N (Serpina3n), mRNA. 
45 Col12a1 27.39104496 Mus musculus collagen, type XII, alpha 1 (Col12a1), mRNA. 
46 Knsl5 26.95470532   
47 Svep1 26.90604697 
Mus musculus sushi, von Willebrand factor type A, EGF and 
pentraxin domain containing 1 (Svep1), mRNA. 
48 Spon2 26.83853041 
Mus musculus spondin 2, extracellular matrix protein (Spon2), 
mRNA. 
49 Plat 26.34455797   
50 Cd248 26.15887428 Mus musculus CD248 antigen, endosialin (Cd248), mRNA. 
51 Col14a1 25.92587138   
52 
LOC63830
1 25.55375508 
PREDICTED: Mus musculus similar to interferon activated gene 
204 (LOC638301), mRNA. 
53 Bicc1 25.1432103 Mus musculus bicaudal C homolog 1 (Drosophila) (Bicc1), mRNA. 
54 Srpx2 24.90728486 
Mus musculus sushi-repeat-containing protein, X-linked 2 (Srpx2), 
transcript variant 2, mRNA. 
55 
LOC10004
4430 24.55997339 
PREDICTED: Mus musculus similar to Interferon activated gene 
205 (LOC100044430), mRNA. 
56 Tnxb 24.27757116 Mus musculus tenascin XB (Tnxb), mRNA. 
57 Sparc 24.11332411 
Mus musculus secreted acidic cysteine rich glycoprotein (Sparc), 
mRNA. 
58 Igfbp4 23.58079355   
59 
scl0001849
.1_2273 23.17580957   
60 
6330406I15
Rik 22.6360887 
Mus musculus RIKEN cDNA 6330406I15 gene (6330406I15Rik), 
mRNA. 
61 Mfap2 22.34155105 Mus musculus microfibrillar-associated protein 2 (Mfap2), mRNA. 
62 Pdgfra 22.29305127 
Mus musculus platelet derived growth factor receptor, alpha 
polypeptide (Pdgfra), transcript variant 1, mRNA. 
63 Itga11 22.19115202 Mus musculus integrin alpha 11 (Itga11), mRNA. 
64 Fbln1 22.09933361   
65 Htra3 21.72598387   
66 Cxcl14 21.70535391 Mus musculus chemokine (C-X-C motif) ligand 14 (Cxcl14), mRNA. 
67 Nid1 21.42034706 Mus musculus nidogen 1 (Nid1), mRNA. 
68 Prelp 21.29436558 
Mus musculus proline arginine-rich end leucine-rich repeat (Prelp), 
mRNA. 
69 
6330406I15
Rik 20.90904317 
Mus musculus RIKEN cDNA 6330406I15 gene (6330406I15Rik), 
mRNA. 
70 Gpx8 20.8173571 Mus musculus glutathione peroxidase 8 (putative) (Gpx8), mRNA. 
71 Scarf2 20.81035285 
Mus musculus scavenger receptor class F, member 2 (Scarf2), 
mRNA. 
72 Sparc 20.49187503 
Mus musculus secreted acidic cysteine rich glycoprotein (Sparc), 
mRNA. 
73 Ccl7 20.40200837   
74 Lum 20.27088078   
75 Bicc1 20.12116588 Mus musculus bicaudal C homolog 1 (Drosophila) (Bicc1), mRNA. 
76 Osr2 19.93992721 Mus musculus odd-skipped related 2 (Drosophila) (Osr2), mRNA. 
77 Olfml2b 19.85429131 Mus musculus olfactomedin-like 2B (Olfml2b), mRNA. 
78 Serpine2 19.81592693   
79 Itgbl1 19.72979134 Mus musculus integrin, beta-like 1 (Itgbl1), mRNA. 
80 Col8a1 19.66821469   
81 
ENSMUSG0
0000043795 19.60575329 
PREDICTED: Mus musculus predicted gene, 
ENSMUSG00000043795 (ENSMUSG00000043795), mRNA. 
Chapter 3. Results I  
 
 
 
121 
82 Timp1 19.04713677 
Mus musculus tissue inhibitor of metalloproteinase 1 (Timp1), 
transcript variant 2, mRNA. 
83 Dcn 18.84139087 Mus musculus decorin (Dcn), mRNA. 
84 Timp1 18.41986061   
85 C1qtnf3 18.41977383 
Mus musculus C1q and tumor necrosis factor related protein 3 
(C1qtnf3), mRNA. 
86 Igfbp4 18.36908763 
Mus musculus insulin-like growth factor binding protein 4 (Igfbp4), 
mRNA. 
87 Ly6c1 18.30177212 
Mus musculus lymphocyte antigen 6 complex, locus C1 (Ly6c1), 
mRNA. 
88 Serpina3h 18.14573816 
Mus musculus serine (or cysteine) peptidase inhibitor, clade A, 
member 3H (Serpina3h), mRNA. 
89 Gp38 17.90928912   
90 
scl0002507
.1_236 17.80258841   
91 Ppic 17.68622567 Mus musculus peptidylprolyl isomerase C (Ppic), mRNA. 
92 Prg4 17.59252918   
93 Col3a1 17.5644643 Mus musculus collagen, type III, alpha 1 (Col3a1), mRNA. 
94 C2 17.55475936 
Mus musculus complement component 2 (within H-2S) (C2), 
mRNA. 
95 
2310016C1
6Rik 17.26052088 
Mus musculus RIKEN cDNA 2310016C16 gene (2310016C16Rik), 
mRNA. 
96 Has1 17.09402607 Mus musculus hyaluronan synthase1 (Has1), mRNA. 
97 Gpx3 17.07563602 
Mus musculus glutathione peroxidase 3 (Gpx3), transcript variant 
2, mRNA. 
98 Olfml3 16.73507945 Mus musculus olfactomedin-like 3 (Olfml3), mRNA. 
99 Rarres2 16.7212608 
Mus musculus retinoic acid receptor responder (tazarotene 
induced) 2 (Rarres2), mRNA. 
100 Axl 16.71865497 Mus musculus AXL receptor tyrosine kinase (Axl), mRNA. 
 
Table 3.1 Top 100 upregulated genes in the MIC signature 
List contains a summary of the MIC gene expression profile data, top upregulated 
genes in MICs compared to nonMICs. Red – genes characterised in this study. 
Blue – genes related to Epithelial-to-Mesenchymal Transition (EMT). 
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Figure 3.8 AXL correlates with the EMT status of cancer cells in human 
breast tumour data and is highly express by MICs 
(A) Gene expression correlation analysis between AXL and Twist, Vimentin and 
Zeb1 mesenchymal markers in human breast carcinoma patient samples - 
cBioportal database. (B) Quantitative real time PCR analysis compares the gene 
expression levels of AXL. Data from 3 different experiments performed in triplicate 
(normalised to Gapdh). Bar represents mean ± sem. (C) Representative images 
show AXL staining (red) and nuclear DAPI (blue) in MICs and nonMICs. Scale bar, 
20 µm. Chart indicates the levels of AXL. Data from one representative experiment 
from a total of 3 are shown. Line and error bar indicate mean ± SD of the 
population. 
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Confirmed the high expression level of AXL in MICs, we decided to focus on the 
AXL+-MICs in order to specifically address the potential contribution of the 
mesenchymal features to metastatic colonisation, independently of the rest of 
stem-like features associated to MICs (i.e. high Wnt signalling, Figure 3.3). We 
started analysing the relationship between the MIC marker (CD90+) and AXL 
among the epithelial tumour cells (CD24+) by flow cytometry in freshly isolated 
MMTV-PyMT tumour cells. The MIC subpool (CD24+CD90+) accounts for 2-3% of 
the alive, lineage negative (LIN-: CD45-, Ter119- and CD31-) cells, of which around 
60% are AXL+ (Figure 3.9.A). The MIC compartment of the tumours displayed a 2-
fold increment in AXL-expressing cells compare to nonMICs (Figure 3.9.A). 
Conversely, the mesenchymal CD24+AXL+ population constitutes around 28% of 
the total alive, lineage negative cells in PyMT tumours, of which around 6.93% of 
the are MICs (CD24+CD90+); the CD24+AXL+ population contains 3 times more 
MICs than the more epithelial CD24+AXL- population (Figure 3.9.B). The relative 
frequency and percentage of overlap between these populations is represented in 
the Venn diagram, where the mesenchymal MICs (triple CD24+CD90+AXL+ - dark 
blue) is indicated, and constitutes around 1% of the alive, lineage negative tumour 
cells (Figure 3.9.C). These results show that MICs expressed higher levels of AXL 
than nonMICs, and the CD24+AXL+ mesenchymal population is enriched in MICs. 
 
 
As shown in the FACS plots, the MICs and CD24+AXL+ mesenchymal populations 
do not show a linear relationship and only partially overlap (Figure 3.9.C). In order 
to specifically address the contribution of the AXL mesenchymal features to the 
metastatic potential of MICs, we focused on the CD24+AXL+ mesenchymal 
population - evaluating the triple CD24+AXL+CD90+ was not technically possible as 
this small population constitutes around 1% of the total tumour cells (Figure 3.9.C), 
and in vivo experimental metastatic assays were not technically possible to perform 
with such low cells numbers. Therefore we proceeded to functionally validate the 
mesenchymal CD24+AXL+ population, which is highly enriched in MICs compared 
to the CD24+AXL- subpool.  
Immunofluorescence analysis revealed, as expected by the presence of the 
mesenchymal marker AXL, that both MICs and the CD24+AXL+ population display 
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a partial mesenchymal phenotype, with significantly higher number of Vimentin-
positive cells and lower E-cadherin compared to the more epithelial nonMICs and 
CD24+AXL- populations, respectively (Figure 3.10.A). 
Next, in order to specifically address the contribution of the mesenchymal features 
to the metastatic potential of MICs, we assayed the metastasis-initiating potential of 
the mesenchymal CD24+AXL+ population in parallel to the more epithelial 
CD24+AXL- tumour fraction. To exclude any advantage to grow a primary tumour 
mass in vivo, we performed in parallel primary tumour formation assays with both 
subpools. We used tail vein injection, or orthotopic transplantation respectively 
(Figure 3.10.B-C). Both assays require the intrinsic ability to self-renew and grow 
either in a collective challenge when locally injected in the mammary fat pad, or in a 
single cell challenge when directly seeded into the circulation as a model of 
experimental metastatic colonisation. Interestingly, we observed a mild decrease 
(not significant) in the primary tumour growth ability of the mesenchymal 
CD24+AXL+ cells compared to the CD24+AXL- more epithelial population (Figure 
3.10.D). Next, we assessed the metastatic colonisation potential of the 
mesenchymal CD24+AXL+ population compared to the rest of the tumour cells by 
intravenous injection into mice. Strikingly, in contrast to the results observed in the 
primary tumour initiation assays only the mesenchymal CD24+AXL+ cancer cells, 
which are highly enriched in MICs, were capable of lung colonisation (Figure 
3.10.E). 
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Figure 3.9 Relationship between MICs and the mesenchymal CD24+AXL+ 
population in PyMT tumour cells 
(A) Representative FACS analysis plots of the percentage of AXL-expressing cells 
(blue gates) in the MIC (red gate) and nonMIC (black gate) compartment of the 
PyMT tumours. (B) Representative FACS analysis plots of the percentage of MICs 
(red gates) in the CD24+AXL+ (blue gate) and CD24+AXL- (black gate) 
compartment of the PyMT tumours. (C) Venn diagram illustrates the relationship 
between MICs and CD24+AXL+ cells, and their relative frequency in PyMT tumours. 
Mean ± sem for each population is indicated (n=5 tumours).  
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Figure 3.10 Tumour-initiating and metastatic potential of the mesenchymal 
CD24+AXL+ population in PyMT tumour cells 
(A) (Left) Representative pictures show E-cadherin and Vimentin expression in the 
indicated MMTV-PyMT subpools. Cells were isolated by FACS sorting from the 
same primary tumour and plated overnight on collagen-coated dishes prior to 
analysis. (Right) Bar graphs indicate the percentage of E-cadherin and Vimentin 
positive cells in each population. Data from one representative experiment from a 
total of two are shown. Line and error bar indicate mean ± sem of the population. 
(B) Schematic shows a collective cell challenge for primary tumour growth. Tumour 
cells are injected into the mammary fat pad into a Matrigel plug. (C) Schematic 
represents a single cell challenge for metastatic growth. A single tumour cell 
suspension dissolved in PBS is directly injected into the tail vein of mice. (D) Box 
plot shows the primary tumour burden of primary PyMT CD24+AXL- versus 
CD24+AXL+ cells in a collective cell challenge. PyMT cells were freshly isolated 
from primary tumour and plated for 16h. The subpools were isolated by FACS 
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sorting and the indicated cell numbers were injected into the mammary fat pad in 
Matrigel plugs (n=4 mice per group). (E) (Left) Box plot shows metastatic potential 
of primary PyMT/aGFP CD24+AXL- versus CD24+AXL+ cells in a single cell 
challenge. 5x105 cells were prepared as a single cell suspension and injected in the 
tail vein directly after cell sorting (2 independent experiments shown with n=5-6 
mice per group). (Right) Representative images of superficial GFP+ lung 
metastases formed by CD24+AXL- or CD24+AXL+. 
 
 
 
Subsequently, we wanted to assess whether MICs mesenchymal features, as 
suggested by the enhanced lung colonisation ability of the CD24+AXL+ cells, are 
essential for metastatic colonisation specifically but not for primary tumour initiation. 
Interestingly, in contrast to the previously reported linear correlation between 
mesenchymal features and stemness in breast cancer (Mani et al., 2008), we 
observed a decrease in tumour growth when mesenchymal AXL+ primary PyMT 
cells were compared to the more epithelial AXL- subpool (Figure 3.10.D). These 
results suggest that the mesenchymal features in the MMTV-PyMT model do not 
correlate with higher tumour-initiating ability or stemness, but confer an advantage 
exclusively for metastatic growth at distant sites (Figure 3.10.E).  
To test this hypothesis, we analysed in parallel the expression of stem-cell antigen-
1 (Sca1), previously described as a functional mammary epithelial stem/progenitor 
cell marker to study tumour initiation in genetically engineered mouse models 
(Welm et al., 2002, Grange et al., 2008). Specifically, the epithelial CD24+Sca1+ 
subpool has been previously reported to define a tumour-initiating population in the 
MMTV-Neu mouse model (Liu et al., 2007b). Therefore, we next checked Sca1 
expression in the MMTV-PyMT tumours as a potential tumour-initiating cell marker, 
and its relationship to the CD90 and AXL markers, and the mesenchymal features 
that define metastasis-initiating properties. The CD24+Sca1+ population accounts 
for 60% of the total tumour cells in the PyMT model (Figure 3.11.A). The majority of 
the Sca1 population (around 75%) is negative for the mesenchymal marker AXL, 
therefore the Sca1+ subpool is not enriched in mesenchymal characteristics (Figure 
3.11.A-B). In line with this observation, both the CD24+Sca1+ and its depleted 
fraction show a similar expression of E-cadherin and Vimentin (Figure 3.11.D-E). 
Furthermore, as expected by its low overlap with the mesenchymal AXL population 
(Figure 3.11.B), the CD24+Sca1+ population is in a more epithelial state compared 
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to MICs and the CD24+AXL+ population (Figure 3.11.F). Moreover, in contrast to 
the observed enrichment in MICs within the AXL+ fraction of tumour cells (Figure 
3.9.B), the Sca1 compartment of the tumour is not enriched in MICs (Figure 3.11.A). 
 
 
Next, we tested in parallel all these more epithelial or more mesenchymal PyMT 
populations for their ability to initiate a primary tumour mass. We isolated the three 
populations MICs, CD24+AXL+ and CD24+Sca1+ cells from the same primary 
tumour and injected either 103 or 104 cells sub-cutaneously. Interestingly, all 
subpools could give rise to primary tumour masses. Notably, MICs generated 
significantly bigger tumours than the likewise mesenchymal CD24+AXL+ subpool 
(Figure 3.12.A-C). Additionally, MICs tumours grew as efficiently as the more 
epithelial CD24+Sca1+ tumours. These data indicate that the mesenchymal 
features per se are not sufficient to boost primary tumour growth in this model, and 
suggest that in this assay other stem-like features of MICs not shared by the 
mesenchymal CD24+AXL+ population, such as high Wnt signalling (Figure 3.3) 
define their tumour-initiating properties. 
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Figure 3.11 Relationship between MICs, AXL+ and Sca1+ epithelial 
populations in PyMT tumours 
(A) Representative FACS analysis plots show the percentage of MICs (red gates) 
or CD24+AXL+ (blue gates) within the CD24+Sca1+ and CD24+Sca1- compartments 
of the PyMT tumours. (B) Venn diagram illustrates the relationship between the 
different PyMT populations, and their relative frequency in PyMT tumours. Mean ± 
sem for each population is indicated (n=5 tumours). (C) Analysis of the percentage 
of MICs (CD90+) expressing AXL and Sca1 markers. Pie graphs display the mean 
± sem of each population (n=5 tumour cell preparations). (D) Representative 
pictures show E-cadherin and Vimentin expression in the indicated MMTV-PyMT 
subpools. (E-F) Graphs indicate the percentage of E-cadherin and Vimentin 
positive cells in each population, all isolated in parallel from the same primary 
tumour. Data from one representative experiment from a total of two are shown. 
Line and error bar indicate mean ± sem of the population. 
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Figure 3.12 Tumour-initiation ability of different primary PyMT populations 
(A) Sub-cutaneous tumour initiation assay. The indicated PyMT populations were 
FACS sorted from the same primary tumour cell preparation after overnight plating 
on collagen-I coated dishes. Either 103 cells or 104 cells from each population were 
transplanted sub-cutaneously into RAG1 mice. (B-C) Images of the tumours 
harvested either 30 or 20 days after transplanting 103 or 104 cells, respectively. 
Scale bars, ∼	  5 mm. 
 
 
 
In conclusion, in the MMTV-PyMT mouse model there is no evidence for a more 
mesenchymal tumour cell pool sustaining primary tumour growth. Nevertheless, the 
mesenchymal characteristics observed in MICs are sufficient to define metastatic 
competency as indicated by the high colonisation ability of the AXL+ subpool 
(Figure 3.10.E), but yet independent of the intrinsic stemness potential required for 
tumour initiation (Figure 3.12). In other words, these results suggest that the 
mesenchymal characteristics observed in MICs are specifically defining metastatic 
competency rather than tumour-initiation abilities. 
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3.2 MICs have an increased ability to activate lung fibroblasts 
In the previous section, we have shown that MICs are in a highly secretory 
mesenchymal state as defined by high AXL expression (Figure 3.3 and 3.8), which 
confers a metastatic advantage independently of stemness (Figure 3.10). 
Therefore, we hypothesised that the secretory mesenchymal features might confer 
MICs an increased ability to generate a favourable environment or niche, as they 
extravasate into the lungs. Notably, this characteristic would be crucial during 
metastatic colonisation when disseminated single cells in a foreign tissue need to 
create a favourable niche (section 1.3.2).  
To test this hypothesis, we used the mesenchymal CD24+AXL+ population that 
likewise MICs displays enhanced metastatic ability (Figure 3.10.E), and we 
analysed their microenvironment for the presence of activated stroma just after 
extravasation into the metastatic tissue. Actin-GFP/CD24+ cells positive or negative 
for AXL were isolated by FACS from primary tumours and intravenously injected 
into mice. Lungs were analysed 3 days post-injection, when single disseminated 
tumour cells have extravasated into the lung parenchyma (Figure 3.13.A). We 
observed that CD24+AXL+ cells were surrounded by a higher number of smooth 
muscle actin (SMA) activated fibroblasts compared to CD24+AXL- cells suggesting 
their exclusive ability to induce a fibroblastic niche (Figure 3.13.B-C). Remarkably, 
no difference in their tissue localisation was detected as measured by their 
proximity to lung endothelial cells stained with endomucin, excluding that 
CD24+AXL+ and CD24+AXL- cells occupy different pre-existing niches upon 
extravasation to the lung (Figure 3.13.B-C). These results indicate that tumour cells 
displaying an AXL-mesenchymal status, in contrast to more epithelial tumour cells, 
show an increased ability to activate fibroblastic stroma upon arrival into the lungs. 
  
Chapter 3. Results I  
 
 
 
132 
 
 
 
 
 
 
Figure 3.13 AXL-mesenchymal cancer cells activate a fibroblastic metastatic 
niche upon extravasation to the lungs 
(A) Experimental set up: Actin-GFP/CD24+AXL+ and CD24+AXL- cells were FACS 
sorted, and 106 cells were injected intravenously into immunodeficient RAG1 mice. 
Lungs were analysed 72h post-seeding. (B) Bar graphs display the number of SMA 
(left) and Endomucin (right) positive cells in direct contact with the GFP+ tumour 
cells (n≥50 cells). (C) Representative pictures show single Actin-GFP/CD24+AXL+ 
and CD24+AXL- cells (green) in the lung, DAPI staining (blue) and SMA and 
Endomucin (red). Scale bars, 8 µm and 10 µm respectively. 
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Subsequently, we validated whether the observed in vivo fibroblast activation by 
the AXL mesenchymal pool is a characteristic of MICs during early metastatic 
colonisation. Due to MICs low frequency within the cancer cells, further in vivo 
testing with this subpool was not technically possible. Therefore we set out to test 
ex vivo the ability of MICs to activate lung fibroblasts. As described beforehand, 
fibroblasts are key components of the metastatic niche and secrete different 
molecules, such as POSTN, that support metastatic colonisation (section 1.3.2) 
(Malanchi et al., 2012). This supportive role of fibroblasts is observed once they are 
activated and display characteristic features of pro-tumorigenic cancer-associated 
fibroblasts (CAFs) (Dumont et al., 2013), such as nuclear YAP translocation and 
increased FAP and SMA expression (Calvo et al., 2013). However, it remains 
unknown how the resident lung fibroblasts are activated during early metastatic 
colonisation. To shed light into this question, we tested whether the exclusive 
metastatic ability of MICs could depend on their higher ability to activate fibroblasts, 
as suggested by the disseminated mesenchymal AXL+ subpool in vivo (Figure 
3.13). We directly cultured FACS sorted cancer cells; either MICS or nonMICs, with 
a GFP labelled normal lung fibroblast cell line (NLF3) and monitored the induction 
of activation markers in the fibroblasts ex vivo (Figure 3.14.A). All tumour cells can 
induce fibroblast activation, therefore we designed a experimental set up where low 
numbers of tumour cells in a short period of time are tested for their differential 
ability to induce fibroblast activation markers. Nuclear YAP translocation, required 
for CAF induction (Calvo et al., 2013), as well as fibroblast activation protein (FAP) 
expression were highly induced in fibroblasts co-cultured with MICs after only 24h, 
while nonMICs were only able to trigger mild FAP expression (Figure 3.14.B-D). 
This result suggests that limited numbers of MICs can trigger fibroblast activation 
more efficiently that the rest of tumour cells.  
 
 
To confirm that the presence of these markers represent features of CAFs, we 
performed a functional gel contraction assay. This assay gives an indirect 
measurement of the enhanced ability of CAFs to physically remodel an ECM 
compared to non-activated normal fibroblasts. Low numbers of MICs or nonMICs 
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isolated by FACS from primary mammary tumours were seeded in the upper 
chamber of a trans-well coculture dish. In the lower chamber of the coculture 
primary lung fibroblasts freshly isolated from wild type mouse lungs (NF) were 
embedded in 2:1 collagen-I:Matrigel matrices (Figure 3.15.A). Remarkably, MICs 
were able to induce stromal cell activation more efficiently compared than the rest 
of primary cancer cells as monitored by the increased fibroblast gel contraction, as 
well as the gain of a CAF gene expression signature (Figure 3.15.B-C).  
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Figure 3.14 MICs display enhanced ability to induce lung fibroblast activation 
phenotypically  
(A) Schematic shows the coculture setting where nonMICs or MICs are seeded on 
top of a thin layer of Matrigel:Collagen-I with GFP+ labelled normal lung fibroblast 
cell line (NLF3). After 24 hours fibroblasts were monitored by immunofluorescence 
for changes in the expression of CAF-defining markers. (B) Representative images 
of FAP levels in NLF3 cells cultured in the presence of nonMICs or MICs for 24h. 
Scale bar, 70 µm. (C) Chart indicates the quantification of the nuclear levels of YAP 
and FAP. Data from one representative experiment from a total of 3 are shown. 
Line and error bar indicate mean ± SD of the populations. (D) Representative 
images of YAP nuclear translocation in NLF3 cells cultured in the presence of 
nonMIC or MIC for 24h. Scale bar, 40 µm. 
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Figure 3.15 MICs display enhanced ability to induce lung fibroblast activation 
functionally 
(A) Schematic shows the coculture setting where primary normal lung fibroblasts 
(NF) are seeded in the lower compartment embedded in Matrigel:Collagen-I. MICs 
and nonMICs are added to a separate compartment on top. Fibroblast activation-
dependent gel contraction is monitored over 5 to 10 days. (B) (Left) Representative 
images of the gel contraction assay 5 and 10 days after coculture. (Right) 
Histogram displays mean ± sem (n=8, number of gels) assessed over 3 
independent experiments. (C) Quantitative real time PCR analysis compares the 
gene expression levels of different CAF-defining genes induced by MICs and 
nonMICs. Data from 3 different experiments performed in triplicate (normalised to 
Gapdh). Bars represent mean ± sem. p=0.0235 by ANOVA comparing the 
signatures of NLF3-nonMIC versus NLF3-MIC. 
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Collectively these data provide direct experimental evidence that cancer cells in an 
AXL-mesenchymal state possess an enhanced ability to trigger fibroblast activation, 
generating their metastatic niche. 
  
Chapter 3. Results I  
 
 
 
138 
3.3 The increased ability of metastatic cells to activate lung 
fibroblasts depends on the secretion of Thrombospondin-
2, a key step for efficient metastasis 
 
3.3.1 MIC-derived THBS2 activates lung fibroblasts 
We have shown in the previous section how AXL defines a mesenchymal state in 
cancer cells conferring high metastatic potential (Figure 3.10.E), and these cells 
also display enhanced ability to induce activated fibroblasts early after 
extravasation into the naïve lung tissue (Figure 3.13.B-C). We sought next to 
elucidate the mechanisms by which MICs activate lung fibroblasts. For this purpose, 
we analysed the secretome observed in the MIC signature (Figure 3.3.B) and 
validated the top differentially expressed secreted factors in MICs compared to 
nonMICs by quantitative PCR (Figure 3.16.A-B). Next, we functionally tested these 
MIC-secreted proteins for their effect to activate normal lung fibroblasts in gel 
contraction assays. We used the recombinant proteins of the different factors 
identified at concentrations previously reported to exert their activity in vitro, THBS2 
(5 µg/ml) (Hirose et al., 2008), ANGPTL4 (5 µg/ml) (Cazes et al., 2006), CCL7 (0.3 
µg/ml) (Gouwy et al., 2008), CCL11 (0.1 µg/ml) (Saunders et al., 2008), CYR61 
(1.5 µg/ml) (Francischetti et al., 2010) and WNT5a (0.5 µg/ml) (Li et al., 2013), and 
added them to normal lung fibroblasts in gel contraction assays. We found that two 
MIC-derived secreted factors, Thromspondin-2 (THBS2) and the Wnt ligand Wnt5a 
were able to boost the gel contraction ability of lung fibroblasts embedded in 
Matrigel:collagen-I matrices (Figure 3.16.C-D). We decided to focus on THBS2 
rather than Wnt5a due to its higher differential expression in MICs compared to 
nonMICs (Figure 3.16.A). THBS2 is normally secreted on a per cell basis at a mean 
value of ∼5 µg/l per 105 cells in vitro (Hankenson and Bornstein, 2002). It is 
therefore to acknowledge that the used of higher concentrations (5 µg/ml) of 
recombinant THBS2 could explain the potent effect and sufficiency of this factor to 
trigger fibroblast activation in vitro, while at physiological levels in vivo the 
synergistic effects of several factors, such as TGFβ, or the other validated MIC-
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derived factors described, might be required. We found purified THBS2 to be 
sufficient to trigger YAP nuclear translocation and FAP expression in normal lung 
fibroblasts 24h after treatment in vitro (Figure 3.16.E), in line with the previous 
results showing YAP/FAP induction in normal lung fibroblasts after 24h coculture 
with MICs. 
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Figure 3.16 THBS2 is differentially expressed in MICs and triggers fibroblast 
activation 
(A) List of some of the top secreted factors found in the MIC signature. Fold change 
expression of each factor obtained by comparing the expression levels in MIC 
versus nonMICs. (B) Quantitative real time PCR analysis shows the expression of 
the MIC secreted factors. Data from 3 different experiments performed in triplicate 
(normalised to Gapdh). Bar represent mean ± sem. p=0.0057 by ANOVA 
comparing the gene set in MICs versus nonMICs. (C) Gel contraction assay by 
NLF3 3 days after addition of the THBS2 (5 µg/ml), ANGPTL4 (5 µg/ml), CCL7 (0.3 
µg/ml), CCL11 (0.1 µg/ml), CYR61 (1.5 µg/ml) and WNT5a (0.5 µg/ml). (D) 
Representative images show the gel contraction quantified in (C) for CCL7, THBS2 
and Wnt5a. (E) Charts indicate the nuclear levels of YAP and total FAP expression 
after addition of THBS2 (5 µg/ml) for 24h. Data from one representative experiment 
from a total of 3 are shown. Line and error bar indicate mean ± SD of the 
populations. 
 
 
 
These data propose THBS2 as a specific MIC-secreted factor mediating their 
enhanced fibroblast activation ability. 
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3.3.2 THBS2 triggers integrin β1 signalling leading to fibroblast activation 
After finding that THBS2 can enhance fibroblast activation, we investigated its 
mechanism of action. We searched in silico potential THBS2 interacting partners 
using the String database to predict THBS2 mediated protein-protein interactions. 
From the predicted interacting partners found many were other secreted proteins 
such as metalloproteases, other thrombospondins and the PDGFBB ligand (Figure 
3.17.A). We focus on the transmembrane receptors identified by this analysis that 
could transduce THBS2 signal directly and found different integrins (Figure 3.17.A). 
As discussed earlier, integrins usually represent the main bridge for cell-ECM 
interactions (section 1.1.2.2). Among the potential THBS2 interacting partners 
(integrins α4, α6, α7 and β1) we found that only integrins α4, α6 and β1 are 
expressed by normal lung fibroblasts (Figure 3.17.B). As integrin complexes signal 
through the β subunit (section 1.1.2.2), we functionally tested the direct interaction 
of THBS2 with integrin β1. By using immunofluorescence and confocal microscopy 
we could detect the colocalisation of the exogenously added recombinant THBS2 
with the endogenous lung fibroblasts integrin β1 (Figure 3.17.C). The images 
revealed that THBS2 addition to the fibroblasts causes integrin clustering and 
potential internalisation. Integrin β1 internalisation is a mechanism required at the 
leading edge of migrating cells to transiently disassemble focal adhesions, further 
facilitating their directional migration (Nishimura and Kaibuchi, 2007). Hence, the 
observed integrin internalisation suggests an enhanced fibroblast migration that 
would go in line with fibroblast activation (Calvo et al., 2013). 
We further tested the functional relevance of THBS2-integrin β1 interaction by 
examining normal lung fibroblast integrin β1 activation by using a specific antibody 
against the active conformation of this integrin. Simultaneously, we monitored the 
phosphorylation of its downstream effector focal adhesion kinase (pFAK) that binds 
to and associates with the integrin-adapter protein–cytoskeleton complex, forming 
the basis of focal adhesions (section 1.1.2.2 and Figure 1.4.B). Both, the active 
isoform of integrin β1 and the phosphorylation levels of pFAK increased 24h after 
THBS2 stimulation. Notably, preventing integrin activation by using a specific 
integrin β1-blocking antibody (β1BA) before THBS2 stimulation halted THBS2-
dependent integrin activation (Figure 3.17.D-E).  
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Figure 3.17 THBS2 binds integrin β1 in normal lung fibroblasts activating its 
downstream signalling 
(A) THBS2 interactome: confidence view represents stronger associations by 
thicker lines. (B) Normal lung fibroblast cell line (NLF3) integrin expression 
assessed by FACS analysis. (C) Confocal images show recombinant THBS2 (red), 
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integrin β1 (green) and DAPI (blue). Note the colocalisation of the THBS2 and the 
integrin β1 clusters signals. (D) Charts indicate the levels of the active isoform of 
integrin β1 and its phosphorylated downstream effector FAK in NLF3, NLF3 + 
THBS2 (5 μg/ml) and NLF3 + THBS2 (5 μg/ml) in the presence of β1 integrin 
blocking antibody (β1BA) (20 μg/ml). Data from one representative experiment 
from a total of 2 are shown. Line and error bar indicate mean ± SD of the 
populations. (E) Representative images of quantification in (D). Scale bars, 20 μm 
and 10 μm, respectively.  
 
 
 
 
We next checked the functional relevance of this THBS2-mediated signalling 
cascade for fibroblast activation. Blocking THBS2-mediated integrin β1 activation 
halted the induction of the early effectors of fibroblast activation as measured by 
YAP nuclear translocation and FAP expression over 24h (Figure 3.18.A-B). 
Moreover, blocking integrin β1 prevented the THBS2 mediated enhanced gel 
contraction ability of fibroblasts (Figure 3.18.C).  
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Figure 3.18 Preventing integrin β1 activation halts THBS2-mediated fibroblast 
activation 
(A) Representative images of YAP nuclear translocation and FAP expression 
induction in NLF3 cultured in the presence of recombinant THBS2 (5 µg/ml) for 24h 
± integrin β1 blocking antibody (20 µg/ml), added 2 hours before THBS2 treatment. 
Scale bar, 20 µm. (B) Chart indicates the quantification of nuclear YAP levels and 
total FAP levels in (A). Data from one representative of four experiments are 
shown. Line and error bar indicate mean ± SD of the populations. (C) Upper panel, 
images show gel contraction by NLF3 cultured in the presence of recombinant 
THBS2 (5 µg/ml) for 24h ± integrin β1 blocking antibody (20 µg/ml), added 2 hours 
before THBS2 treatment. Lower panel, histogram shows the mean ± sem (n= 
number of gels: NLF3, 16; NLF3 + THBS2, 16; NLF3 + THBS2 (β1BA), 4), 
assessed over multiple experiments. 
 
 
Altogether, these data reveal a novel mechanism by which THBS2 enhances 
normal fibroblasts activation through integrin β1 signalling. 
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3.3.3 THBS2-mediated fibroblast activation is crucial for lung metastatic 
colonisation 
In light of the previous results, we sought to investigate the relevance of THBS2 
expression for metastasis. We used a lentiviral EGFP-reporter construct to express 
specific short-hairpin RNAs targeting THBS2 mRNA upon lentiviral infection (Figure 
3.19.A); infected primary PyMT cancer cells were selected by cell sorting based on 
their EGFP expression. We used two different short-hairpin sequences and 
evaluated their corresponding knockdown efficiency at the protein level by ELISA 
(Figure 3.19.B). The first shRNA sequence (shTHBS2 I) reduced THBS2 levels by 
a third of its original expression, while the second (shTHBS2 II) was more efficient 
and no THBS2 was detected in the ELISA assay (Figure 3.19.B). Importantly, 
cancer cells with depleted THBS2 reduced their ability to activate lung fibroblasts in 
gel contraction assays (Figure 3.19.C). Together, these data propose THBS2 as a 
cancer cell secreted co-factor facilitating fibroblast activation.  
 
To assess the role of MIC-derived THBS2 secretion during metastatic colonisation 
we tested shTHSB2 cancer cells to grow in vitro and in vivo. In vitro, we excluded 
that THBS2 could have a direct effect on the intrinsic potential of the cancer cells 
by measuring the ability of shTHSB2 cells to form spheres as a measurement of 
their self-renewal capacity in vitro. No significant effects were observed on the 
ability of shTHBS2 cells to form spheres in non-adherent conditions (Figure 3.20.A). 
Then, we performed the gold standard in vivo test for self-renewal assessing 
shTHBS2 cells to initiate tumour growth in orthotopic transplantation assays. Early 
primary tumour initiation ability was not affected in the absence of THBS2 (Figure 
3.20.B). Collectively, these results indicate that THBS2 does not affect the intrinsic 
ability of PyMT tumour cells to self-renew and initiate a tumour mass.  
Given that THBS2 depletion does not impact in the intrinsic potential of tumour 
cells to grow, we tested the metastatic colonisation potential of shTHBS2 PyMT 
cells. We used experimental metastasis assays where EGFP+ sorted cells 
expressing shTHBS2 are directly injected into the tail vein of mice (as in Figure 
3.10.C). Strikingly, THBS2 depletion impairs the metastatic colonisation ability of 
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primary PyMT cells (Figure 3.20.C). These results highlight the crucial role of MIC- 
derived THBS2 for metastatic colonisation. 
 
 
 
 
 
 
 
Figure 3.19 THBS2 knockdown in PyMT cells reduces their fibroblast 
activation ability 
(A) Schematic shows the lentiviral reporter used to express the shRNA sequences. 
The shRNA sequences were cloned under the expression of a CMV enhancer 
followed by the H1 promoter. An independent mouse PGK promoter controls EGFP 
expression. (B) Histogram shows the relative levels of secreted THBS2 measured 
by ELISA present in the media conditioned by PyMT cells expressing shCONTROL 
or shTHBS2 lentiviral constructs. Data from 3 different experiments performed in 
duplicate. Bars represent mean ± sem. (B) (Upper panel) Images show gel 
contraction by normal lung fibroblasts (NLF3) cocultured with primary PyMT cells 
expressing shCONTROL or shTHBS2 lentiviral constructs. (Lower panel) 
Histogram shows the mean ± sem (n=4, number of gels). 
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Figure 3.20 THBS2 depletion does not affect self-renewal and tumour 
initiation in primary PyMT cells but impairs metastatic colonisation ability 
(A) Images show spheres formed by PyMT cells in suspension expressing 
shCONTROL and shTHBS2 lentiviral constructs. Histogram shows the mean ± sem 
of 2 independent experiments. Spheres were quantified 10 days after plating a 
single PyMT suspension (primary) and 10 days after the first passage (secondary). 
(B) Early primary tumour growth potential. Cells were FACS sorted to select for 
lentiviral expression and 50,000 shCONTROL or shTHBS2 PyMT cells were 
injected into the mammary fad pat. Tumour weight was evaluated 20 days post-
injection (n=4-10). (C) Metastatic colonisation ability of shCONTROL and shTHBS2 
PyMT cells. Positively infected PyMT cells were sorted as GFP+, and 5x106 cells 
were directly injected into the tail vein of mice. (Left) Micrometastasis evaluation 30 
days post-injection. (Right) Representative images of lung sections with 
micrometastasis. 
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Next, to further assess the role of THBS2 during metastasis we engineered a 
lentiviral reporter construct containing the open reading frame (ORF) of the mouse 
THBS2 gene under the expression of a mouse PGK promoter. The lentiviral 
construct contained also a truncated isoform of the human CD2 receptor (hCD2) 
and a VENUS reporter gene (3.21.A). We confirmed THBS2 overexpression by real 
time PCR in the mouse 4T1 cell line after infection and EGFP selection, detecting a 
15-fold increase in THBS2 secretion (Figure 3.21.B). Normally, in PyMT primary 
cells THBS2 expression is limited to the small MIC population within the tumour; by 
infecting total PyMT cells with this construct we broadened the number of cells that 
secrete THBS2 in the tumour cell mass. Subsequently, we evaluated the metastatic 
colonisation ability of THBS2ORF PyMT cells after intravenous injection. FACS 
analysis of the tumour cell content in the lungs 20 days post-intravenous injection 
revealed a higher cancer cell number in the lungs of mice injected with THBS2ORF 
PyMT cells, indicating an increased metastatic colonisation ability by PyMT cells 
when THBS2 is expressed by a larger cell number (Figure 3.21.C).  
 
 
Using GOBO (Gene expression-based Outcome for Breast cancer Online) we 
performed a Distant Metastasis-Free Survival (DMFS) analysis over 5 years in 
breast carcinoma patient data, correlating THBS2 expression with tumour grade. 
We found that in tumours classified as grade 3, THBS2 high expression 
dramatically reduces the patients’ DMFS over 5 years, indicating a correlation 
between high THBS2 levels and increased metastatic risk in advanced breast 
carcinoma (Figure 3.22). Notably, these clinical data reaffirm our findings indicating 
that THBS2 expression correlates with high metastatic risk in advanced stages of 
human breast carcinoma. 
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Figure 3.21 THBS2 overexpression enhances early metastatic colonisation 
(A) Lentiviral construct expresses the mouse THBS2 coding sequence 
(THBS2ORF) under the mouse PGK promoter. An independent human PGK 
promoter controls VENUS and hCD2 reporter genes expression. (B) Quantitative 
real time PCR showing a 15-fold THBS2 mRNA expression in 4T1 cell line after 
infection with the THBS2ORF construct and hCD2+ selection. (C) FACS 
quantification of tumour cell content in the lungs 20 days after intravenous injection 
of VENUS+ selected CONTROL or THBS2ORF PyMT cells (n=8-9). 
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Figure 3.22 High THBS2 expression correlates with higher metastatic risk in 
breast carcinoma 
Data generated using GOBO (Gene expression-based Outcome for Breast cancer 
Online). Plots show the percentage of Distant Metastasis-Free Survival (DMFS) 
over 5 years in breast cancer patients divided according to tumour grade. Within 
each grade, patients are further subdivided in low (grey), medium (red) or high 
(blue) THBS2 expression. Note the significant positive correlation between high 
THBS2 expression and decreased DMFS in grade 3 invasive breast carcinomas. 
 
 
 
 
 
Overall, the data presented in this chapter corroborates our initial hypothesis that 
MICs induce a favourable microenvironment at the newly colonised tissue. 
Specifically, we have identified a novel role of THBS2 to mediate metastatic niche 
induction contributing to the metastatic potential of MICs. 
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3.3.4 THBS2 is a potent microenvironmental regulator during mammary 
carcinoma development  
Next, we wanted to further analyse the role of THBS2 in tumorigenesis. We have 
shown that depleting THBS2 did not affect early tumour development (Figure 
3.18.B, note tumour weight around 0.2 g). Strikingly, at later stages of tumour 
growth the absence of THBS2 led to increased tumour burden (Figure 3.22.A). We 
previously reviewed how changes in the ECM composition have profound effects in 
the tumour microenvironment (section 1.1.2.2). In particular, complex processes 
such as angiogenesis are tightly regulated by the surrounding ECM. Indeed, 
THBS2 have been reported as an antiangiogenic factor in a xenograft model of 
breast cancer using the mesenchymal cell line MDA-MB-435 (Koch et al., 2011). 
Therefore, we performed some histological analysis of shTHBS2 tumours and 
analyse specifically potential changes in the vasculature staining blood vessels with 
Endomucin, a membrane glycoprotein specifically expressed in the vascular 
endothelium (Kuhn et al., 2002). We found that THBS2 depletion lead to the 
development of longer and more interconnected vessels (Figure 3.22.A), which 
might increase the supply of oxygen and nutrients to tumour cells explaining the 
increased tumour growth.  
 
Additionally, we generated primary PyMT tumour cells that exogenously expressed 
THBS2ORF by infecting them with the lentiviral construct in Figure 3.20.A, and 
tested their ability to generate primary tumours. In line with the previous observed 
increased tumour growth when depleting THBS2, increasing its expression 
dramatically reduced PyMT tumour burden (Figure 3.22.B). Histological analysis of 
these tumours revealed profound microenvironmental changes that affect both the 
vasculature and tumour cells spatial organisation (Figure 3.22.B). THBS2ORF 
tumours show decreased blood vessels density and reduced endothelial wall 
thickness, but also a different tumour cell organisation that suggests additional 
roles of THBS2 during tumour development. Interestingly, despite the reduced 
vascularisation we did not observe an evident increase in tumour necrotic areas. 
 
 
 
Chapter 3. Results I  
 
 
 
152 
 
 
 
Figure 3.23 THBS2 effects in the primary tumour microenvironment 
(A) Box plot shows late primary tumour growth: 3x105 shCONTROL or shTHBS2 
PyMT cells were injected into the fad mammary pat and tumour weight was 
evaluated 42 days post-injection (n=8). Histological analysis of shCONTROL or 
shTHBS2 PyMT tumours; (Left) H&E stain and (Right) Endomucin stain, 
endothelial cells (brown) and DAPI (blue). (B) Box plot shows late primary tumour 
growth evaluation, 3x105 CONTROL or THBS2ORF PyMT cells were injected into 
the fad mammary pat and tumour weight was evaluated 42 days post-injection 
(n=6). Histological analysis of CONTROL or THBS2ORF PyMT tumours: (Right) 
H&E stain and (Left) Endomucin stain, endothelial cells (brown) and DAPI (blue). 
 
 
 
 
Chapter 3. Results I  
 
 
 
153 
Altogether, these findings suggest that different THBS2-mediated mechanisms 
operate during tumour initiation, progression and metastatic initiation, and propose 
THBS2 as a key microenvironmental regulator throughout disease progression. 
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Chapter 4. Early metastatic colonisation relies on 
the AXL-mesenchymal status and niche induction 
ability of cancer cells  
 
4.1 Cancer cell niche induction ability is linked to their AXL-
mesenchymal phenotype 
 
In the previous chapter we described the metastatic niche activation ability as a 
crucial characteristic of mesenchymal cancer cells (Figure 3.13 and 3.15). In 
addition, we found the mesenchymal status of cancer cells, defined by AXL 
expression, to be sufficient to define their metastatic competence (Figure 3.10.E). 
Therefore, we next addressed whether the enhanced THBS2-dependent niche 
activation ability of metastatic could be linked to their AXL-mesenchymal phenotype. 
We checked in breast carcinoma patient samples whether THBS2 expression 
directly correlates with the mesenchymal features of breast cancer cells. First, 
using GOBO database (http://co.bmc.lu.se/gobo/coexpressed_genes.pl) we 
performed a gene co-expression analysis of the mesenchymal gene AXL in human 
breast carcinoma samples. We found that AXL is highly co-expressed with a 
signature containing THBS2 (Table 4.1). Importantly, this AXL co-expression gene 
list also contained the MIC marker (CD90 or Thy1), confirming in human breast 
tumours the link CD90-AXL that we observed in MICs in mice (Table 4.1). Note the 
perfect positive linear correlation, Pearson correlation coefficient r=1, of these 
genes with AXL (Table 4.1). Second, we analysed the specific correlation of 
THBS2 expression with genes used in this study to define a more mesenchymal 
status in breast cancer. Using the cBioPortal database for Cancer Genomics 
(http://www.cbioportal.org/) we found a direct correlation between THBS2 
expression and the EMT-associated markers AXL, Vimentin, Twist1 and Zeb1 
(Figure 4.1).  
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Gene 
symbol 
Locus 
link  
Correlation 
Pearson 
STDdev Gene name Gene correlation network  
 (all tumours) 
AXL 558 1 0.77 AXL 
Tyrosine 
kinase  
receptor 
ABL1;ADAM12;AEBP1;AKAP1
2;ANGPTL2;BGN;BMP1;BNC2
;C10orf72;C1R;C1S; 
C5orf13;CALD1;CD200; 
CD248;CD81;CD93;CD99; 
CDH11;CILP;CLEC11A; 
CLIP3;CNN1;COL15A1; 
COL1A1;COL4A2;COL5A1;CO
L5A2;COL5A3;COL6A1;COL6
A2;COL6A3;COL8A2;COMP;C
PZ;CRISPLD2; 
CSF1R;CTGF;CTSK;CTSO;CU
GBP2;CXCL12;CYR61; 
DAB2;DCN;DDR2;DIO2; 
DPYSL3;DVL3;ECM2; 
EDNRA;EFEMP2;EGR1; 
EHD2;ELN;EMILIN1;EMP3;EN
G;ENTPD1;F13A1;FAP; 
FBLN1;FBLN2;FBLN5;FBN1;F
ERMT2;FHL1;FILIP1L; 
FLRT2;FNTB;FOXF2; 
FOXN3;FST;FSTL1;FYN; 
GAS1;GAS6;GAS7;GFPT2;GL
G1;GPR124;GPX3;GSN;HEG1
;HSPG2;HTRA1;IGFBP3;IGFB
P6;ILK;ISLR;ITGA5;ITGBL1;JA
M3;JUNB;KCTD12;KIAA1462;L
AMB1;LOX; 
LOXL1;LRP1;LRRC15; 
LRRC17;LRRC32;LTBP2;LY86
;MFAP2;MFAP4;MITF;MMP11;
MMP14;MMP19; 
MMP2;MN1;MSN;MXRA5;MXR
A8;MYH9;MYL9;NAP1L3;NBL1
;NDN;NID1;NID2;ODZ4;OLFM
L1;OLFML2B;OLFML3;OMD;P
ALLD;PCOLCE;PDGFRB;PDG
FRL;PECAM1;PKD2;PLAU;PL
VAP;PLXNC1;PPAP2B;PRKC
DBP;PRRX1;PTRF;RCAN2;RH
OG;RUNX1T1;SEPT11;SERPI
NF1;SERPING1;SFRP4;SH2B
3;SH3PXD2A;SHOX2;SLIT2;S
NAI2;SPARC;SPOCK1; 
SPON1;SRPX;SSH1;SULF1;S
YNPO;TAGLN;TCF4;TGFB1I1;
TGFB3;THBS2;THY1;TIMP3;T
RAM2;TSPAN4;UNC5B;VCAN;
WIPF1;WISP1;WISP2;WNT2;Z
CCHC24;ZEB1;ZFHX4 
 
Table 4.1 AXL co-expressed genes analysis  
AXL co-expressed genes in human breast carcinoma patient samples was 
analysed using GOBO database. The Co-expressed Genes algorithm in GOBO for 
a given gene, in this case AXL, uses Pearson as a correlation method, and returns 
gene lists that highly correlate with AXL expression in human breast tumours 
(correlation cut-off, 0.4). The list displayed in this table was the top co-expressed 
gene list with a Pearson correlation coefficient of 1 (absolute positive correlation). 
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Figure 4.1 THBS2 expression correlates with different mesenchymal markers 
in human breast carcinoma patient data 
Correlation plots show the gene expression correlation analysis between THBS2 
and AXL, Vimentin, Twist1 and Zeb1 in human breast carcinoma patient samples 
using cBioportal data. The gene expression correlation algorithm in cBioPortal for 
Cancer Genomics uses Pearson as a correlation method comparing the expression 
of two given genes in a selected breast cancer patient data cohort (correlation cut-
off, 0.4). The patient data cohort analysed was the Cancer Genome Atlas (TCGA 
provisional) containing 1098 patient samples, published in the Breast Invasive 
Carcinoma project (Cancer Genome Atlas, 2012). 
 
 
 
These data strongly suggest that in human breast cancer there is a direct link 
between AXL expression and THBS2 secretion in breast cancer cells. 
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Next, we wanted to functionally validate the observed link between THBS2 and 
AXL expression. In order to do this, we inhibited the mesenchymal phenotype of 
tumour cells by targeting the EMT-associated receptor AXL in cancer cells and 
checked the impact of inhibiting the mesenchymal status on THBS2 secretion. AXL 
has been previously reported to directly interfere with the mesenchymal status of 
breast cancer cells (Asiedu et al., 2013, Vuoriluoto et al., 2011). We used two 
different approaches to block AXL; the specific small molecule inhibitor R428 that 
blocks the receptor activation and leads to its downregulation (Holland et al., 2010). 
This inhibitor allowed us to perform temporally controlled in vivo experiments. The 
second approach consisted of knocking down AXL expression by using previously 
described shRNA sequences against AXL delivered via lentiviral infection 
(Gjerdrum et al., 2010). 
First, we validated that the specific inhibitor R428 interferes with AXL levels and 
leads to the inhibition of the EMT phenotype in MICs. We treated MICs with 1.5 µm 
R428 for 3 hours, and phenotypically evaluated the expression of the EMT-
associated markers E-cadherin, AXL and Vimentin by immunofluorescence (Figure 
4.2.A), as well as the levels of the EMT core transcription factors by real 
quantitative PCR (Figure 4.2.B). We could confirm that inhibiting AXL attenuates 
the mesenchymal status of MICs donwregulating AXL, Vimentin, the EMT 
transcription factors and upregulating E-cadherin. Second, we tested that this 
phenotypic changes translated into functional differences in cell behaviour by 
assessing MIC motility in 2D after R428 treatment. Remarkably, AXL 
downregulation was enough to decrease the overall motility of MICs (Figure 4.2.C). 
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Figure 4.2 AXL inhibition attenuates the mesenchymal status of MICs 
(A) Representative images show the expression of E-cadherin, Vimentin and AXL 
in MICs and MICs cultured overnight after FACS isolation and treated with DMSO 
or 1.5 µM R428. Data from one representative experiment from a total of 5 are 
shown. Chart line and error bars indicate mean ± SD of the population. Scale bar, 
20 µm. (B) Quantitative real time PCR analysis compares the gene expression 
levels of different EMT transcription factors in MICs and MICs treated with R428. 
Data from 3 different experiments performed in triplicate (normalised to Gapdh). 
Bar represent mean ± sem. p=0.0308 by ANOVA comparing the gene set in MICs 
versus MICs-R428. (C) Rose plots show the tracking path of MICs and MICs 
treated with 1.5 μM R428. (Lower panel) Histogram shows the mean ± sem of the 
cell speed quantified in 2 independent experiments. 
 
 
  
Chapter 4. Results II 
 
 
 
159 
 
In order to corroborate these results in a human model, we decided to search for 
human cell lines that highly express AXL. We examined AXL expression in a panel 
of breast carcinoma human cell lines using the GOBO database that compiles the 
data from a study where a panel of 30 human breast carcinoma cell lines were 
sequenced (Neve et al., 2006). In line with our data showing phenotypic expression 
of mesenchymal markers in MICs, high AXL expression was clearly restricted to 
basal B cell lines that cluster together based on their mesenchymal-like status, 
displaying Vimentin expression and loss of cytokeratins (Figure 4.3.A). We chose 
the broadly used MDA-MB-231 cell line, as it is one of the two with highest AXL 
expression. Then, we inhibited AXL in the MDA-MB-231 (MDA231) in a time course 
manner to assess how long is AXL downregulation sustained. The MDA231 cell 
line is homogeneously positive for AXL (Figure 4.3.B). After 24h treatment with 
R428 the overall expression of the receptor in the population is reduced by 50%, 
and 20% of cells completely lost AXL expression (Figure 4.3.B). AXL levels were 
nearly restored 48h after a single 3h treatment with the inhibitor (Figure 4.3.C). 
Alongside AXL we observed Vimentin downregulation (Figure 4.3.D), and 
functionally the overall cell motility of the MDA231 population decreased 24h after 
treatment with R428 (Figure 4.3.E).  
Once we validated that AXL inhibition attenuates the mesenchymal status of both 
MICs and the MDA231 cells, we tested whether this would have a direct impact on 
the secretion of THBS2, establishing a direct link between the mesenchymal status 
of the tumour cells and their niche induction ability mediated by THBS2. First, we 
observed that the overall secretory status of MICs was compromised after AXL 
inhibition. We detected a general decrease in the expression of MIC secreted 
factors 24h after attenuating their mesenchymal features by blocking AXL (Figure 
4.4.A). Particularly, we observed THBS2 secretion to decrease in both MICs and 
MDA231 cells after AXL mesenchymal inhibition (Figure 4.4.B). The level of 
secreted THBS2 into the cell culture media was measured by ELISA.  
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Figure 4.3 AXL inhibition attenuates the mesenchymal features of the MDA-
MB-231 human cell line  
(A) Analysis of AXL expression levels in a panel of 39 human cell lines, classified 
as luminal (ESR1+) or basal (ESR1-), the basal subtype was further divided into 
basal A (Krt5+, Krt14+) and basal B (Vimentin+), using GOBO database. (B) 
Schematic shows the time course of AXL inhibition (R428) in the MDA231 cell line. 
Cells were treated with R428 3 µM 72, 48 or 24h prior to FACS analysis when AXL 
expression was determined. Bar graph shows the percentage of AXL+ cells after 
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R428 treatment. (C) FACS analysis of AXL expression levels in MDA231 treated as 
in (B). Bar graph shows AXL intensity mean signal. FACS histogram plot displays 
the overall intensity of AXL in the MDA231 cell line treated as in (B). (D) Images 
show the expression levels of Vimentin and AXL in MDA231 and MDA231 treated 
with R428 3 µM for 24h. (E) Rose plots show the tracking path of MDA231 and 
MDA231 treated with 3 μM R428. (Lower panel) Histogram shows the mean ± sem 
of the cell speed quantified in 2 independent experiments. 
 
 
 
 
 
 
Figure 4.4 THBS2 secretion depends on the AXL-mesenchymal features of 
cancer cells 
(A) Quantitative real time PCR analysis compares the gene expression levels of 
MIC secreted factors in nonMICs, MICs and MICs treated with 1.5 µM R428 for 
24h. Data from 3 different experiments performed in triplicate (normalised to 
Gapdh). Bar represent mean ± sem. p=0.0041 by ANOVA comparing the gene set 
in MICs versus MICs-R428. (B) ELISA assay shows the levels of secreted THBS2 
in (Left) nonMICs, MICs and MICs treated with 1.5 µM R428, and (Right) MDA231 
and MDA231 treated with R428 3 µM for 24h.  
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Considering the crucial role of THBS2 secretion in mediating MICs stromal 
activation advantage (Figure 3.19), we next assessed the consequences of 
inhibiting the mesenchymal features and therefore THBS2 secretion, on fibroblasts 
activation. We pre-treated freshly isolated MICs with R428 for 3h, and 24h after we 
assessed their lung fibroblast activation ability in coculture assays. Given that AXL 
inhibition effects last for up to 48h (Figure 4.3.B-C) we monitored the induction of 
early fibroblast activation markers in normal lung fibroblasts (NLF3). We observed 
that pre-treating MICs with R428, in line with the reduced secretion of THBS2 
(Figure 4.4.B) attenuates their ability to induce nuclear YAP translocation and FAP 
expression in normal fibroblasts (Figure 4.5.A-B). We also confirmed these results 
using the MDA231 cell line. In this case, without the limitation of isolating high 
numbers of MICs from primary tumours we increased the number of cells per assay 
to decrease the time of the coculture assay. This allowed us to pre-treat the 
MDA231 cell line with R428 for 3h, and 24h after we washed the inhibitor and set 
the coculture assay as in Figure 3.13 to assess the gel contraction ability of the 
fibroblasts. As previously shown, in R428 pre-treated MDA231 cells AXL inhibition 
last up to 48-72h (Figure 4.3.A-B), which is the total duration of the gel contraction 
assay performed. R428 pre-treated MDA231 cells showed a delayed induction of 
fibroblast-driven gel contraction (Figure 4.5.C) in line with their loss of 
mesenchymal features (Figure 4.3.B) and THBS2 expression (Figure 4.4.B). 
 
To confirm that the above effects are the result of a targeted inhibition and 
downregulation of AXL and not unspecific effects from the small molecule inhibitor 
R428, we engineered a lentiviral reporter construct containing a validated shRNA 
sequence against AXL. The lentiviral vector contained an EGFP reporter gene that 
allows us to select the infected cells by FACS (Figure 4.6.A). First, we validated the 
knockdown efficiency in primary PyMT tumour cells after lentiviral infection (Figure 
4.6.B). Second, we verified that upon AXL knockdown the mesenchymal status of 
the shAXL cells was attenuated as observed by the reduced Vimentin expression 
and the upregulation of E-cadherin in primary infected PyMT cells (Figure 4.6.C). In 
line with the results obtained with the AXL inhibitor, we could detect a decrease in 
THBS2 secretion levels in shAXL PyMT cells (Figure 4.6.D). Last, we functionally 
tested the ability of PyMT shAXL cells to induce fibroblast activation in a gel 
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contraction assay. As expected from the reduced secretion of THBS2, knocking 
down AXL in PyMT cells reduced their ability to activate lung fibroblasts (Figure 
4.6.E).  
To determine the relevance of AXL expression during metastatic colonisation we 
tested shAXL cancer cells to grow in vitro and in vivo. We excluded that depleting 
AXL could have a direct effect on the intrinsic stemness potential of cancer cells by 
measuring the ability of shAXL cells to form spheres in vitro. No significant effects 
were observed in the sphere formation ability of shAXL cells (Figure 4.6.F). Next, to 
confirm the innocuous effect on stemness when depleting AXL, we tested the 
tumour initiation ability of shAXL cells in vivo. As expected from the in vitro results, 
primary tumour initiation was not affected in the absence of AXL (Figure 4.6.G). 
Collectively, these results indicate that AXL does not affect the intrinsic abilities of 
tumour cells to self-renew and initiate a tumour mass. Finally, we assessed the 
ability of shAXL cells to metastasise following intravenous injection. In line with the 
reduction of THBS2-dependent stromal activation, shAXL cells showed a decrease 
ability to initiate metastasis (Figure 4.6.H).  
We corroborated these results in the highly metastatic 4T1 mouse cell line that 
homogeneously expresses high levels of AXL (Figure 4.7.A). Either THBS2 or AXL 
depletion decreased the lung colonisation ability of 4T1 cells in an experimental 
metastasis setting (Figure 4.7.B).  
 
 
In summary, we have shown that the AXL-mesenchymal status of cancer cells is 
functionally required not only to support their invasion at the primary site but also to 
trigger the niche activation at the target metastatic site. Moreover, these results 
highlight the crucial requirement of AXL-mesenchymal features as metastatic cells 
infiltrate the new tissue. 
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Figure 4.5 AXL inhibition partially blocks the ability of mesenchymal cancer 
cells to activate fibroblasts 
(A) Representative images show YAP nuclear staining in NLF3 cells cultured in the 
presence of MIC or MICs pre-treated with 1.5 µM R428 for 24h before the 
coculture. Scale bar, 100 µm. (B) Charts indicate the quantification of the nuclear 
levels of YAP and total expression of FAP. Data from one representative 
experiment from a total of 2 are shown. Line and error bar indicate mean ± SD of 
the populations. (C) (Upper panel) Representative images display the gel 
contraction assay 3 days after coculture with MDA231 or MDA231 pre-treated with 
R428 3 µM for 24h. (Lower panel) Histogram displays mean ± sem (n=12-13, 
number of gels assessed over 3 independent experiments).  
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Figure 4.6 AXL knockdown attenuates the mesenchymal phenotype and 
reduces THBS2 secretion, fibroblast activation and metastatic colonisation 
(A) Schematic shows the lentiviral reporter used to express the shRNA sequences. 
The shRNA sequences were cloned under the expression of a CMV enhancer 
followed by the H1 promoter. An independent mouse PGK promoter controls EGFP 
expression. (B) FACS dot plot displays AXL expression levels in PyMT cells 
expressing shCONTROL or shAXL lentiviral constructs. (C) Charts indicate the 
expression levels of E-cadherin, Vimentin and AXL in PyMT cells expressing 
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shCONTROL or shAXL lentiviral constructs. Line and error bars indicate mean ± 
SD of the population. (D) ELISA assay measures the levels of secreted THBS2 by 
PyMT cells expressing shCONTROL or shAXL lentiviral constructs. Histogram 
displays mean ± sem of 2 independent cell preparations. (E) (Upper panel) 
Representative images of the gel contraction assay 3 days after coculture with 
PyMT cells expressing shCONTROL or shAXL lentiviral constructs. (Lower panel) 
Histogram displays mean ± sem (n=7-9, number of gels assessed over multiple 
experiments). (F) Sphere assay by PyMT cells in suspension expressing 
shCONTROL and shAXL lentiviral constructs. Histogram shows the mean ± sem of 
2 independent experiments. Spheres were quantified 10 days after plating a single 
PyMT suspension (primary) and 10 days after the first passage (secondary). (G) 
Primary tumour growth potential. Cells were FACS sorted to select for lentiviral 
expression and 50,000 shCONTROL or shAXL PyMT cells were injected into the 
mammary fad pat. Tumour weight was evaluated 20 days post-injection (n=6). (H) 
Metastatic colonisation ability of shCONTROL and shAXL PyMT cells. Positively 
infected PyMT cells were sorted as GFP+, and 5x106 cells were directly injected 
into the tail vein of mice. (Left) Micrometastasis were evaluated 30 days post-
injection. (Right) Representative images of lung sections with micrometastasis.  
 
 
 
 
 
 
Figure 4.7 Metastatic ability of 4T1 cells upon THBS2 or AXL knockdown  
(A) FACS histogram displays the level of AXL expression in 4T1 cell line. (B) Box 
plot shows the lung experimental metastasis after intravenous injection of 4T1 cell 
line expressing shCONTROL, shAXL and shTHBS2 lentiviral constructs (n=4 mice 
per group). Representative images of H&E stain of lung sections displaying 4T1 
metastatic nodules. 
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4.2 The AXL-mesenchymal status of cancer cells is required 
upon extravasation for effective metastatic colonisation  
The previous results show that MICs isolated from primary tumours are in a 
mesenchymal state characterised by the expression of AXL. Therefore, in order to 
understand the regulation and dynamics of this mesenchymal phenotype during 
metastatic colonisation following arrival in the lungs, we monitored the expression 
of AXL on cancer cells after intravenous injection. Based on the presence of AXL, 
we could discriminate two distinct phases during lung colonisation: a first phase 
early after extravasation where MICs still maintain a mesenchymal phenotype; and 
a second phase where alongside proliferation and enrichment among the total 
cancer cells in the lungs, MICs lose their AXL-mesenchymal phenotype (Figure 
4.8.A).  
 
We have also shown that the ability of metastatic cells to activate the niche is 
crucial for metastatic establishment (Figure 3.19) and depends on the 
mesenchymal phenotype of cancer cells (Figure 4.6). Therefore, we next tested 
whether the AXL-mesenchymal status needs to be maintained specifically during 
the first colonisation phase when disseminated cancer cells maintain AXL 
expression. To this end, we used the AXL small molecule inhibitor R428 that allows 
us to block AXL expression in vivo during this specific window of time. We pre-
treated cancer cells in vitro prior to intravenous injection and then continued the 
treatment in vivo for 7 days (Figure 4.8.B). We checked that in vivo administration 
of R428 could indeed block AXL expression in cancer cells following intravenous 
injection (Figure 4.8.C), and that extravasation into the lungs 24h post-seeding was 
not affected by the pre-treatment in vitro (Figure 4.8.D). Remarkably, the in vitro 
pre-treatment was sufficient to decrease the metastatic initiating potential of PyMT 
cells 30 days post-injection, and this effect was further exacerbated by the 
continuous 1 week treatment in vivo (Figure 4.8.E). Notably, these results reaffirm 
that the highly AXL-expressing MICs (Figure 3.10.A) are the main population 
driving lung colonisation in this model (Malanchi et al., 2012). 
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Figure 4.8 AXL–mesenchymal features are required during the early 
colonisation phase of metastasis 
(A) FACS analysis of the percentage of AXL+ MICs (red-left Y axis) and total MICs 
(black-right Y axis) among total GFP+ cancer cells in the lung at 4 and 12 days after 
tail vein injection. Graph represents mean ± sem per time point (n=8-9 mice per 
group of 2 independent experiments). (B) Experimental setup: PyMT cells were 
pre-treated in vitro with vehicle (DMSO) or 1.5 μM R428, 24h hours before 
intravenous injection. In vivo, mice were treated daily with 12.5 mg/kg of R428 
during the indicated days, and metastases were evaluated 30 days post-injection. 
(C) FACS analysis of AXL+ cancer cells after R428 treatment in vivo. Mice were 
intravenously injected with primary PyMT GFP+ cells, and treated daily with DMSO 
(vehicle) or R428 (12.5 mg/kg) for 3 days, when lungs were analysed by FACS. 
Chart shows mean ± sem (n=3-5 per group). (D) FACS analysis of MIC and 
nonMIC cells presence in the lung. PyMT GFP+ cells were treated in vitro with 
DMSO or 1.5 µM R428 24 hours prior to intravenous injection into mice. FACS 
analysis was performed 24h post-injection after lung perfusion with PBS. Chart 
shows mean ± sem (n=5-6 per group). (E) Box plot displays the metastatic burden 
of PyMT cells intravenously injected into mice as specified in (B). PyMT-DMSO, n= 
10 mice per group; PyMT R428 (24h), n= 5 mice per group; PyMT-R428 (1 week), 
n= 9 mice per group. Superficial lung metastasis number was evaluated. (Right) 
Representative H&E staining of metastatic lung sections from mice of indicated 
groups.  
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Similar results were obtained using the human cell line MDA-MB-231. Following 
intravenous injection, this AXL highly positive cell line spontaneously 
downregulates AXL as the cells grow in the lung transitioning from the first to the 
second phase of metastatic colonisation (Figure 4.9.A). We could confirm the 
requirement of AXL during the first phase of colonisation applying the same in vivo 
treatment scheme that depletes AXL expression during the first week of 
colonisation (Figure 4.8.B) obtaining reduced metastatic burden 35 days post-
injection (Figure 4.9.B).  
 
 
 
Figure 4.9 The MDA-MB-231 human cell line requires an active AXL–
mesenchymal programme during early metastatic colonisation  
(A) FACS analysis of the percentage of AXL+ MDA-MB-231 (MDA231) among total 
GFP+ cancer cells in the lung at 4 and 12 days after tail vein injection. Graph 
represents mean ± sem per time point (n=3 mice per group). (B) Box plot shows 
the metastatic burden of MDA231 cells after pre-treatment in vitro with vehicle 
(DMSO) or 3 μM R428, 24h hours before intravenous injection. In vivo, mice were 
treated daily with 12.5 mg/kg of R428 from day 1 to 7 post-injection, and 
metastases were evaluated 25 days post-injection. MDA231-DMSO, n= 13 per 
group; MDA231-R428 (Day1-7), n= 8 mice per group. Superficial lung metastasis 
number was evaluated. 
 
 
These results corroborate the crucial requirement of AXL-mesenchymal features 
precisely during the first phase of colonisation, when the niche induction ability of 
metastatic cells provides metastatic advantage. 
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We next tested whether the used short-term AXL inhibition would have an effect in 
the intrinsic abilities of cancer cells to grow and self-renew. In vitro, AXL inhibition 
did not have an effect on proliferation as measured in a BrdU incorporation assay in 
both PyMT cells and the MDA231 cell line (Figure 4.10.A-B). Also, we excluded a 
negative effect of AXL inhibition on the self-renewal capacity of primary PyMT cells 
as measured by their sphere formation capacity (Figure 4.10.C) and their ability to 
grow 3D organoids when embedded into Matrigel (Figure 4.10.D). Last, we 
checked the effect of a single AXL inhibitor treatment on cancer cells tumorigenic 
potential. R428 pre-treatment leading to a three-day AXL down-regulation (Figure 
4.3.C) is enough to reduce PyMT cells metastatic potential (Figure 4.8.E). However, 
primary tumour development was not affected by the reversible early inhibition of 
AXL in both PyMT primary cells and MDA231 cells (Figure 4.10.E). This is in line 
with the observation that in the PyMT model permanent downregulation of AXL by 
shRNA does not affect primary tumour initiation (Figure 4.6.G). Altogether, these 
results suggest that while AXL is required by breast cancer cells to re-initiate 
tumour growth at distant sites (Figure 4.8.E and 4.9.B), it is dispensable to start a 
tumour when cells are locally transplanted into the mammary fad pat (Figure 4.6.G 
and 4.10.E). 
 
Our data indicate that AXL is required during early colonisation to allow efficient 
metastasis. We have also shown that AXL-mesenchymal features provide an 
advantage in niche activation via THBS2 secretion. Thus, we next tested whether 
THBS2 overexpression could partially rescue the effects of blocking AXL in vivo. In 
order to test this, we generated a MDA231 cell line clone that expresses 
THBS2ORF lentiviral construct (Figure 3.21.A) and confirmed the increase in 
THBS2 expression (30-fold increment) (Figure 4.11.A). Then, we assessed the 
metastatic potential of R428 treated MDA231 cells expressing the control VENUS 
or THBS2ORF lentiviral constructs. Cells were pre-treated with R428 in vitro, and 
then continued treating the mice in vivo for the first week of metastatic colonisation 
after intravenous injection (as in Figure 4.8.B). We showed that despite the broader 
effects that AXL inhibition might have on tumour cells, THBS2 overexpression 
could partially rescue the deleterious effects of blocking AXL in this early stage of 
metastasis (Figure 4.11.B). However, in contrast to what we observed in the PyMT 
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cells (Figure 3.21.C), THBS2 overexpression was not enough by itself to 
significantly enhance the overall metastatic efficiency of the MDA231 cell line. This 
is likely due to the fact that all cells within the MDA231 cell line already express 
AXL and produce THBS2. These results strengthen the functional link previously 
described between AXL and THBS2 (Figure 4.4). 
 
 
 
 
Figure 4.10 AXL inhibition effects on cancer cell proliferation, self-renewal 
and tumour initiation  
(A) FACS analysis shows BrdU incorporation over a 3 hours pulse by primary 
PyMT cells and PyMT cells treated with 1.5 µM R428. Data from 4 different 
tumours performed in triplicate. (B) FACS analysis shows BrdU incorporation over 
a 3 hours pulse by MDA231 and MDA231 cells treated with 3 µM R428. Histogram 
shows mean ± sem of 3 independent experiments. (C) Sphere culture assay. (Left) 
Histogram shows mean ± sem of 3 independent experiments. Spheres were 
quantified 7 days after plating a single PyMT suspension (primary) and 7 days after 
the first passage (secondary). (Right) Images show representative pictures of 
spheres formed by primary PyMT cells and PyMT cells treated with 1.5 µM R428 in 
suspension. Scale bar, 200 µm. (D) Organoid assay. (Upper panel) Images show 
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representative pictures of organoids formed by primary PyMT cells and PyMT cells 
treated with 1.5 µM R428, and seeded in Matrigel. Scale bar, 200 µm. (Lower 
panel) Histogram shows the mean ± sem of 2 independent experiments. (E) Box 
plots display tumour burden assessed 3 weeks after engraftment of PyMT cells 
pre-treated with 1.5 µM R428, and MDA231 cells pre-treated with 3 µM R428 (n=6 
per group). 
 
 
 
 
 
 
Figure 4.11 THBS2 overexpression partially rescues AXL inhibition in 
MDA231 cells 
(A) Quantitative real time PCR showing a 30-fold THBS2 mRNA expression in 
MDA231 cell line after infection with the THBS2ORF construct and selection for 
VENUS positive cells. (B) Box plot shows the flow cytometry quantification of the 
percentage of VENUS+ cells in the lungs of mice injected with MDA231-VENUS or 
MDA231-THBS2ORF treated with/without R428. Mice were injected with 5x105 
cells pre-treated with DMSO or 3 µm R428 in vitro 24h before. After intravenous 
injection mice were treated with DMSO or 12.5 mg/kg for 1 week. MDA231 cell 
content in the lungs was evaluated 20 days post-seeding by flow cytometry of 4 
lung lobes (n=4-6 mice per group). (Left) Representative images show lung 
micrometastasis for the indicated groups in the lobe that was not used for the 
FACS analysis. 
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The results presented in this chapter suggest that the niche activation ability 
provided by the AXL-mesenchymal status and THBS2 is crucial for the first phase 
of metastatic colonisation, before cancer cells begin to actively grow. 
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Chapter 5. The activated niche tunes the cancer cell 
mesenchymal status in a temporally controlled 
manner during the second phase of metastasis 
5.1 The newly activated niche attenuates the mesenchymal 
features of cancer cells 
In the previous chapters, our results highlight the metastatic advantage provided by 
a mesenchymal status as single cells infiltrate into the target site. Subsequently, we 
observed that this AXL-mesenchymal programme is spontaneously downregulated 
in vivo as tumour cells start growing in the lungs (Figure 4.8.A and 4.9.A), 
suggesting that the requirement of the previously reported mesenchymal-to-
epithelial transition (MET) at the secondary site (Ocana et al., 2012, Tsai et al., 
2012) might be temporally controlled during this second phase of colonisation. 
Therefore, we next set out to investigate the epithelial modulations occurring in 
cancer cells during metastatic colonisation. In order to do this, we used 
ImageStream technology to examine the dynamics of different intracellular factors 
in disseminated tumour cells in the lungs during colonisation. ImageStream is an 
imaging flow cytometer that allows the acquisition of high-resolution images of each 
cell directly in the flow. These capabilities allow quantitating the intensity and 
location of fluorescent protein stains in rare cell populations. As previously 
discussed colonisation is the bottleneck of the metastatic process (section 1.2.3), 
where the total number of tumour cells found in the lungs is lower than 0.1% of the 
originally disseminated cells (Luzzi et al., 1998). Therefore ImageStream allows the 
acquisition of quantitative imaging data from each whole lung cell preparation and 
the analysis of rare populations, which would be very challenging to localise by 
standard histological sectioning of the tissue and microscopy. 
The experimental setting for subsequent ImageStream analysis consisted of 
seeding GFP labelled CD24+AXL+ cancer cells directly into the lungs via tail vein 
injection two days (first phase) or twelve days (second phase) prior to analysis 
(Figure 5.1.A). We observed that alongside the previously described AXL down-
regulation (Figure 4.8.A and 5.1.B) the EMT-TF Twist1 was concomitantly loss 
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indicating a reversion of the mesenchymal state. The total percentage of Twist1+ 
cells decreased in the transition from early to late colonisation (Figure 5.1.C). 
Moreover, in those cells that remained Twist1+, the overall Twist1 protein levels 
were dramatically reduced as cancer cells expanded in the lungs as shown by the 
representative images and the contour FACS plot displaying the overall Twist1 
intensity decrease in metastatic cells at day 12 in the lungs (Figure 5.1.D-E). These 
data are in line with the previously reported mesenchymal inhibition at the 
secondary site (Ocana et al., 2012, Tsai et al., 2012), and reaffirm the use of AXL 
as a bona-fide marker to track the mesenchymal status of breast metastatic cells in 
vivo.  
 
Next, given the solid evidence for a mesenchymal reversion during late metastatic 
colonisation we wanted to investigate the causes of these epithelial modulations 
within the target site. Our previous results show that the induction of a metastatic 
niche is a pre-requisite for colonisation (Figure 3.20) and its activation temporally 
coincides AXL is loss (Figure 4.8.A). Therefore, we set out to test the potential 
regulatory role of the activated niche fibroblasts on cancer cells epithelial plasticity 
during late metastatic colonisation. First, we analysed ex vivo the effects of 
fibroblasts activation on cancer cells. We repeated the previous coculture assays 
used to monitor fibroblast activation where freshly isolated MICs are seeded on top 
of a thin layer of Matrigel:collagen-I gels with GFP labelled normal fibroblasts over 
3-5 days (Figure 3.14.A and 5.2.A). We found that as fibroblast become activated, 
MICs downregulated AXL expression in these cocultures (Figure 5.2.B). Moreover, 
alongside AXL, MICs downregulated the expression of the core EMT transcription 
factors as monitored by their RNA expression levels (Figure 5.2.C). Notably, in line 
with our in vivo data Twist1 was the EMT-TF showing a higher decrease upon 
fibroblast activation in the coculture assays. Accordingly, we specifically checked 
whether Twist1 protein levels could be negatively regulated by activated fibroblasts 
ex vivo. We monitored Twist1 expression in MICs using ImageStream analysis and 
found that as fibroblast become activated in the coculture MICs downregulate 
Twist1 expression (Figure 5.2.D). This result suggests that activated fibroblasts can 
trigger the re-epithelialisation of mesenchymal cancer cells.  
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Figure 5.1 AXL and Twist1 expression is downregulated in metastasising 
cells during late colonisation  
(A) Schematic shows the experimental set up for the metastasis time course. Mice 
were intravenously injected with primary actinGFP-PyMT CD24+AXL+ cells 12 or 2 
days before analysis. At day 0, lungs were depleted from lineage cells (CD45+ 
CD31+ Ter119+ cells) and then half of the lung was freshly analysed for AXL 
expression by FACS, and the other half fixed for intracellular stain and 
ImageStream analysis. (B) Box plot shows the in vivo evaluation of the percentage 
of AXL+ cells in the lung in a metastasis time course. The percentage of LIN-GFP+ 
CD24+AXL+ cells was evaluated (n=8-9 mice). One representative experiment out 
of five is shown. (C) Chart shows the in vivo evaluation of the percentage of Twist1+ 
cells in the lung in a metastasis time course. The percentage of LIN-GFP+ Twist1+ 
cells was evaluated (n=4-5 mice). Data from one representative experiment out of 
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three are shown. (D) Representative images show the reduction in Twist1 in cells 
isolated from 2 or 12 days metastasis, quantified in (C). (E) FACS contour plot 
shows the intensity of Twist1, and (Left) bar graph the quantification of its intensity 
mean in CD24+AXL+ tumour cells in the lung at 2 and 12 days of metastasis. Data 
from one representative experiment out of three are shown.  
 
 
 
Figure 5.2 Activated fibroblasts induce AXL and Twist1 downregulation in 
MICs 
(A) Schematic shows the coculture setting where nonMICs or MICs are seeded on 
top of a thin layer of Matrigel-Collagen with GFP+ labelled normal lung fibroblast 
cell line (NLF3) for 3-5 days. (B) FACS quantification of AXL expression levels in 
MICs and MICs cocultured with NLF3 as in (A). Histogram shows the mean ± sem 
(n= 2 number of cocultures). (C) Quantitative real time PCR analysis compares the 
gene expression levels of different EMT transcription factors in MICS and MICS 
cocultured with NLF3 for 5 days as in (A). Data from 3 different experiments 
performed in triplicate (normalised to Gapdh). Bar represent mean ± sem. p= 
0.0018 by ANOVA comparing the gene set in MICs versus MICs-NLF3. (D) 
ImageStream evaluation of the percentage of Twist1+ in MICs and MICs cocultured 
with NLF3 as in (A). Chart shows data from 4 independent experiments. 
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To further confirm the phenotypic changes following Twist1 decrease in cancer 
cells upon contact with activated fibroblasts, we used fully activated CAFs isolated 
from lung metastases in a coculture with mesenchymal cancer cells for 24h (Figure 
5.3.A). Consistent with our previous observations, MICs in the presence of CAFs 
reduced Vimentin, AXL expression and increased E-cadherin levels (Figure 5.3.B). 
These results suggest that once fibroblasts change to an activated state they 
trigger a crosstalk of signals that can modulate cancer cells epithelial plasticity.  
As the mesenchymal phenotype confers cancer cells with high invasion ability 
(section 1.2.1.1), to functionally validate these phenotypic changes upon coculture 
with CAFs we analysed the three-dimensional invasion modality of cancer cells as 
they first come into contact with CAFs. In collaboration with Danielle Park from the 
Sahai Lab we previously showed that in Matrigel:collage-I matrices MICs invade as 
single cells forming elongated protrusions (Figure 3.7.B), a hallmark of 
mesenchymal cells. Therefore, we repeated this assay in the presence or absence 
of CAFs to evaluate their effect on the mesenchymal-like motility of cancer cells. 
We freshly isolated MICs and nonMICs from primary tumours and made spheroids 
overnight in suspension. Next day, pure MICs and nonMICs spheroids were 
embedded into Matrigel:collagen-I gels with or without CAFs and their invasion was 
evaluated 48h after. As previously reported (Gaggioli et al., 2007), breast cancer 
cells in a more epithelial non-invasive state (nonMICs) activated both single and 
collective cell invasion when surrounded by CAFs (Figure 5.3.C – black bars). 
Strikingly, in line with the observed inhibition of mesenchymal markers MICs 
showed reduced single cell invasion in the presence of CAFs whereas collective 
invasion was still enhanced (Figure 5.3.C - blue bars). Consequently, in the 
presence of CAFs the overall invasion capacity of MICs and nonMICs spheroids 
results similar (Figure 5.3.D). These results confirm that activated fibroblasts can 
mitigate the mesenchymal features of cancer cells as they first come into contact 
with them.  
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Figure 5.3 CAFs attenuate the mesenchymal status of MICs 
(A) Schematic shows the coculture setting where tumours cells are seeded on 
collagen coated dishes, and CAFs are placed in the upper chamber of the 
coculture. After 24 hours tumour cells were monitored for changes in the 
expression of EMT-associated markers. (B) Representative images show the 
expression of E-cadherin, Vimentin and Axl in MICs and MICs cocultured with 
CAFs for 24 hours. Scale bar, 20 µm. (Lower panel) Charts indicate the expression 
levels of E-cadherin, AXL and Vimentin in MICs and MICs cocultured with CAFs for 
24 hours. Data from one representative experiment of 2 are shown. Line and error 
bar indicate mean ± SD of the population. (C) Histograms show the quantification of 
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single (upper histogram) or collective (lower histogram) cell migration on spheroids 
made from FACS sorted PyMT/aGFP MICs or nonMICs, embedded in a Matrigel-
Collagen matrices with or without CAFs. Data from one representative experiment 
of two are shown. (D) Representative fluorescent images of spheroids quantified in 
(C), PyMT/aGFP MICs or nonMICs spheroids (green), embedded in a 
Matrigel:Collagen-I matrices with or without mCherry labelled CAFs (red). 
Spheroids were allowed to invade for 48 hours before imaging. 
 
 
 
 
In light of these last results, we next investigated the potential mechanism 
underlying these CAF-driven changes in cancer cells. As we discussed in the 
introduction, TGFβ signalling has been extensively implicated in metastasis driving 
the initial epithelial-to-mesenchymal switch at the invasive front (Heldin et al., 2012), 
and the maintenance of the EMT state while cells travel in the blood stream 
(Labelle et al., 2011) (Figure 1.6.B). Particularly during metastatic colonisation, high 
TGFβ signalling favours extravasation and early colonisation but a subsequent 
reduction is needed for metastatic outgrowth (Giampieri et al., 2009). Indeed, MICs 
undergo TGFβ signalling when isolated from late-stage tumours (Figure 3.3) 
coinciding with the display of mesenchymal traits (Figure 3.4). Also, it was 
previously reported that breast cancer cells upon infiltration to the distant site 
negatively modulate TGFβ signalling (Giampieri et al., 2009). Therefore, we 
hypothesised that the re-acquisition of epithelial characteristics could depend on 
this reverse modulation of TGFβ signalling upon arrival at the target site. In order to 
test this idea, we monitored the dynamics of the TGFβ effector SMAD2-3 in 
metastasising cells in vivo. We performed an ImageStream analysis of actinGFP-
expressing CD24+AXL+ PyMT cells in the lungs two days (first phase) or twelve 
days (second phase) after intravenous injection (Figure 5.4.A). We found that as 
cells in an AXL-mesenchymal status transit from the first to the second phase of 
colonisation, the total number and staining intensity of pSMAD2-3+ cells decreases 
(Figure 5.4.B-C), following the same overall dynamics than Twist1 (Figure 5.1.C-D). 
This result is in line with our hypothesis that an attenuation of TGFβ signalling 
could trigger mesenchymal inhibition during metastatic colonisation. 
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I have previously discussed in the introduction how the alternative branch of the 
TGFβ signalling pathway, i.e. canonical BMP signalling can antagonise 
TGFβ (section 1.2.1.1) (Wakefield and Hill, 2013). Therefore, we next investigated 
changes in BMP signalling as TGFβ is downregulated in metastasising cells. 
Indeed, we observed an increase in BMP activity during the second phase of 
colonisation. We monitored the expression of the immediate BMP effector 
pSMAD1-5 detecting an increase in the total number of pSMAD1-5+ cells in the 
second phase of colonisation (Figures 5.4.E). In contrast to pSMAD2-3 levels, 
pSMAD1-5 was maintained during colonisation in the overall tumour cell population 
in the lungs, inversely correlating with Twist1 dynamics (Figure 5.4.F-G). In line 
with this increase in BMP activity, we observed the maintenance of the canonical 
BMP/pSMAD1-5 target gene ID1 (Figure 5.4.H). Moreover, further analysis 
revealed an increase in the percentage of ID1+ cells specifically among those that 
lost Twist1 expression in the second phase of colonisation (Figure 5.4.I).  
 
 Collectively, these data show that the phenotypic changes towards a more 
epithelial state during the second phase of colonisation correlate with an inhibition 
of TGFβ signalling, which favours BMP-dependent metastatic outgrowth. 
Importantly, we also observe the maintenance of ID1 throughout colonisation, a 
downstream BMP effector previously reported to be required during metastatic 
outgrowth (Gupta et al., 2007). 
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Figure 5.4 In vivo dynamics of pSMAD1-5 and pSMAD2-3 during metastatic 
colonisation  
(A) Schematic shows the experimental set up for the metastasis time course. Mice 
were intravenously injected with primary actinGFP-PyMT CD24+AXL+ cells 12 or 2 
days before analysis. At day 0, lungs were depleted from lineage cells (CD45+ 
CD31+ Ter119+ cells) and then half of the lung was freshly analysed for AXL 
expression, and the other half fixed for intracellular stain and ImageStream 
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analysis. (B) Chart shows the in vivo evaluation of the percentage of pSMAD2-3+ 
cells in the lung in the metastasis time course in (A). The percentage of LIN-
GFP+/pSMAD2-3+ cells was evaluated (n=4 mice). (C) FACS contour plot show the 
intensity of Twist1 versus pSMAD2-3 in CD24+AXL+ tumour cells in the lung at 2 
(red) and 12 (purple) days post metastatic seeding. Green arrows indicate the 
decrease in Twist1 and pSMAD2-3 expression. (D) Representative images show 
pSMAD2-3 and Twist1 dynamics in cells isolated from 2 or 12 days metastasis. (E) 
Chart shows the in vivo evaluation of the percentage of pSMAD1-5+ cells in the 
lung in the metastasis time course in (A). The percentage of LIN-GFP+/pSMAD1-5+ 
cells was evaluated (n=3-4 mice). (F) FACS contour plot show the intensity of 
Twist1 versus pSMAD1-5 in CD24+AXL+ tumour cells in the lung at 2 (red) and 12 
(purple) days post metastatic seeding. The green arrow indicates the decrease in 
Twist1 expression. (G) Representative images show pSMAD1-5 and Twist1 
dynamics in cells isolated from 2 or 12 days metastasis. (H-I) Charts show the in 
vivo evaluation of the percentage of ID1+ cells in the lung in the metastasis time 
course in (A). The percentage of LIN-GFP+/ID1+ cells (H) and LIN-GFP+Twist1-/ID1+ 
cells (I) was evaluated (n=4-5 mice).  
 
 
 
We have shown that one of the main microenvironmental differences between the 
first and second phase of colonisation is the presence of the newly activated 
fibroblasts, which coincides with these TGFβ/BMP modulations observed in tumour 
cells as colonisation progresses (Figure 5.1.A-B and 5.4.B-I). Therefore, we next 
analysed the changes that CAFs induce in cancer cells along with the AXL/Twist1 
mesenchymal modulation previously shown and how they relate to the in vivo 
situation (Figure 5.2.A-D). CAF-conditioned media (CCM) on primary CD24+AXL+ 
mesenchymal cells for 24h was enough to induce ID1 expression in cancer cells as 
measured by western blot (Figure 5.5.A). We confirmed this increase in ID1 
expression upon CCM exposure by immunofluorescence, where we could also 
observed its nuclear localisation (Figure 5.5.B). To assess whether ID1 increase 
depends on a canonical BMP/pSMAD1-5 signalling as suggested by the in vivo 
data we used the specific BMP inhibitor LDN193189 (LDN) in the CCM. LDN 
blocks the BMP specific receptors ALK2 and ALK3 preventing SMAD1-5 
phosphorylation. Accordingly, when added to the CCM LDN prevented the 
increased ID1 expression in primary PyMT CD24+AXL+ cells (Figure 5.5.A-B). This 
result suggests that ID1 induction can be partially explained via BMP activation. 
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CAFs are known to secrete both TGFβ and BMP ligands (Kalluri and Zeisberg, 
2006), and ID1 activity can be transiently induced as well via TGFβ signalling 
(Kang et al., 2003). Therefore, we next tested the potential contribution of TGFβ to 
ID1 activation. For this purpose, we used the specific TGFβ inhibitor SB431542 
(SB) that blocks the TGFβ receptor ALK5 preventing SMAD2-3 phosphorylation. 
We tested in parallel both the BMP and the TGFβ inhibitors added to the CCM. 
Blocking BMP signalling prevented the increase in ID1 and E-cadherin levels 
induced by the CCM alone (Figure 5.5.C), whereas the TGFβ inhibitor did not have 
any significant effect on ID1 or E-cadherin levels (Figure 5.5.D). These results 
suggest that the observed CAF-mediated ID1 induction mainly relies on 
BMP/pSMAD1-5 activity.  
Since ID1 is required for breast cancer cell proliferation during metastatic outgrowth 
(Gupta et al., 2007), we next tested whether this CAF-mediated ID1 induction 
would functionally correlate with cell proliferation ex vivo. We used the CCM with or 
without the BMP and TGFβ inhibitors on primary CD24+AXL+ mesenchymal cells 
and monitored cell growth every 3h over 3-4 days. CCM dramatically boosted the 
proliferation rate of cancer cells (Figure 5.5.E). Note that although there is 
variability in the growth displayed by the different tumour cell preparations (table in 
Figure 5.5.E), all experiments showed a consistent increase in tumour cell 
proliferation upon CCM treatment. Furthermore, in line with ID1 expression, 
inhibiting BMP/pSMAD1-5 activity reliably decreased the proliferative effects of the 
CCM, while inhibiting TGFβ/pSMAD2-3 activity did not show a consistent read-out 
in cell proliferation (Figure 5.5.E). The results shown in the table also indirectly 
indicate, when comparing the un-stimulated CONTROL versus CCM with inhibitors 
that the negative effect on the proliferation of inhibiting BMP/pSMAD1-5 activity is 
greater than when inhibiting TGFβ/pSMAD2-3. This suggests an endogenous BMP 
signalling activity in PyMT cells in basal state sustaining proliferation, as recently 
reported (Owens et al., 2015).  
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Figure 5.5 CAFs induce ID1 expression and cell proliferation in mesenchymal 
cancer cells in vitro 
(A) Western blot shows the expression levels of ID1 in primary CD24+AXL+ tumour 
cells plated 2D on collagen coated dishes for 24h with normal media, CAF-
conditioned media (CCM) or CCM with 1µm LDN. Actin used as loading control. 
Data from one representative experiment of two are shown. (B) Representative 
images show ID1 expression levels in primary CD24+AXL+ cells cultured 2D on 
collagen coated dishes for 24h with normal media, CAF-conditioned media (CCM) 
or CCM with 1µm LDN. Scale bar, 40 µm. (C) Charts show the 
immunofluorescence quantification of E-cadherin and ID1 expression levels in 
primary CD24+AXL+ cells cultured 2D on collagen coated dishes for 24h with 
normal media, CAF-conditioned media (CCM) or CCM with 1µm LDN. Data from 
one representative experiment out of two are shown. (D) Charts show the 
immunofluorescence quantification of E-cadherin and ID1 expression levels in 
primary CD24+AXL+ cells cultured 2D on collagen coated dishes for 24h with 
normal media, CAF-conditioned media (CCM) or CCM with 10µm SB. (E) Graph 
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shows the growth curve generated by primary CD24+AXL+ tumour cells monitor 
every 3 hours for 90h in normal media (CONTROL), CAF-conditioned media (CCM) 
and CCM with 1μm LDN or 10 µm SB. Table summarises the effects on cell 
proliferation in 3 independent experiments using 3 different PyMT primary tumours. 
The symbols represent the p value generated by ANOVA for each comparison, and 
the red arrows indicate a significant increase (up) or decrease (down).  
 
 
 
 
In summary, these results suggest that secreted factors from activated fibroblasts 
increase the active BMP/pSMAD1-5 signalling in mesenchymal cancer cells, 
inducing de novo ID1 expression and a more epithelial/proliferative phenotype.  
 
Finally, we wanted to functionally validate the requirement of pSMAD1-5/ID1 
activity during the second phase of metastatic colonisation in our model. To this 
end, we used the specific BMP inhibitor in vivo to block pSMAD1-5/ID1 activity 
while cells transition from the first to the second phase of colonisation. We treated 
mice from day 5 to 12 post tail vein injection (Figure 5.6.A), during the time window 
when Twist1 and AXL are downregulated and BMP becomes the dominant 
signalling observed in metastasising cancer cells (Figure 5.1.B-E). Remarkably, 
pSMAD1-5 activity is functionally relevant during the second phase of colonisation 
as its inhibition reduces metastatic outcome (Figure 5.6.B).  
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Figure 5.6 BMP signalling is required for metastatic outgrowth 
(A) Scheme shows the in vivo LDN treatment during the second phase of 
colonisation. Mice were injected with 106 PyMT cells, and treated with LDN193189 
(35 mg/kg) twice a day from day 5 to 12 post intravenous injection. Metastases 
were evaluated 20 days post-injection. (B) (Left) Box plot displays the metastatic 
burden of PyMT cells in mice treated with vehicle or LDN as specified in (A). 
Superficial lung metastases were evaluated. (Right) Representative metastatic lung 
sections of control versus LDN treated mice (n=9-12 mice per group). 
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Collectively, these data support our hypothesis that the phenotypic changes in 
mesenchymal cancer cells observed in vivo during the second colonisation phase, 
where they switch towards a more epithelial AXL-/Twist1- state, are the 
consequence of an inhibition of TGFβ signalling that favours the activation of the 
BMP branch of the pathway. Subsequently, the increased BMP/pSMAD1-5 activity 
sustains metastatic outgrowth. Importantly, the secreted factors from activated 
fibroblasts can induce ex vivo the ID1-driven phenotypic changes in cancer cells, 
switching them towards a more epithelial/proliferative phenotype. 
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5.2 The second phase of colonisation needs to be temporally 
controlled for efficient metastasis 
 
We have previously shown that metastatic cells initially require the mesenchymal 
features to induce their niche as they extravasate to the distant site. However, 
these mesenchymal features are lost during the second phase of colonisation. 
These data together with the previous evidence of a mesenchymal-to-epithelial 
transition during metastatic colonisation (Ocana et al., 2012, Tsai et al., 2012) 
suggest that these epithelial modulations might be temporally controlled during 
colonisation. According to this model, a temporal regulation of epithelial plasticity 
would be critical for metastatic outgrowth and the two events of niche activation 
and epithelial reversion would be dependent on each other. To validate this 
hypothesis, we tested whether interfering with the AXL-mesenchymal status of 
cancer cells would impact on their metastatic capacity.  
 
First, we used the AXL inhibitor R428 in vivo during the second phase of 
colonisation when AXL is transitioning from high to low levels (Figure 4.8.A and 
4.9.A) to exogenously trigger a faster epithelial reversion. We injected primary 
PyMT cells and MDA231 cells into mice and treated them with R428 from day 10 to 
15 post-injection (Figure 5.7.A). We previously showed that AXL inhibition during 
the first week of metastasis reduces the metastatic potential of both PyMT and 
MDA231 cells (Figure 4.8.E and 4.9.B). Interestingly, in this second phase of 
colonisation the inhibitor no longer blocked the metastatic establishment of 
MDA231 cells (Figure 5.7.B) and significantly increased the metastatic burden of 
primary PyMT cells (Figure 5.7.C). Notably, no effect in the number of metastatic 
nodules was observed upon AXL inhibition at later stages of metastasis (day 25 – 
30 post-injection) when metastatic nodules are fully developed (Figure 5.7.C). 
These results, in line with the previous studies by Ocana et al. and Tsai et al., 
suggest that facilitating mesenchymal reversion at the target site enhances 
metastatic outgrowth. 
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Figure 5.7 AXL inhibition during late metastasis 
(A) FACS analysis of the percentage of AXL+ MICs (red-left Y axis) and total MICs 
(black-right Y axis) among total GFP+ cancer cells in the lung at 4 and 12 days after 
tail vein injection. Graph represents mean ± sem per time point (n=8-9 mice per 
group of 2 independent experiments). (B) Experimental setup: Mice injected with 
106 PyMT or MDA231 cells were treated daily with 12.5 mg/kg of R428 from day 10 
to 15 (blue) or from day 25 to 35 (grey), and metastases were evaluated around 
day 35 post-injection. (C) Box plot displays the metastatic burden of MDA231 cells 
treated from day 10 to 15 post injection as indicated in (B). MDA231-DMSO, n= 3 
mice per group; MDA231-R428 (10-15 days), n= 4 mice per group. Superficial lung 
metastasis number was evaluated. (D) Box plot displays the metastatic burden of 
PyMT cells intravenously injected into mice as specified in (B). PyMT-DMSO, n= 11 
mice per group; PyMT-R428 (10-15 days), n= 10 mice per group; PyMT-R428 (25-
35 days), n= 7 mice per group. Superficial lung metastasis number was evaluated. 
(Right) Representative H&E staining of metastatic lung sections from mice of 
indicated groups. 
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Second, we engineered a lentiviral reporter construct containing the open reading 
frame (ORF) of the human AXL gene in order to exogenously express AXL in 
cancer cells delaying their mesenchymal reversion. To avoid the potential 
confounding effects on cell proliferation that high levels of AXL are reported to 
cause in other cancer types (Ben-Batalla et al., 2013, Ammoun et al., 2014, Paccez 
et al., 2013) we used a strategy where the LTR regions of the lentiviral construct 
controls AXL expression (LTR-AXL) (Figure 5.8.A). This leads to a modest 
overexpression of the receptor in both PyMT and MDA231 cells (Figure 5.8.B). As 
expected, AXL overexpression led to an exacerbated mesenchymal phenotype with 
increased Vimentin expression in the MDA231 cell line (Figure 5.8.C), and 
increased Vimentin and reduced E-cadherin levels in primary PyMT cells (Figure 
5.8.D-E).  
Next, we addressed the effect of overexpressing AXL in vivo as cells extravasated 
into the lungs. We used the MDA231 cell line expressing GFP or the LTRAXL 
constructs monitored their AXL expression levels as they grew in the lungs for a 
24h period early after extravasation (from day 3 to 4 post-injection) (Figure 5.9.A). 
We could observe that AXL overexpression leads to a delay in the ability of the 
tumour cells to induce its early downregulation preventing their accumulation in the 
lungs. While the control MDA231-GFP cells reduced to half AXL expression and 
doubled in number, the MDA231-LTRAXL cells maintained AXL expression levels 
and did not grow in the lungs (Figure 5.9.B). This result indicates that exogenous 
AXL expression delays tumour cell growth in the early phase of colonisation. We 
next excluded that this delayed growth in vivo was due to a defect in proliferation in 
the AXL-overexpressing cells. We performed a BrdU chase experiment in vitro and 
did not detect any difference in the BrdU incorporation rate of MDA231-GFP and 
MDA231-LTRAXL over 3 hours (Figure 5.9.C) excluding a direct negative impact on 
tumour cell proliferation. Thus, we next injected both PyMT and MDA231 cells 
expressing GFP or LTRAXL into the lungs and assessed metastatic outcome 20-30 
days post-seeding. In both models the exogenous expression of AXL impaired 
metastatic outgrowth (Figure 5.9.D-E). This result suggests that for efficient 
metastasis epithelial reversion needs to occur in a temporally controlled manner 
during the second phase of metastatic colonisation. 
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Figure 5.8 LTR-driven AXL overexpression exacerbates the mesenchymal 
phenotype of cancer cells  
(A) Lentiviral construct expressing the human AXL coding sequence under the 
control of the viral LTR regions (LTRAXL). An independent human PGK promoter 
controls EGFP reporter gene expression. (B) FACS histogram displays AXL 
expression levels in PyMT and MDA231 cells expressing GFP (black) or LTRAXL 
(blue) lentiviral constructs. (C) Chart indicates the expression levels of Vimentin in 
primary PyMT cells expressing GFP or LTRAXL lentiviral construct assessed by 
immunofluorescence. (D) Representative images and (E) charts indicate the 
expression levels of E-cadherin and Vimentin in primary PyMT cells expressing 
GFP or LTRAXL lentiviral construct. Chart line and error bars indicate mean ± SD 
of the population. Scale bar, 20 µm.  
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Figure 5.9 AXL exogenous expression effects on cancer cell proliferation and 
metastatic colonisation 
(A) Experimental setup: Mice were injected with 106 PyMT or MDA231 expressing 
GFP or LTRAXL lentiviral constructs. We evaluated the effects of AXL 
overexpression during the early phase of metastatic colonisation over 24h, from 
day 3 to 4 (brown window). Metastatic outcome was evaluated 30 days post-
injection. (B) FACs analysis of the total cell growth and in vivo dynamics of AXL in 
MDA231 cells expressing GFP (left panel) or LTRAXL (right panel), from day 3 to 4 
of the metastatic time course shown in (A). Dot plot represents the average of the 
percentage of positive cells in the lung: Total cells (measure as GFP+ cells) and 
AXL-expressing cells (measure as AXL+ cells) (n=3 mice per group). (C) FACS 
histogram plot shows BrdU incorporation over a 3 hours pulse by MDA231 cells 
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expressing GFP (black) or LTRAXL (blue) lentiviral constructs. (D) Box plot 
displays the metastatic potential of MDA231 cells expressing GFP or LTRAXL 
lentiviral constructs, as specified in (A) (n=8 mice per group). (Left) Representative 
images of H&E stain show MDA231 metastatic nodules in the lung of the indicated 
groups. (E) Box plot displays the metastatic potential of PyMT cells expressing 
GFP or LTRAXL lentiviral constructs, as specified in (A) (n=10-12 mice per group).  
 
 
 
 
 
 
To further characterise the role of AXL in tumorigenesis, we evaluated the effects 
of overexpressing AXL on the intrinsic cancer cells abilities. First, we tested the 
ability of PyMT primary LTRAXL cells to form spheres to assess their self-renewal 
capacity in vitro. We observed that AXL overexpression negatively affects the 
ability of PyMT cells to grow in suspension (Figure 5.10.A). Second, we performed 
the gold standard stemness assay in vivo analysing their ability to initiate primary 
tumours. Interestingly, LTRAXL cells displayed an enhanced ability to initiate 
primary tumours in both models, PyMT and MDA231 (Figure 5.10.B-C) in contrast 
to their reduced ability to form spheres (Figure 5.10.A). Overall, the enhanced 
ability to grow primary tumours in vivo excludes a direct negative impact on the 
intrinsic stemness abilities of AXL overexpressing cells. Next, we performed some 
histological analysis on these fully established tumours and found no difference in 
proliferation as measured by Ki67 expression (Figure 5.10.D-E). Also, the overall 
tumour morphology revealed by the H&E stain and the tumour vasculature 
(endomucin stain) was unaltered in LTRAXL tumours (Figure 5.10.D-E).  
 
 
 
 
 
 
Chapter 5. Results III 
 
 
 
195 
 
 
Figure 5.10 Effects of overexpressing AXL on self-renewal and tumour 
growth 
(A) (Left) Images show representative pictures of spheres formed by PyMT cells 
expressing GFP and LTRAXL lentiviral constructs in suspension. Scale bar, 200 
µm. (Right) Histogram shows the mean ± sem of 2 independent experiments. 
Spheres were quantified 7 days after plating a single PyMT suspension (primary) 
and 7 days after the first passage (secondary). (B) Box plots display tumour burden 
assessed 2 weeks after engraftment of PyMT cells expressing GFP or LTR-AXL 
(n=6 per group). (C) Box plots display tumour burden assessed 2 weeks after 
engraftment of MDA231 cells expressing GFP or LTR-AXL (n=6 per group). (D) 
Histological analysis of MDA231 tumours, control and LTRAXL, stain for H&E, Ki67 
(brown signal) and Endomucin (brown signal). Scale bar, 100 μm. (E) Histological 
analysis of PyMT tumours, control and LTRAXL, stain for H&E, Ki67 (brown signal) 
and Endomucin (brown signal). Scale bar, 100 μm.  
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These results suggest that AXL displays differential roles during primary tumour 
initiation and development, and metastatic colonisation, as previously observed 
with the secreted ECM glycoprotein THBS2. 
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5.3 AXL loss is a transient effect required during colonisation  
We have shown in the previous sections evidence for a biphasic model governing 
early metastatic colonisation of breast cancer cells to the lungs. Our results support 
the idea that after extravasation into the target site, tumour cells maintain their 
mesenchymal status displaying high levels of AXL, Twist1 and the niche activation 
effector THBS2 (Figures 5.1 and 4.3). Subsequently, following the appearance of 
the induced niche, activated fibroblasts will trigger the inhibition of cancer cells 
mesenchymal features favouring cell growth (Figures 5.3 and 5.4). Once metastatic 
colonisation is completed, tumour cells are re-wired to grow a tumour cell mass that 
will recapitulate a similar structure to the original primary tumour at a distant 
location. During this outgrowth phase, new stroma recruitment and stromal-cancer 
cell interactions will take place in the context of a continuously evolving 
microenvironment (section 1.3.2). Therefore, we next asked whether in late-stage 
metastases, when metastatic nodules have successfully outgrown, the original 
AXL-mesenchymal features displayed by MICs at the primary site would be re-
acquired. In order to test this idea, we performed a longer metastasis time course 
experiment where we monitored AXL expression on total cancer cells and MICs in 
the lungs after intravenous injection during early colonisation (4 days post-seeding), 
late colonisation (12 days post-seeding) and metastasis (30 days post-seeding). As 
previously observed, AXL expression in MICs decreases as the pool expands in 
the lungs in the transition from early to late colonisation (Figure 5.11.A). 
Remarkably, in late-stage metastases (30 days post injection) the subpool regains 
expression of AXL as the number of MICs goes down to their normal frequency in 
the tumour mass (around 2-3%) (Figure 5.11.A). In contrast, the overall levels of 
AXL in total tumour cells in the lung did not change significantly throughout the time 
course, being the percentage of total AXL+ PyMT cells in the lungs around 10-15% 
(Figure 5.11.A). These results indicate that MICs in late-stage metastases regain 
the mesenchymal characteristics displayed at the primary site when they 
disseminate to colonise distant tissues with a highly secretory mesenchymal 
phenotype.  
Additionally, the analysis of AXL expression in total tumour cells in the lungs shows 
that AXL dynamics during metastasis are confined to the MIC subpool, highlighting 
the plasticity of this population of metastasis-initiating cells (Figure 5.11.A).  
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We previously showed that inhibiting AXL with R428 during this late metastatic 
stage (day 25-35 post intravenous injection) did not affect the total number of lung 
metastases (Figure 5.7.D). Further histological analysis revealed a reduction in the 
size of the metastatic nodules after a 10 days treatment of fully established 
metastases with the inhibitor (Figure 5.11.B).  
 
 
 
 
Figure 5.11 Complete AXL dynamics during metastasis and effects of AXL 
inhibition in fully established nodules 
(A) Complete AXL dynamics time course during metastatic progression. 
Representative images show the amount and size of metastasis in the lung 4 days 
(first colonisation phase), 12 days (second colonisation phase) and 30 days (late 
stage metastasis) post-intravenous injection of 106 actinGFP/PyMT cells. Graph 
shows the dynamics in the percentage of total AXL+ tumour cells (black), the 
percentage of total MICs (grey) and the percentage of AXL+ MICs (purple) in the 
lungs at 4, 12 and 30 days port-seeding measured by FACS analysis (n=8-9 mice 
per group). (B) AXL inhibition during late stage metastasis. Mice were injected 
intravenously with 106 actinGFP/PyMT cells, and treated with DMSO or 12.5 mg/kg 
of R428 from day 25 to 35 post-seeding. Metastasis were analysed the last day of 
treatment. Box plot shows the evaluation of superficial lung metastasis in mice 
treated with DMSO or R428 (25-35 days). Representative pictures show an H&E 
staining in whole lung scans of the indicated groups. Bar graph displays the size 
distribution of the metastatic nodules in mice treated with DMSO or R428 (25-35 
days). The area of each metastatic nodule in the lung sections was evaluated using 
ImageJ and classified attending to their size into the indicated 3 categories.  
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This result indicates that in late-stage metastasis, when AXL is re-expressed in the 
MIC subpool, its inhibition can limit metastatic cell growth.  
 
 
Chapter 6. Discussion 
 
 
 
200 
Chapter 6. Discussion 
The major goal of this work was to determine what intrinsic features of the 
previously described metastasis-initiating cells (MICs) in the MMTV-PyMT model 
(Malanchi et al., 2012) drive breast cancer metastatic colonisation to the lungs.  
 
Collectively our results provide a refined model of distant metastatic colonisation 
when metastatic cells display a mesenchymal state. We found MICs to display a 
highly secretory mesenchymal state characterised by the expression of AXL when 
isolated from invasive carcinomas. Notably, this AXL-mesenchymal status is 
crucially maintained upon extravasation to the lungs in an experimental-metastasis 
setting. Dependent on the mesenchymal status of cancer cells, we propose a 
biphasic model of distant colonisation (Figure 6.1). In the first phase, the AXL-
mesenchymal status of cancer cells provides them the crucial advantage of 
inducing niche activation. Particularly, MICs trigger a novel cancer cell-stromal 
crosstalk mediated by THBS2 secretion that enhances fibroblast activation at the 
target site contributing to MICs metastasis initiating advantage. Moreover, our work 
provides evidence of this cancer cell-stroma crosstalk ultimately governing 
epithelial plasticity during the second phase of colonisation, when the activated 
niche feeds back to tune cancer cells epithelial phenotype in a temporally controlled 
manner. We uncover that the fibroblasts of the newly activated niche trigger a 
crosstalk of signals that attenuates TGFβ signalling and the mesenchymal status 
(AXL/Twist1 loss) of cancer cells, driving a BMP-dependent re-epithelialisation.  
 
Importantly, using a combination of in vivo primary tumour initiation assays and ex 
vivo sphere formation assays we show that MICs maintain their intrinsic stem-like 
features throughout epithelial plasticity. These results suggest that the activated 
niche modulates the epithelial plasticity of metastasis-initiating cancer cells leaving 
unaltered their intrinsic stemness properties.  
 
Finally, the temporally controlled AXL downregulation that allows metastatic 
outgrowth in the lungs during late colonisation is a transient event. In fully 
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developed late-stage metastases the initially high AXL expression in MICs is 
restored. 
 
 
 
 
 
Figure 6.1 Biphasic model of breast to lung metastatic colonisation 
In the MMTV-PyMT model metastatic colonisation is divided into two temporally 
distinct phases defined by the AXL-mesenchymal status of cancer cells. During the 
first phase upon extravasation MICs display a partial mesenchymal state 
characterised by high Twist1 and AXL expression, TGFβ signalling (pSMAD2-3) 
and BMP signalling  (pSMAD1-5). Dependent on this mesenchymal status, MICs 
secrete THBS2 that triggers lung fibroblast activation. In the second phase, the 
newly activated fibroblasts trigger a crosstalk of signals that mediate cancer cell re-
epithelialisation via the attenuation of TGFβ (pSMAD2-3) signalling that favours 
BMP activation (pSMAD1-5). Alongside TGFβ, AXL and Twist1 expression are also 
downregulated in this second phase of colonisation. Functionally tumour cells 
switch from a mesenchymal motile state to a proliferative phenotype sustained by 
BMP/ID1 that is compatible with metastatic outgrowth. 
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6.1 AXL-mesenchymal features of MICs promote metastatic 
colonisation beyond invasion 
6.1.1 Metastasis-initiating cells: stemness throughout epithelial plasticity  
As previously described, successful establishment of metastases requires cancer 
cells with self-renewal properties to disseminate from their tissue of origin and re-
initiate tumour growth at favourable secondary sites (section 1.3.1). The fact that 
inducing EMT in non-malignant epithelial cells can lead to the generation of cancer 
stem cells (Morel et al., 2008, Mani et al., 2008) suggests a unified molecular 
programme underlying metastasis. In line with this idea we found that the MICs of 
the MMTV-PyMT tumour model (Malanchi et al., 2012) display a mesenchymal 
phenotype characterised by high AXL expression (Figure 3.3 and 3.8). However, as 
previously mentioned, the reversible nature of the EMT programme combined with 
the crucial requirement of stemness during the metastatic process makes the linear 
relationship between EMT and stemness controversial (section 1.4). Although we 
did not performed lineage tracing to determine the epithelial origin of MICs 
(CD24+CD90+), the isolation strategy with CD24 allows the isolation of mammary 
tumour cells of epithelial origin with high purity. Indeed, the isolation of CD24-
CD90+ or CD24-CD90- and examination in pure 3D Matrigel cultures showed that 
these populations are phenotypically and functionally fully mesenchymal cells that 
form a reticular network invading into the gels (data not shown); in contrast, the 
CD24+CD90+ MIC subpool in the same matrices formed mammary branching 
organoids (Figure 4.10.D).  
 
We used the CD24+AXL+ more mesenchymal population isolated from the epithelial 
compartment of PyMT tumours that displays a similar EMT phenotype to MICs 
(Figure 3.10.A), and compared their tumour initiation ability using orthotopic 
transplantations as the gold standard test for stemness in vivo (Figure 3.10.B). 
These in vivo assays revealed that despite their similar mesenchymal phenotype 
the tumour-initiating capacity of MICs was higher when compared to the AXL+ 
subpool (Figure 3.12). This result suggests that additional stem-like features of 
MICs such as high Wnt signalling (Figures 3.2 and 3.3) rather than their 
mesenchymal phenotype confers enhanced tumour-initiating properties to MICs. In 
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addition, the predominantly epithelial population of CD24+Sca1+ cells (Figure 3.11), 
previously described as a tumour-initiating pool in the MMTV-Neu model (Liu et al., 
2007b), displayed a tumorigenic potential similar to that of the more mesenchymal 
MICs (Figure 3.12). This result indicates that in the MMTV-PyMT model the 
mesenchymal status per se does not correlate with the stemness needed to initiate 
tumour growth. Notably, the fact that more mesenchymal characteristics did not 
provide an advantage in tumour initiation ability indicates that both subpools retain 
similar levels of stemness. 
 
We further analysed the reversible nature of the EMT programme and the crucial 
requirement of stemness during the metastatic process. We tested the CD24+AXL+ 
mesenchymal PyMT population versus the more epithelial AXL- tumour fraction in 
parallel in tumour initiation and metastatic colonisation assays (Figure 3.10.B-C). 
Both assays require cancer cell intrinsic stemness properties to self-renew and 
grow either in a collective challenge when locally injected in its tissue of origin, or in 
a single cell challenge when directly seeded into a foreign microenvironment. 
Therefore a comparison of cells behaviour in these two settings allows 
understanding whether a particular EMT status would provide additional advantage 
to metastasise. Indeed, the CD24+AXL+ mesenchymal PyMT population displayed 
enhanced metastatic colonisation ability whereas its tumour-initiating capabilities 
were unaltered compared to the AXL- fraction (Figure 3.10.D-E). This result 
suggests that the AXL-mesenchymal status provides an advantage in metastatic 
colonisation independent from cancer cells intrinsic stemness. 
 
Typically, studies analysing the relationship between epithelial plasticity and 
stemness alter the expression of the EMT core transcription factors to change the 
EMT status of the cells and assess the impact on stemness (Mani et al., 2008, 
Beck et al., 2015, De Craene et al., 2014, Chaffer et al., 2013). In this study we 
chose to manipulate the mesenchymal phenotype of cancer cells via the 
downstream effector of the EMT programme AXL (section 1.2.1.1). The idea 
behind this approach was to revert the mesenchymal features of cancer cells 
without inducing broader changes in cellular functions caused by the alteration of 
EMT-TFs. Indeed, it is known that manipulating the expression of EMT-TFs can 
induce extensive epigenetic changes directly affecting survival and self-renewal 
Chapter 6. Discussion 
 
 
 
204 
(Chaffer et al., 2013, Wellner et al., 2009, Mani et al., 2008). In contrast, by 
blocking AXL in MICs we confirmed the extensively reported phenotypic inhibition 
of the AXL-mesenchymal status, and also achieved a modest decrease in the 
expression levels of the EMT-TFs and a functional reduction in cell motility (Figure 
4.2). Similar effects were observed in the MDA-MB-231 basal cell line that shares 
the AXL-mesenchymal status of the MIC subpool of MMTV-PyMT cells (Figure 4.3).  
In agreement with our previous data comparing the CD24+AXL+ PyMT population 
to the AXL- tumour fraction, the exogenous depletion of AXL from total PyMT cells 
using a shRNA against AXL or the specific inhibitor R428 blocked their metastatic 
ability (Figure 4.6.H and 4.8.E) but did not have any effect on tumour initiation 
(Figure 4.6.G and 4.10.D). Importantly, we further confirmed that the intrinsic 
stemness abilities required to initiate tumour growth were not altered upon AXL 
depletion in PyMT cells performing sphere formation assays in vitro (Figure 4.6.F 
and 4.10.G). These results reiterate the crucial role of AXL expression specifically 
during metastatic colonisation.  
 
The requirement of the AXL-mesenchymal status during early metastatic 
colonisation was confirmed using the AXL-expressing human MDA-MB-231 cell 
line and the mouse 4T1 cell line in experimental metastasis assays (Figure 4.9.B 
and 4.7.B). In sharp contrast to the expendable role of AXL during primary tumour 
initiation in the primary MMTV-PyMT model, the tumour growth ability of these cell 
lines upon AXL depletion have been reported to be impaired (Gjerdrum et al., 
2010). This study excluded deleterious effects in cell survival and proliferation upon 
orthotopic transplantation, two cellular functions that AXL depletion can negatively 
affect in other cancer types when functioning as a tyrosine kinase receptor upon 
Gas6 stimulation (Paccez et al., 2014). These results suggest that these basal-like 
cell lines are highly dependent on AXL, a protein that all cells homogeneously 
express (Figure 4.3.C and 4.7.A), having AXL additional functions that could impact 
on cell intrinsic properties like stemness. This possibility could represent a limitation 
when using highly homogeneous cell lines to study stem-like properties of tumour 
cells.  
 
The role of the AXL-mesenchymal status and its relationship with stemness was 
further analysed by exogenously expressing AXL. This resulted in an increase in 
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the number of AXL-expressing cells among the PyMT population (Figure 5.8.B), 
whereas in MDA-MB-231 cells AXL exogenous expression increased the overall 
AXL levels and exacerbated their mesenchymal phenotype (Figure 5.8.B-C). This 
exogenous AXL expression led to increased tumour growth in both models, but 
neither the proliferation nor the microenvironmental composition of these fully 
established tumours were altered (Figure 5.10.B-E). However, we did not exclude 
that a boost in proliferation due to enhanced AXL signalling occurred earlier during 
tumour initiation. A possible explanation for this enhanced tumour growth in vivo 
could be a direct AXL stimulation by its ligand Gas6 (Korshunov, 2012, Dormady et 
al., 2000). Indeed, several components of the tumour microenvironment such as 
monocytes and fibroblasts secrete Gas6 (Ben-Batalla et al., 2013, Dormady et al., 
2000). This could activate AXL tyrosine kinase function triggering PI3K-AKT-NFkB 
mediated survival (Figure 1.4.B – purple arrows) making tumour cells more 
resistant to apoptosis just after the post-orthotopic transplantation period. Although 
it has been reported that AXL does not enhance survival or proliferation in breast 
cancer cells (Paccez et al., 2014), its overexpression might lower the threshold to 
respond to Gas6 levels. In agreement with this hypothesis, when AXL-
overexpressing cells were assayed in sphere conditions in vitro where they lack 
microenvironmental Gas6-AXL stimulation, their sphere formation ability was 
indeed impaired (Figure 5.10.A). The efficient primary tumour formation achieved 
by AXL-overexpressing cells excludes that their reduced in vitro sphere formation 
ability depends on a direct negative effect on self-renewal. Indeed, when culturing 
total primary PyMT cells in non-adherent conditions the endogenous AXL levels are 
downregulated (data not shown). This result together with the evidence that AXL 
depletion does not alter the sphere formation ability of PyMT cells (Figure 4.6.F and 
4.10.G) suggest that to adapt to the non-adherent sphere culture conditions AXL 
loss is required. Collectively, these data suggest that AXL-mesenchymal features 
per se do not alter self-renewal. 
 
Similarly to the requirement of AXL downregulation for cancer cells to adapt to the 
specific in vitro non-adherent conditions in sphere assays, we observed that AXL is 
lost during metastatic colonisation as cancer cell grow in the lungs (Figure 4.8.B 
and 4.9.B). Accordingly, maintaining AXL expression with an exogenous promoter 
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and thereby retarding its downregulation during metastatic colonisation (Figure 
5.9.B) reduces metastatic outcome (Figure 5.9.D-E). 
As briefly mentioned above, AXL apart from a key EMT downstream effector of the 
EMT programme (Paccez et al., 2014) functions as a tyrosine kinase receptor 
activated by its ligand Gas6 (Korshunov, 2012). It has been shown in leukemia that 
AXL mediates a paracrine crosstalk with the stroma establishing a cancer cell niche 
at the primary site (Ben-Batalla et al., 2013). Leukemic cells educate bone-marrow 
stromal cells to secrete Gas6, which in turn stimulates AXL+ leukemic cells 
enhancing their proliferation (Ben-Batalla et al., 2013). A similar mechanism in 
breast cancer metastasis could lead to decreased metastatic potential when 
inhibiting AXL independently of the epithelial/mesenchymal modulations. 
Nevertheless, we observe AXL to be downregulated in disseminated cancer cells 
when they start proliferating in the lungs (Figure 4.8.A and 4.9.A). Therefore, the 
stromal derived signals promoting metastatic establishment in breast cancer 
metastasis are likely to be independent from this AXL-Gas6 axis observed in 
leukemia that promotes proliferation. Moreover, AXL overexpression reduces early 
cancer cell accumulation in the lungs and impairs metastatic outgrowth (Figure 
5.9.B and 5.9.D-E) inversely correlating with the proliferative promoting-effects 
described in leukemia (Ben-Batalla et al., 2013). Importantly, our data are in line 
with several studies in breast cancer highlighting the role of AXL as an EMT 
effector independently of its tyrosine kinase receptor function regulating 
proliferation and survival (Gjerdrum et al., 2010, Holland et al., 2010, Paccez et al., 
2014). Furthermore, we observed that AXL is expendable for cell proliferation in 
vitro and tumour initiation in vivo (Figure 4.10.A-E). 
 
In summary, our data illustrates the maintenance of stemness and tumour initiating 
ability throughout AXL-mesenchymal modulations rather than a direct correlation 
between EMT and stemness (Figure 6.2). A harmonising model to explain this 
complex relationships between EMT and stemness in cancer cells is the gradient 
EMT model (Figure 1.6.A) (Ombrato and Malanchi, 2014). In line with our results, 
this model proposes that cancer cells with stem-like properties can transit between 
more mesenchymal or more epithelial phenotypes in a context dependent manner 
within the limits of a ‘stemness window’ where the maintenance of their intrinsic 
stemness abilities is preserved (Figure 1.6.A). In line with this model, exacerbating 
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the mesenchymal state of cancer cells through AXL exogenous expression (Figure 
5.9.D-E) or as previously reported inducing the expression of an additional EMT-TF 
such as Prrx1 (Ocana et al., 2012, Brabletz, 2012a) pushes cells out of the 
‘stemness window’ proposed by the gradient EMT model to a very mesenchymal 
state that reduces cancer cells plasticity. This impairs the ability of cancer cells to 
adapt to a new environment such as the one encounter during metastatic 
colonisation resulting deleterious for the process.  
On the other hand, we have described that AXL positive cells show enhanced 
metastatic activity, and that the AXL-mesenchymal status despite the requirement 
of its later downregulation, provides an initial advantage in metastasis (Figure 
3.10.E and 4.6.H). Therefore, we propose the requirement of a plastic AXL-
mesenchymal state that can be modulated throughout metastatic colonisation. 
Indeed, confirming the previous conclusion reached by Ocana et al., we observed 
that the mesenchymal phenotype induced via EMT and stemness are uncoupled, 
as required for a context dependent modulation. In line with this suggested context-
dependent modulations of the AXL-mesenchymal status we showed how during 
early metastatic colonisation AXL downregulation depends on specific features, like 
the secretion of the niche inducing factor THBS2, linked to its presence (Figure 
3.13 and 3.14); whereas AXL absence correlates with active BMP signalling 
required for metastatic outgrowth (Figure 5.4.E-G).  
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Figure 6.2 Functional readouts of AXL modulations in PyMT cells 
Scheme displays the relative comparison of the sphere formation/self-renewal 
ability in vitro (green line), tumour initiation (blue line) and metastatic ability (purple 
line) of PyMT primary cells according to their AXL expression levels. (A) Effects of 
AXL depletion. In basal state (endogenous AXL levels) around 30% of PyMT cells 
express AXL; by infecting the cells with a lentiviral construct expressing shAXL we 
completely deplete AXL expression (0% of cells). (B) Effects of AXL 
overexpression. Exogenous expression of AXL (LTR-AXL) generates a 
homogeneous cell preparation were all PyMT cells express AXL (100%). 
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6.1.2 THBS2, a potential targetable niche component to prevent metastatic 
outgrowth 
The crucial induction of a favourable metastatic niche upon arrival to the target site 
is a pre-requisite for metastasis (section 1.3.2). We have previously discussed how 
fibroblast-derived ECM components, such as POSTN and TNC are crucially 
required for breast to lung metastatic colonisation (Malanchi et al., 2012, 
Oskarsson et al., 2011). Our work highlights the requirement of a highly secretory 
mesenchymal phenotype linked to AXL expression mediating fibroblast activation 
at the naïve target site (Figure 3.13), providing a potential mechanism to explain 
how the fibroblastic metastatic niche is induced upon cancer cell arrival to the lungs. 
Moreover, we show that MICs displaying an AXL-mesenchymal state show an 
enhanced ability to activate normal lung fibroblasts ex vivo compared to the 
nonMIC subpool of the tumours (Figures 3.14, 3.15). 
All cancer cells can trigger stromal activation by secreting factors such as TGFβ. 
Here we show that cells in an AXL-mesenchymal state show an overall enhanced 
secretory activity that can potentially perturb their surrounding microenvironment 
(Figure 3.2 and 3.3). Particularly, we identified the ECM glycoprotein THBS2 to 
have a novel role as key effector enhancing fibroblast activation during metastatic 
colonisation. MICs displaying an AXL-mesenchymal phenotype secrete high levels 
of THBS2 (Figure 3.8 and 3.16), which enhances fibroblast activation through 
integrin β1 signalling (Figure 3.17 and 3.18). The crucial consequence of this 
activity is that a single cell expressing THBS2 will be more efficient in activating its 
surrounding microenvironment compared to a cell that do not secrete this stroma 
co-activator. Indeed, using experimental metastasis assays we confirmed that the 
THBS2-mediated MIC-fibroblast crosstalk is required for efficient metastatic 
colonisation, (Figure 3.19.C and 3.20.C). Conversely, broadening THBS2 
expression to all PyMT cells by exogenously expressing it in the nonMIC fraction of 
the tumour led to an increase in actively metastasising cells in the lungs (Figure 
3.21.C), suggesting that expressing THBS2 helps a larger number of tumour cells 
to successfully induce their niche and thereby enhancing their early metastatic 
colonisation ability. 
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In the context of previous studies showing the key role of recruited fibroblasts to 
form a niche for disseminated breast cancer cells in the lung (Malanchi et al., 2012, 
Oskarsson et al., 2011), we now provide a molecular mechanism explaining how 
this cancer cell-fibroblast alliance is established in the first place. THBS2 is one 
crucial mediator of this fibroblast activation, and thereby promotes metastatic 
colonisation. Importantly, given its direct constant requirement during early 
metastatic colonisation (Figure 3.20.C and 3.21.C), THBS2 represents a potential 
therapeutically targetable molecule to prevent the outgrowth of disseminated 
tumour cells at distant sites in patients. The therapeutic relevance of THBS2 is 
supported by computational analyses defining it as one of the three genes 
associated with stromal desmoplastic reaction and high metastatic risk (Kim et al., 
2010), as well as the clinical evidences of its correlation with poor distant 
metastasis free survival (DMFS) in high grade human breast carcinomas (Figure 
3.22). 
 
The decisive pro-metastatic role of THBS2 we observed during early breast to lung 
metastatic colonisation opposes to the described pro-dormancy function of 
endothelial cell derived THBS1 in the same context (Ghajar et al., 2013). Ghajar et 
al. showed that upon extravasation to the lungs, breast cancer cells remain in a 
perivascular niche were endothelial cell derived THBS1 maintains tumour cells in a 
dormancy state. Subsequently, upon tumour cell induced vascular sprouting 
dormancy is overcome dependent on TGFβ signalling stimulation (Ghajar et al., 
2013). Although both THBS1 and THBS2 belong to the same glycoprotein family, 
THBS2 is a smaller protein lacking the TGFβ interacting domain that THBS1 
harbours. This could explain the observed TGFβ mediated effect on releasing 
THBS1 sustained dormancy at perivascular lung niches. Concomitantly, in the very 
same temporal window of the metastatic process early after extravasation, we have 
also found AXL-mesenchymal cells undergoing TGFβ signalling (Figure 5.3.B), and 
as consequence of their TGFβ sustained AXL-mesenchymal phenotype they 
secrete THBS2 inducing a fibroblastic niche (Figure 3.13.B-C). Notably, we showed 
that these fibroblastic niches are exclusively formed around mesenchymal AXL+ 
cells metastasis-initiating cells, whereas both mesenchymal AXL+ and more 
epithelial AXL- cells can be found in dormant perivascular niches (Figure 3.13.B-C).  
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The example explained above with THBS1 and THBS2 illustrates how two similar 
glycoproteins in the same context of early metastatic colonisation can mediate 
antagonistic functions. However, in fully developed breast tumours, both THBS1 
and THBS2 have been shown to exert antiangiogenic functions (Jimenez et al., 
2000). The antiangiogenic effect of Thrombospondins is mediated by the common 
N-terminal TSR domain of these proteins that binds CD36 in endothelial cells 
triggering apoptosis (Koch et al., 2011). This was shown in a breast cancer 
xenograft model using the MDA-MB-435 cell line (Koch et al., 2011). In the MMTV-
PyMT model, we confirmed that long-term depletion of THBS2 led to increased 
tumour vascularisation and consequently higher tumour growth (Figure 3.23.A). 
Importantly, no effects were observed in early primary tumour initiation when 
depleting THBS2 (Figure 3.20.B), excluding the role of this factor in regulating 
intrinsic cancer cells features such as stemness. Conversely, overexpressing 
THBS2 in PyMT tumours impaired tumour vascularisation and led to decreased 
tumour growth (Figure 3.23.B). Moreover, as expected when altering the ECM 
composition throughout tumour progression (section 1.1.2.2) histological analysis 
of THBS2 overexpressing tumours revealed changes in stromal organisation 
beyond the expected decrease in vasculature. Epithelial cell organisation was 
altered in THBS2 overexpressing compared to normal PyMT tumours, and the 
number of infiltrated stroma areas was dramatically increased (Figure 3.23.B).  
 
Altogether, these results depict THBS2 as a key tumour microenvironment 
component with distinctive roles during tumour initiation, progression and 
metastatic colonisation (Figure 6.3). Beyond its effects in vascularisation, given that 
we observed that: 1) THBS2 enhances lung fibroblast activation, and 2) THBS2 
overexpressing tumours show a distinct stromal composition, it would be interesting 
to further characterise THBS2 mediated effects on the fibroblastic stroma at the 
primary site. 
 
Overall, our work describes a novel role of THBS2 as a key mediator of metastatic 
colonisation. Importantly, THBS2 represents a potential therapeutically targetable 
molecule to prevent the outgrowth of disseminated tumour cells at distant sites in 
patients after primary tumour excision. Given the pro-angiogenic effects following 
THBS2 depletion from the tumour microenvironment, primary tumour excision 
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would be a pre-requisite to anti-THBS2 therapies. As commented throughout the 
introduction (section 1.2), current efforts to develop new anti-metastatic therapies 
go in this direction, trying to identify new targets that could prevent the outgrowth of 
disseminated tumour cells. Therefore, THBS2 blocking strategies, such as blocking 
peptides or antibodies represent a promising approach to test in preclinical 
spontaneous mouse models upon tumour resection. In this study, the differences in 
tumour growth observed when genetically manipulating THBS2 expression levels 
(Figure 3.23) precluded the examination of metastatic outcome in a spontaneous 
metastasis setting, as differences in tumour size do not necessarily correlate in a 
linear manner with dissemination and metastatic outcome.  
 
 
 
 
Figure 6.3 Functional readouts of THBS2 modulations in PyMT cells 
Scheme displays the relative comparison of the sphere formation/self-renewal 
ability in vitro (green line), tumour initiation (blue line) and metastatic ability (purple 
line) of PyMT primary cells according to their THBS2 expression levels. (A) Effects 
of THBS2 depletion. In basal state (endogenous THBS2 levels) THBS2 is highly 
expressed by MICs that constitute around 5% of the tumour cells, and AXL+ cells 
that conform around 30%; by infecting the cells with a lentiviral construct 
expressing shTHBS2 we completely deplete THBS2 expression (0% of cells). (B) 
Effects of THBS2 overexpression. Exogenous expression of THBS2 (THBS2ORF) 
generates a homogeneous cell preparation were all PyMT cells express AXL 
(100%). 
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6.1.3 The mesenchymal status of MICs defines their niche induction ability 
We have described that AXL-mesenchymal MICs are in a highly secretory state 
defined by the expression of different previously characterised secreted factors that 
to contribute to their metastatic potential, such as TNC, SPARC, MMPs (Figure 3.2 
and 3.3). Importantly, we observed that THBS2 is dependent on the AXL 
mesenchymal traits in metastatic cells (Figure 4.4.A-B), which are indeed 
maintained upon extravasation at the distant tissue (Figure 4.8.A). These results 
establish a direct link between the niche induction ability via THBS2 and the AXL-
mesenchymal status of MICs (AXL). Remarkably, both the MIC subpool of MMTV-
PyMT cancer cells as well as the metastatic human MDA-MB-231 cell line show 
higher niche activation ability dependent on their mesenchymal phenotype (Figure 
4.5). Furthermore, in microarray data from human carcinoma biopsies THBS2 
expression correlates with AXL, Vimentin, Twist1 and Zeb1 expression supporting 
this link (Table 4.1 and Figure 4.1). Indeed, the dependency of the niche induction 
on AXL-mesenchymal status during metastatic colonisation was confirmed in vivo 
when overexpression of THBS2 in the MDA-MB-231 cell line partially recued the 
deleterious effects of inhibiting AXL (Figure 4.11). 
 
These results show for the first time that EMT is not only required during cancer 
cell dissemination (Figure 1.6.B) but also early upon arrival to the target site. We 
describe that the mesenchymal status of cancer cells is required during early 
metastatic colonisation as it mediates the expression of crucial niche co-activators 
such as THBS2. These niche co-activators trigger a faster ‘education’ of the 
surrounding stroma that in turn creates a favourable microenvironment supporting 
metastatic cell growth.  
 
Whereas we believe that the mesenchymal status of MICs confers an advantage 
when metastasising as single cells, certainly there might be other mechanisms by 
which tumour cells metastasise. As previously referred, epithelial cells clusters can 
locally invade and can be found in patients blood samples (section 1.2.1.2 and 
1.2.2). Although it is still unclear how tumour cell clusters sometimes composed by 
up to 10 cells can extravasate at distant sites (Krebs et al., 2014), a recent study by 
Aceto et al. showed that rare CTC-clusters are 50-fold more efficiently 
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metastasising than single CTCs in a mouse model of experimental metastasis 
(Aceto et al., 2014). It seems evident that being part of a cell cluster has several 
advantages to promote metastatic colonisation: 1) More efficient niche induction 
ability - cancer cells within a cluster collectively secrete a higher concentration of 
any niche-activation factor compared to a single disseminated cell, therefore they 
can more effectively induce changes in the naïve microenvironment upon 
extravasation; and 2) Existence of an in-house niche before extravasation - cell 
clusters can serve as their own niche: the first possibility is that the tumour cell 
heterogeneity within the oligoclonal cluster might be sufficient to self provide a 
favourable niche; the second possibility is that different stromal cells and ECM 
niche components are part of these epithelial clusters, which so far can not be 
excluded (Yu et al., 2013). With either possibility, epithelial tumour cells in the 
cluster would circumvent the requirement of early niche induction within the 
metastatic tissue, being the mesenchymal features described in this work 
redundant for metastasising cell clusters. 
Moreover, as previously mentioned (section 1.2.2), circulating tumour cell analyses 
in breast, prostate and lung cancer patient samples have revealed that within the 
clusters there are cells displaying partial EMT states (Armstrong et al., 2011, Hou 
et al., 2011). The fact that cells within the cluster show cell-cell junctions does not 
exclude EMT heterogeneity. Therefore, cells displaying a partial EMT state, such 
as the MMTV-PyMT MICs (Figure 3.4), could form part of these clusters. This 
possibility could explain why ‘epithelial looking’ clusters display enhanced survival 
and metastatic ability (Aceto et al., 2014). 
 
It still remains to be determined whether the main route towards metastatic lung 
colonisation is mediated by more abundant mesenchymal-like single MICs or rare 
but more potent epithelial cell clusters. Our work using single cell experimental 
metastatic assays describes a novel targetable mechanism that prevents 
metastatic outgrowth when cells in a more mesenchymal state are driving the 
metastatic process. 
 
 
Chapter 6. Discussion 
 
 
 
215 
6.2 The metastatic niche:  key determinant for metastatic 
progression 
We have discussed in the previous section how the niche activation in the early 
phase of colonisation is a crucial step for efficient metastasis and it depends on the 
AXL-mesenchymal status of MICs. It is now accepted that mesenchymal activation 
within the primary tumour is needed for dissemination while its inhibition within the 
distant site is required for metastatic outgrowth (Ocaña et al., 2012; Tsai et al., 
2012). In line with the requirement of mesenchymal reversion at the metastatic site, 
we observed that AXL as well as the highly expressed EMT-TF Twist1 are 
spontaneously downregulated in the lungs as metastatic colonisation progresses 
(Figure 4.8.A, 4.9.A and 5.1.B-E). The fact that the attenuation of the AXL-
mesenchymal features temporally coincides with the niche activation, led us to test 
whether the newly activated fibroblast at the metastatic niche could modulate the 
epithelial status of cancer cells. Indeed, co-culturing MICs with fully activated 
fibroblasts (CAFs) mimicked the observed in vivo modulations mediating both AXL 
and Twist1 downregulation in MICs (Figure 5.2.A-D). Moreover, CAFs 
phenotypically and functionally reverted MICs mesenchymal state (Figure 5.3).  
 
We have previously introduced TGFβ as one of the main EMT inducers providing 
cancer cells with mesenchymal features at the primary site (Figure 1.4.B) (section 
1.2.1.1). Indeed, TGFβ positively regulates AXL expression alongside the EMT-TFs 
(Li et al., 2014b). In line with these observations we showed that during the second 
phase of colonisation TGFβ activity, as monitored by pSMAD2-3 expression, is 
downregulated along with the AXL-mesenchymal features and Twist1 in 
metastasising cells in the lung (Figure 5.4.B-D). Importantly, it has been widely 
characterised that the two different branches of the TGFβ pathway, TGFβ and BMP 
interfere each others activity (Wakefield and Hill, 2013). Accordingly we detected 
alongside TGFβ downregulation that the overall number of cells undergoing BMP 
signalling increased in metastasising cells being BMP-dependent pSMAD1-5 
activity maintained as cells transit from early to late colonisation (Figure 5.4.E-G). 
This was further corroborated by the increased in the number of cells that gained 
ID1 expression, a canonical BMP downstream effector, as they lost Twist1 
expression (Figure 5.4.H-I). These data suggest that the attenuation of TGFβ 
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signalling during the second phase of colonisation as a potential cause for the 
reversion of the AXL-mesenchymal state in cancer cells transitioning towards a 
more epithelial phenotype. 
 
Certainly, in contrast to the pro-invasive abilities triggered by TGFβ, BMP usually 
controls cell proliferation (Wakefield and Hill, 2013) and finely tunes the balance 
between self-renewal and differentiation in normal and cancer stem cells (Lonardo 
et al., 2011, He et al., 2004). Therefore, the TGFβ-BMP switch could mediate the 
functionally antagonistic ‘go or grow’ cell states observed in primary tumours 
(Patsialou et al., 2015) at distant secondary sites, reversing the initial mesenchymal 
migratory state to allow proliferation. Indeed, it was previously described that the 
downstream BMP effectors ID proteins are required for breast cancer cell 
proliferation and are critically expressed during metastatic outgrowth (Gupta et al., 
2007). Accordingly, we confirmed that blocking BMP signalling and thereby its 
downstream effector ID1 in PyMT cells specifically during the second phase of 
colonisation, prevents metastatic outgrowth (Figure 5.6.A-B).  
 
Importantly, CAF-secreted factors were capable of mimicking in vitro the BMP-
dependent ID1 induction on AXL-mesenchymal cells (Figure 5.5.A-B) suggesting 
that the stromal activation at the metastatic site in vivo would be capable of 
inducing the TGFβ-BMP switch. The TGFβ superfamily of ligands is one of the 
defining signatures of activated fibroblasts (Calvo et al., 2013). Thus, activated 
fibroblasts can secrete ligands from the two different branches of the pathway, 
TGFβ and BMP. By using inhibitors to disrupt the downstream signalling of each 
branch of the pathway specifically, we found that CAF-mediated ID1 induction is 
primarily sustained by BMP signalling (Figure 5.5.C-D). Additionally, we observed 
that CAF-mediated BMP-dependent ID1 induction correlates with increased cell 
proliferation and E-cadherin expression (Figure 5.5.C-E) suggesting a switch in 
AXL-mesenchymal cells towards a more epithelial proliferative state in vitro. 
 
Altogether, our findings suggest that the newly activated fibroblasts during the 
second phase of colonisation trigger a crosstalk of signals that attenuates TGFβ 
activity, leading to the re-epithelialisation of cancer cells. Based on these data, it is 
tempting to think that once activated, lung fibroblasts could secrete TGFβ 
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antagonists such as Decorin (Zhang et al., 2007), THBS1 (Rojas et al., 2008) or 
LTBP1 (Lorda-Diez et al., 2010) that would decrease TGFβ signalling favouring 
BMP activation, however further experimental evidence would be required to prove 
this.  
 
The idea of a balance between TGFβ and BMP signalling regulating EMT 
modulations at the target site is in line with the fact that TGFβ signalling is finely 
controlled throughout metastasis (Figure 1.6.B). TGFβ is the master EMT inducer 
at the invasive front of primary tumours (Giampieri et al., 2009, Xu et al., 2009); 
subsequently in the circulation platelet-derived TGFβ have been shown to maintain 
the mesenchymal characteristics of CTCs (Labelle et al., 2011). Our data complete 
this picture by describing a bi-phasic colonisation model correlating with TGFβ 
dynamics: in the early phase extravasated mesenchymal tumour cells display 
active TGFβ signalling (pSMAD2-3 expression) along with AXL and Twist1, 
whereas in the second phase TGFβ signalling is attenuated and BMP becomes the 
predominant signal of the pathway driving a phenotypic switch that mediates 
metastatic outgrowth.  
Additionally, we observed that BMP signalling rather than being induced de novo 
during the second phase colonisation when TGFβ activity is lost, is active 
throughout the process as indicated by the high pSMAD1-5 activity already present 
upon extravasation (Figure 5.4.E-G). This is line with a recently published report 
describing that inhibiting BMP signalling during primary tumour development in the 
MMTV-PyMT model impairs metastatic outcome in this preclinical therapeutic 
setting (Owens et al., 2015). The authors highlight that beyond BMP inhibition 
affecting primary tumour development at the primary site, BMP signalling is 
required through metastatic invasion (Owens et al., 2015). Based on these 
observations, it is reasonable to speculate that BMP activity in PyMT tumour cells 
is a fundamental signalling that is always active, and modulates its activation level 
in the presence or absence of TGFβ signalling, exerting a more recessive or 
dominant effect on cell functions. Epithelial plasticity could be the functional 
outcome of these TGFβ-BMP modulations shifting cancer cells purposes (i.e. high 
niche induction versus cancer cell outgrowth) throughout the dynamic metastatic 
progression.  
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Interestingly, although the effector ID1 is a canonical BMP target and its expression 
is sustained after BMP stimulation (Hollnagel et al., 1999), TGFβ signalling has 
been shown to transiently activate ID1 coupled to stress signalling in epithelial cells 
(Kang et al., 2003). Indeed, we observed that in the early phase of colonisation 
breast cancer cells undergoing TGFβ signalling and displaying an AXL/Twist1 
mesenchymal state also express ID1 (Figure 5.1.C and 5.4.H). Moreover, ID1 
expression is maintained in the second phase of colonisation when TGFβ is 
downregulated and BMP/pSMAD1-5 signalling increases (Figure 5.4.H), suggesting 
that ID1 expression in metastasising cancer cells is sustained by TGFβ attenuation 
rather than its stimulation (Figure 5.4). In contrast to our results showing the 
concomitant expression of Twist1 and ID1 during early colonisation, a recent report 
from Stankic et al. suggested that TGFβ driven ID1 expression could antagonise 
Twist1 during metastatic colonisation. This correlative antagonistic expression of 
ID1 and Twist1 was examined in vitro using the human epithelial HMLE 
exogenously expressing Twist1. When stimulated with TGFβ, HMLE-Twist1 
mesenchymal cells induced ID1 expression while normal HMLE epithelial cells 
cannot induce ID1 expression (Stankic et al., 2013). The discrepancy between our 
results and the observed function of ID1 as a negative regulator of Twist1 observed 
by Stankic et al. could have many explanations. An important difference to note is 
the fact that Stankic et al. used normal epithelial cells overexpressing Twist1 and 
not cancer cells to define this antagonistic activity in vitro, whereas we are 
monitoring ID1 and Twist1 expression in cancer cells metastasising in vivo. This 
fundamental difference in the approach used to observe ID1 and Twist1 dynamics 
makes it difficult to relate their findings to ours in the context of metastatic 
colonisation in vivo. 
 
Adding to the proposed complex TGFβ-BMP modulations described in our work, it 
has been shown that during the first colonisation phase, when we observed tumour 
cells to display AXL-mesenchymal features and active TGFβ signalling, breast 
cancer cells secrete the TGFβ ligands antagonist Coco to exit dormancy and 
progress towards colonisation (Gao et al., 2012). In this study Gao et al. propose 
that Coco secretion enables a fraction of metastatic cells to overcome BMP-driven 
dormancy in the lung parenchyma. Although Coco has been shown to function as a 
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ligand trap for BMPs, it can also antagonise TGFβ ligands (Walsh et al., 2010, 
Bates et al., 2013). Therefore, as discussed by the authors, the possibility that in 
the lung metastatic niche Coco induces metastatic reactivation through BMP 
independent mechanisms cannot be excluded (Gao et al., 2012). Indeed, in line 
with our data, Coco expression during early colonisation could mediate an 
autocrine mechanism that reinforces the initial requirement to maintain the TGFβ-
BMP balance in favour of TGFβ. Upon extravasation, Coco mediated TGFβ 
signalling maintenance would ensure the mesenchymal-dependent niche activation 
ability of MICs, which likely reduces their entrance into a dormant state.  
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6.3 Biphasic model of lung metastatic colonisation 
We have observed that based on AXL expression metastatic colonisation can be 
divided in two temporal phases: during the early phase after extravasation, single 
disseminated cells maintain AXL-expression, along with Twist1 expression and 
TGFβ signalling, which provides an enhanced niche induction activity; in a later 
stage, temporally coinciding with the appearance of the activated niche, AXL is 
downregulated alongside Twist1 and TGFβ shifting cancer cell functions towards a 
BMP-dependent proliferation (Figure 4.8.A and 5.4). We also showed that AXL loss 
during the second phase of metastasis is functionally required for efficient 
metastatic growth (Figure 5.7) confirming that in order to efficiently generate a 
cancer cell mass at the distant site cells regain a more epithelial phenotype (Tsai et 
al., 2012). Indeed, inducing AXL-mesenchymal reversion using AXL chemical 
inhibition during this second phase of metastasis promoted metastatic outgrowth 
(Figure 5.7.D). 
 
Previous reports proposed that Twist1 driven mesenchymal features need to be 
spatiotemporally controlled during colonisation (Tsai et al., 2012). Our results refine 
the suggested temporal regulation according to cancer cells AXL-mesenchymal 
status, and show that cancer cell epithelial modulations during the second phase of 
metastatic colonisation depend on the metastatic niche induced during the first 
phase. In this view, the mesenchymal status represents the trigger of its own 
inhibition via stromal activation. Indeed, stabilisation of the mesenchymal status via 
exogenous AXL expression in cancer cells delays AXL downregulation and strongly 
impairs metastatic ability in vivo (Figure 5.9.C-E). Supporting this model, Giampieri 
et al. showed that breast cancer cells overexpressing TGFβ1, which likely stabilises 
the AXL-mesenchymal status, are impaired in their colonisation capacity (Giampieri 
et al., 2009). Altogether these findings suggest epithelial cancer cell plasticity to be 
temporally regulated by a unified mechanism involving the inhibition of TGFβ 
signalling, and subsequently AXL and Twist1 expression. Importantly, exogenously 
expressing any of these EMT related components halts epithelial reversion and 
metastatic outgrowth. 
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Altogether, our findings show that the reversion of the mesenchymal status of 
cancer cells during the second phase of metastasis is a pre-requisite for metastatic 
outgrowth. Importantly, the fact that chemical inhibition of AXL during this second 
phase of metastasis favours epithelial reversion and enhances metastatic growth 
supports the previously raised concerns about anti-EMT therapies as double-edged 
swords in cancer therapeutics (Franco-Chuaire et al., 2013, Nieto, 2013). Indeed, 
the AXL inhibitor used in this work (R428 or BGB324) was the first AXL inhibitor to 
enter clinical trials two year ago (Sheridan, 2013). According to our results, AXL 
treatment should prevent dissemination from the primary site in patients; at the 
target site, we have shown that upon extravasation AXL is crucially maintained 
mediating niche initiation (Figure 4.8), therefore its inhibition could halt metastatic 
outgrowth. However, due to the asynchronous nature of the metastatic process, 
disseminated cells in different EMT states coexist at the target site in patients 
making it difficult to predict treatment outcome. Moreover, AXL inhibition could 
affect different microenvironmental components at the target site making it even 
more difficult to predict the global effect of this treatment.  
 
Therefore, trying to shed some light into the potential beneficial effects of AXL 
inhibition during metastasis, we further examined AXL dynamics at the target site 
not only during colonisation, but also in fully established metastasis. We showed 
that after the previously reported AXL loss during the late colonisation phase, AXL 
expression in MICs is re-acquired in fully developed metastatic nodules (Figure 
5.11.A). As expected, inhibiting AXL from tumour cells specifically during this late 
metastatic stage did not affect the number of metastases found in the lungs (Figure 
5.7.D). However, we observed a dramatic reduction in the size of the metastatic 
nodules, indicating that tumour cell growth is being directly or indirectly sustained 
by AXL (Figure 5.11). This effect on metastatic outgrowth can be explained through 
two complementary hypotheses: 1) A direct effect on tumour cells; AXL at this late 
metastatic stage is highly expressed in MICs (Figure 5.11.A). The role of AXL 
expression on MIC in metastasis is not defined, therefore AXL-mesenchymal MICs 
could be required either to maintain functional heterogeneity among cancer cells or 
as the sub-set of cells responsible to sustain metastatic growth. In any case, AXL 
inhibition will mainly target MICs within the tumour cell compartment impairing 
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metastatic growth. 2) An indirect effect in tumour growth exerted by AXL-
expressing microenvironmental components that sustain metastatic outgrowth. 
There are two key cellular components in the tumour microenvironment that highly 
express AXL and could be affected by the inhibitor treatment. TAMs usually 
express AXL in the tumour microenvironment (Sheridan, 2013) and play a pro-
tumorigenic role during metastasis supporting tumour cell growth (Qian and Pollard, 
2010); indeed, relevant for breast to lung metastasis, resident lung macrophages 
have been shown to upregulate AXL in the inflamed lung environment (Fujimori et 
al., 2015) being a potential target of the inhibitor during this late stage of metastasis. 
Also dendritic cells are known to express AXL (Scutera et al., 2009), although their 
role at metastatic sites is less characterised.  
Overall, our results using an experimental synchronised metastatic setting support 
a global beneficial effect of AXL inhibition; early-disseminated cells would be 
prevented from growing and late metastatic nodules would partially regress, being 
only those cells transitioning from the first to the second colonisation phase 
positively supported by AXL inhibition.  
 
Mechanistically, the fact that MICs re-gain AXL expression in late-stage metastasis 
poises intriguing questions. Based on this observation it could be hypothesised that 
at this stage, with entirely reconstituted tumours formed at the distant site, 
metastatic cells could become invasive again re-initiating the metastatic cascade. 
However, whether established metastases can metastasise have been long debate 
and still remains unclear (Tait et al., 2004, Holzel et al., 2010, Goldstein et al., 
2005). Additionally, the overall AXL dynamics in metastasising cells in the lungs 
indicate that AXL modulations are mainly occurring within the MIC compartment 
while total tumour cells maintain AXL expression constant throughout the process 
(Figure 5.11.A). This is suggestive of the high plasticity displayed by MICs 
compared to the bulk of the tumour cells, correlating with their stem-like features. 
Also, this high plasticity illustrated by the changes in AXL expression supports the 
experimental evidence that MICs drive the metastatic process (Malanchi et al., 
2012), and their presence is crucial throughout. 
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6.4 Concluding remarks 
Mesenchymal features enhance stemness and metastatic spreading (Mani et al., 
2008, Rhim et al., 2012), while growth at the distant site requires its inhibition 
(Ocaña et al., 2012; Tsai et al., 2012). Our findings indicate that a mesenchymal 
state characterised by AXL expression expeditiously triggers a cancer cell-stroma 
interaction upon infiltrating the secondary site. This crosstalk critically governs 
metastatic colonisation, and ultimately leads cancer cells to regain a more epithelial 
phenotype compatible with proliferation. Importantly, we identify THBS2 as a novel 
cofactor in the AXL-mesenchymal cell–stromal interplay. This study highlights the 
importance of a dynamic modulation of the epithelial-mesenchymal status of cancer 
cells during metastatic progression and supports the previously reported concerns 
about anti-EMT therapies as double-edged swords in cancer therapeutics (Tsai et 
al., 2012).  
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Chapter 7. Appendix 
This appendix table contains the list of genes that show ≥3 fold increment 
expression in MICs (CD24+CD90+) compared to nonMICs (CD24+CD90-). The 
complete microarray raw data are deposited in the Gene Expression Omnibus 
(GEO) database and are publicly available at http://www.ncbi.nlm.nih.gov/geo/ with 
accession number GEO:GSE63558. 
 
Red – genes described in this thesis to play a crucial role in the metastatic potential of MICs. 
Blue – EMT-related genes. 
Bold – genes previously shown to contribute to the metastatic potential of breast cancer cells. 
 
POSITION 
GENE 
SYMBOL 
FOLD 
INCREMENT DEFINITION 
1 Fn1 73.60964635 Mus musculus fibronectin 1 (Fn1), mRNA. 
2 Serping1 60.46920116 
Mus musculus serine (or cysteine) peptidase inhibitor, 
clade G, member 1 (Serping1), mRNA. 
3 Lum 60.06918146 Mus musculus lumican (Lum), mRNA. 
4 Thy1 59.32025165 
Mus musculus thymus cell antigen 1, theta (Thy1), 
mRNA. CD90. 
5 Mmp3 56.8142886 
Mus musculus matrix metallopeptidase 3 (Mmp3), 
mRNA. 
6 Serping1 54.48133702   
7 Mmp13 50.80097994 
Mus musculus matrix metallopeptidase 13 (Mmp13), 
mRNA. 
8 Loxl1 49.87156687 Mus musculus lysyl oxidase-like 1 (Loxl1), mRNA. 
9 Col1a1 47.68421086   
10 Ctsk 44.40448725 Mus musculus cathepsin K (Ctsk), mRNA. 
11 Dcn 43.61584256 Mus musculus decorin (Dcn), mRNA. 
12 Col6a1 43.02501894 
Mus musculus procollagen, type VI, alpha 1 (Col6a1), 
mRNA. 
13 Mmp2 42.58322206 
Mus musculus matrix metallopeptidase 2 (Mmp2), 
mRNA. 
14 Adamts2 41.75490813 
Mus musculus a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin type 1 motif, 2 
(Adamts2), mRNA. 
15 Lrrc15 41.68029907   
16 Mfap5 41.64301515 
Mus musculus microfibrillar associated protein 5 (Mfap5), 
mRNA. 
17 Col5a1 41.04235801 
Mus musculus procollagen, type V, alpha 1 (Col5a1), 
mRNA. 
18 Rnase4 40.18861336 
Mus musculus ribonuclease, RNase A family 4 (Rnase4), 
transcript variant 1, mRNA. 
19 Pi16 39.30356586 Mus musculus peptidase inhibitor 16 (Pi16), mRNA. 
20 Rarres2 38.82640932 
Mus musculus retinoic acid receptor responder (tazarotene 
induced) 2 (Rarres2), mRNA. 
21 Adamts2 37.03161082 
Mus musculus a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin type 1 motif, 2 
(Adamts2), mRNA. 
22 Pla1a 35.33017006 
Mus musculus phospholipase A1 member A (Pla1a), 
mRNA. 
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23 Cpxm1 34.56071134 
Mus musculus carboxypeptidase X 1 (M14 family) (Cpxm1), 
mRNA. 
24 Cygb 34.15923397 Mus musculus cytoglobin (Cygb), mRNA. 
25 Ccdc80 34.05706562 
Mus musculus coiled-coil domain containing 80 (Ccdc80), 
mRNA. 
26 Ccl11 33.36436321 
Mus musculus small chemokine (C-C motif) ligand 11 
(Ccl11), mRNA. 
27 Fstl1 32.97793885 Mus musculus follistatin-like 1 (Fstl1), mRNA. 
28 Lox 32.66522761 Mus musculus lysyl oxidase (Lox), mRNA. 
29 Col6a1 32.32838235 
Mus musculus procollagen, type VI, alpha 1 (Col6a1), 
mRNA. 
30 Col6a2 32.24366031 
Mus musculus procollagen, type VI, alpha 2 (Col6a2), 
mRNA. 
31 Serpinf1 32.22446558 
Mus musculus serine (or cysteine) peptidase inhibitor, 
clade F, member 1 (Serpinf1), mRNA. 
32 Pcolce 32.16013333 
Mus musculus procollagen C-endopeptidase enhancer 
protein (Pcolce), mRNA. 
33 Scara3 31.79005897 
Mus musculus scavenger receptor class A, member 3 
(Scara3), mRNA. 
34 Aebp1 31.55275609 Mus musculus AE binding protein 1 (Aebp1), mRNA. 
35 Fbln1 31.30597931 Mus musculus fibulin 1 (Fbln1), mRNA. 
36 Mmp3 31.29927231 
Mus musculus matrix metallopeptidase 3 (Mmp3), 
mRNA. 
37 Fbn1 30.84942594   
38 Ogn 30.62286362 Mus musculus osteoglycin (Ogn), mRNA. 
39 Mmp3 30.22038636 
Mus musculus matrix metallopeptidase 3 (Mmp3), 
mRNA. 
40 Tnxb 29.18681299 Mus musculus tenascin XB (Tnxb), mRNA. 
41 Dpt 28.81349432 Mus musculus dermatopontin (Dpt), mRNA. 
42 Thbs2 27.92699494 Mus musculus thrombospondin 2 (Thbs2), mRNA. 
43 
LOC10004758
3 27.8890865 
PREDICTED: Mus musculus similar to apolipoprotein D 
(LOC100047583), mRNA. 
44 Serpina3n 27.67160631 
Mus musculus serine (or cysteine) peptidase inhibitor, 
clade A, member 3N (Serpina3n), mRNA. 
45 Col12a1 27.39104496 
Mus musculus collagen, type XII, alpha 1 (Col12a1), 
mRNA. 
46 Knsl5 26.95470532   
47 Svep1 26.90604697 
Mus musculus sushi, von Willebrand factor type A, EGF 
and pentraxin domain containing 1 (Svep1), mRNA. 
48 Spon2 26.83853041 
Mus musculus spondin 2, extracellular matrix protein 
(Spon2), mRNA. 
49 Plat 26.34455797   
50 Cd248 26.15887428 Mus musculus CD248 antigen, endosialin (Cd248), mRNA. 
51 Col14a1 25.92587138   
52 LOC638301 25.55375508 
PREDICTED: Mus musculus similar to interferon activated 
gene 204 (LOC638301), mRNA. 
53 Bicc1 25.1432103 
Mus musculus bicaudal C homolog 1 (Drosophila) (Bicc1), 
mRNA. 
54 Srpx2 24.90728486 
Mus musculus sushi-repeat-containing protein, X-linked 2 
(Srpx2), transcript variant 2, mRNA. 
55 
LOC10004443
0 24.55997339 
PREDICTED: Mus musculus similar to Interferon activated 
gene 205 (LOC100044430), mRNA. 
56 Tnxb 24.27757116 Mus musculus tenascin XB (Tnxb), mRNA. 
57 Sparc 24.11332411 
Mus musculus secreted acidic cysteine rich 
glycoprotein (Sparc), mRNA. 
58 Igfbp4 23.58079355   
59 
scl0001849.1_
2273 23.17580957   
60 
6330406I15Ri
k 22.6360887 
Mus musculus RIKEN cDNA 6330406I15 gene 
(6330406I15Rik), mRNA. 
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61 Mfap2 22.34155105 
Mus musculus microfibrillar-associated protein 2 (Mfap2), 
mRNA. 
62 Pdgfra 22.29305127 
Mus musculus platelet derived growth factor receptor, alpha 
polypeptide (Pdgfra), transcript variant 1, mRNA. 
63 Itga11 22.19115202 Mus musculus integrin alpha 11 (Itga11), mRNA. 
64 Fbln1 22.09933361   
65 Htra3 21.72598387   
66 Cxcl14 21.70535391 
Mus musculus chemokine (C-X-C motif) ligand 14 (Cxcl14), 
mRNA. 
67 Nid1 21.42034706 Mus musculus nidogen 1 (Nid1), mRNA. 
68 Prelp 21.29436558 
Mus musculus proline arginine-rich end leucine-rich repeat 
(Prelp), mRNA. 
69 
6330406I15Ri
k 20.90904317 
Mus musculus RIKEN cDNA 6330406I15 gene 
(6330406I15Rik), mRNA. 
70 Gpx8 20.8173571 
Mus musculus glutathione peroxidase 8 (putative) (Gpx8), 
mRNA. 
71 Scarf2 20.81035285 
Mus musculus scavenger receptor class F, member 2 
(Scarf2), mRNA. 
72 Sparc 20.49187503 
Mus musculus secreted acidic cysteine rich 
glycoprotein (Sparc), mRNA. 
73 Ccl7 20.40200837   
74 Lum 20.27088078   
75 Bicc1 20.12116588 
Mus musculus bicaudal C homolog 1 (Drosophila) (Bicc1), 
mRNA. 
76 Osr2 19.93992721 
Mus musculus odd-skipped related 2 (Drosophila) (Osr2), 
mRNA. 
77 Olfml2b 19.85429131 Mus musculus olfactomedin-like 2B (Olfml2b), mRNA. 
78 Serpine2 19.81592693   
79 Itgbl1 19.72979134 Mus musculus integrin, beta-like 1 (Itgbl1), mRNA. 
80 Col8a1 19.66821469   
81 
ENSMUSG00
000043795 19.60575329 
PREDICTED: Mus musculus predicted gene, 
ENSMUSG00000043795 (ENSMUSG00000043795), 
mRNA. 
82 Timp1 19.04713677 
Mus musculus tissue inhibitor of metalloproteinase 1 
(Timp1), transcript variant 2, mRNA. 
83 Dcn 18.84139087 Mus musculus decorin (Dcn), mRNA. 
84 Timp1 18.41986061   
85 C1qtnf3 18.41977383 
Mus musculus C1q and tumor necrosis factor related 
protein 3 (C1qtnf3), mRNA. 
86 Igfbp4 18.36908763 
Mus musculus insulin-like growth factor binding protein 4 
(Igfbp4), mRNA. 
87 Ly6c1 18.30177212 
Mus musculus lymphocyte antigen 6 complex, locus C1 
(Ly6c1), mRNA. 
88 Serpina3h 18.14573816 
Mus musculus serine (or cysteine) peptidase inhibitor, 
clade A, member 3H (Serpina3h), mRNA. 
89 Gp38 17.90928912   
90 
scl0002507.1_
236 17.80258841   
91 Ppic 17.68622567 Mus musculus peptidylprolyl isomerase C (Ppic), mRNA. 
92 Prg4 17.59252918   
93 Col3a1 17.5644643 Mus musculus collagen, type III, alpha 1 (Col3a1), mRNA. 
94 C2 17.55475936 
Mus musculus complement component 2 (within H-2S) 
(C2), mRNA. 
95 
2310016C16Ri
k 17.26052088 
Mus musculus RIKEN cDNA 2310016C16 gene 
(2310016C16Rik), mRNA. 
96 Has1 17.09402607 Mus musculus hyaluronan synthase1 (Has1), mRNA. 
97 Gpx3 17.07563602 
Mus musculus glutathione peroxidase 3 (Gpx3), transcript 
variant 2, mRNA. 
98 Olfml3 16.73507945 Mus musculus olfactomedin-like 3 (Olfml3), mRNA. 
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99 Rarres2 16.7212608 
Mus musculus retinoic acid receptor responder (tazarotene 
induced) 2 (Rarres2), mRNA. 
100 Axl 16.71865497 
Mus musculus AXL receptor tyrosine kinase (Axl), 
mRNA. 
101 Nbl1 16.51841458 
Mus musculus neuroblastoma, suppression of 
tumorigenicity 1 (Nbl1), mRNA. 
102 Tnxb 16.48466591 Mus musculus tenascin XB (Tnxb), mRNA. 
103 Cthrc1 16.29152784 
Mus musculus collagen triple helix repeat containing 1 
(Cthrc1), mRNA. 
104 Igfbp6 16.24186696 
Mus musculus insulin-like growth factor binding protein 6 
(Igfbp6), mRNA. 
105 C1qtnf3 16.18213201 
Mus musculus C1q and tumor necrosis factor related 
protein 3 (C1qtnf3), mRNA. 
106 Ndn 16.00439486 Mus musculus necdin (Ndn), mRNA. 
107 Pla1a 15.98069561 
Mus musculus phospholipase A1 member A (Pla1a), 
mRNA. 
108 Htra1 15.89958642 Mus musculus HtrA serine peptidase 1 (Htra1), mRNA. 
109 Fbln2 15.59466235 Mus musculus fibulin 2 (Fbln2), transcript variant 2, mRNA. 
110 Apbh 15.5632681 
Mus musculus androgen-binding protein eta (Apbh), 
mRNA. 
111 Emp3 15.4061342 
Mus musculus epithelial membrane protein 3 (Emp3), 
mRNA. 
112 Eln 15.3439034 Mus musculus elastin (Eln), mRNA. 
113 Adamts12 15.29473237   
114 Srpx2 15.20458847 
Mus musculus sushi-repeat-containing protein, X-linked 2 
(Srpx2), mRNA. 
115 Gpc3 15.12293152 Mus musculus glypican 3 (Gpc3), mRNA. 
116 Gpc3 15.06075292 Mus musculus glypican 3 (Gpc3), mRNA. 
117 Hsd11b1 15.05374854 
Mus musculus hydroxysteroid 11-beta dehydrogenase 1 
(Hsd11b1), transcript variant 1, mRNA. 
118 Gstm2 14.98089895 
Mus musculus glutathione S-transferase, mu 2 (Gstm2), 
mRNA. 
119 Ppic 14.92166286 Mus musculus peptidylprolyl isomerase C (Ppic), mRNA. 
120 Htra1 14.87834633 Mus musculus HtrA serine peptidase 1 (Htra1), mRNA. 
121 
4632401N01Ri
k 14.87217679   
122 Mxra8 14.60561279 
Mus musculus matrix-remodelling associated 8 (Mxra8), 
mRNA. 
123 Ptx3 14.47368284   
124 Mgp 14.41053925 Mus musculus matrix Gla protein (Mgp), mRNA. 
125 Hsd11b1 14.34060143   
126 Gpx8 14.23827364 
Mus musculus glutathione peroxidase 8 (putative) (Gpx8), 
mRNA. 
127 Mmp14 14.21967435 
Mus musculus matrix metallopeptidase 14 (membrane-
inserted) (Mmp14), mRNA. 
128 Col4a2 14.15140118 Mus musculus collagen, type IV, alpha 2 (Col4a2), mRNA. 
129 Tnc 13.99480871 Mus musculus tenascin C (Tnc), mRNA. 
130 Aoc3 13.97009189 
Mus musculus amine oxidase, copper containing 3 (Aoc3), 
mRNA. 
131 Vim 13.96666284 Mus musculus vimentin (Vim), mRNA. 
132 Slit2 13.93949435 Mus musculus slit homolog 2 (Drosophila) (Slit2), mRNA. 
133 Pla1a 13.86746308   
134 Bgn 13.84886971 Mus musculus biglycan (Bgn), mRNA. 
135 Gstm2 13.74789223 
Mus musculus glutathione S-transferase, mu 2 (Gstm2), 
mRNA. 
136 Abi3bp 13.73997695 
Mus musculus ABI gene family, member 3 (NESH) binding 
protein (Abi3bp), transcript variant 1, mRNA. 
137 
LOC10004441
1 13.5902578 
PREDICTED: Mus musculus similar to Epidermal growth 
factor-containing fibulin-like extracellular matrix protein 1 
(LOC100044411), mRNA. 
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138 Reg1 13.53237984 Mus musculus regenerating islet-derived 1 (Reg1), mRNA. 
139 Col12a1 13.35145322 
Mus musculus collagen, type XII, alpha 1 (Col12a1), 
mRNA. 
140 Fhl1 13.34526116 
Mus musculus four and a half LIM domains 1 (Fhl1), 
transcript variant 1, mRNA. 
141 Hsd11b1 13.25327208   
142 Mdk 13.2393174 Mus musculus midkine (Mdk), transcript variant 3, mRNA. 
143 Col6a3 13.20660539 Mus musculus collagen, type VI, alpha 3 (Col6a3), mRNA. 
144 Rgs5 13.16965062 
Mus musculus regulator of G-protein signaling 5 (Rgs5), 
mRNA. 
145 Osr2 13.07743619 
Mus musculus odd-skipped related 2 (Drosophila) (Osr2), 
mRNA. 
146 Srpx 13.03833319 
Mus musculus sushi-repeat-containing protein (Srpx), 
mRNA. 
147 Dpep1 12.98310729 Mus musculus dipeptidase 1 (renal) (Dpep1), mRNA. 
148 Col15a1 12.95927171 
Mus musculus collagen, type XV, alpha 1 (Col15a1), 
mRNA. 
149 Gpx7 12.94201412 Mus musculus glutathione peroxidase 7 (Gpx7), mRNA. 
150 Tnc 12.67230295   
151 
A730054J21Ri
k 12.6517808   
152 Igf1 12.60755528 
Mus musculus insulin-like growth factor 1 (Igf1), transcript 
variant 1, mRNA. 
153 LOC98434 12.50090703   
154 Islr 12.47561738   
155 Cnrip1 12.45654948 
Mus musculus cannabinoid receptor interacting protein 1 
(Cnrip1), mRNA. 
156 Fbn1 12.41247655   
157 F2r 12.26877546 
Mus musculus coagulation factor II (thrombin) receptor 
(F2r), mRNA. 
158 C1qtnf2 12.26538819 
Mus musculus C1q and tumor necrosis factor related 
protein 2 (C1qtnf2), mRNA. 
159 Mfap4 12.20664523 
Mus musculus microfibrillar-associated protein 4 (Mfap4), 
mRNA. 
160 Cxcl14 12.20266731   
161 Pcolce2 12.18776088 
Mus musculus procollagen C-endopeptidase enhancer 2 
(Pcolce2), mRNA. 
162 Gsn 12.17223337 Mus musculus gelsolin (Gsn), mRNA. 
163 Gfpt2 12.17179246 
Mus musculus glutamine fructose-6-phosphate 
transaminase 2 (Gfpt2), mRNA. 
164 Col4a1 12.09414721 
Mus musculus procollagen, type IV, alpha 1 (Col4a1), 
mRNA. 
165 Mmp23 11.92813464 
Mus musculus matrix metallopeptidase 23 (Mmp23), 
mRNA. 
166 Col8a1 11.77557179 Mus musculus collagen, type VIII, alpha 1 (Col8a1), mRNA. 
167 Nfatc4 11.72374054 
Mus musculus nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 4 (Nfatc4), mRNA. 
168 Fhl1 11.66187462 
Mus musculus four and a half LIM domains 1 (Fhl1), 
transcript variant 2, mRNA. 
169 Fstl 11.5832149   
170 
scl0003799.1_
2 11.57461662   
171 
4930533K18Ri
k 11.47648384   
172 Mmp11 11.293549 
Mus musculus matrix metallopeptidase 11 (Mmp11), 
mRNA. 
173 Srpx 11.22391775 
Mus musculus sushi-repeat-containing protein (Srpx), 
mRNA. 
174 
1110032E23Ri
k 11.22230787 
Mus musculus RIKEN cDNA 1110032E23 gene 
(1110032E23Rik), mRNA. 
175 Nuak1 11.10986255 Mus musculus NUAK family, SNF1-like kinase, 1 (Nuak1), 
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mRNA. 
176 Itm2a 11.09825089 
Mus musculus integral membrane protein 2A (Itm2a), 
mRNA. 
177 Emp3 10.99672096 
Mus musculus epithelial membrane protein 3 (Emp3), 
mRNA. 
178 Nav1 10.9777688 Mus musculus neuron navigator 1 (Nav1), mRNA. 
179 Rbms3 10.96545835 
Mus musculus RNA binding motif, single stranded 
interacting protein (Rbms3), mRNA. 
180 Nrp1 10.89297674 Mus musculus neuropilin 1 (Nrp1), mRNA. 
181 Mfap2 10.85579253 
Mus musculus microfibrillar-associated protein 2 (Mfap2), 
mRNA. 
182 Tpst1 10.84192048 
Mus musculus protein-tyrosine sulfotransferase 1 (Tpst1), 
transcript variant 2, mRNA. 
183 Col14a1 10.79839664 
Mus musculus collagen, type XIV, alpha 1 (Col14a1), 
mRNA. 
184 Slc10a6 10.70926301 
Mus musculus solute carrier family 10 (sodium/bile acid 
cotransporter family), member 6 (Slc10a6), mRNA. 
185 Sulf1 10.69460088 Mus musculus sulfatase 1 (Sulf1), mRNA. 
186 Pdgfrl 10.56613483 
Mus musculus platelet-derived growth factor receptor-like 
(Pdgfrl), mRNA. 
187 Hoxc6 10.55822625 Mus musculus homeo box C6 (Hoxc6), mRNA. 
188 Cxcl12 10.55634498 
Mus musculus chemokine (C-X-C motif) ligand 12 (Cxcl12), 
transcript variant 1, mRNA. 
189 Leprel2 10.53419854 Mus musculus leprecan-like 2 (Leprel2), mRNA. 
190 Pmp22 10.53268759 
Mus musculus peripheral myelin protein 22 (Pmp22), 
mRNA. 
191 Ltbp4 10.52977486 
Mus musculus latent transforming growth factor beta 
binding protein 4 (Ltbp4), mRNA. 
192 Gstm2 10.49749813 
Mus musculus glutathione S-transferase, mu 2 (Gstm2), 
mRNA. 
193 Adam23 10.47713536 
Mus musculus a disintegrin and metallopeptidase domain 
23 (Adam23), mRNA. 
194 Fmo1 10.45863328 
Mus musculus flavin containing monooxygenase 1 (Fmo1), 
mRNA. 
195 Pdlim2 10.4544022 Mus musculus PDZ and LIM domain 2 (Pdlim2), mRNA. 
196 Plac8 10.41172549 Mus musculus placenta-specific 8 (Plac8), mRNA. 
197 Ccl7 10.40747058 
Mus musculus chemokine (C-C motif) ligand 7 (Ccl7), 
mRNA. 
198 Igf1 10.38754511 
Mus musculus insulin-like growth factor 1 (Igf1), transcript 
variant 1, mRNA. 
199 Adamts4 10.38026328   
200 Emilin2 10.37389995 
Mus musculus elastin microfibril interfacer 2 (Emilin2), 
mRNA. 
201 Dcn 10.31850318   
202 Mxra8 10.26065219 
Mus musculus matrix-remodelling associated 8 (Mxra8), 
mRNA. 
203 Dkk3 10.08815324 
Mus musculus dickkopf homolog 3 (Xenopus laevis) 
(Dkk3), mRNA. 
204 Antxr1 10.08575451 Mus musculus anthrax toxin receptor 1 (Antxr1), mRNA. 
205 Figf 10.07256421 Mus musculus c-fos induced growth factor (Figf), mRNA. 
206 
6720469N11Ri
k 10.066945   
207 Igsf10 10.06111353   
208 Rab31 10.02736051 
Mus musculus RAB31, member RAS oncogene family 
(Rab31), mRNA. 
209 Tmem204 9.920325228 
Mus musculus transmembrane protein 204 (Tmem204), 
mRNA. 
210 Dpysl3 9.889673519 Mus musculus dihydropyrimidinase-like 3 (Dpysl3), mRNA. 
211 
1200002N14Ri
k 9.88003959 
Mus musculus RIKEN cDNA 1200002N14 gene 
(1200002N14Rik), mRNA. 
212 Cyp7b1 9.868252777 
Mus musculus cytochrome P450, family 7, subfamily b, 
polypeptide 1 (Cyp7b1), mRNA. 
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213 Gtl2 9.848498444   
214 Nrp1 9.759641328 Mus musculus neuropilin 1 (Nrp1), mRNA. 
215 Lama2 9.75878158 Mus musculus laminin, alpha 2 (Lama2), mRNA. 
216 Galntl1 9.726280213 
Mus musculus UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 1 (Galntl1), mRNA. 
217 Ugt1a10 9.589501087 
Mus musculus UDP glycosyltransferase 1 family, 
polypeptide A10 (Ugt1a10), mRNA. 
218 Bmp1 9.566890084 
Mus musculus bone morphogenetic protein 1 (Bmp1), 
mRNA. 
219 Ptx3 9.539933898 Mus musculus pentraxin related gene (Ptx3), mRNA. 
220 
E430002G05R
ik 9.486767531   
221 Wisp1 9.358076979 
Mus musculus WNT1 inducible signaling pathway protein 1 
(Wisp1), mRNA. 
222 Fcgrt 9.293550364 
Mus musculus Fc receptor, IgG, alpha chain transporter 
(Fcgrt), mRNA. 
223 Igfbp2 9.250518105 
Mus musculus insulin-like growth factor binding protein 2 
(Igfbp2), mRNA. 
224 Adamts2 9.153997096 
Mus musculus a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin type 1 motif, 2 
(Adamts2), mRNA. 
225 Sulf1 9.133300368   
226 Vgll3 9.126427489 
PREDICTED: Mus musculus vestigial like 3 (Drosophila) 
(Vgll3), mRNA. 
227 Lgals1 9.096955479   
228 Lpl 9.073909345 Mus musculus lipoprotein lipase (Lpl), mRNA. 
229 
0610007N19Ri
k 9.019834825   
230 Nav1 9.009249262 Mus musculus neuron navigator 1 (Nav1), mRNA. 
231 Dkk3 9.003944861 
Mus musculus dickkopf homolog 3 (Xenopus laevis) 
(Dkk3), mRNA. 
232 H19 8.956570966 
Mus musculus H19 fetal liver mRNA (H19), non-coding 
RNA. 
233 Sema7a 8.950043087 
Mus musculus sema domain, immunoglobulin domain (Ig), 
and GPI membrane anchor, (semaphorin) 7A (Sema7a), 
mRNA. 
234 Hspg2 8.881396465 
PREDICTED: Mus musculus perlecan (heparan sulfate 
proteoglycan 2) (Hspg2), mRNA. 
235 Gdf10 8.860918267 
Mus musculus growth differentiation factor 10 (Gdf10), 
mRNA. 
236 Fkbp10 8.761584854 Mus musculus FK506 binding protein 10 (Fkbp10), mRNA. 
237 
B230343A10R
ik 8.753546693   
238 
5430433G21R
ik 8.738872938 
PREDICTED: Mus musculus RIKEN cDNA 5430433G21 
gene (5430433G21Rik), mRNA. 
239 
6330404C01Ri
k 8.676706937   
240 Nnmt 8.569832134 
Mus musculus nicotinamide N-methyltransferase (Nnmt), 
mRNA. 
241 Cxcl1 8.566788776 
Mus musculus chemokine (C-X-C motif) ligand 1 (Cxcl1), 
mRNA. 
242 Il33 8.558051769 Mus musculus interleukin 33 (Il33), mRNA. 
243 Ltbp4 8.540455004 
Mus musculus latent transforming growth factor beta 
binding protein 4 (Ltbp4), mRNA. 
244 Mfap2 8.535282497 
Mus musculus microfibrillar-associated protein 2 (Mfap2), 
mRNA. 
245 Col8a2 8.513234912   
246 Ybx3 8.476330854   
247 Ugt1a10 8.456354016 
Mus musculus UDP glycosyltransferase 1 family, 
polypeptide A10 (Ugt1a10), mRNA. 
Appendix 
 
 
 
231 
248 Msc 8.443293072 Mus musculus musculin (Msc), mRNA. 
249 LOC381283 8.365092809   
250 Igfbp2 8.267617353 
Mus musculus insulin-like growth factor binding protein 2 
(Igfbp2), mRNA. 
251 C1qtnf3 8.170119331 
Mus musculus C1q and tumor necrosis factor related 
protein 3 (C1qtnf3), mRNA. 
252 Spsb1 8.153919249 
Mus musculus splA/ryanodine receptor domain and SOCS 
box containing 1 (Spsb1), mRNA. 
253 Kdelr3 8.152718986 
Mus musculus KDEL (Lys-Asp-Glu-Leu) endoplasmic 
reticulum protein retention receptor 3 (Kdelr3), mRNA. 
254 
4732458O05R
ik 8.088876917   
255 Lrrn4cl 8.047674754 Mus musculus LRRN4 C-terminal like (Lrrn4cl), mRNA. 
256 Bmp1 8.032494117 
Mus musculus bone morphogenetic protein 1 (Bmp1), 
mRNA. 
257 Angpt2 8.026455493 Mus musculus angiopoietin 2 (Angpt2), mRNA. 
258 C3 8.018252266   
259 
LOC10004604
4 7.961090315 
PREDICTED: Mus musculus similar to COUP-TFI 
(LOC100046044), mRNA. 
260 Abca8a 7.857631269 
Mus musculus ATP-binding cassette, sub-family A (ABC1), 
member 8a (Abca8a), mRNA. 
261 BC034076 7.827990125 
Mus musculus cDNA sequence BC034076 (BC034076), 
mRNA. 
262 C1s 7.821812507 
Mus musculus complement component 1, s subcomponent 
(C1s), transcript variant 1, mRNA. 
263 
2310047A01Ri
k 7.805485724 
PREDICTED: Mus musculus RIKEN cDNA 2310047A01 
gene (2310047A01Rik), mRNA. 
264 Antxr1 7.802778109 Mus musculus anthrax toxin receptor 1 (Antxr1), mRNA. 
265 Lamc1 7.763953761 Mus musculus laminin, gamma 1 (Lamc1), mRNA. 
266 Serpine2 7.75617188 
Mus musculus serine (or cysteine) peptidase inhibitor, 
clade E, member 2 (Serpine2), mRNA. 
267 Ccnd2 7.749395349 Mus musculus cyclin D2 (Ccnd2), mRNA. 
268 Srpx2 7.72744666 
Mus musculus sushi-repeat-containing protein, X-linked 2 
(Srpx2), transcript variant 2, mRNA. 
269 Tnfrsf11b 7.676307058 
Mus musculus tumor necrosis factor receptor superfamily, 
member 11b (osteoprotegerin) (Tnfrsf11b), mRNA. 
270 Flnc 7.65353693 Mus musculus filamin C, gamma (Flnc), mRNA. 
271 Ahnak2 7.629407811 Mus musculus AHNAK nucleoprotein 2 (Ahnak2), mRNA. 
272 Ace 7.623792453 
Mus musculus angiotensin I converting enzyme (peptidyl-
dipeptidase A) 1 (Ace), transcript variant 1, mRNA. 
273 Ly6a 7.61962991 
Mus musculus lymphocyte antigen 6 complex, locus A 
(Ly6a), mRNA. 
274 
LOC10004833
2 7.600835989 
PREDICTED: Mus musculus similar to a disintegrin-like and 
metalloprotease (reprolysin type) with thrombospondin type 
1 motif, 5 (aggrecanase-2) (LOC100048332), mRNA. 
275 Lgmn 7.586219868 Mus musculus legumain (Lgmn), mRNA. 
276 Fkbp9 7.577225363 Mus musculus FK506 binding protein 9 (Fkbp9), mRNA. 
277 Bdh2 7.573490344 
Mus musculus 3-hydroxybutyrate dehydrogenase, type 2 
(Bdh2), mRNA. 
278 Zeb1 7.56712924 
Mus musculus zinc finger E-box binding homeobox 1 
(Zeb1), mRNA. 
279 Fcgrt 7.542821239   
280 Clec11a 7.537562454 
Mus musculus C-type lectin domain family 11, member a 
(Clec11a), mRNA. 
281 Cxcl12 7.524150068 
Mus musculus chemokine (C-X-C motif) ligand 12 (Cxcl12), 
transcript variant 3, mRNA. 
282 Col3a1 7.520186864 Mus musculus collagen, type III, alpha 1 (Col3a1), mRNA. 
283 C4b 7.502715142 
Mus musculus complement component 4B (Childo blood 
group) (C4b), mRNA. XM_921663 XM_921673 XM_921676 
XM_921678 
284 Lhfp 7.49817863 Mus musculus lipoma HMGIC fusion partner (Lhfp), mRNA. 
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285 
E430002G05R
ik 7.443727172 
Mus musculus RIKEN cDNA E430002G05 gene 
(E430002G05Rik), mRNA. 
286 Nkd2 7.400644254 
Mus musculus naked cuticle 2 homolog (Drosophila) 
(Nkd2), mRNA. 
287 Bmp1 7.361966014 
Mus musculus bone morphogenetic protein 1 (Bmp1), 
mRNA. 
288 Vcam1 7.287574407 
Mus musculus vascular cell adhesion molecule 1 (Vcam1), 
mRNA. 
289 Tshz3 7.278179942 
Mus musculus teashirt zinc finger family member 3 (Tshz3), 
mRNA. 
290 Emilin2 7.254095849   
291 Ifitm1 7.189531058 
Mus musculus interferon induced transmembrane protein 1 
(Ifitm1), mRNA. 
292 Hmgcs2 7.181414572 
Mus musculus 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 2 (Hmgcs2), nuclear gene encoding mitochondrial 
protein, mRNA. 
293 Hspg2 7.173981521   
294 Csrp2 7.112671625 
Mus musculus cysteine and glycine-rich protein 2 (Csrp2), 
mRNA. 
295 Hbb-b1 7.098136446 
Mus musculus hemoglobin, beta adult major chain (Hbb-
b1), mRNA. 
296 Lbh 6.990659631 Mus musculus limb-bud and heart (Lbh), mRNA. 
297 Ecm1 6.97615217 
Mus musculus extracellular matrix protein 1 (Ecm1), 
mRNA. 
298 Itga11 6.973263024 Mus musculus integrin alpha 11 (Itga11), mRNA. 
299 Saa3 6.95296686 Mus musculus serum amyloid A 3 (Saa3), mRNA. 
300 C4a 6.937980951 
Mus musculus complement component 4A (Rodgers blood 
group) (C4a), mRNA. 
301 Pdlim2 6.833377099 Mus musculus PDZ and LIM domain 2 (Pdlim2), mRNA. 
302 Olfml1 6.806360733 Mus musculus olfactomedin-like 1 (Olfml1), mRNA. 
303 
2310014H01Ri
k 6.789759138 
PREDICTED: Mus musculus RIKEN cDNA 2310014H01 
gene, transcript variant 3 (2310014H01Rik), mRNA. 
304 9530064J02 6.7670163   
305 Pdgfrb 6.764712002 
Mus musculus platelet derived growth factor receptor, beta 
polypeptide (Pdgfrb), mRNA. 
306 Fxyd5 6.741233889 
Mus musculus FXYD domain-containing ion transport 
regulator 5 (Fxyd5), mRNA. 
307 Rgs4 6.70527763 
Mus musculus regulator of G-protein signaling 4 (Rgs4), 
mRNA. 
308 B3gnt9 6.694206763 
Mus musculus UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 9 (B3gnt9), mRNA. 
309 Crlf1 6.691824294 
Mus musculus cytokine receptor-like factor 1 (Crlf1), 
mRNA. 
310 Adra2a 6.690351503 
Mus musculus adrenergic receptor, alpha 2a (Adra2a), 
mRNA. 
311 Hbb-b1 6.663288727   
312 Gpr176 6.656021427 
Mus musculus G protein-coupled receptor 176 (Gpr176), 
mRNA. 
313 Fbln1 6.6170484 Mus musculus fibulin 1 (Fbln1), mRNA. 
314 Crtap 6.570610638 Mus musculus cartilage associated protein (Crtap), mRNA. 
315 Avpr1a 6.554498008 
Mus musculus arginine vasopressin receptor 1A (Avpr1a), 
mRNA. 
316 H6pd 6.502122685 
Mus musculus hexose-6-phosphate dehydrogenase 
(glucose 1-dehydrogenase) (H6pd), mRNA. 
317 Adap1 6.496166082 
Mus musculus ArfGAP with dual PH domains 1 (Adap1), 
mRNA. 
318 Hba-a1 6.495490043 
Mus musculus hemoglobin alpha, adult chain 1 (Hba-a1), 
mRNA. 
319 D1Ertd471e 6.487376378   
320 Crtap 6.462248258 Mus musculus cartilage associated protein (Crtap), mRNA. 
321 Mrgprf 6.459751937 
Mus musculus MAS-related GPR, member F (Mrgprf), 
mRNA. 
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322 C4a 6.452434731 
Mus musculus complement component 4A (Rodgers blood 
group) (C4a), mRNA. 
323 Clec3b 6.451191499 
Mus musculus C-type lectin domain family 3, member b 
(Clec3b), mRNA. 
324 Cyp1b1 6.435526321 
Mus musculus cytochrome P450, family 1, subfamily b, 
polypeptide 1 (Cyp1b1), mRNA. 
325 Emb 6.430169501 Mus musculus embigin (Emb), mRNA. 
326 Ccl11 6.419525408 
Mus musculus small chemokine (C-C motif) ligand 11 
(Ccl11), mRNA. 
327 Crim2 6.403401936 
Mus musculus cysteine rich BMP regulator 2 (chordin like) 
(Crim2), mRNA. 
328 Msx1 6.384307352 Mus musculus homeobox, msh-like 1 (Msx1), mRNA. 
329 H19 6.371270015 
Mus musculus H19 fetal liver mRNA (H19), non-coding 
RNA. 
330 Ppap2b 6.348022187 
Mus musculus phosphatidic acid phosphatase type 2B 
(Ppap2b), mRNA. 
331 Tppp3 6.328415276 
Mus musculus tubulin polymerization-promoting protein 
family member 3 (Tppp3), mRNA. 
332 Lamc1 6.253883258 Mus musculus laminin, gamma 1 (Lamc1), mRNA. 
333 Akr1b8 6.25130073 
Mus musculus aldo-keto reductase family 1, member B8 
(Akr1b8), mRNA. 
334 Lhfp 6.238413758 Mus musculus lipoma HMGIC fusion partner (Lhfp), mRNA. 
335 Twist2 6.170337225   
336 P4ha2 6.155396133   
337 Hbb-b1 6.125085656 
Mus musculus hemoglobin, beta adult major chain (Hbb-
b1), mRNA. 
338 Twist1 6.120875056 
Mus musculus twist gene homolog 1 (Drosophila) (Twist1), 
mRNA. 
339 Antxr2 6.095402066 Mus musculus anthrax toxin receptor 2 (Antxr2), mRNA. 
340 LOC214403 6.087443937   
341 Lhfp 6.070946877 Mus musculus lipoma HMGIC fusion partner (Lhfp), mRNA. 
342 Igfbp3 6.069970871 
Mus musculus insulin-like growth factor binding protein 3 
(Igfbp3), mRNA. 
343 Tbc1d2b 6.068722696 
Mus musculus TBC1 domain family, member 2B 
(Tbc1d2b), mRNA. 
344 Rasa3 6.045737317 Mus musculus RAS p21 protein activator 3 (Rasa3), mRNA. 
345 Epha3 6.038110421 Mus musculus Eph receptor A3 (Epha3), mRNA. 
346 Tgfbr2 6.032781351 
Mus musculus transforming growth factor, beta receptor II 
(Tgfbr2), transcript variant 1, mRNA. 
347 Col1a2 5.969973792 Mus musculus collagen, type I, alpha 2 (Col1a2), mRNA. 
348 Gpc1 5.965503473 Mus musculus glypican 1 (Gpc1), mRNA. 
349 Bmper 5.959845423 
Mus musculus BMP-binding endothelial regulator (Bmper), 
mRNA. 
350 Inmt 5.954676497 
Mus musculus indolethylamine N-methyltransferase (Inmt), 
mRNA. 
351 
2210023G05R
ik 5.941521573 
Mus musculus RIKEN cDNA 2210023G05 gene 
(2210023G05Rik), mRNA. 
352 Hbb-b1 5.913740116   
353 Glipr2 5.909285785 Mus musculus GLI pathogenesis-related 2 (Glipr2), mRNA. 
354 Ugt1a10 5.885704487 
Mus musculus UDP glycosyltransferase 1 family, 
polypeptide A10 (Ugt1a10), mRNA. 
355 Tmem100 5.864433868 
Mus musculus transmembrane protein 100 (Tmem100), 
mRNA. 
356 Dlk1 5.855761782 
Mus musculus delta-like 1 homolog (Drosophila) (Dlk1), 
mRNA. 
357 Dnm3os 5.84507897 
Mus musculus dynamin 3, opposite strand (Dnm3os), non-
coding RNA. 
358 Hexa 5.840892392 Mus musculus hexosaminidase A (Hexa), mRNA. 
359 Sfrp2 5.833282582 
Mus musculus secreted frizzled-related protein 2 (Sfrp2), 
mRNA. 
360 Apcdd1 5.82763171 Mus musculus adenomatosis polyposis coli down-regulated 
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1 (Apcdd1), mRNA. 
361 Rhoj 5.810529961 
Mus musculus ras homolog gene family, member J (Rhoj), 
mRNA. 
362 Agtr1a 5.773748093 
Mus musculus angiotensin II receptor, type 1a (Agtr1a), 
mRNA. 
363 AI607873 5.759651473 
PREDICTED: Mus musculus expressed sequence 
AI607873 (AI607873), mRNA. 
364 B3gnt9 5.752546721 
Mus musculus UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 9 (B3gnt9), mRNA. 
365 Sfrp1 5.722724878 
Mus musculus secreted frizzled-related protein 1 (Sfrp1), 
mRNA. 
366 Gadd45g 5.690641453 
Mus musculus growth arrest and DNA-damage-inducible 45 
gamma (Gadd45g), mRNA. 
367 
LOC10004568
0 5.65258775 
PREDICTED: Mus musculus similar to complement C4 
(LOC100045680), mRNA. 
368 Hbb-b1 5.645586056 
Mus musculus hemoglobin, beta adult major chain (Hbb-
b1), mRNA. 
369 Bcat1 5.635819657 
Mus musculus branched chain aminotransferase 1, 
cytosolic (Bcat1), transcript variant 2, mRNA. 
370 Prnp 5.629650665 Mus musculus prion protein (Prnp), mRNA. 
371 C1s 5.622593016 
Mus musculus complement component 1, s subcomponent 
(C1s), mRNA. 
372 Fap 5.610018287 Mus musculus fibroblast activation protein (Fap), mRNA. 
373 Tnfaip2 5.593331022 
Mus musculus tumor necrosis factor, alpha-induced protein 
2 (Tnfaip2), mRNA. 
374 Vegfc 5.586212784 
Mus musculus vascular endothelial growth factor C (Vegfc), 
mRNA. 
375 Angptl4 5.552567496 Mus musculus angiopoietin-like 4 (Angptl4), mRNA. 
376 Gucy1a3 5.535833951 
Mus musculus guanylate cyclase 1, soluble, alpha 3 
(Gucy1a3), mRNA. 
377 Olfm1 5.530388783 
Mus musculus olfactomedin 1 (Olfm1), transcript variant 1, 
mRNA. XM_923993 XM_923996 XM_924001 
378 Dpp7 5.510989633 Mus musculus dipeptidylpeptidase 7 (Dpp7), mRNA. 
379 
E130203B14R
ik 5.507898256 
Mus musculus RIKEN cDNA E130203B14 gene 
(E130203B14Rik), mRNA. 
380 Igsf10 5.507376589 
PREDICTED: Mus musculus immunoglobulin superfamily, 
member 10, transcript variant 4 (Igsf10), mRNA. 
381 Mmp13 5.505782672 
Mus musculus matrix metallopeptidase 13 (Mmp13), 
mRNA. 
382 Ptgis 5.500260194 
Mus musculus prostaglandin I2 (prostacyclin) synthase 
(Ptgis), mRNA. 
383 Col18a1 5.492024252 
Mus musculus procollagen, type XVIII, alpha 1 (Col18a1), 
mRNA. 
384 
LOC10004855
4 5.490793963 
PREDICTED: Mus musculus similar to monocyte 
chemoattractant protein-2 (MCP-2) (LOC100048554), 
mRNA. 
385 LOC631037 5.467126093 
PREDICTED: Mus musculus similar to CYP4B1 
(LOC631037), mRNA. 
386 Tmem119 5.456973331 
Mus musculus transmembrane protein 119 (Tmem119), 
mRNA. 
387 Syde1 5.440898397 
PREDICTED: Mus musculus synapse defective 1, Rho 
GTPase, homolog 1 (C. elegans) (Syde1), mRNA. 
388 Prkcdbp 5.429395253 
Mus musculus protein kinase C, delta binding protein 
(Prkcdbp), mRNA. 
389 Nav1 5.395931352   
390 Hbb-b1 5.392454602   
391 Mmp10 5.381211415 
Mus musculus matrix metallopeptidase 10 (Mmp10), 
mRNA. 
392 BC020108 5.38074711   
393 
LOC10004578
0 5.377562508 
PREDICTED: Mus musculus similar to metalloprotease-
disintegrin meltrin beta (LOC100045780), mRNA. 
394 Pcolce2 5.377187401 
Mus musculus procollagen C-endopeptidase enhancer 2 
(Pcolce2), mRNA. 
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395 Fhl2 5.371558153 
Mus musculus four and a half LIM domains 2 (Fhl2), 
mRNA. 
396 Cdkn2b 5.36666227 
Mus musculus cyclin-dependent kinase inhibitor 2B (p15, 
inhibits CDK4) (Cdkn2b), mRNA. 
397 Nox4 5.362865481 Mus musculus NADPH oxidase 4 (Nox4), mRNA. 
398 C1qtnf5 5.353976382 
Mus musculus C1q and tumor necrosis factor related 
protein 5 (C1qtnf5), transcript variant 1, mRNA. 
399 Lgi2 5.338651634 
Mus musculus leucine-rich repeat LGI family, member 2 
(Lgi2), mRNA. 
400 Arhgap24 5.298224244 
Mus musculus Rho GTPase activating protein 24 
(Arhgap24), transcript variant 1, mRNA. 
401 Snx24 5.26805474 Mus musculus sorting nexing 24 (Snx24), mRNA. 
402 Flrt2 5.255317218 
Mus musculus fibronectin leucine rich transmembrane 
protein 2 (Flrt2), mRNA. 
403 Lrrc17 5.245065145 
PREDICTED: Mus musculus leucine rich repeat containing 
17, transcript variant 1 (Lrrc17), mRNA. 
404 Rgl1 5.222704127 
Mus musculus ral guanine nucleotide dissociation 
stimulator,-like 1 (Rgl1), mRNA. XM_924428 
405 Serpinh1 5.220445571 
Mus musculus serine (or cysteine) peptidase inhibitor, 
clade H, member 1 (Serpinh1), mRNA. 
406 Cercam 5.214353606 
Mus musculus cerebral endothelial cell adhesion molecule 
(Cercam), mRNA. 
407 Olfm1 5.205603895 
Mus musculus olfactomedin 1 (Olfm1), transcript variant 4, 
mRNA. 
408 C4b 5.204238332 
Mus musculus complement component 4B (Childo blood 
group) (C4b), mRNA. XM_921663 XM_921673 XM_921676 
XM_921678 
409 Epb4.1l3 5.18599776 
Mus musculus erythrocyte protein band 4.1-like 3 
(Epb4.1l3), mRNA. 
410 Palld 5.157538801 
Mus musculus palladin, cytoskeletal associated protein 
(Palld), mRNA. 
411 Thbs3 5.144567551 Mus musculus thrombospondin 3 (Thbs3), mRNA. 
412 Plekha4 5.140839916 
Mus musculus pleckstrin homology domain containing, 
family A (phosphoinositide binding specific) member 4 
(Plekha4), mRNA. 
413 Cpz 5.13657056 Mus musculus carboxypeptidase Z (Cpz), mRNA. 
414 Nope 5.126967854 Mus musculus neighbor of Punc E11 (Nope), mRNA. 
415 Gstm1 5.12583511 
Mus musculus glutathione S-transferase, mu 1 (Gstm1), 
mRNA. 
416 Prkcdbp 5.11828371 
Mus musculus protein kinase C, delta binding protein 
(Prkcdbp), mRNA. 
417 Col6a2 5.092910982   
418 
LOC10004733
9 5.058052108 
PREDICTED: Mus musculus similar to lysyl oxidase-like 2 
(LOC100047339), mRNA. 
419 Ednra 5.054522861 Mus musculus endothelin receptor type A (Ednra), mRNA. 
420 Enc1 5.049121692 Mus musculus ectodermal-neural cortex 1 (Enc1), mRNA. 
421 
1500015O10R
ik 5.03376504 
Mus musculus RIKEN cDNA 1500015O10 gene 
(1500015O10Rik), mRNA. 
422 Tns1 4.998380128 PREDICTED: Mus musculus tensin 1 (Tns1), mRNA. 
423 Fbln2 4.988346562 Mus musculus fibulin 2 (Fbln2), transcript variant 1, mRNA. 
424 Efemp2 4.988084206 
Mus musculus epidermal growth factor-containing fibulin-
like extracellular matrix protein 2 (Efemp2), mRNA. 
425 Fbln2 4.98218623 Mus musculus fibulin 2 (Fbln2), transcript variant 2, mRNA. 
426 Ntrk2 4.962973058 
Mus musculus neurotrophic tyrosine kinase, receptor, type 
2 (Ntrk2), transcript variant 1, mRNA. 
427 Sfrp1 4.960135914   
428 Tgfbi 4.94676836 
Mus musculus transforming growth factor, beta induced 
(Tgfbi), mRNA. 
429 Hbb-b1 4.945302652   
430 Pmp22 4.94469321 
Mus musculus peripheral myelin protein 22 (Pmp22), 
mRNA. 
431 1200009O22R 4.928538517 Mus musculus RIKEN cDNA 1200009O22 gene 
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ik (1200009O22Rik), mRNA. 
432 Adora2b 4.919606764 Mus musculus adenosine A2b receptor (Adora2b), mRNA. 
433 Hspb8 4.900864319 Mus musculus heat shock protein 8 (Hspb8), mRNA. 
434 Slc10a6 4.835781344 
Mus musculus solute carrier family 10 (sodium/bile acid 
cotransporter family), member 6 (Slc10a6), mRNA. 
435 Pscd3 4.814836213 
Mus musculus pleckstrin homology, Sec7 and coiled-coil 
domains 3 (Pscd3), mRNA. 
436 Ugcg 4.808652342   
437 Rgs16 4.797272207 
Mus musculus regulator of G-protein signaling 16 (Rgs16), 
mRNA. 
438 Plau 4.77643973 
Mus musculus plasminogen activator, urokinase (Plau), 
mRNA. 
439 Ccnd2 4.767402436   
440 Pdlim2 4.762010824 Mus musculus PDZ and LIM domain 2 (Pdlim2), mRNA. 
441 Prrx1 4.754127085 
Mus musculus paired related homeobox 1 (Prrx1), 
transcript variant 2, mRNA. 
442 Gli3 4.752647745 
Mus musculus GLI-Kruppel family member GLI3 (Gli3), 
mRNA. 
443 Adamts1 4.747836998 
Mus musculus a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin type 1 motif, 1 
(Adamts1), mRNA. 
444 Timp2 4.747585368 
Mus musculus tissue inhibitor of metalloproteinase 2 
(Timp2), mRNA. 
445 Emilin1 4.734763949   
446 
B430201A12R
ik 4.721831546 
PREDICTED: Mus musculus RIKEN cDNA B430201A12 
gene (B430201A12Rik), mRNA. 
447 Frmd6 4.690317255 Mus musculus FERM domain containing 6 (Frmd6), mRNA. 
448 Sema5a 4.670822095 
Mus musculus sema domain, seven thrombospondin 
repeats (type 1 and type 1-like), transmembrane domain 
(TM) and short cytoplasmic domain, (semaphorin) 5A 
(Sema5a), mRNA. 
449 C4b 4.656553995 
Mus musculus complement component 4B (Childo blood 
group) (C4b), mRNA. XM_921663 XM_921673 XM_921676 
XM_921678 
450 Pftk1 4.653916766 Mus musculus PFTAIRE protein kinase 1 (Pftk1), mRNA. 
451 Entpd2 4.640691497 
Mus musculus ectonucleoside triphosphate 
diphosphohydrolase 2 (Entpd2), mRNA. 
452 Wnt2 4.624019829 
Mus musculus wingless-related MMTV integration site 2 
(Wnt2), mRNA. 
453 Mxra7 4.604726233 
Mus musculus matrix-remodelling associated 7 (Mxra7), 
mRNA. 
454 Prrx2 4.59972339   
455 Arhgdib 4.597389683 
Mus musculus Rho, GDP dissociation inhibitor (GDI) beta 
(Arhgdib), mRNA. 
456 Igfbp3 4.582770632 
Mus musculus insulin-like growth factor binding protein 3 
(Igfbp3), mRNA. 
457 
LOC10004688
3 4.58146411 
PREDICTED: Mus musculus similar to CKLF-like MARVEL 
transmembrane domain containing 3 (LOC100046883), 
mRNA. 
458 Angptl1 4.572594928 Mus musculus angiopoietin-like 1 (Angptl1), mRNA. 
459 Palld 4.569097527 
PREDICTED: Mus musculus palladin, cytoskeletal 
associated protein, transcript variant 6 (Palld), mRNA. 
460 Snai2 4.565399611 
Mus musculus snail homolog 2 (Drosophila) (Snai2), 
mRNA. 
461 Igfbp7 4.542608254 
Mus musculus insulin-like growth factor binding protein 7 
(Igfbp7), mRNA. 
462 Ccdc3 4.534040135   
463 Klf4 4.527074658 Mus musculus Kruppel-like factor 4 (gut) (Klf4), mRNA. 
464 
LOC10004741
9 4.509440587 
PREDICTED: Mus musculus similar to c-Maf long form 
(LOC100047419), mRNA. 
465 Tgfb1i1 4.509108841 
Mus musculus transforming growth factor beta 1 induced 
transcript 1 (Tgfb1i1), mRNA. 
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466 Podn 4.498653098 Mus musculus podocan (Podn), mRNA. 
467 
1200015N20Ri
k 4.478369979   
468 Fst 4.471524522 Mus musculus follistatin (Fst), mRNA. 
469 Ugcg 4.47030687 
Mus musculus UDP-glucose ceramide glucosyltransferase 
(Ugcg), mRNA. 
470 Dpysl2 4.457439995 Mus musculus dihydropyrimidinase-like 2 (Dpysl2), mRNA. 
471 Hic1 4.450206366 
Mus musculus hypermethylated in cancer 1 (Hic1), 
transcript variant 1, mRNA. 
472 
2010004A03Ri
k 4.4419843 
Mus musculus RIKEN cDNA 2010004A03 gene 
(2010004A03Rik), mRNA. 
473 Crabp1 4.408758003 
Mus musculus cellular retinoic acid binding protein I 
(Crabp1), mRNA. 
474 Fcgr2b 4.38846322 
Mus musculus Fc receptor, IgG, low affinity IIb (Fcgr2b), 
transcript variant 2, mRNA. 
475 Lhfpl2 4.386253632 
Mus musculus lipoma HMGIC fusion partner-like 2 (Lhfpl2), 
mRNA. 
476 Mdk 4.38506791 Mus musculus midkine (Mdk), transcript variant 1, mRNA. 
477 Fgf7 4.377519277 Mus musculus fibroblast growth factor 7 (Fgf7), mRNA. 
478 Angptl2 4.355187382 Mus musculus angiopoietin-like 2 (Angptl2), mRNA. 
479 Fam13c 4.342874705 
Mus musculus family with sequence similarity 13, member 
C (Fam13c), mRNA. 
480 Epdr1 4.340659051 
Mus musculus ependymin related protein 1 (zebrafish) 
(Epdr1), mRNA. 
481 Ifi27 4.34043673 
Mus musculus interferon, alpha-inducible protein 27 (Ifi27), 
mRNA. 
482 Larp6 4.337924773 
Mus musculus La ribonucleoprotein domain family, member 
6 (Larp6), mRNA. 
483 Hoxc9 4.333790914 Mus musculus homeo box C9 (Hoxc9), mRNA. 
484 Hdac7 4.331227078 
Mus musculus histone deacetylase 7 (Hdac7), mRNA. 
XM_001003311 XM_001003316 XM_001004168 
XM_001004172 XM_001004178 XM_001004180 
XM_001004182 XM_001004187 XM_001004194 
XM_001004198 
485 Eml1 4.330343362 
Mus musculus echinoderm microtubule associated protein 
like 1 (Eml1), transcript variant 1, mRNA. XM_901775 
XM_901779 XM_978946 XM_978978 XM_979015 
XM_979053 XM_979124 XM_979166 XM_979204 
486 Mylk 4.322904976 
Mus musculus myosin, light polypeptide kinase (Mylk), 
mRNA. 
487 Lepre1 4.319777906 
Mus musculus leprecan 1 (Lepre1), transcript variant 1, 
mRNA. 
488 Id3 4.307567608 Mus musculus inhibitor of DNA binding 3 (Id3), mRNA. 
489 Papss2 4.305862379 
Mus musculus 3'-phosphoadenosine 5'-phosphosulfate 
synthase 2 (Papss2), mRNA. 
490 Fkbp14 4.295855041 Mus musculus FK506 binding protein 14 (Fkbp14), mRNA. 
491 Fscn1 4.294279192 
Mus musculus fascin homolog 1, actin bundling protein 
(Strongylocentrotus purpuratus) (Fscn1), mRNA. 
492 Inhba 4.284512396 Mus musculus inhibin beta-A (Inhba), mRNA. 
493 Emid2 4.284184633 Mus musculus EMI domain containing 2 (Emid2), mRNA. 
494 Gpr23 4.270372953   
495 Timp3 4.244932016 
Mus musculus tissue inhibitor of metalloproteinase 3 
(Timp3), mRNA. 
496 Serpina1b 4.243623953 
Mus musculus serine (or cysteine) preptidase inhibitor, 
clade A, member 1b (Serpina1b), mRNA. 
497 Slit3 4.239530102   
498 Tbc1d2b 4.228200931 
Mus musculus TBC1 domain family, member 2B 
(Tbc1d2b), mRNA. 
499 Ebf2 4.20390548 Mus musculus early B-cell factor 2 (Ebf2), mRNA. 
500 Ramp2 4.199349443 
Mus musculus receptor (calcitonin) activity modifying 
protein 2 (Ramp2), mRNA. 
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501 Acta2 4.199110926   
502 Meox1 4.197568662 Mus musculus mesenchyme homeobox 1 (Meox1), mRNA. 
503 Moxd1 4.187369732 
Mus musculus monooxygenase, DBH-like 1 (Moxd1), 
mRNA. 
504 Ppap2b 4.186768068 
Mus musculus phosphatidic acid phosphatase type 2B 
(Ppap2b), mRNA. 
505 Gadd45b 4.18350809 
Mus musculus growth arrest and DNA-damage-inducible 45 
beta (Gadd45b), mRNA. 
506 Ncam1 4.168593966 
Mus musculus neural cell adhesion molecule 1 (Ncam1), 
transcript variant 1, mRNA. 
507 Pvrl3 4.159275865 
Mus musculus poliovirus receptor-related 3 (Pvrl3), 
transcript variant alpha, mRNA. 
508 Ifi202b 4.156378254 
Mus musculus interferon activated gene 202B (Ifi202b), 
mRNA. 
509 Ccl2 4.138499247 
Mus musculus chemokine (C-C motif) ligand 2 (Ccl2), 
mRNA. 
510 Tgfb1i1 4.138408835 
Mus musculus transforming growth factor beta 1 induced 
transcript 1 (Tgfb1i1), mRNA. 
511 Cd248 4.132471638 Mus musculus CD248 antigen, endosialin (Cd248), mRNA. 
512 Serpinh1 4.125075992   
513 Fn1 4.121693703 Mus musculus fibronectin 1 (Fn1), mRNA. 
514 Ror2 4.118040162 
Mus musculus receptor tyrosine kinase-like orphan receptor 
2 (Ror2), mRNA. 
515 Hspb8 4.115789016 Mus musculus heat shock protein 8 (Hspb8), mRNA. 
516 Edg2 4.114688284   
517 Il11ra1 4.112155465 
Mus musculus interleukin 11 receptor, alpha chain 1 
(Il11ra1), mRNA. 
518 Prrx1 4.109263218   
519 Calu 4.108320913 
Mus musculus calumenin (Calu), transcript variant 1, 
mRNA. 
520 Rgs10 4.105957554 
Mus musculus regulator of G-protein signalling 10 (Rgs10), 
mRNA. 
521 Pdia5 4.096982649 
Mus musculus protein disulfide isomerase associated 5 
(Pdia5), mRNA. 
522 Gprc5b 4.079881579 
Mus musculus G protein-coupled receptor, family C, group 
5, member B (Gprc5b), mRNA. 
523 Adh1 4.061195457 
Mus musculus alcohol dehydrogenase 1 (class I) (Adh1), 
mRNA. 
524 
B430305P08R
ik 4.05116071   
525 Cd47 4.040192953 
Mus musculus CD47 antigen (Rh-related antigen, integrin-
associated signal transducer) (Cd47), mRNA. 
526 Kremen 4.035825323   
527 Tnc 3.984531463 Mus musculus tenascin C (Tnc), mRNA. 
528 Ak1 3.977036046 Mus musculus adenylate kinase 1 (Ak1), mRNA. 
529 Cep170 3.975884225 Mus musculus centrosomal protein 170 (Cep170), mRNA. 
530 
LOC10004720
0 3.974096024 
PREDICTED: Mus musculus similar to T-box 3 protein 
(LOC100047200), mRNA. 
531 Meis2 3.965613813 
Mus musculus Meis homeobox 2 (Meis2), transcript variant 
2, mRNA. 
532 Acta2 3.958913088 
Mus musculus actin, alpha 2, smooth muscle, aorta 
(Acta2), mRNA. 
533 Lgals3bp 3.952935763 
Mus musculus lectin, galactoside-binding, soluble, 3 
binding protein (Lgals3bp), mRNA. 
534 Mylk 3.951876438 
Mus musculus myosin, light polypeptide kinase (Mylk), 
mRNA. 
535 Tmem45a 3.951013258 
Mus musculus transmembrane protein 45a (Tmem45a), 
mRNA. 
536 Rassf2 3.944571743 
Mus musculus Ras association (RalGDS/AF-6) domain 
family member 2 (Rassf2), mRNA. 
537 Dpp4 3.941721695 Mus musculus dipeptidylpeptidase 4 (Dpp4), mRNA. 
538 LOC10004556 3.941014782 PREDICTED: Mus musculus similar to purine nucleoside 
Appendix 
 
 
 
239 
7 phosphorylase (LOC100045567), mRNA. 
539 6430511F03 3.932307008   
540 MGC41689 3.926167661   
541 Emp1 3.925984664 
Mus musculus epithelial membrane protein 1 (Emp1), 
mRNA. 
542 Sema5a 3.922217117   
543 Icam1 3.915216655 
Mus musculus intercellular adhesion molecule 1 (Icam1), 
mRNA. 
544 Sdk1 3.910325094 
Mus musculus sidekick homolog 1 (chicken) (Sdk1), 
mRNA. 
545 Wipf1 3.900819437 
Mus musculus WAS/WASL interacting protein family, 
member 1 (Wipf1), mRNA. 
546 Pygl 3.89256788 Mus musculus liver glycogen phosphorylase (Pygl), mRNA. 
547 Gli2 3.88701841 
Mus musculus GLI-Kruppel family member GLI2 (Gli2), 
mRNA. 
548 Klf4 3.873314389 Mus musculus Kruppel-like factor 4 (gut) (Klf4), mRNA. 
549 Rftn1 3.866958425 Mus musculus raftlin lipid raft linker 1 (Rftn1), mRNA. 
550 Tnfsf13b 3.865518993   
551 Zeb2 3.862980214 
Mus musculus zinc finger E-box binding homeobox 2 
(Zeb2), transcript variant 2, mRNA. 
552 Rcn3 3.855784511 
Mus musculus reticulocalbin 3, EF-hand calcium binding 
domain (Rcn3), mRNA. 
553 Pip4k2a 3.836679409 
Mus musculus phosphatidylinositol-5-phosphate 4-kinase, 
type II, alpha (Pip4k2a), mRNA. 
554 Tek 3.835260998 
Mus musculus endothelial-specific receptor tyrosine kinase 
(Tek), mRNA. 
555 AI115600 3.834594177 
PREDICTED: Mus musculus expressed sequence 
AI115600 (AI115600), mRNA. 
556 Ptrf 3.831666768 
Mus musculus polymerase I and transcript release factor 
(Ptrf), mRNA. 
557 Magee1 3.786953719 
Mus musculus melanoma antigen, family E, 1 (Magee1), 
mRNA. 
558 Plxdc1 3.78297656 Mus musculus plexin domain containing 1 (Plxdc1), mRNA. 
559 Nnmt 3.782062493 
Mus musculus nicotinamide N-methyltransferase (Nnmt), 
mRNA. 
560 En1 3.779463664   
561 Pard6g 3.77164835 
Mus musculus par-6 partitioning defective 6 homolog 
gamma (C. elegans) (Pard6g), mRNA. 
562 Adm 3.753670118 Mus musculus adrenomedullin (Adm), mRNA. 
563 Klf4 3.743955282 Mus musculus Kruppel-like factor 4 (gut) (Klf4), mRNA. 
564 Vcan 3.736829115 Mus musculus versican (Vcan), transcript variant 1, mRNA. 
565 Cbr3 3.726992773 Mus musculus carbonyl reductase 3 (Cbr3), mRNA. 
566 
LOC10004382
2 3.725877207 
PREDICTED: Mus musculus hypothetical protein 
LOC100043822 (LOC100043822), mRNA. 
567 Gm106 3.724318701 Mus musculus gene model 106, (NCBI) (Gm106), mRNA. 
568 Rasl11b 3.723342891 
Mus musculus RAS-like, family 11, member B (Rasl11b), 
mRNA. 
569 Palm 3.721679806 Mus musculus paralemmin (Palm), mRNA. 
570 
D130032J17Ri
k 3.717827164   
571 
LOC10004598
1 3.709831039 
PREDICTED: Mus musculus similar to synaptotagmin XI 
(LOC100045981), mRNA. 
572 Clip4 3.708089268 
Mus musculus CAP-GLY domain containing linker protein 
family, member 4 (Clip4), mRNA. 
573 3830612M24 3.683409541   
574 Gpnmb 3.680596775 
Mus musculus glycoprotein (transmembrane) nmb 
(Gpnmb), mRNA. 
575 Cyp4b1 3.67698453 
Mus musculus cytochrome P450, family 4, subfamily b, 
polypeptide 1 (Cyp4b1), mRNA. 
576 Tgfbr3 3.668251385 Mus musculus transforming growth factor, beta receptor III 
Appendix 
 
 
 
240 
(Tgfbr3), mRNA. 
577 Egr2 3.666314795   
578 Ifitm3 3.664312778 
Mus musculus interferon induced transmembrane protein 3 
(Ifitm3), mRNA. 
579 Gadd45g 3.660280398 
Mus musculus growth arrest and DNA-damage-inducible 45 
gamma (Gadd45g), mRNA. 
580 Hoxd8 3.659365193 Mus musculus homeo box D8 (Hoxd8), mRNA. 
581 Qpct 3.658413624 
Mus musculus glutaminyl-peptide cyclotransferase 
(glutaminyl cyclase) (Qpct), mRNA. 
582 Ebf2 3.654617266 Mus musculus early B-cell factor 2 (Ebf2), mRNA. 
583 D10Ertd610e 3.650436698 
Mus musculus DNA segment, Chr 10, ERATO Doi 610, 
expressed (D10Ertd610e), mRNA. 
584 Pcsk6 3.647645426 
PREDICTED: Mus musculus proprotein convertase 
subtilisin/kexin type 6, transcript variant 4 (Pcsk6), mRNA. 
585 Lrrk1 3.64510029 Mus musculus leucine-rich repeat kinase 1 (Lrrk1), mRNA. 
586 Gas7 3.629626594 Mus musculus growth arrest specific 7 (Gas7), mRNA. 
587 Larp6 3.623947602 
Mus musculus La ribonucleoprotein domain family, member 
6 (Larp6), mRNA. 
588 Enpp2 3.62100446 
Mus musculus ectonucleotide 
pyrophosphatase/phosphodiesterase 2 (Enpp2), mRNA. 
589 Itgb5 3.614958138 Mus musculus integrin beta 5 (Itgb5), mRNA. 
590 Marcks 3.612535024 
Mus musculus myristoylated alanine rich protein kinase C 
substrate (Marcks), mRNA. 
591 Serpina1b 3.611669653   
592 Myl9 3.607691967 
PREDICTED: Mus musculus myosin, light polypeptide 9, 
regulatory (Myl9), mRNA. 
593 Actg2 3.599723104 
Mus musculus actin, gamma 2, smooth muscle, enteric 
(Actg2), mRNA. 
594 Acta2 3.596437311 
Mus musculus actin, alpha 2, smooth muscle, aorta 
(Acta2), mRNA. 
595 Gm22 3.595226124 
PREDICTED: Mus musculus gene model 22, (NCBI) 
(Gm22), mRNA. 
596 
2810022L02Ri
k 3.594467067 
Mus musculus RIKEN cDNA 2810022L02 gene 
(2810022L02Rik), mRNA. 
597 Glipr2 3.592952285   
598 Kng1 3.58600218 Mus musculus kininogen 1 (Kng1), mRNA. 
599 Acta2 3.583407209 
Mus musculus actin, alpha 2, smooth muscle, aorta 
(Acta2), mRNA. 
600 Ebf3 3.579098377 Mus musculus early B-cell factor 3 (Ebf3), mRNA. 
601 Edg2 3.567951381 
Mus musculus endothelial differentiation, lysophosphatidic 
acid G-protein-coupled receptor, 2 (Edg2), mRNA. 
602 
A830080H07R
ik 3.566599725   
603 Fzd2 3.565383173 
Mus musculus frizzled homolog 2 (Drosophila) (Fzd2), 
mRNA. 
604 Reck 3.558061288 
Mus musculus reversion-inducing-cysteine-rich protein with 
kazal motifs (Reck), mRNA. 
605 Agpat4 3.549790501 
Mus musculus 1-acylglycerol-3-phosphate O-
acyltransferase 4 (lysophosphatidic acid acyltransferase, 
delta) (Agpat4), mRNA. 
606 Ccbp2 3.544428803 
Mus musculus chemokine binding protein 2 (Ccbp2), 
mRNA. 
607 Calu 3.535731204 
Mus musculus calumenin (Calu), transcript variant 1, 
mRNA. 
608 Cacna2d1 3.529198204 
Mus musculus calcium channel, voltage-dependent, 
alpha2/delta subunit 1 (Cacna2d1), mRNA. 
609 Rasl11a 3.520396698 
Mus musculus RAS-like, family 11, member A (Rasl11a), 
mRNA. 
610 Ifitm1 3.518466255 
Mus musculus interferon induced transmembrane protein 1 
(Ifitm1), mRNA. 
611 P4ha2 3.517754806 
Mus musculus procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase), alpha II polypeptide 
(P4ha2), transcript variant 2, mRNA. 
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612 BC028528 3.51213461 
Mus musculus cDNA sequence BC028528 (BC028528), 
mRNA. 
613 Hmcn1 3.503830688 Mus musculus hemicentin 1 (Hmcn1), mRNA. 
614 Palld 3.500867359 
Mus musculus palladin, cytoskeletal associated protein 
(Palld), mRNA. 
615 Cd34 3.496261377 Mus musculus CD34 antigen (Cd34), mRNA. 
616 Slc8a1 3.495638719   
617 H2-M3 3.494915791 
Mus musculus histocompatibility 2, M region locus 3 (H2-
M3), mRNA. 
618 Mylk 3.483111196 
Mus musculus myosin, light polypeptide kinase (Mylk), 
mRNA. 
619 Nlgn2 3.476929054 Mus musculus neuroligin 2 (Nlgn2), mRNA. 
620 Robo1 3.473528285 
Mus musculus roundabout homolog 1 (Drosophila) 
(Robo1), mRNA. 
621 Gpr133 3.468579242 
Mus musculus G protein-coupled receptor 133 (Gpr133), 
mRNA. 
622 
LOC10003899
3 3.467787997 
Mus musculus similar to interleukin 11 receptor, alpha 
chain 2 (LOC100038993), mRNA. 
623 Olfm1 3.439957859 
Mus musculus olfactomedin 1 (Olfm1), transcript variant 2, 
mRNA. 
624 Fxyd6 3.431361652 
Mus musculus FXYD domain-containing ion transport 
regulator 6 (Fxyd6), mRNA. 
625 Evc 3.429880756 
Mus musculus Ellis van Creveld gene homolog (human) 
(Evc), mRNA. 
626 
6720477C19Ri
k 3.422870973   
627 Ugt1a6b 3.419591896 
Mus musculus UDP glucuronosyltransferase 1 family, 
polypeptide A6B (Ugt1a6b), mRNA. 
628 Ckb 3.40549571 Mus musculus creatine kinase, brain (Ckb), mRNA. 
629 Hoxb7 3.389518398 Mus musculus homeo box B7 (Hoxb7), mRNA. 
630 Rnf144a 3.381684332 
Mus musculus ring finger protein 144A (Rnf144a), transcript 
variant 2, mRNA. 
631 Gpr153 3.376826404 
Mus musculus G protein-coupled receptor 153 (Gpr153), 
mRNA. 
632 Txndc5 3.375589741 
Mus musculus thioredoxin domain containing 5 (Txndc5), 
mRNA. 
633 
A730040I05Ri
k 3.367608382   
634 Pdlim7 3.364379593   
635 Higd1b 3.363995028 
Mus musculus HIG1 domain family, member 1B (Higd1b), 
mRNA. 
636 Ugt1a6a 3.357359355 
Mus musculus UDP glucuronosyltransferase 1 family, 
polypeptide A6A (Ugt1a6a), mRNA. 
637 BC023892 3.350637106 
PREDICTED: Mus musculus cDNA sequence BC023892, 
transcript variant 2 (BC023892), mRNA. 
638 Ttc28 3.343255499 
PREDICTED: Mus musculus tetratricopeptide repeat 
domain 28 (Ttc28), mRNA. 
639 Mapre2 3.332880818 
Mus musculus microtubule-associated protein, RP/EB 
family, member 2 (Mapre2), mRNA. 
640 Nid2 3.310204895 Mus musculus nidogen 2 (Nid2), mRNA. 
641 Evc2 3.298378115 
Mus musculus Ellis van Creveld syndrome 2 homolog 
(human) (Evc2), mRNA. 
642 Vasn 3.296063147 Mus musculus vasorin (Vasn), mRNA. 
643 Col5a2 3.292749309 Mus musculus collagen, type V, alpha 2 (Col5a2), mRNA. 
644 Thbd 3.283632522 Mus musculus thrombomodulin (Thbd), mRNA. 
645 
1700023M03R
ik 3.282949054   
646 LOC385644 3.280234247   
647 Sphk1 3.263337115 
Mus musculus sphingosine kinase 1 (Sphk1), transcript 
variant 1, mRNA. 
648 Serpina1b 3.261771015 
Mus musculus serine (or cysteine) preptidase inhibitor, 
clade A, member 1b (Serpina1b), mRNA. 
Appendix 
 
 
 
242 
649 Myh10 3.253924087 
Mus musculus myosin, heavy polypeptide 10, non-muscle 
(Myh10), mRNA. 
650 Abpe 3.24865393 
Mus musculus androgen binding protein epsilon (Abpe), 
mRNA. 
651 Cdon 3.242064552   
652 Ifi202b 3.239265413 
Mus musculus interferon activated gene 202B (Ifi202b), 
mRNA. 
653 Col7a1 3.233973377 Mus musculus collagen, type VII, alpha 1 (Col7a1), mRNA. 
654 
9130415E20Ri
k 3.218585116   
655 Plod2 3.217801918   
656 Vkorc1 3.208534942 
Mus musculus vitamin K epoxide reductase complex, 
subunit 1 (Vkorc1), mRNA. 
657 Adh1 3.208316914 
Mus musculus alcohol dehydrogenase 1 (class I) (Adh1), 
mRNA. 
658 Sdc2 3.205144247 Mus musculus syndecan 2 (Sdc2), mRNA. 
659 Tpbg 3.203659409 Mus musculus trophoblast glycoprotein (Tpbg), mRNA. 
660 Camk2n1 3.203230182 
Mus musculus calcium/calmodulin-dependent protein 
kinase II inhibitor 1 (Camk2n1), mRNA. 
661 Tnfaip3 3.199697623 
Mus musculus tumor necrosis factor, alpha-induced protein 
3 (Tnfaip3), mRNA. 
662 Serpina1d 3.196721631 
Mus musculus serine (or cysteine) peptidase inhibitor, 
clade A, member 1d (Serpina1d), mRNA. 
663 Tnfsf13b 3.19091891 
Mus musculus tumor necrosis factor (ligand) superfamily, 
member 13b (Tnfsf13b), mRNA. 
664 Il11ra1 3.190578862 
Mus musculus interleukin 11 receptor, alpha chain 1 
(Il11ra1), mRNA. 
665 Fkbp7 3.189973451 Mus musculus FK506 binding protein 7 (Fkbp7), mRNA. 
666 Eno2 3.184671905 Mus musculus enolase 2, gamma neuronal (Eno2), mRNA. 
667 Efnb1 3.18393579 Mus musculus ephrin B1 (Efnb1), mRNA. 
668 Spnb2 3.174541699 
Mus musculus spectrin beta 2 (Spnb2), transcript variant 2, 
mRNA. 
669 Lynx1 3.173694319 Mus musculus Ly6/neurotoxin 1 (Lynx1), mRNA. 
670 Tcea3 3.17086412   
671 Ext1 3.166493427 Mus musculus exostoses (multiple) 1 (Ext1), mRNA. 
672 Islr2 3.151379122 
Mus musculus immunoglobulin superfamily containing 
leucine-rich repeat 2 (Islr2), mRNA. 
673 Nid1 3.140692241   
674 Rbms1 3.139106411 
Mus musculus RNA binding motif, single stranded 
interacting protein 1 (Rbms1), mRNA. 
675 Vtn 3.131049002 Mus musculus vitronectin (Vtn), mRNA. 
676 Gngt2 3.117441027 
Mus musculus guanine nucleotide binding protein (G 
protein), gamma transducing activity polypeptide 2 (Gngt2), 
transcript variant 2, mRNA. 
677 Mras 3.116815796 
Mus musculus muscle and microspikes RAS (Mras), 
mRNA. 
678 Xpnpep2 3.113105435 
Mus musculus X-prolyl aminopeptidase (aminopeptidase P) 
2, membrane-bound (Xpnpep2), transcript variant 1, 
mRNA. 
679 Gria3 3.112921797 
Mus musculus glutamate receptor, ionotropic, AMPA3 
(alpha 3) (Gria3), mRNA. 
680 Col6a3 3.104032826 
Mus musculus procollagen, type VI, alpha 3 (Col6a3), 
mRNA. 
681 Pkig 3.102270657 
Mus musculus protein kinase inhibitor, gamma (Pkig), 
transcript variant 1, mRNA. 
682 Gata6 3.094015265 Mus musculus GATA binding protein 6 (Gata6), mRNA. 
683 Adprh 3.084452344 
Mus musculus ADP-ribosylarginine hydrolase (Adprh), 
mRNA. 
684 Gcnt2 3.083116715 
Mus musculus glucosaminyl (N-acetyl) transferase 2, I-
branching enzyme (Gcnt2), transcript variant 3, mRNA. 
685 
9030024J15Ri
k 3.076528325   
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686 Vkorc1 3.074806113 
Mus musculus vitamin K epoxide reductase complex, 
subunit 1 (Vkorc1), mRNA. 
687 Sod3 3.070193872 
Mus musculus superoxide dismutase 3, extracellular 
(Sod3), mRNA. 
688 Ddah1 3.057856839   
689 Mtap1b 3.053114628 
Mus musculus microtubule-associated protein 1 B 
(Mtap1b), mRNA. 
690 Synpo 3.045770447   
691 Pcdh19 3.034510441 
PREDICTED: Mus musculus protocadherin 19 (Pcdh19), 
mRNA. 
692 Cacna1g 3.031008926 
Mus musculus calcium channel, voltage-dependent, T type, 
alpha 1G subunit (Cacna1g), mRNA. 
693 LOC676420 3.026731005 
PREDICTED: Mus musculus similar to ceramide kinases 
(LOC676420), misc RNA. 
694 Abcc9 3.023704495 
Mus musculus ATP-binding cassette, sub-family C 
(CFTR/MRP), member 9 (Abcc9), transcript variant 4, 
mRNA. 
695 Gpsm1 3.017429681 
Mus musculus G-protein signalling modulator 1 (AGS3-like, 
C. elegans) (Gpsm1), mRNA. 
696 Cdc42ep2 3.015979174 
Mus musculus CDC42 effector protein (Rho GTPase 
binding) 2 (Cdc42ep2), mRNA. 
697 Ppap2a 3.003742226 
Mus musculus phosphatidic acid phosphatase 2a 
(Ppap2a), transcript variant 1, mRNA. 
698 Ctgf 3.003457243 
Mus musculus connective tissue growth factor (Ctgf), 
mRNA. 
699 H2-Q5 3.001312804 
Mus musculus histocompatibility 2, Q region locus 5 (H2-
Q5), mRNA. 
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